"","nct_id","trial_title","Conditions","condition","Interventions","intervention_type","Sponsor_Collaborators","Gender","Age_Groups","Enrollment","Start_Date","Completion_Date","title","z","direction","m2"
"1","NCT00988208","Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer","Prostate Cancer","cancer","Drug: Lenalidomide|Drug: Docetaxel|Drug: Prednisone|Drug: Placebo","drug","Celgene Corporation","Male","Adult|Senior",1059,"November 2009","May 2008","Overall Survival (OS)",-3.1382,"-1",24101
"2","NCT01151137","Permanent Atrial fibriLLAtion Outcome Study Using Dronedarone on Top of Standard Therapy","Atrial Fibrillation","cardiovascular","Drug: Dronedarone|Drug: Placebo (for Dronedarone)","drug","Sanofi","Both","Adult|Senior",3236,"July 2010","February 2009","Overview of the Two Co-primary Outcomes",-3.105434027,"-1",24110
"3","NCT00373113","A Clinical Trial Comparing Efficacy And Safety Of Sunitinib And Capecitabine","Breast Neoplasms","cancer","Drug: Capecitabine|Drug: Sunitinib malate","drug","Pfizer","Female","Adult|Senior",482,"November 2006","July 2008","Progression-Free Survival (PFS)",-3.090232306,"-1",24103
"4","NCT00373256","A Study Of SU011248 Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel In Patients With Advanced Breast Cancer","Breast Neoplasms","cancer","Drug: Sunitinib|Drug: paclitaxel|Drug: bevacizumab|Drug: paclitaxel","drug","Pfizer","Both","Adult|Senior",488,"November 2006","August 2008","Progression-Free Survival (PFS)",-2.988882267,"-1",24104
"5","NCT00768300","(ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF","Idiopathic Pulmonary Fibrosis","respiratory","Drug: Ambrisentan|Drug: Placebo","drug","Gilead Sciences","Both","Adult|Senior",494,"December 2008","February 2008","Time to Death or Disease (IPF) Progression.",-2.575829304,"-1",24098
"6","NCT00367133","Intravitreal Triamcinolone Acetonide Versus Laser for Diabetic Macular Edema","Diabetic Macular Edema","other","Procedure: Standard of Care Group|Drug: 1mg triamcinolone acetonide|Drug: 4mg triamcinolone acetonide","drug","Diabetic Retinopathy Clinical Research Network|National Eye Institute (NEI)|Allergan","Both","Adult|Senior",840,"July 2004","September 2010","Change In Visual Acuity [Measured With Electronic-Early Treatment Diabetic Retinopathy Study (E-ETDRS)]Baseline to 2 Years.",-2.326347874,"-1",24129
"7","NCT00988091","Investigation of 1.2% Sodium Hyaluronate for Treatment of Painful Chronic Osteoarthritis of the Knee","Osteoarthritis of the Knee","other","Device: 1.2% Sodium Hyaluronate|Device: Buffered Saline","device","Ferring Pharmaceuticals","Both","Adult|Senior",596,"September 2009","September 2010","Change From Baseline in the Visual Analogue Score (VAS) Pain Score of the 50-foot Walk Test at Week 26",-2.1201,"-1",24129
"8","NCT00099268","Efficacy and Safety of Carbidopa/Levodopa/Entacapone in Patients With Parkinson's Disease Requiring Initiation of Levodopa Therapy","Parkinson's Disease","mental health","Drug: Carbidopa/levodopa/entacapone|Drug: Immediate release carbidopa/levodopa","drug","Novartis Pharmaceuticals|Orion Corporation, Orion Pharma|Novartis","Both","Adult|Senior",747,"September 2004","March 2009","Time to First Occurrence of Dyskinesia",-2.053748911,"-1",24111
"9","NCT00545740","Prevention of Recurrence of Diverticulitis","Diverticulitis","other","Drug: SPD476 (1.2g)|Drug: SPD476 (2.4 g)|Drug: SPD476 (4.8 g)|Drug: Placebo","drug","Shire","Both","Adult|Senior",590,"November 2007","April 2009","",-1.986300204,"-1",24112
"10","NCT00596830","Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology","Carcinoma, Squamous Cell|Carcinoma, Adenosquamous|Carcinoma, Large Cell|Carcinoma, Non-","cancer","Drug: CP-751,871 (Figitumumab)|Drug: Carboplatin|Drug: Paclitaxel|Drug: Carboplatin|Drug: Paclitaxel","drug","Pfizer","Both","Adult|Senior",681,"April 2008","March 2008","Overall Survival (OS)",-1.852179859,"-1",24099
"11","NCT00112918","Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer","Colorectal Cancer","cancer","Biological: Bevacizumab|Drug: Capecitabine|Drug: 5-Fluorouracil (5-FU)|Drug: Leucovorin calcium|Drug: Oxaliplatin","biolog","Hoffmann-La Roche|National Cancer Institute (NCI)","Both","Adult|Senior",3451,"December 2004","July 2008","Disease-free Survival in Stage III Cancer Patients - Time to Event",-1.811910673,"-1",24103
"12","NCT00745290","A Phase 3 Study to Evaluate the Safety and Efficacy of SKY0402 in Subjects Undergoing Total Knee Arthroplasty","Postoperative Pain","other","Drug: Bupivacaine HCl|Drug: SKY0402","drug","Pacira Pharmaceuticals, Inc","Both","Adult|Senior",245,"August 2008","April 2008","Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) With Activity (NRS-A) Pain Intensity Scores",-1.5971,"-1",24100
"13","NCT00435409","A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer","Breast Neoplasms","cancer","Drug: Sunitinib + Capecitabine|Drug: Capecitabine","drug","Pfizer","Both","Adult|Senior",442,"February 2007","October 2009","Progression Free Survival (PFS)",-1.562373611,"-1",24118
"14","NCT01152190","A Study in Benign Prostatic Hyperplasia","Benign Prostatic Hyperplasia","other","Drug: Tadalafil|Drug: Placebo","drug","Eli Lilly and Company","Male","Adult|Senior",97,"September 2010","July 2008","Change From Baseline to 8-Week Endpoint in Arterial Resistive Index (RI) in the Prostate Transition Zone",-1.550589875,"-1",24103
"15","NCT00410410","A Study of Abatacept in Patients With Active Ulcerative Colitis","Ulcerative Colitis","other","Drug: abatacept (ABA)|Drug: placebo|Drug: abatacept","drug","Bristol-Myers Squibb","Both","Adult|Senior",591,"December 2006","December 2009","Induction Period (IP); Number of Participants With Clinical Response (Per Mayo Score) at Week 12: IP Cohort 1 (IP1C)",-1.538198859,"-1",24120
"16","NCT00594568","Effect of LY450139 on the Long Term Progression of Alzheimer's Disease","Alzheimer's Disease","mental health","Drug: LY450139|Drug: Placebo","drug","Eli Lilly and Company","Both","Adult|Senior",1537,"March 2008","November 2008","Change From Baseline in Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11) Score at 76 Weeks",-1.498513068,"-1",24107
"17","NCT00497146","The PRIMO Study: Paricalcitol Capsules Benefits Renal Failure Induced Cardiac Morbidity in Subjects With Chronic Kidney Disease Stage 3/4","Chronic Kidney Disease|Left Ventricular Hypertrophy","other","Drug: paricalcitol|Drug: placebo","drug","AbbVie (prior sponsor, Abbott)|Massachusetts General Hospital|AbbVie","Both","Adult|Senior",227,"February 2008","December 2009","Change From Baseline in Left Ventricular Mass Index (LVMI) Over 48 Weeks Measured by Cardiac Magnetic Resonance Imaging (MRI)",-1.457421739,"-1",24120
"18","NCT00762762","Investigate Plaque and Gingival Index","Periodontitis","other","Drug: Triclosan and fluoride|Drug: Fluoride","drug","Colgate Palmolive","Both","Adult",46,"March 2006","April 2008","HbA1c Levels in Blood",-1.3615,"-1",24100
"19","NCT00744848","Study to Evaluate Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy","Hemorrhoids","other","Drug: Bupivacaine HCl|Drug: SKY0402","drug","Pacira Pharmaceuticals, Inc","Both","Adult|Senior",204,"August 2008","September 2012","Area Under the Curve (AUC) of the Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores",-1.2963,"-1",24153
"20","NCT00251004","Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients","Kidney Transplantation|Graft Rejection","other","Drug: Everolimus|Drug: Mycophenolic Acid (MPA)|Drug: Cyclosporine A (CsA)|Drug: Basiliximab|Drug: Corticosteroids","drug","Novartis","Both","Adult|Senior",833,"October 2005","April 2008","Number of Participants With Composite Efficacy Endpoints - 12 Month Analysis",-1.296,"-1",24100
"21","NCT00490815","Pharmacokinetic and Efficacy Study of Fluocinolone Acetonide Inserts in Patients With Diabetic Macular Edema","Diabetic Macular Edema","other","Drug: Fluocinolone Acetonide|Drug: Fluocinolone Acetonide","drug","Alimera Sciences","Both","Adult|Senior",37,"August 2007","February 2008","Levels of Fluocinolone Acetonide in Plasma and Aqueous Humor",-1.287,"-1",24098
"22","NCT00191646","An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy","Genital Neoplasms, Female|Fallopian Tube Neoplasms|Ovarian Neoplasms|Pelvic Neoplasms|P","cancer","Drug: Gemcitabine|Drug: Paclitaxel|Drug: Carboplatin","drug","Eli Lilly and Company","Female","Adult|Senior",919,"October 2002","December 2010","Progression Free Survival (PFS)",-1.284405813,"-1",24132
"23","NCT00574275","Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer","Pancreatic Neoplasm","cancer","Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|Drug: Placebo|Drug: Gemcitabine","drug","Sanofi|Regeneron Pharmaceuticals","Both","Adult|Senior",546,"December 2007","November 2008","Overall Survival (OS)",-1.271924348,"-1",24107
"24","NCT00402363","Evaluation of Efficacy and Safety of Lovaza (Omega-3-Acid Ethyl Esters) in Recurrent, Symptomatic Atrial Fibrillation","Fibrillation, Atrial|Atrial Fibrillation","cardiovascular","Drug: omega-3-acid ethyl esters|Drug: Placebo","drug","GlaxoSmithKline","Both","Adult|Senior",663,"November 2006","February 2008","Number of Participants With Paroxysmal AF With an Event of Documented Symptomatic Atrial Fibrillation (AF)/Flutter",-1.119328551,"-1",24098
"25","NCT00348374","Exubera vs Lispro in a Lantus-based Regimen for Improved Glycemic Control in Type 2 Diabetes","Diabetes Mellitus","endocrine and metabolic","Drug: Insulin Lispro|Drug: Exubera","drug","Pfizer","Both","Adult|Senior",191,"June 2006","April 2008","Change From Baseline in Glycosylated Hemoglobin A1c (HbA1c) at End of Treatment",-1.118,"-1",24100
"26","NCT00046930","Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia","Leukemia|Myelodysplastic Syndromes","cancer","Biological: filgrastim|Biological: sargramostim|Drug: cytarabine|Drug: daunorubicin hydrochloride|Drug: zosuquidar trihydrochloride|Drug: Placebo","biolog","Eastern Cooperative Oncology Group|National Cancer Institute (NCI)|Eli Lilly and Company|Kanisa Pharmaceuticals","Both","Adult|Senior",449,"July 2002","May 2008","Overall Survival (OS)",-1.080319341,"-1",24101
"27","NCT00135330","An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus","Diabetes Mellitus, Type 2","endocrine and metabolic","Drug: exenatide|Drug: rosiglitazone","drug","AstraZeneca|Eli Lilly and Company","Both","Adult|Senior",137,"October 2005","November 2009","Change in ASIiAUC During a Hyperglycemic Clamp Test.",-1.075837361,"-1",24119
"28","NCT00972621","Clinical Evaluation of a New Viscoelastic for Cataract Surgery","Cataract","other","Device: Vitrax II|Device: Viscoat","device","Abbott Medical Optics","Both","Adult|Senior",400,"September 2009","May 2011","Percent of Intraocular Pressure Spikes 30 mm Hg or Greater Postoperatively",-1.0642,"-1",24137
"29","NCT01077973","Study Evaluating A Novel Ibuprofen Formulation In Episodic Tension-Type Headache","Pain","other","Drug: Novel Ibuprofen|Drug: Standard Ibuprofen|Drug: Placebo","drug","Pfizer","Both","Adult",200,"March 2010","April 2008","Time-weighted Sum of Pain Relief Rating and Pain Intensity Difference From 0-3 Hours (SPRID 0-3) for Ibuprofen Sodium Versus Placebo Tablet",-1.038580239,"-1",24100
"30","NCT00604214","Efficacy and Safety of Drotrecogin Alfa (Activated) in Adult Patients With Septic Shock","Sepsis","other","Drug: Drotrecogin alfa (activated)|Drug: Placebo","drug","Eli Lilly and Company","Both","Adult|Senior",1696,"March 2008","January 2009","28-Day All-Cause Mortality",-1.00894711,"-1",24109
"31","NCT00439140","Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder","Overactive Bladder","other","Biological: botulinum toxin Type A|Drug: Normal Saline (Placebo)","biolog","Allergan","Both","Adult|Senior",41,"June 2007","March 2009","Change From Baseline in Forced Vital Capacity (FVC)",-0.998,"-1",24111
"32","NCT00501631","ALK21-014: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) After Enforced Abstinence","Alcohol Dependence","mental health","Drug: VIVITROL 380 mg|Drug: Placebo for VIVITROL 380 mg","drug","Alkermes, Inc.","Both","Adult",300,"July 2007","August 2008","Cumulative Percentage of Participants by Heavy Drinking Rate",-0.962098754,"-1",24104
"33","NCT00673049","Trial Of CP-751, 871 And Erlotinib In Refractory Lung Cancer","Carcinoma, Large Cell|Carcinoma, Non-Small-Cell Lung|Carcinoma, Squamous Cell|Carcinoma","cancer","Drug: CP 751,871 (Figitumumab)|Drug: Erlotinib|Drug: Erlotinib","drug","Pfizer","Both","Adult|Senior",583,"May 2008","April 2009","Overall Survival",-0.9346,"-1",24112
"34","NCT00172185","Safety and Efficacy Study of Teduglutide in Subjects With Short Bowel Syndrome Who Completed Protocol CL0600-004 (NCT00081458)","Short Bowel Syndrome","other","Drug: teduglutide 0.05 mg/kg/d|Drug: teduglutide 0.10 mg/kg/d","drug","NPS Pharma","Both","Adult|Senior",65,"January 2005","April 2008","Number of Subjects Achieving a 20% Reduction at Week 28",-0.903,"-1",24100
"35","NCT00457691","Study Of FOLFIRI Chemotherapy With Or Without Sunitinib In Patients With Metastatic Colorectal Cancer","Metastatic Colorectal Cancer","cancer","Drug: 5 fluorouracil|Drug: irinotecan|Drug: levo- leucovorin|Drug: sunitinib|Drug: 5 fluorouracil|Drug: irinotecan|Drug: levo- leucovorin|Drug: placebo","drug","Pfizer","Both","Adult|Senior",768,"June 2007","December 2009","Progression-free Survival (PFS)",-0.867624372,"-1",24120
"36","NCT00631371","Study Comparing Bevacizumab + Temsirolimus vs. Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects","Renal Cell Carcinoma","cancer","Drug: Bevacizumab|Drug: Temsirolimus|Drug: Bevacizumab|Drug: Interferon-Alfa 9MU","drug","Pfizer","Both","Adult|Senior",791,"April 2008","March 2009","Progression-Free Survival (PFS): Independent-Assessment",-0.8416,"-1",24111
"37","NCT00093015","Trial to Reduce Cardiovascular Events With Aranesp® Therapy (TREAT)","Kidney Disease|Diabetes Mellitus|Anemia","cardiovascular","Drug: Placebo|Drug: darbepoetin alfa","drug","Amgen","Both","Adult|Senior",4038,"August 2004","January 2008","Time to All-cause Mortality or Cardiovascular (CV) Events Including Hospitalization Due to Acute Myocardial Ischemia， Congestive Heart Failure (CHF)， Myocardial Infarction (MI)， and Cerebrovascular Accident (CVA)",-0.82389363,"-1",24097
"38","NCT00761319","Phase III Clinical Trial of TRAVATAN Z in Ocular Surface Health","Open-angle Glaucoma|Ocular Hypertension","other","Drug: Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Drug: Latanoprost ophthalmic solution 0.005% (XALATAN®)","drug","Alcon Research","Both","Adult|Senior",705,"October 2008","June 2008","Mean Change at Day 90 From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score",-0.8176,"-1",24102
"39","NCT00332488","Efficacy and Safety of Prandial Inhalation of Technosphere/Insulin in Combination With Metformin or Technosphere/Insulin Alone Versus 2 Oral Anti-Diabetic Agents in","Diabetes Mellitus, Type 2","endocrine and metabolic","Drug: Technosphere Insulin|Drug: Metformin & Secretagogues|Drug: Technosphere Insulin & Metformin","drug","Mannkind Corporation","Both","Adult|Senior",547,"December 2004","June 2012","Difference in Change From Baseline for HbA1c Between TI+ Metformin and Metformin+Secretagogue",-0.806421247,"-1",24150
"40","NCT00324896","Treatment of Insomnia in Patients With Parkinson's Disease: A Multi-site, Placebo-controlled Study of Eszopiclone","Parkinson's Disease|Insomnia","mental health","Drug: eszopiclone|Other: placebo","drug","University of Medicine and Dentistry of New Jersey|Sunovion|Rutgers, The State University of New Jersey","Both","Adult|Senior",30,"May 2006","June 2008","TST",-0.708,"-1",24102
"41","NCT00337779","Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).","Relapsing Remitting Multiple Sclerosis","mental health","Drug: Glatiramer Acetate (GA) 40 mg|Drug: glatiramer acetate 20 mg","drug","Teva Pharmaceutical Industries","Both","Adult",1155,"August 2006","May 2008","The Rate of Confirmed Relapses During the Double-blind Phase (12 Months).",-0.696844682,"-1",24101
"42","NCT00368108","Efficacy, Safety, and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations","Parkinson's Disease","mental health","Drug: 2 mg perampanel|Drug: 4 mg perampanel|Drug: placebo comparator","drug","Eisai Inc.","Both","Adult|Senior",752,"August 2006","October 2008","Mean Change From Baseline in Total Daily OFF Time (Hours) to Week 20 (Including Last Observation Carried Forward [LOCF] Data)",-0.691,"-1",24106
"43","NCT00486759","A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Predn","B-cell Lymphoma","cancer","Drug: Bevacizumab|Drug: Rituximab|Drug: CHOP|Drug: Placebo","drug","Hoffmann-La Roche|Genentech, Inc.","Both","Adult|Senior",787,"July 2007","January 2009","Progression-free Survival (PFS)",-0.690308824,"-1",24109
"44","NCT00734071","An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder","Generalized Anxiety Disorder","mental health","Drug: Vortioxetine|Drug: Placebo","drug","Takeda|H. Lundbeck A/S","Both","Adult|Senior",304,"June 2008","October 2008","Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score at Week 8",-0.6464,"-1",24106
"45","NCT01011816","Treatment of Symptomatic Lumbar Internal Disc Disruption (IDD) With the Biostat® System","Back Pain|Chronic Low Back Pain|Internal Disc Disruption|Degenerative Disc Disease","other","Biological: BIOSTAT BIOLOGX|Drug: Saline","biolog","Spinal Restoration, Inc.","Both","Adult|Senior",220,"March 2010","January 2009","Subject Composite Success",-0.643345405,"-1",24109
"46","NCT00373334","Safety and Efficacy Study of Axid Use in Infants Suffering From Gastroesophageal Reflux Disease (GERD)","Gastroesophageal Reflux Disease|GERD|Heartburn","other","Drug: nizatidine (axid)|Drug: nizatidine (axid)|Drug: placebo","drug","Braintree Laboratories","Both","Child",138,"August 2006","April 2008","Infant Gastroesophageal Reflux Questionnaire Revised (I-GERQ-R) Success",-0.631061979,"-1",24100
"47","NCT00762411","Effects of LY450139, on the Progression of Alzheimer's Disease as Compared With Placebo","Alzheimer's Disease","mental health","Drug: LY450139|Drug: Placebo","drug","Eli Lilly and Company","Both","Adult|Senior",1111,"September 2008","December 2008","Change From Baseline in Alzheimer's Disease Assessment Scale- Cognitive Subscale (ADAS-Cog11) at 76 Weeks",-0.5828,"-1",24108
"48","NCT00396097","Individualized, Target-Driven Treatment Of Children With Idiopathic Short Stature","Idiopathic Short Stature","endocrine and metabolic","Drug: Genotropin|Drug: Genotropin","drug","Pfizer","Both","Child",316,"December 2006","July 2009","Absolute On-target Difference (AOTD) at 24 Months",-0.558943911,"-1",24115
"49","NCT00305162","A Clinical Trial to Demonstrate the Efficacy of Cangrelor","Myocardial Infarction (MI)|Acute Coronary Syndromes (ACS)","cardiovascular","Drug: Cangrelor (P2Y12 inhibitor)|Drug: clopidogrel (oral P2Y12 inhibitor)|Drug: Placebo bolus & placebo infusion|Drug: Placebo capsules - end of infusion|Drug: Placebo capsules - as soon as possible after randomization","drug","The Medicines Company","Both","Adult|Senior",8882,"April 2006","October 2008","Incidence of All-cause Mortality， Myocardial Infarction (MI)， and Ischemia-driven Revascularization (IDR)",-0.53883603,"-1",24106
"50","NCT00225017","Switch to Atazanavir and Brachial Artery Reactivity (SABAR) Study","HIV Infection|Hyperlipidemia","respiratory","Drug: Atazanavir|Drug: current antiretroviral regimen","drug","Northwestern University|Bristol-Myers Squibb","Both","Adult|Senior",50,"June 2005","March 2010","Percentage Change in Brachial Artery Flow Mediated (FMD) Vasodilation Between Arms From Baseline to Week 24",-0.522963002,"-1",24123
"51","NCT00320489","Olanzapine Pamoate Depot Versus Oral Olanzapine on Treatment Outcomes in Outpatients With Schizophrenia","Schizophrenia","mental health","Drug: olanzapine|Drug: olanzapine pamoate depot","drug","Eli Lilly and Company","Both","Adult",524,"April 2006","October 2008","Median Time to Discontinuation for Any Reason (Excluding Sponsor Decision)",-0.507220661,"-1",24106
"52","NCT00069784","The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention)","Diabetes Mellitus, Non-Insulin-Dependent","cardiovascular","Drug: insulin glargine (HOE901)|Drug: omega-3 polyunsaturated fatty acids (PUFA)|Drug: placebo|Device: reusable pen device for insulin injection","device","Sanofi|Population Health Research Institute","Both","Adult|Senior",12537,"August 2003","August 2009","Composite of the First Occurrence of Cardiovascular (CV) Death， Nonfatal Myocardial Infarction (MI) or Nonfatal Stroke",-0.485530617,"-1",24116
"53","NCT01413958","Effects of Phenylephrine Extended-Release Tablets on Allergy-Related Nasal Congestion (P08498 AM1)","Seasonal Allergic Rhinitis","other","Drug: Phenylephrine|Drug: Placebo|Drug: Loratadine","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",575,"August 2011","April 2008","Mean Change From Baseline in Daily Reflective Nasal Congestion Score",-0.42,"-1",24100
"54","NCT01049217","Pregabalin Versus Placebo In The Treatment Of Neuropathic Pain Associated With HIV Neuropathy","Neuropathy","mental health","Drug: pregabalin|Drug: placebo","drug","Pfizer","Both","Adult|Senior",377,"April 2010","June 2008","Change From Baseline in Mean Pain Score at Endpoint (up to Week 16)",-0.373199457,"-1",24102
"55","NCT00394706","Resuscitation Outcomes Consortium (ROC) Prehospital Resuscitation Using an Impedance Valve","Heart Arrest","cardiovascular","Device: Impedance Threshold Device (ITD)|Device: Sham ITD|Other: Analyze early|Other: Analyze later","device","University of Washington|National Heart, Lung, and Blood Institute (NHLBI)|National Institute of Neurological Disorders and Stroke (NINDS)|Canadian In","Both","Adult|Senior",11738,"June 2007","July 2012","Survival to Hospital Discharge With Satisfactory Function (Modified Rankin Scale [MRS] of Less Than or Equal to 3).",-0.371856089,"-1",24151
"56","NCT00642694","Time to Remission of Depressive Symptoms With Combined SSRI and Ramelteon","Major Depressive Disorder|Insomnia","mental health","Drug: Escitalopram|Drug: Ramelteon|Other: Placebo","drug","University of Texas Southwestern Medical Center|Takeda Pharmaceuticals North America, Inc.","Both","Adult|Senior",29,"May 2007","August 2008","Percentage of Remitters on IDS-C30 at Week 12",-0.345,"-1",24104
"57","NCT00756938","Study of Losartan in Pediatric Patients With Hypertension (MK-0954-337)","Hypertension","cardiovascular","Drug: losartan potassium","drug","Merck Sharp & Dohme Corp.","Both","Child",101,"March 2009","January 2009","Mean Change From Baseline in Systolic Blood Pressure",-0.3147,"-1",24109
"58","NCT01499667","Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to Fingolimod","Relapsing Remitting Multiple Sclerosis (RRMS)","mental health","Drug: Fingolimod|Drug: Placebo","drug","Novartis Pharmaceuticals|Novartis","Both","Adult",142,"September 2011","May 2008","Number of Active (New or Newly Enlarging) T2 Lesions From the Last Natalizumab Infusion (Baseline) Through 8 Weeks of Fingolimod Treatment",-0.301,"-1",24101
"59","NCT00300274","Efficacy and Safety of Everolimus in Recipients of Heart Transplants to Prevent Acute and Chronic Rejection","Graft Rejection","other","Drug: everolimus|Drug: mycophenolate mofetil|Drug: cyclosporine|Drug: corticosteroids","drug","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior",721,"January 2006","December 2009","Percentage of Participants With Composite Efficacy Failure at 12 Months",-0.288,"-1",24120
"60","NCT00500682","A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease (EPPIC-1)","Chronic Kidney Disease","other","Drug: Placebo|Drug: AST-120","drug","Mitsubishi Tanabe Pharma Corporation|Kureha Corporation","Both","Adult|Senior",1020,"July 2007","May 2008","Composite of Dialysis Initiation， Kidney Transplantation， and Serum Creatinine Doubling",-0.279319034,"-1",24101
"61","NCT00709956","Iloprost Power 15 in Pulmonary Arterial Hypertension","Pulmonary Arterial Hypertension","cardiovascular","Drug: iloprost (5 µg)|Drug: placebo","drug","Actelion","Both","Adult|Senior",64,"July 2008","November 2009","6-minute-walk Distance (6MWD)",-0.2685,"-1",24119
"62","NCT00762515","Clinical Study to Evaluate the Treatment of Gingivitis of Two Toothpastes","Dental Plaque","other","Drug: Fluoride|Drug: Triclosan|Drug: Fluoride","drug","Colgate Palmolive","Both","Adult",44,"February 2008","March 2008","Control Established Plaque in Adults",-0.1986,"-1",24099
"63","NCT00890097","Geographic Atrophy Treatment Evaluation","Geographic Atrophy|Age-Related Macular Degeneration","other","Drug: AL-8309B Ophthalmic Solution|Drug: AL-8309B Vehicle","drug","Alcon Research","Both","Adult|Senior",772,"April 2009","March 2012","Mean Annualized Lesion Enlargement Rate From Baseline as Assessed With Fundus Autofluorescence Imaging",-0.198,"-1",24147
"64","NCT00689221","Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma and Methylated Gene Promoter Status","Glioblastoma","cancer","Drug: Cilengitide|Drug: Temozolomide|Radiation: Radiotherapy","drug","EMD Serono|European Organisation for Research and Treatment of Cancer - EORTC|Merck KGaA","Both","Adult|Senior",545,"September 2008","February 2009","Overall Survival (OS) Time",-0.1734,"-1",24110
"65","NCT00759187","Evaluate Clinical Research From Commerical Oral Care Products","Gingival Diseases","other","Drug: Fluoride|Drug: Triclosan/Fluoride|Drug: Chlorhexidine Gluconate","drug","Colgate Palmolive","Both","Adult",25,"January 2008","April 2008","Dental Plaque Index",-0.1622,"-1",24100
"66","NCT00624065","Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure","Hypertension","cardiovascular","Drug: carvedilol controlled release/lisinopril|Drug: lisinopril + placebo","drug","GlaxoSmithKline","Both","Adult|Senior",348,"March 2008","March 2008","Number of Participants With Mean Sitting Cuff Blood Pressure <140/90 mmHg at the End of 6 Weeks of Treatment",-0.1482,"-1",24099
"67","NCT00532155","A Study of Aflibercept Versus Placebo in Patients With Second-Line Docetaxel for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer","Carcinoma|Non Small Cell Lung","cancer","Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|Drug: Placebo|Drug: Docetaxel (Taxotere®)|Drug: Dexamethasone (pre- and post-medication for docetaxel)","drug","Sanofi|Regeneron Pharmaceuticals","Both","Adult|Senior",913,"September 2007","August 2008","Overall Survival (OS)",-0.127556447,"-1",24104
"68","NCT00777153","Cediranib in Combination With Lomustine Chemotherapy in Recurrent Glioblastoma","Recurrent Glioblastoma","cancer","Drug: Cediranib|Drug: Cediranib|Drug: Lomustine Chemotherapy|Drug: Placebo Cediranib","drug","AstraZeneca","Both","Adult|Senior",423,"October 2008","March 2009","Progression Free Survival (PFS)",-0.1257,"-1",24111
"69","NCT00477672","A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis","Parkinson's Disease Psychosis","mental health","Drug: Pimavanserin tartrate (ACP-103)|Drug: Pimavanserin tartrate (ACP-103)|Drug: Placebo","drug","ACADIA Pharmaceuticals Inc.","Both","Adult|Senior",298,"June 2007","March 2009","Antipsychotic Efficacy",-0.103,"-1",24111
"70","NCT00690794","Travatan Z in Ocular Surface Health in Patients With Open-Angle Glaucoma or Ocular Hypertension","Open-angle Glaucoma|Ocular Hypertension","other","Drug: Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Drug: Latanoprost ophthalmic solution 0.005% (XALATAN®)","drug","Alcon Research","Both","Adult|Senior",726,"July 2008","April 2009","Mean Change at Day 90 From Baseline (Day 0) in Ocular Surface Disease Index (OSDI) Score",-0.0743,"-1",24112
"71","NCT00762034","A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer","Non-small Cell Lung Cancer","cancer","Drug: Pemetrexed|Drug: Pemetrexed|Drug: Paclitaxel|Drug: Carboplatin|Biological: Bevacizumab|Biological: Bevacizumab","biolog","Eli Lilly and Company","Both","Adult|Senior",939,"December 2008","April 2009","Overall Survival",-0.0629,"-1",24112
"72","NCT00872001","The Effect Of Acadesine On Reducing Cardiovascular and Cerebrovascular Adverse Events In Coronary Artery Bypass Graft (CABG) Surgery (Study P05633 AM1)(TERMINATED)","Coronary Artery Bypass|Myocardial Infarction|Ventricular Dysfunction, Left|Stroke|Cardi","cardiovascular","Drug: Acadesine|Drug: Normal Saline","drug","Merck Sharp & Dohme Corp.|Duke Clinical Research Institute","Both","Adult|Senior",3080,"April 2009","October 2010","Incidence of All-cause Death， Non-fatal Stroke， and Need for Mechanical Support for Severe Left Ventricular Dysfunction (SLVD) (Intent-to-Treat Population)",-0.0585,"-1",24130
"73","NCT00796120","An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS)","Sarcoma","cancer","Drug: Trabectedin|Drug: Doxorubicin|Drug: Ifosfamide","drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|PharmaMar","Both","Adult|Senior",121,"November 2008","July 2011","Progression - Free Survival (PFS)",-0.0535,"-1",24139
"74","NCT00708305","Evaluation of Plaque Fluid Fluoride Retention From Fluoride Toothpastes","Dental Caries","other","Drug: Sodium Fluoride (NaF)|Drug: Placebo","drug","GlaxoSmithKline","Both","Adult",65,"June 2008","October 2008","Natural Log Transformed Area Under the Fluoride Concentration in Plaque Fluid by Time Curve (AUC) Between 0-4 Hours",-0.0298,"-1",24106
"75","NCT00535782","A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis","Rheumatoid Arthritis","other","Drug: Tocilizumab|Drug: Placebo|Drug: Methotrexate","drug","Hoffmann-La Roche","Both","Adult|Senior",132,"October 2007","November 2008","Change From Baseline in Small Low Density Lipoprotein (sLDL) Particle Numbers",-0.024,"-1",24107
"76","NCT00242710","Study Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Postmenopausal Women","Endometrial Hyperplasia|Osteoporosis","endocrine and metabolic","Drug: Bazedoxifene/Conjugated Estrogen|Drug: Bazedoxifene/Conjugated Estrogen|Drug: CE 0.45 mg/MPA 1.5mg|Other: Placebo","drug","Pfizer","Female","Adult",1083,"September 2005","March 2010","Percentage of Participants With Hyperplasia at Screening",0,"1",24123
"77","NCT00316017","Hypertonic Resuscitation Following Traumatic Injury","Shock, Traumatic","other","Drug: 7.5% hypertonic saline/6% Dextran-70 (HSD)|Drug: 7.5% hypertonic saline  (HS)|Drug: 0.9% normal saline","drug","University of Washington|National Heart, Lung, and Blood Institute (NHLBI)|National Institute of Neurological Disorders and Stroke (NINDS)|The Institu","Both","Child|Adult|Se",895,"May 2006","June 2009","28 Day Survival",0,"1",24114
"78","NCT00316121","Safety and Efficacy Study of Healos as a Bone Replacement to Treat Degenerative Disc Disease","Degenerative Disc Disease","other","Device: HEALOS and Leopard Cage|Device: Leopard Cage and Autograft","device","Advanced Technologies and Regenerative Medicine, LLC (ATRM)|DePuy Spine","Both","Adult|Senior",138,"April 2006","January 2010","Subject Success (Success is Defined Only if All of These Criteria Are Fulfilled)",0,"1",24121
"79","NCT00422292","Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers","Meningococcal Meningitis|Measles|Mumps|Rubella|Varicella","other","Biological: Meningococcal Polysaccharide Diphtheria Conjugate Vaccine|Biological: Meningococcal Polysaccharide Diphtheria Conjugate Vaccine|Biological: Meningococcal Polysaccharide Diphtheria Conjugate Vaccine|Biological: Mea","biolog","Sanofi Pasteur, a Sanofi Company|Sanofi","Both","Child",1664,"December 2006","March 2010","Measles， Mumps， Rubella， and Varicella (MMRV) Antibody Values in Participants Who Received MMRV Vaccine (Groups 2 and 4 Only)",0,"1",24123
"80","NCT00443820","Efficacy Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail","Onychomycosis","other","Drug: terbinafine|Drug: Placebo|Drug: terbinafine|Drug: Placebo","drug","Novartis Pharmaceuticals|Novartis","Both","Child|Adult|Se",526,"December 2006","November 2008","Efficacy Assessed by the Percentage of Participants With Complete Cure at the End of Study (Week 52) After Treating for 24 or 48 Weeks",0,"1",24107
"81","NCT00443898","Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail","Onychomycosis","other","Drug: terbinafine|Drug: Placebo|Drug: terbinafine|Drug: Placebo","drug","Novartis Pharmaceuticals|Novartis","Both","Child|Adult|Se",518,"December 2006","June 2009","Efficacy Assessed by Complete Cure Rate at the End of Study (Week 52) After Treating for 24 or 48 Weeks.",0,"1",24114
"82","NCT00549939","Alfuzosin Treatment in Children and Adolescents With Neurogenic Urinary Bladder Dysfunction","Neurogenic Urinary Bladder","mental health","Drug: Alfuzosin|Drug: Placebo","drug","Sanofi","Both","Child",172,"October 2007","December 2011","Number of Patients With Detrusor Leak Point Pressure (LPP) < 40 cm H2O",0,"1",24144
"83","NCT00626548","A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer","Prostate Cancer","cancer","Drug: ZD4054|Drug: Palcebo","drug","AstraZeneca","Male","Adult|Senior",2577,"January 2008","May 2009","Overall Survival",0,"1",24113
"84","NCT00677807","Safety, Tolerability and Efficacy of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)","COPD","respiratory","Drug: Indacaterol|Drug: Placebo","drug","Novartis","Both","Adult|Senior",415,"May 2008","September 2010","The Number of Participants With a Clinically Notable Pulse Rate During 52 Weeks of Treatment With Indacaterol 150 µg or 300 µg Compared to Placebo",0,"-1",24129
"85","NCT00747227","Safety and Efficacy of a Violet Visible Light Blocking Intraocular Lens (IOL)","Cataract","other","Device: modified light transmission intraocular lens|Device: monofocal acrylic intraocular lens","device","Abbott Medical Optics","Both","Adult|Senior",250,"December 2006","January 2009","Best Corrected Distance Visual Acuity",0,"1",24109
"86","NCT00756548","BLI850-302: BLI850 vs an Approved Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy","Colon Cancer","cancer","Drug: BLI850|Drug: polyethylene glycol 3350 based bowel preparation","drug","Braintree Laboratories","Both","Adult|Senior",386,"August 2008","February 2009","Efficacy - Preparation Quality Using a 4 Point Scale",0,"1",24110
"87","NCT01206660","Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis","Psoriasis","other","Drug: Desoximetasone Spray 0.25%|Drug: placebo","drug","Taro Pharmaceuticals USA","Both","Adult|Senior",120,"August 2010","May 2008","Clinical Success ITT",0,"1",24101
"88","NCT01209689","A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antago","Spondylitis, Ankylosing","other","Drug: Tocilizumab|Drug: Placebo","drug","Hoffmann-La Roche","Both","Adult|Senior",113,"October 2010","September 2011","Percentage of ASsessment in Ankylosing Spondylitis 20 (ASAS20) Responders at Week 12",0,"-1",24141
"89","NCT00849901","A Study in the Treatment of Children and Adolescents With Major Depressive Disorder","Major Depressive Disorder","mental health","Drug: duloxetine|Drug: Placebo|Drug: fluoxetine","drug","Eli Lilly and Company","Both","Child",337,"March 2009","April 2009","Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at Week 10 Endpoint",0.0013,"1",24112
"90","NCT00317642","A Study of Clofarabine and Cytarabine for Older Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)(CLASSIC I)","Acute Myelogenous Leukemia","cancer","Drug: clofarabine (IV formulation)|Drug: placebo|Drug: cytarabine","drug","Genzyme, a Sanofi Company|Sanofi","Both","Adult|Senior",326,"August 2006","December 2008","Overall Survival – Overall and by Calculated Strata (CSR 7-April-11)",0.006141278,"1",24108
"91","NCT00671502","A Study to Evaluate Two Formulations of Carisoprodol in Subjects With Musculoskeletal Spasm of the Lower Back","Lower Back Pain","other","Drug: Carisoprodol SR|Drug: Carisoprodol SR|Drug: Placebo","drug","Meda Pharmaceuticals","Both","Adult|Senior",840,"April 2008","April 2010","Subject Rating of Pain on a 100-point Visual Analog Scale (VAS)",0.027,"1",24124
"92","NCT01176240","A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease","Orthostatic Hypotension|Parkinson's Disease","cardiovascular","Drug: Droxidopa|Other: Placebo","drug","Chelsea Therapeutics","Both","Adult|Senior",225,"June 2010","June 2009","306A Efficacy: Change in Orthostatic Hypotension Questionnaire Score (OHQ)",0.027576406,"1",24114
"93","NCT00958776","A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hosp","Cough|Sore Throat|Nasal Congestion|Headache|Fever|Seasonal Influenza","other","Drug: Peramivir+SOC|Drug: Placebo+SOC","drug","BioCryst Pharmaceuticals|Department of Health and Human Services","Both","Child|Adult|Se",405,"November 2009","April 2008","Time to Clinical Resolution (Kaplan-Meier Estimate)",0.033845943,"1",24100
"94","NCT00617669","A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) and Docetaxel in Metastatic Hormone Resistant Prostate Cancer","Prostate Cancer","cancer","Drug: Docetaxel|Drug: ZD4054|Drug: Placebo","drug","AstraZeneca","Male","Adult|Senior",1494,"January 2008","May 2011","Overall Survival",0.046389256,"1",24137
"95","NCT01009047","An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia","Schizophrenia","mental health","Drug: Paliperidone extended release (ER)|Drug: Aripiprazole","drug","Janssen Research & Development, LLC","Both","Child",228,"December 2009","July 2011","Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Day 56",0.0816,"1",24139
"96","NCT01033825","Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis","Perennial Allergic Rhinitis","other","Drug: Ciclesonide HFA Nasal Aerosol 320 mcg|Drug: Ciclesonide HFA Nasal Aerosol 160 mcg|Drug: HFA Nasal Aerosol placebo|Drug: Ciclesonide Aqueous Nasal Spray 200 mcg|Drug: AQ Nasal Spray Placebo|Drug: Placebo plus Dexamethaso","drug","Sunovion","Both","Child|Adult|Se",310,"January 2010","July 2009","Serum Cortisol Area Under the Concentration-time Curve (AUC)(0-24h) at Baseline",0.082,"1",24115
"97","NCT00471146","Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer.","Carcinoma, Pancreatic Ductal","cancer","Drug: AG-013736|Drug: Gemcitabine|Drug: Gemcitabine|Drug: placebo","drug","Pfizer","Both","Adult|Senior",630,"July 2007","August 2009","Overall Survival (OS)",0.109507466,"1",24116
"98","NCT00503698","The Effect of Somatropin Treatment in Adult Patients on Chronic Dialysis","Chronic Kidney Disease|End-Stage Renal Disease","other","Drug: somatropin|Drug: placebo","drug","Novo Nordisk A/S","Both","Adult|Senior",712,"July 2007","July 2011","Mortality - Time to All-cause Death",0.113038541,"1",24139
"99","NCT00744497","Randomized Study Comparing Docetaxel Plus Dasatinib to Docetaxel Plus Placebo in Castration-resistant Prostate Cancer","Prostatic Neoplasms","cancer","Drug: Placebo|Drug: Dasatinib|Drug: Docetaxel|Drug: Prednisone","drug","Bristol-Myers Squibb","Male","Adult|Senior",1930,"October 2008","September 2011","Overall Survival: Time From Randomization to Date of Death",0.1245,"1",24141
"100","NCT00252967","Atorvastatin Therapy for the Prevention of Atrial Fibrillation (SToP-AF)","Atrial Fibrillation|Inflammation","cardiovascular","Drug: Atorvastatin|Drug: Placebo","drug","Emory University|Pfizer","Both","Adult|Senior",64,"October 2005","December 2012","Time of Atrial Fibrillation Recurrence",0.125661347,"1",24156
"101","NCT01079143","Progression of Renal Interstitial Fibrosis / Tubular Atrophy (IF/TA) According to Epithelial-mesenchymal Transition (EMT) and Immunosuppressive Regimen (Everolimus B","Renal Interstitial Fibrosis","other","Drug: Certican®|Drug: Neoral|Drug: Myfortic|Drug: Simulect®|Drug: Corticosteroids","drug","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior",194,"September 2009","October 2010","Number of Participants With Progression of Renal Graft Fibrosis (Primary Comparison - ITT Population",0.145,"1",24130
"102","NCT01023035","Boceprevir/Peginterferon/Ribavirin for Chronic Hepatitis C: Erythropoietin Use Versus Ribavirin Dose Reduction for Anemia (P06086 AM2)","Hepatitis C, Chronic","other","Drug: Boceprevir|Drug: Peginterferon alfa-2b (PEG2b)|Drug: Ribavirin (RBV)|Drug: Erythropoietin","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",687,"December 2009","April 2010","Percentage of Participants With Sustained Virologic Response (SVR)",0.1737,"1",24124
"103","NCT00627497","DIAM™ Spinal Stabilization System vs. Decompression, Formerly vs. Posterolateral Fusion","Degenerative Lumbar Spinal Stenosis","other","Procedure: Single-Level Posterior Decompression|Device: DIAM Spinal Stabilization|Device: DIAM Spinal Stabilization|Device: Fusion","device","Medtronic Spinal and Biologics","Both","Adult|Senior",32,"February 2008","February 2010","Rate of Overall Success",0.1757,"1",24122
"104","NCT00249795","Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE I)","Atrial Fibrillation|Cardiovascular Disease","cardiovascular","Drug: Irbesartan|Drug: placebo","drug","Sanofi|Bristol-Myers Squibb","Both","Adult|Senior",9016,"June 2003","July 2009","First Occurence of Any Component of the Composite of Myocardial Infarction， Stroke or Vascular Death as Per Adjudication",0.180194342,"1",24115
"105","NCT01529632","Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patien","Chronic Obstructive Pulmonary Disease","respiratory","Drug: QVA149|Drug: NVA237|Drug: QAB149|Drug: Placebo","drug","Novartis Pharmaceuticals|Novartis","Both","Child|Adult|Se",193,"May 2012","June 2009","Trough Forced Expiratory Volume in 1 Second (FEV1) After 28 Days of Blinded Treatment",0.225,"1",24114
"106","NCT00891735","A Study of Ranibizumab Administered Monthly or on an As-needed Basis in Patients With Subfoveal Neovascular Age-related Macular Degeneration (HARBOR)","Age-related Macular Degeneration","other","Drug: Ranibizumab","drug","Genentech, Inc.","Both","Adult|Senior",1097,"July 2009","March 2008","Change From Baseline in Best Corrected Visual Acuity (BCVA) at Month 12",0.2346,"1",24099
"107","NCT01188928","LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)","Psoriasis Vulgaris","other","Drug: Calcipotriol plus betamethasone|Drug: Betamethasone-17,21-dipropionate|Drug: Calcipotriene|Drug: Topical suspension vehicle","drug","LEO Pharma","Both","Adult|Senior",1152,"September 2010","June 2011","Controlled Disease According to the Investigator’s Global Assessment of Disease Severity (IGA) at Weeks 4",0.251,"1",24138
"108","NCT00483548","Adjunctive Ziprasidone in the Treatment of Bipolar I Depression","Bipolar Disorder|Depression, Bipolar","mental health","Drug: Ziprasidone|Drug: Placebo","drug","Pfizer","Both","Adult|Senior",298,"October 2007","October 2012","Change From Baseline to Week 6 in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score",0.263584634,"1",24154
"109","NCT00076336","Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis","Hepatitis|Hepatitis B, Chronic|Cirrhosis","other","Drug: Telbivudine|Drug: Lamivudine|Drug: Placebo","drug","Novartis Pharmaceuticals|Novartis","Both","Child|Adult|Se",232,"December 2003","July 2009","Number of Participants With Clinical Response",0.267,"1",24115
"110","NCT00545103","Prevention of Recurrence of Diverticulitis","Diverticulitis","other","Drug: SPD476, MMX™ mesalazine, 1.2g extended release tablet|Drug: SPD476, MMX™ mesalazine, 1.2g extended release tablet|Drug: SPD476, MMX™ mesalazine, 1.2g extended release tablet|Drug: Placebo","drug","Shire","Both","Adult|Senior",592,"December 2007","April 2012","Percent of Subjects Without Recurrence of Diverticulitis",0.28192633,"1",24148
"111","NCT00117338","A Study of an Intravenous Drug in Pediatric Patients With Acute Asthma (0476-301)","Asthma","respiratory","Drug: montelukast sodium|Drug: Comparator: placebo (unspecified)","drug","Merck Sharp & Dohme Corp.","Both","Child",276,"July 2005","November 2010","Improvement in FEV1 (Forced Expiratory Volume in 1 Second) Over the First 60 Minutes After Administration",0.285840875,"1",24131
"112","NCT00079001","Zoledronate in Preventing Skeletal (Bone)-Related Events in Men Who Are Receiving Androgen Deprivation Therapy For Prostate Cancer and Bone Metastases","Metastatic Cancer|Prostate Cancer","cancer","Drug: zoledronic acid|Other: placebo|Drug: androgen deprivation therapy|Drug: GnRH agonist|Dietary Supplement: Calcium supplement|Dietary Supplement: Vitamin D","drug","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|Southwest Oncology Group|Eastern Cooperative Oncology Group|NCIC Clinical Tri","Male","Adult|Senior",645,"January 2004","August 2012","Time to First Skeletal Related Event",0.292374896,"1",24152
"113","NCT00130728","A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer","Non-Small Cell Lung Cancer","cancer","Drug: bevacizumab|Drug: erlotinib HCl|Drug: placebo","drug","Genentech, Inc.","Both","Adult|Senior",636,"June 2005","September 2009","Overall Survival (OS) Among All Randomized Patients",0.307713955,"1",24117
"114","NCT00449150","Cetrorelix Pamoate Regimens in Patients With Symptomatic Benign Prostatic Hypertrophy (BPH)","Benign Prostatic Hypertrophy","other","Drug: Cetrorelix|Drug: Cetrorelix|Drug: Placebo","drug","AEterna Zentaris","Male","Adult|Senior",667,"March 2007","June 2010","International Prostate Symptoms Score (IPSS)",0.328676789,"1",24126
"115","NCT00364351","Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy","Non Small Cell Lung Cancer","cancer","Drug: Vandetanib|Drug: Erlotinib","drug","AstraZeneca","Both","Adult|Senior",1574,"August 2006","August 2010","Progression-Free Survival (PFS)",0.357122635,"1",24128
"116","NCT00145496","Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (A7501013)(COMPLETED)(P05771)","Schizophrenia","mental health","Drug: Asenapine|Drug: Olanzapine","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",468,"December 2004","July 2010","Change From Baseline in Negative Symptoms of Schizophrenia Measured by the Negative Symptom Assessment (NSA) Scale Total Score",0.361534392,"1",24127
"117","NCT00879229","ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis","Idiopathic Pulmonary Fibrosis|Pulmonary Hypertension","cardiovascular","Drug: Ambrisentan|Drug: Placebo","drug","Gilead Sciences","Both","Adult|Senior",40,"July 2009","May 2011","Change From Baseline in Six-minute Walk Distance (6MWD).",0.3907,"1",24137
"118","NCT00436969","ORTHOVISC Shoulder RCT","Glenohumeral Osteoarthritis","other","Device: Orthovisc|Drug: Control|Drug: Control","device","DePuy Mitek","Both","Adult|Senior",275,"December 2006","June 2012","Visual Analog Scale (VAS) Pain Score (Per Protocol)",0.3907257,"1",24150
"119","NCT01255423","Efficacy and Safety of Diclofenac Sodium Topical Gel 1% Applied 4 Times Daily in Subjects With Acute Ankle Sprain","Ankle Sprain","other","Drug: Diclofenac sodium topical gel 1%|Drug: Placebo","drug","Novartis","Both","Adult|Senior",206,"November 2010","July 2010","Pain on Movement",0.408,"1",24127
"120","NCT01059565","Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis and Chronic Burkholderia Species Infection","Cystic Fibrosis|Burkholderia Infections","respiratory","Drug: AZLI|Drug: Placebo","drug","Gilead Sciences","Both","Child|Adult|Se",102,"February 2010","August 2010","AUCave of Relative Change in FEV1 % Predicted From Baseline to Week 24",0.435774978,"1",24128
"121","NCT00683930","A Study to Assess the Effect of CellCept (Mycophenolate Mofetil) and Reduced Corticosteroids in Patients With Active Pemphigus Vulgaris (PV)","Pemphigus Vulgaris (PV)","other","Drug: Mycophenolate Mofetil 2 g/Day|Drug: Mycophenolate Mofetil (MMF) 3 g/Day|Drug: Placebo","drug","Hoffmann-La Roche|Aspreva Pharmaceuticals","Both","Adult|Senior",96,"May 2004","May 2011","Percentage of Patients Achieving Responder Status at Week 52",0.4457,"1",24137
"122","NCT00343252","Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis","Osteoporosis, Postmenopausal|Back Pain|Spinal Fracture","endocrine and metabolic","Drug: teriparatide|Drug: risedronate|Drug: placebo|Drug: placebo","drug","Eli Lilly and Company","Female","Adult|Senior",712,"June 2006","June 2010","Number of Participants Responding With at Least a 30% Reduction in 24-Hour Worst Back Pain Severity at the 6-Month Endpoint",0.464904288,"1",24126
"123","NCT01259297","A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People","Cardiovascular Events","cardiovascular","Drug: Aliskiren|Drug: Amlodipine|Drug: Hydrochlorothiazide (HCTZ)|Drug: Placebo for Aliskiren|Drug: Placebo for Amlodipine|Drug: Placebo for Hydrochlorothiazide (HCTZ)","drug","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior",2336,"January 2011","August 2010","Number of Participants With Composite Cardiovascular Endpoints in Aliskiren Based Regimen Versus Non-Aliskiren Based Regimen",0.48172685,"1",24128
"124","NCT00676338","Safety and Efficacy of Exenatide Once Weekly Injection Versus Metformin, Dipeptidyl Peptidase-4 Inhibitor, or Thiazolidinedione as Monotherapy in Drug-Naive Patients","Type 2 Diabetes Mellitus","endocrine and metabolic","Drug: exenatide once weekly|Drug: metformin|Drug: sitagliptin|Drug: pioglitazone","drug","AstraZeneca|Eli Lilly and Company","Both","Adult|Senior",820,"November 2008","November 2009","Change in HbA1c From Baseline to Week 26",0.4959,"1",24119
"125","NCT00695396","A Study Evaluating Epoetin Alfa 40,000 IU (International Units) Every Week or 80,000 IU Every Week Compared to Placebo in Patients With Low or Intermediate-1 Risk My","Myelodysplastic Syndromes|Anemia","cancer","Drug: Placebo|Drug: Epoetin alfa|Drug: Placebo|Drug: Epoetin alfa","drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Centocor Ortho Biotech Services, L.L.C.","Both","Adult|Senior",25,"June 2008","November 2010","Red Blood Cell (RBC) Transfusion",0.4968,"1",24131
"126","NCT00141271","A Six-Week Study Evaluating The Efficacy And Safety Of Geodon In Patients With A Diagnosis Of Bipolar I Depression","Bipolar Disorder","mental health","Drug: Geodon (Ziprasidone)|Drug: Geodon (Ziprasidone)|Drug: Placebo","drug","Pfizer","Both","Adult|Senior",536,"July 2005","July 2011","Change in Montgomery-Asberg Depression Rating Scale (MADRS)Total Score",0.497,"1",24139
"127","NCT00542386","A Study of MCI-196 in Chronic Kidney Disease Subjects on Dialysis With Hyperphosphatemia and Dyslipidaemia","Chronic Kidney Disease|Dialysis|Hyperphosphatemia|Dyslipidemia","endocrine and metabolic","Drug: MCI-196|Drug: Placebo","drug","Mitsubishi Tanabe Pharma Corporation","Both","Adult|Senior",642,"December 2007","January 2011","The Change in Serum Phosphorus",0.505,"1",24133
"128","NCT00406653","A Study of Abatacept in Patients With Active Crohn's Disease","Crohn's Disease","other","Drug: abatacept|Drug: placebo|Drug: abatacept","drug","Bristol-Myers Squibb","Both","Adult|Senior",451,"December 2006","July 2012","Induction Period (IP); Number of Participants With Crohn's Disease Activity Index (CDAI)-Defined Clinical Response at Both Day IP-57 and Day IP-85",0.508646541,"1",24151
"129","NCT00856635","A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Functi","Optic Neuritis","mental health","Drug: Glatiramer Acetate|Drug: placebo","drug","Teva Pharmaceutical Industries","Both","Adult",44,"February 2009","December 2010","Retinal Nerve Fiber Layer Thickness at Baseline and Month 6",0.5088,"1",24132
"130","NCT00759031","Investigation of Dental Plaque and Gingival Index","Dental Plaque","other","Drug: Sodium Monofluorophosphate|Drug: Triclosan/Fluoride/Copolymer","drug","Colgate Palmolive","Both","Adult",19,"February 2008","October 2011","Gingival Margin Plaque Index",0.509,"1",24142
"131","NCT00574873","Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML","Chronic Myeloid Leukemia","cancer","Drug: Bosutinib|Drug: imatinib","drug","Pfizer|Wyeth is now a wholly owned subsidiary of Pfizer","Both","Adult|Senior",502,"February 2008","November 2011","Percentage of Participants With Complete Cytogenetic Response (CCyR) at Year 1",0.522963002,"1",24143
"132","NCT01179516","Safety and Efficacy Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder","Depressive Disorder, Major","mental health","Drug: Vortioxetine|Drug: Placebo","drug","Takeda","Both","Adult|Senior",469,"August 2010","February 2012","Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score",0.528719569,"1",24146
"133","NCT00349752","Corticosteroid Sparing Effect of Certolizumab in Crohn's Disease","Crohn's Disease","other","Biological: certolizumab pegol 400 mg|Other: Placebo","biolog","UCB Pharma","Both","Adult|Senior",174,"November 2006","June 2011","Percentage of Subjects Who Have Been Withdrawn From Prednisone or Prednisolone Therapy According to the Corticosteroid Tapering Schedule and Have Remained Off Corticosteroids and in Disease Remission at Week 38",0.532,"1",24138
"134","NCT00762450","Effect on Bacterial Glycolytic Acid Formation on Plaque","Dental Plaque","other","Drug: Triclosan, Fluoride|Drug: fluoride|Drug: Fluoride, triclosan, amino acid","drug","Colgate Palmolive","Both","Senior",6,"April 2008","July 2012","ph of Dental Plaque After Sucrose Challenge",0.545,"1",24151
"135","NCT00708097","In Situ Caries Efficacy of Fluoride Toothpastes","Caries","other","Drug: NaF|Drug: Placebo|Drug: NaMFP","drug","GlaxoSmithKline","Both","Adult|Senior",57,"April 2008","December 2012","Percentage Surface Microhardness Recovery (%SMHR) of Sound Enamel Specimens Exposed to NaF Toothpaste (1450ppmF) and NaF Toothpaste (1400ppmF)",0.5597,"1",24156
"136","NCT00672620","Efficacy and Safety of Vortioxetine (Lu AA21004) in the Treatment of Patients With Major Depressive Disorder","Major Depressive Disorder","mental health","Drug: Vortioxetine|Drug: Duloxetine|Drug: Placebo","drug","Takeda|H. Lundbeck A/S","Both","Adult|Senior",611,"April 2008","December 2012","Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Week 8",0.5598,"1",24156
"137","NCT00762177","Investigate Oral Bacteria in Adult Population","Oral Bacteria","other","Drug: Fluoride|Drug: Fluoride, Triclosan|Drug: Stannous Fluoride","drug","Colgate Palmolive","Both","Adult|Senior",24,"May 2008","June 2011","Antimicrobial Species in Plaque(Actinomyces)",0.572,"1",24138
"138","NCT00661687","Comparative Performance of PureVision Lens Designs","Myopia","other","Device: Currently Marketed PureVision Contact Lens.|Device: Alternate Design of the PureVision Contact Lens.","device","Bausch & Lomb Incorporated","Both","Adult|Senior",206,"December 2007","December 2012","Subjective Responses to Symptoms/Complaints",0.5791,"1",24156
"139","NCT00282347","A Study to Evaluate the Efficacy and Safety of Rituximab in Subjects With International Society of Nephrology/Renal Pathology Society (ISN/RPS) 2003 Class III or IV","Lupus Nephritis","other","Drug: Rituximab|Drug: Placebo|Drug: Mycophenolate mofetil|Drug: Methylprednisolone|Drug: Diphenhydramine|Drug: Acetaminophen|Drug: Prednisone","drug","Genentech, Inc.","Both","Child|Adult|Se",144,"January 2006","January 2012","Percentage of Participants Who Achieved a Complete Renal Response (CRR)， a Partial Renal Response (PRR)， or no Renal Response (NRR) at Week 52",0.592075548,"1",24145
"140","NCT00758758","Performance of the Hedrocel(R) Cervical Fusion Device","Symptomatic Cervical Disc Disease","other","Device: Anterior Cervical Discectomy and Fusion|Device: Anterior Cervical Discectomy and Fusion|Device: Anterior Cervical Discectomy and Fusion","device","Zimmer, Inc.","Both","Adult|Senior",231,"December 2001","January 2012","Overall Clinical Success (NDI， Fusion， Additional Surgical Procedures)",0.5936,"1",24145
"141","NCT00046228","A Study of Abciximab and Reteplase When Administered Prior to Catherization After a Myocardial Infarction (Finesse)","Myocardial Infarction","cardiovascular","Drug: abciximab placebo; reteplase placebo, abciximab, abciximab|Drug: Abciximab; reteplase; abciximab placebo; abciximab|Drug: abciximab; reteplase placebo; abciximab placebo; abciximab|Drug: abciximab placebo; reteplase pla","drug","Centocor, Inc.|Eli Lilly and Company","Both","Adult|Senior",2461,"August 2002","August 2011","The Composite of All-Cause Mortality or Complications of MI at 90 Days.",0.596262318,"1",24140
"142","NCT00004978","An International Study to Evaluate Recombinant Interleukin-2 in HIV Positive Patients Taking Anti-retroviral Therapy","HIV Infections","other","Drug: Recombinant interleukin-2 (rIL-2)","drug","National Institute of Allergy and Infectious Diseases (NIAID)|Chiron Corporation","Both","Adult|Senior",4150,"March 2000","June 2011","New or Recurrent HIV Disease Progression Event Including Death",0.597760126,"1",24138
"143","NCT00352053","Safety and Efficacy of Tenofovir DF in HIV-1 Infected Adolescents Failing Their Current Antiretroviral Therapy","HIV Infections","other","Drug: Tenofovir DF|Drug: Placebo","drug","Gilead Sciences","Both","Child",87,"July 2006","December 2011","Time-weighted Average Change From Baseline Through Week 24 (DAVG24) in Plasma HIV-1 RNA",0.597760126,"1",24144
"144","NCT00796666","Study Looking at Combination Therapy (Sitaxsentan+Sildenafil) Vs. Monotherapy (Sitaxsentan Alone) SR-PAAS -Sitaxsentan Efficacy And Safety Trial With A Randomized Pr","Pulmonary Arterial Hypertension|Pulmonary Hypertension","cardiovascular","Drug: Sitaxsentan|Drug: Sitaxsentan and Sildenafil","drug","Pfizer","Both","Child|Adult|Se",131,"May 2009","December 2012","Time to Clinical Worsening (TTCW)",0.6104,"1",24156
"145","NCT00393939","Study Of Sunitinib In Combination With Docetaxel Vs Docetaxel In Patients With Advanced Breast Cancer","Breast Neoplasms","cancer","Drug: Sunitinib malate|Drug: Taxotere","drug","Pfizer","Female","Adult|Senior",594,"February 2007","July 2011","Progression-Free Survival (PFS)",0.627700741,"1",24139
"146","NCT00404924","ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures","Non-Small-Cell Lung Carcinoma","cancer","Drug: ZD6474 (vandetanib)|Other: Best Supportive Care","drug","AstraZeneca","Both","Adult|Senior",1140,"November 2006","March 2011","",0.632592172,"1",24135
"147","NCT00337675","Intermittent and Daily Dosing for Episodic (Periodic) Asthma (0476-302)(COMPLETED)","Asthma","respiratory","Drug: montelukast sodium|Drug: Comparator: Placebo (unspecified)|Drug: montelukast sodium","drug","Merck Sharp & Dohme Corp.","Both","Child",1771,"October 2006","April 2011","Number of Asthma Episodes Culminating in Asthma Attack Over the 1-year Treatment Period",0.658837693,"1",24136
"148","NCT00633880","Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)","Symptomatic Neurogenic Orthostatic Hypotension (NOH)|Non-diabetic Neuropathy|Primary Au","cardiovascular","Drug: Placebo|Drug: Droxidopa","drug","Chelsea Therapeutics|Chiltern International Inc.","Both","Adult|Senior",181,"January 2008","December 2012","Change in Dizziness/ Lightheadedness/ Feeling Faint/ or Feeling Like You Might Blackout (OHSA Item 1)",0.6604,"1",24156
"149","NCT00518323","A Double-blind, Placebo-controlled Study of the Safety and Efficacy of Paliperidone Extended Release (ER) in the Treatment of Schizophrenia in Adolescent Patients","Schizophrenia","mental health","Drug: Paliperidone ER|Drug: Placebo|Drug: Paliperidone ER|Drug: Paliperidone ER","drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Both","Child",201,"August 2007","June 2011","Change in the PANSS Total Score From Baseline to the Last Postrandomization Assessment in the Double-blind Period of the Study.",0.661955096,"1",24138
"150","NCT00992459","Study of the Efficacy and Safety of HPN-100, Glyceryl Tri-(4-phenylbutyrate), for the Treatment of Adults With Urea Cycle Disorders (Help UCD)","Urea Cycle Disorders","endocrine and metabolic","Drug: HPN-100|Drug: Buphenyl (NaPBA)","drug","Hyperion Therapeutics, Inc.","Both","Adult|Senior",46,"October 2009","September 2012","The Primary Endpoint Was the 24-hour Area Under the Curve for Blood Ammonia (NH324-hour AUC) on Days 14 and 28.",0.672,"1",24153
"151","NCT00884585","Efficacy and Safety Study of Cyclosporine 0.010% to Treat Atopic Keratoconjunctivitis","Atopic Conjunctivitis","other","Drug: Cyclosporine Vehicle|Drug: Cyclosporine 0.010%","drug","Allergan","Both","Child|Adult|Se",176,"May 2009","November 2012","Percentage of Treatment Responders",0.69,"1",24155
"152","NCT00818662","A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatment of Mild-to-Moderate Alzheimer´s Disease","Alzheimer´s Disease","mental health","Biological: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg|Biological: Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg|Biological: Placebo solution: Human Albumin 0.25% - 4 mL/kg|Biological: Pla","biolog","Baxter Healthcare Corporation|Alzheimer's Disease Cooperative Study (ADCS)","Both","Adult|Senior",390,"December 2008","January 2012","Change From Baseline at 18 Months in the Alzheimer´s Disease Assessment Scale- Cognitive Subscale (ADAS-Cog)",0.7128,"1",24145
"153","NCT01292473","A Study to Evaluate the Efficacy, Response Duration and Safety of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticar","Chronic Idiopathic Urticaria","other","Drug: Placebo|Drug: Omalizumab","drug","Genentech, Inc.","Both","Child|Adult|Se",323,"March 2011","January 2012","Change From Baseline in the Weekly Itch Severity Score at Week 12",0.732767904,"1",24145
"154","NCT00763048","Collection of Gingival Crevicular Fluid From Periodontitis Patients","Gingival Diseases","other","Drug: Fluoride|Drug: Fluoride, triclosan","drug","Colgate Palmolive","Both","Adult|Senior",39,"March 2008","June 2012","Metabolite Associated With Inflammation (Cadaverine)",0.7342,"1",24150
"155","NCT00537680","Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia","Friedreich's Ataxia","mental health","Drug: Idebenone|Drug: Idebenone|Drug: Placebo","drug","Santhera Pharmaceuticals","Both","Child",70,"December 2007","November 2011","ICARS",0.743,"1",24143
"156","NCT01328379","Study of Fampridine-ER Tablets in Patients With Multiple Sclerosis","Multiple Sclerosis","mental health","Drug: Dalfampridine-ER 5mg|Drug: Dalfampridine-ER 10mg|Other: Placebo","drug","Acorda Therapeutics","Both","Adult|Senior",430,"March 2011","November 2012","Change From Baseline in Walking Speed Near Maximum Plasma Concentration at Steady State (CmaxSS) of Placebo and Dalfampridine-ER (5mg and 10mg)， Using the Timed 25 Foot Walk (T25FW).",0.743795835,"1",24155
"157","NCT01323660","An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642","Pulmonary Disease, Chronic Obstructive","respiratory","Drug: GSK573719/GW642444 125/25|Drug: GSK573719/GW642444 62.5/25|Drug: GSK573719 125|Drug: GSK573719 62.5|Drug: GW642444 25|Device: placebo","device","GlaxoSmithKline","Male","Adult|Senior",307,"March 2011","October 2011","Change From Baseline in Exercise Endurance Time Post-dose at Week 12 of Each Treatment Period",0.745449548,"1",24142
"158","NCT00623428","A Study of Combination Therapy With PEGASYS (Pegylated Interferon Alfa-2a (40KD)) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 2 or 3 Who Do","Hepatitis C, Chronic","other","Drug: peginterferon alfa-2a|Drug: Ribavirin","drug","Hoffmann-La Roche","Both","Adult|Senior",235,"June 2008","February 2012","Percentage of Participants With a Sustained Virologic Response 24 Weeks After Scheduled Completion of Treatment",0.7459,"1",24146
"159","NCT00798707","Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder","Major Depressive Disorder","mental health","Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR)|Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR)|Drug: placebo","drug","Pfizer","Both","Adult|Senior",709,"December 2008","November 2012","Change From Baseline in HAM-D17 Total Score at the Final On-therapy (FOT)Evaluation (Week 8 or ET)",0.7521,"1",24155
"160","NCT00057330","HerpeVac Trial for Young Women","Herpes Simplex Infection","other","Biological: HSV vaccine or SB208141, GSK Biologicals' glycoprotein D (gD)-Alum/3-deacylated form of Monophosphoryl Lipid A  (MPL) candidate genital herpes vaccine|Biological: Havrix™, GlaxoSmithKline (GSK) Biologicals' lice","biolog","GlaxoSmithKline","Female","Adult",8323,"January 2003","March 2012","Number of Subjects With Newly Acquired Genital Herpes Disease， Caused by Either Herpes Simplex Virus (HSV)-1 or HSV-2",0.767,"1",24147
"161","NCT00413062","Efficacy and Safety Study of the Combined Oral Contraceptive NOMAC-E2 Compared to a COC Containing DRSP/EE (292002)(P05722)","Contraception","other","Drug: NOMAC-E2|Drug: DRSP-EE","drug","Merck Sharp & Dohme Corp.","Female","Adult",2281,"June 2006","March 2012","Number of In-treatment Pregnancies (With +2 Day Window) Per 100 Woman Years of Exposure (Pearl Index)",0.772193214,"1",24147
"162","NCT00414609","Safety and Efficacy of Aliskiren in Post Myocardial Infarction Patients (ASPIRE)","Myocardial Infarction","cardiovascular","Drug: Aliskiren|Drug: placebo","drug","Novartis","Both","Adult|Senior",820,"December 2006","December 2012","Core Study: Change From Baseline in Left Ventricular End Systolic Volume (LVESV) as Measured by Echocardiography at End of Study.",0.772193214,"1",24156
"163","NCT00738062","Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH)","Neurogenic Orthostatic Hypotension|Non-Diabetic Autonomic Neuropathy|Multiple System At","cardiovascular","Drug: Droxidopa|Drug: Placebo","drug","Chelsea Therapeutics","Both","Adult|Senior",103,"January 2008","February 2012","Change in Orthostatic Hypotension Questionnaire Composite Score (OHQ)",0.7756,"1",24146
"164","NCT00396877","Efficacy And Safety Of Clopidogrel In Neonates /Infants With Systemic To Pulmonary Artery Shunt Palliation","Heart Defects, Congenital","cardiovascular","Drug: Clopidogrel (SR25990)|Drug: placebo","drug","Sanofi|Bristol-Myers Squibb","Both","Child",906,"November 2006","October 2012","Number of Participants Reaching Primary Endpoint Criteria (First Occurrence of Death / Shunt Thrombosis / Cardiac Procedure < 120 Days Considered of Thrombotic Nature)",0.782365165,"1",24154
"165","NCT01224171","Study of Vedolizumab in Patients With Moderate to Severe Crohn's Disease","Crohn's Disease","other","Drug: vedolizumab|Other: Placebo","drug","Millennium Pharmaceuticals, Inc.","Both","Adult|Senior",416,"November 2010","July 2012","Percentage of Participants in Clinical Remission in the Tumor Necrosis Factor Alpha (TNFα) Antagonist Failure Subpopulation",0.783727539,"1",24151
"166","NCT00712166","Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis, Mild Lung Disease, and P. Aeruginosa","Cystic Fibrosis|Lung Infection|Pseudomonas Aeruginosa","respiratory","Drug: AZLI 75 mg three times daily (TID)|Drug: Placebo three times daily (TID)","drug","Gilead Sciences","Both","Child|Adult|Se",160,"May 2008","October 2012","Change From Baseline in Cystic Fibrosis Questionnaire – Revised (CFQ-R) Respiratory Symptoms Scale (RSS) Score at Day 28",0.7841,"1",24154
"167","NCT01659853","Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea","Erythema|Rosacea","other","Drug: CD07805/47 gel 0.5%/CD07805/47 Vehicle|Drug: azelaic acid gel 15%","drug","Galderma Laboratories, L.P.","Both","Adult|Senior",70,"September 2012","June 2012","Composite Success",0.797,"1",24150
"168","NCT00513305","Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia","Acute Myeloid Leukemia","cancer","Drug: Arsenic trioxide|Drug: Low-dose cytarabine alone","drug","Cephalon|Teva Pharmaceutical Industries","Both","Adult|Senior",67,"October 2007","November 2012","Percentage of Participants in Complete Remission (CR)",0.797776846,"1",24155
"169","NCT00599872","Efficacy Study of Sublingual Immunotherapy to Treat Ragweed Allergies","Allergic Rhinitis","other","Biological: Standardized Ragweed Allergenic Extract|Biological: Placebo","biolog","Greer Laboratories","Both","Adult",430,"March 2008","October 2012","Scores on a Scale (Average of Daily Rhinoconjunctivitis Symptom Score (RSS) Recorded During the Ragweed Season",0.806,"1",24154
"170","NCT00440050","DHA (Docosahexaenoic Acid), an Omega 3 Fatty Acid, in Slowing the Progression of Alzheimer's Disease","Alzheimer's Disease","mental health","Drug: DHA (Docosahexaenoic Acid)|Drug: Placebo","drug","Alzheimer's Disease Cooperative Study (ADCS)|National Institute on Aging (NIA)|DSM Nutritional Products, Inc.","Both","Adult|Senior",402,"February 2007","October 2012","Rate of Change on the ADAS-Cog 11.",0.82389363,"1",24154
"171","NCT00901901","Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma","Carcinoma, Hepatocellular","cancer","Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Sorafenib (Nexavar, BAY43-9006) + Erlotinib, Tarceva","drug","Bayer","Both","Adult|Senior",732,"May 2009","November 2012","Overall Survival",0.827418321,"1",24155
"172","NCT00536744","Effectiveness of dermaPACE™ Device and Standard Treatment Compared to Standard Treatment Alone for Diabetic Foot Ulcers","Diabetic Foot Ulcers","cardiovascular","Device: acoustical pulse energy (extracorporeal shockwave)|Other: Sham","device","SANUWAVE, Inc.","Both","Adult|Senior",206,"October 2007","September 2012","The Primary Variable for Effectiveness of the dermaPACE Device Will be Assessed by Comparing the Incidence of Complete Wound Closure of the dermaPACE and Control Groups 12 Weeks Post Initial Application.",0.829,"1",24153
"173","NCT00672958","Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Adults With Major Depressive Disorder","Major Depressive Disorder","mental health","Drug: Vortioxetine|Drug: Placebo","drug","Takeda|H. Lundbeck A/S","Both","Adult|Senior",600,"April 2008","January 2012","Change From Baseline in the 24-item Hamilton Depression Scale Total Score at Week 6",0.8292,"1",24145
"174","NCT00813111","Phase 3 Study of Local Administration of SKY0402 for Postoperative Analgesia in Subject Undergoing Breast Augmentation","Pain","other","Drug: SKY0402|Drug: Bupivacaine HCl","drug","Pacira Pharmaceuticals, Inc","Female","Adult|Senior",136,"November 2008","September 2011","Area Under the Curve (AUC) of the Numeric Rating Scale (NRS) With Activity (NRS-A) Pain Intensity Scores",0.8299,"1",24141
"175","NCT00894387","Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure","Acute Decompensated Heart Failure|Congestive Heart Failure","cardiovascular","Drug: Aliskiren|Drug: Placebo","drug","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior",1639,"May 2009","October 2009","",0.8308,"1",24118
"176","NCT01153347","A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder","Major Depressive Disorder|Depression","mental health","Drug: TC-5214|Drug: Placebo","drug","AstraZeneca|Targacept Inc.","Both","Adult",2409,"June 2010","June 2009","Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Randomization to End of Treatment.",0.841,"1",24114
"177","NCT00191152","A Phase III Trial For Patients With Metastatic Breast Cancer","Breast Cancer|Breast Neoplasms|Cancer of the Breast","cancer","Drug: gemcitabine|Drug: docetaxel|Drug: capecitabine","drug","Eli Lilly and Company","Both","Adult|Senior",475,"February 2002","February 2011","",0.868720547,"1",24134
"178","NCT00519285","Aflibercept in Combination With Docetaxel in Metastatic Androgen Independent Prostate Cancer","Prostatic Neoplasms|Neoplasm Metastasis","cancer","Drug: Aflibercept|Drug: Placebo (for aflibercept)|Drug: Docetaxel|Drug: Prednisone or Prednisolone","drug","Sanofi|Regeneron Pharmaceuticals","Male","Adult|Senior",1224,"August 2007","May 2008","Overall Survival Time",0.877527848,"1",24101
"179","NCT01316913","24-week Trial Comparing GSK573719/GW642444 With GSK573719 and With Tiotropium in Chronic Obstructive Pulmonary Disease","Pulmonary Disease, Chronic Obstructive","respiratory","Drug: GSK573719/GW642444 125/25|Drug: GSK573719/GW642444 62.5/25|Drug: GSK573719|Drug: tiotropium bromide","drug","GlaxoSmithKline","Both","Adult|Senior",872,"March 2011","October 2010","Change From Baseline in Clinic Visit Trough Forced Expiratory Volume in One Second (FEV1) at Day 169",0.883437384,"1",24130
"180","NCT00549718","Lurasidone HCl: A Phase 3 Study of Patients With Acute Schizophrenia","Schizophrenia","mental health","Drug: Lurasidone HCl","drug","Sunovion","Both","Adult|Senior",489,"October 2007","November 2008","",0.884,"1",24107
"181","NCT00501046","A Study of AST-120 for Evaluating Prevention of Progression In Chronic Kidney Disease Including Assessment of Quality of Life (EPPIC-2)","Chronic Kidney Disease","other","Drug: Placebo|Drug: AST-120","drug","Mitsubishi Tanabe Pharma Corporation|Kureha Corporation","Both","Adult|Senior",1015,"July 2007","February 2012","Composite of Dialysis Initiation， Kidney Transplantation， and Serum Creatinine Doubling",0.896473364,"1",24146
"182","NCT00442546","Efficacy And Safety Of Pregabalin For Pain Following Total Knee Replacement","Osteoarthritis|Postoperative Pain","other","Drug: pregabalin|Drug: pregabalin|Drug: Placebo","drug","Pfizer","Both","Adult|Senior",307,"May 2007","March 2011","Subject Reported Worst Pain Score in Daily Diaries Using the Worst Pain Item of the Modified Brief Pain Inventory - Short Form (m-BPI-sf)",0.911560735,"1",24135
"183","NCT00820222","Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer","Metastases, Brain","cancer","Drug: capecitabine|Drug: lapatinib|Drug: trastuzumab","drug","GlaxoSmithKline","Female","Adult|Senior",546,"April 2009","June 2010","Number of Participants With Central Nervous System (CNS) Metastases (as Assessed by Independent Review) as the Site of First Relapse",0.9154,"1",24126
"184","NCT00671853","Quetiapine Extended Release (XR) in Bipolar Patients With Comorbid Generalized Anxiety Disorder (GAD)","Bipolar Disorder|Anxiety|Anxiety Disorders|Substance Use Disorders","mental health","Drug: Quetiapine XR|Drug: Placebo for quetiapine XR","drug","University Hospital Case Medical Center|National Alliance for Research on Schizophrenia and Depression|AstraZeneca","Both","Adult",120,"April 2008","January 2009","Change in the 17 Item Hamilton Rating Scale for Depression (HAM-D-17) Score",0.922,"1",24109
"185","NCT00095238","Irbesartan in Heart Failure With Preserved Systolic Function (I-Preserve)","Congestive Heart Failure","cardiovascular","Drug: Irbesartan|Drug: Placebo","drug","Bristol-Myers Squibb|Sanofi","Both","Adult|Senior",4128,"June 2002","December 2009","Percentage of Participants With First Occurrence of the Composite Outcome of Death (All Cause) or Protocol-Specified Cardiovascular (CV) Hospitalization at Given Timepoints",0.934589291,"1",24120
"186","NCT01157078","A Study to Assess the Efficacy and Safety of TC-5214 as an Adjunct Therapy in Patients With Major Depressive Disorder (MDD)","Major Depressive Disorder|Depression","mental health","Drug: TC-5214|Drug: Placebo","drug","AstraZeneca|Targacept Inc.","Both","Adult",319,"June 2010","July 2012","Change in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score From Randomization to End of Treatment.",0.936530727,"1",24151
"187","NCT00206440","Nexium Study To Suppress Nausea During Chemotherapy","Nausea","other","Drug: esomeprazole|Drug: Esomeprazole (aka Nexium)|Other: Placebo","drug","Baylor Breast Care Center|AstraZeneca","Female","Adult|Senior",43,"August 2005","June 2009","Number of Times a Subject Felt Sick to Her Stomach and Number of Times a Subject Required Rescue Medication",0.956,"1",24114
"188","NCT00662818","Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034)","Migraine Disorders|Heart Disease|Cerebrovascular Accident|TIA (Transient Ischemic Attac","mental health","Drug: Telcagepant|Drug: Acetaminophen/Paracetamol|Drug: Placebo to Telcagepant|Drug: Placebo to Acetaminophen/Paracetamol","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",165,"March 2008","May 2011","Percentage of Participants With Pain Freedom at 2 Hours Post-dose (Period 1， Migraine Attack 1)",0.9761,"1",24137
"189","NCT01328444","An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642","Pulmonary Disease, Chronic Obstructive","respiratory","Drug: GSK 573719 +GW642444 125/25|Drug: GSK573719 + GW642444 62.5/25|Drug: GSK 573719 125|Drug: GSK 573719 62.5|Drug: GW642444 25|Drug: Plb","drug","GlaxoSmithKline","Both","Adult|Senior",349,"March 2011","September 2010","Change From Baseline in Exercise Endurance Time Post-dose at Week 12 of Each Treatment Period",0.992405002,"1",24129
"190","NCT00763256","The Effect of Periodontal Treatment and the Use of Dentifrice on Glycaemic Control in Diabetics","Periodontal Disease","endocrine and metabolic","Drug: Triclosan, Fluoride|Drug: Fluoride","drug","Colgate Palmolive","Both","Adult|Senior",33,"May 2006","December 2008","HbA1c Levels in Blood",0.9979,"1",24108
"191","NCT00376675","Methylphenidate in Treating Patients With Fatigue Caused by Cancer","Fatigue|Unspecified Adult Solid Tumor, Protocol Specific","other","Drug: methylphenidate hydrochloride|Other: placebo","drug","Alliance for Clinical Trials in Oncology|National Cancer Institute (NCI)|McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.","Both","Adult|Senior",148,"February 2008","February 2009","Prorated AUC of Total Fatigue as Measured by the Brief Fatigue Inventory (BFI) at Baseline and at Weeks 1-4",1.000641829,"1",24110
"192","NCT00529555","Periocline as an Adjunct to Scaling and Root Planing for Adult Periodontitis","Adult Periodontitis","other","Drug: minocycline HCl 2.1%|Procedure: Scaling and root planing","drug","Sunstar Americas","Both","Adult|Senior",602,"January 2006","August 2009","Change in Pocket Depth.",1.004,"1",24116
"193","NCT00475852","A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure","Heart Decompensation","cardiovascular","Drug: Nesiritide|Drug: Placebo","drug","Scios, Inc.","Both","Adult|Senior",7141,"May 2007","September 2009","Composite of Rehospitalization Due to Heart Failure and All-Cause Mortality",1.00894711,"1",24117
"194","NCT01495858","Evaluate Analgesic / Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain","Pain, Postoperative","other","Drug: Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)|Drug: Naproxen Sodium 440 mg (BAYH6689)|Drug: DPH 50 mg","drug","Bayer","Both","Child|Adult|Se",267,"December 2011","August 2009","Wake Time After Sleep Onset (WASO) Measured by Actigraphy",1.026406533,"1",24116
"195","NCT00335452","Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS","Acute Coronary Disease|Angina Unstable","cardiovascular","Drug: Clopidogrel|Drug: acetylsalicyclic acid (ASA)","drug","Sanofi|Bristol-Myers Squibb","Both","Adult|Senior",25086,"June 2006","October 2009","First Occurrence of CV Death / MI / Stroke - Clopidogrel Treatment Regimen Comparison",1.028531247,"1",24118
"196","NCT01382225","Sodium Hyaluronate Ophthalmic Solution, 0.18% for Treatment of Dry Eye Syndrome","Dry Eye Syndrome","other","Drug: Sodium Hyaluronate Ophthalmic Solution, 0.18%|Other: Vehicle","drug","Alcon Research","Both","Adult|Senior",1936,"July 2011","January 2010","Change From Baseline in Lissamine Green Staining (LGS) Total Score at Day 7",1.055,"1",24121
"197","NCT00679380","(CB-01-02/02) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis","Ulcerative Colitis","other","Procedure: Blood sampling, endoscopy|Drug: Budesonide MMX® 6 mg|Drug: Budesonide MMX® 9 mg|Drug: Entocort EC® 3 mg|Drug: Placebo","drug","Salix Pharmaceuticals|Cosmo Technologies Ltd","Both","Adult|Senior",514,"June 2008","August 2008","Clinical and Endoscopic Remission.",1.0633,"1",24104
"198","NCT01209702","A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDs","Spondylitis, Ankylosing","other","Biological: tocilizumab|Drug: Placebo","biolog","Hoffmann-La Roche","Both","Adult|Senior",306,"September 2010","June 2009","Part 1: Percentage of Participants Achieving a 20% Improvement in Assessment in Ankylosing Spondylitis (ASAS20) at Week 12",1.075837361,"1",24114
"199","NCT00468559","Phase 3/Safety & Efficacy of Esomeprazole in Infants","Gastroesophageal Reflux Disease (GERD)","other","Drug: Open Label Run In Esomeprazole|Drug: Double Blind Esomeprazole|Drug: Double Blind Placebo","drug","AstraZeneca","Both","Child",98,"April 2007","July 2008","Number of Participants Discontinuing Due to Symptom Worsening in the Randomized Treatment Withdrawal Phase (Treatment Withdrawal Phase Endpoint)",1.080319341,"1",24103
"200","NCT00731120","Study of Efficacy and Safety of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder","Generalized Anxiety Disorder","mental health","Drug: Vortioxetine|Drug: Placebo","drug","Takeda|H. Lundbeck A/S","Both","Adult|Senior",457,"June 2008","November 2010","Change From Baseline in the Hamilton Anxiety Scale (HAM-A) Total Score",1.0826,"1",24131
"201","NCT01408303","[E]PANOVA Combined With a [S]TATIN in [P]ATIENTS With HYPERT[R]IGLYCER[I]DEMIA to Reduce Non-HDL CHOLES[T]EROL","Hypertriglyceridemia|Cardiovascular Disease","cardiovascular","Drug: Olive oil, 4g|Drug: omega-3-carboxylic acids, 2g|Drug: omega-3-carboxylic acids, 4g","drug","AstraZeneca|Omthera Pharmaceuticals, Inc|Medpace, Inc.","Both","Adult|Senior",646,"August 2011","October 2010","Serum Non-HDL Cholesterol",1.096,"1",24130
"202","NCT00522379","Trial to Assess Parkinson's Disease (PD) Symptom Control to Four Doses of Rotigotine in a Transdermal Patch","Parkinson's Disease","mental health","Drug: Rotigotine|Drug: Rotigotine|Other: Placebo|Drug: Rotigotine|Drug: Rotigotine","drug","UCB Pharma","Both","Adult|Senior",514,"July 2007","September 2011","The Change in the Absolute Time Spent ""Off"" From Baseline to the End of the Maintenance Period as Recorded by the Subject in a Daily Diary",1.134,"1",24141
"203","NCT00730691","Efficacy of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder","Generalized Anxiety Disorder","mental health","Drug: Placebo|Drug: Vortioxetine|Drug: Duloxetine","drug","Takeda|H. Lundbeck A/S","Both","Adult",781,"June 2008","December 2012","Change From Baseline in the Hamilton Anxiety (HAM-A) Scale Total Score at Week 8",1.1383,"1",24156
"204","NCT00762619","Clinical Study to Examine Brushing on Dental Implants","Gingival Diseases","other","Drug: Fluoride|Drug: Triclosan, fluoride","drug","Colgate Palmolive","Both","Adult|Senior",105,"April 2007","January 2011","Mombelli Plaque Index (mPI) for Natural Teeth",1.1468,"1",24133
"205","NCT00811473","Pediatric Bipolar Depression","Bipolar Depression","mental health","Drug: Quetiapine XR|Drug: Placebo","drug","AstraZeneca","Both","Child",193,"January 2009","March 2011","Change in the Children Depression Rating Scale， Revised (CDRS-R) Total Score From Baseline to Final Assessment (Day 57)",1.1508,"1",24135
"206","NCT00969150","Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder","Major Depressive Disorder","mental health","Drug: Levomilnacipran ER|Drug: Placebo","drug","Forest Laboratories","Both","Adult|Senior",362,"September 2009","January 2008","Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score",1.1523,"1",24097
"207","NCT00554229","A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Hormone Resistant Prostate Cancer With Bone Metastases","Prostate Cancer","cancer","Drug: ZD4054|Drug: Placebo","drug","AstraZeneca","Male","Adult|Senior",896,"November 2007","March 2010","Overall Survival",1.174986792,"1",24123
"208","NCT00089895","EARLY ACS: Early Glycoprotein IIb/IIIa Inhibition in Patients With Non-ST-segment Elevation Acute Coronary Syndrome (Study P03684AM2)(COMPLETED)","Myocardial Ischemia|Acute Coronary Syndrome","cardiovascular","Drug: Eptifibatide (Integrilin)|Drug: Placebo","drug","Merck Sharp & Dohme Corp.|Duke Clinical Research Institute","Both","Adult|Senior",9406,"November 2004","April 2012","Incidence of the Composite of Death， Myocardial Infarction (MI)， Recurrent Ischemia Requiring Urgent Revascularization (RI-UR)， and Thrombotic Bail-out.",1.200358858,"1",24148
"209","NCT00788593","A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (C","Chronic Pancreatitis|Exocrine Pancreatic Insufficiency","other","Drug: Placebo|Drug: EUR-1008 (APT-1008)  High Dose|Drug: EUR-1008 (APT-1008)  Low Dose","drug","Aptalis Pharma","Both","Adult|Senior",82,"January 2008","July 2009","Percent Coefficient of Fat Absorption (CFA) of Participants Treated With High Dose EUR-1008 and Low Dose EUR-1008",1.2055,"1",24115
"210","NCT00412061","Everolimus and Octreotide in Patients With Advanced Carcinoid Tumor","Carcinoid Tumor|Malignant Carcinoid Syndrome","cancer","Drug: Octreotide|Drug: Placebo|Drug: Everolimus","drug","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior",429,"December 2006","September 2009","Progression Free Survival (PFS) as Per Adjudicated Central Radiology Review",1.205526796,"1",24117
"211","NCT01035346","Study Evaluating The Efficacy Of A Novel Ibuprofen Formulation On Fever In Patients With An Uncomplicated Acute Infection","Infection","other","Drug: Ibuprofen|Drug: Placebo","drug","Pfizer","Both","Child|Adult",16,"January 2010","March 2008","Time-weighted Sum of The Temperature Differences From Baseline Through Hour 6 (STEMPD 0-6)",1.205526796,"1",24099
"212","NCT00244621","Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age","Hypertension","cardiovascular","Drug: candesartan cilexetil (Atacand)|Drug: candesartan cilexetil (Atacand)|Drug: candesartan cilexetil (Atacand)","drug","AstraZeneca","Both","Child",95,"November 2004","June 2009","Mean Change From Baseline to Week 4 in Systolic Blood Pressure (SBP)",1.216,"1",24114
"213","NCT00205777","Study Evaluating Bazedoxifene Acetate In Osteoporosis In Postmenopausal Women","Osteoporosis","endocrine and metabolic","Drug: Bazedoxifene Acetate|Other: Placebo","drug","Pfizer","Female","Adult|Senior",7609,"December 2001","October 2008","Percentage of Participants With New Vertebral Fractures Through Month 36",1.22652812,"1",24106
"214","NCT00616772","Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patie","Coronary Artery Disease|Coronary Heart Disease|Dyslipidemia","cardiovascular","Drug: ABT-335|Drug: Placebo|Other: Atorvastatin","drug","AbbVie (prior sponsor, Abbott)|AbbVie","Both","Adult|Senior",682,"February 2008","January 2008","Rate of Change in Mean Posterior-wall Carotid Intima-media Thickness (cIMT)",1.22652812,"1",24097
"215","NCT00770315","Efficacy and Long-Term Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adults With a History of Ragweed-Induced Rhinoconjunctivitis With","Rhinitis, Allergic|Conjunctivitis","other","Biological: Ambrosia artemisiifolia allergen extract (Amb a 1-U)|Biological: Placebo","biolog","Merck Sharp & Dohme Corp.","Both","Adult",784,"September 2009","November 2011","Combined (Sum of) Rhinoconjunctivitis Daily Symptom Score (DSS) and Daily Medication Score (DMS) Averaged Over the Peak Ragweed Season (RS)",1.2287,"1",24143
"216","NCT00423176","The Study of Nasonex® Compared With Placebo for the Relief of Symptoms Associated With Acute Bacterial Sinusitis When Used With Antibiotics (Study P04824AM3)","Sinusitis","other","Drug: MFNS and antibiotic|Drug: Matching Placebo nasal spray plus antibiotic","drug","Merck Sharp & Dohme Corp.","Both","Child|Adult|Se",237,"December 2006","January 2009","Baseline Change in AM/PM PRIOR Major Symptoms Score (Mss) Minus Sinus Headache Averaged Over Days 1 to 29.",1.232,"1",24109
"217","NCT00530348","Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis, Study One","Multiple Sclerosis, Relapsing-Remitting","mental health","Biological: Alemtuzumab|Biological: Interferon beta-1a","biolog","Genzyme, a Sanofi Company|Bayer|Sanofi","Both","Adult",581,"August 2007","December 2012","Percentage of Participants With Sustained Accumulation of Disability (SAD)",1.233739473,"1",24156
"218","NCT01005966","In Situ Caries Model of Fluoride Toothpastes","Caries","other","Drug: Sodium Fluoride Toothpaste|Drug: Amine Fluoride Toothpaste|Drug: Sodium monofluorophosphate/Sodium Fluoride Toothpaste|Drug: Placebo|Drug: 675 ppmf toothpaste","drug","GlaxoSmithKline","Both","Adult|Senior",65,"November 2008","February 2008","Percent Surface Microhardness (SMH) Recovery of Enamel Specimens Exposed to NaF Toothpaste (1426ppmF) and AmF Toothpaste (1400ppmF)",1.2489,"1",24098
"219","NCT00699998","A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects","Acute Coronary Syndrome","cardiovascular","Drug: Clopidogrel|Drug: Prasugrel|Drug: Commercially-available Aspirin","drug","Eli Lilly and Company|Daiichi Sankyo Co., Ltd.|Duke Clinical Research Institute","Both","Adult|Senior",9326,"June 2008","April 2011","Percentage of Participants With a Composite Endpoint of Cardiovascular (CV) Death， Myocardial Infarction (MI)， or Stroke",1.2536,"1",24136
"220","NCT00810199","A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid","Rheumatoid Arthritis","other","Drug: tocilizumab [RoActemra/Actemra]|Drug: methotrexate|Drug: placebo","drug","Hoffmann-La Roche","Both","Adult|Senior",556,"March 2009","August 2012","Percentage of Participants With Disease Activity Score 28 Joints (DAS28) Remission at Week 24",1.266,"1",24152
"221","NCT00124748","Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity)","Leukemia, Myeloid, Chronic Phase","cancer","Drug: Imatinib mesylate","drug","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior",476,"June 2005","May 2009","Percentage of Participants With Major Molecular Response (MMR) Rates at 12 Months",1.271642976,"1",24113
"222","NCT00400179","A Safety and Efficacy Study in Patients With Gastric Cancer","Gastric Cancer","cancer","Drug: S-1/Cisplatin|Drug: 5-FU/cisplatin","drug","Taiho Oncology, Inc.|Quintiles","Both","Adult|Senior",1053,"May 2005","June 2008","",1.286410029,"1",24102
"223","NCT00546637","""Fesoterodine \""add-on\"" Male Overactive Bladder Study""","Overactive Bladder Syndrome","other","Drug: Fesoterodine|Drug: Placebo","drug","Pfizer","Male","Adult|Senior",947,"November 2007","September 2009","Numerical Change From Baseline in Micturition-Related Urgency Episodes Per 24 Hours at Week 12",1.293321175,"1",24117
"224","NCT00457392","A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone","Carcinoma, Non-Small Cell Lung","cancer","Drug: erlotinib|Drug: sunitinib|Drug: erlotinib|Drug: placebo","drug","Pfizer","Both","Adult|Senior",960,"July 2007","December 2011","Overall Survival (OS)",1.300878636,"1",24144
"225","NCT00849693","A Study in the Treatment of Children and Adolescents With Major Depressive Disorder","Major Depressive Disorder","mental health","Drug: Placebo|Drug: fluoxetine|Drug: duloxetine|Drug: duloxetine","drug","Eli Lilly and Company","Both","Child",463,"March 2009","October 2011","Change From Baseline in Children's Depression Rating Scale-Revised (CDRS-R) Total Score at Week 10 Endpoint",1.3018,"1",24142
"226","NCT00492024","BAY12-8039: 5 Days for Sinusitis vs Placebo","Sinusitis","other","Drug: Moxifloxacin (Avelox, BAY12-8039)|Drug: Placebo","drug","Bayer","Both","Adult|Senior",374,"January 2005","May 2012","Percentage of Subjects With Clinical Cure (Modified Intent-to-Treat (MITT))",1.313543123,"1",24149
"227","NCT00299104","A Study to Evaluate Rituximab in Combination With Methotrexate in Methotrexate-Naive Patients With Active Rheumatoid Arthritis","Rheumatoid Arthritis","other","Drug: folate|Drug: methotrexate|Drug: methylprednisolone|Drug: placebo|Drug: rituximab","drug","Genentech, Inc.|Hoffmann-La Roche","Both","Adult|Senior",755,"January 2006","November 2009","Change From Baseline in Modified Total Sharp Score (mTSS) From Screening at Week 52",1.333401745,"1",24119
"228","NCT01009463","A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive","respiratory","Drug: FF/GW642444 Inhalation Powder|Drug: GW642444 Inhalation Powder","drug","GlaxoSmithKline","Both","Adult|Senior",1626,"September 2009","May 2010","Annual Rate of Moderate and Severe COPD Exacerbations Expressed as Least Square Mean",1.3377,"1",24125
"229","NCT00282464","A Six-Week Flexible Dose Study Evaluating the Efficacy and Safety of Geodon in Patients With Bipolar I Depression.","Bipolar Disorder","mental health","Drug: Placebo|Drug: Geodon (Ziprasidone)","drug","Pfizer","Both","Adult|Senior",392,"February 2006","August 2012","",1.340755034,"1",24152
"230","NCT00838916","A Study to Determine the Safety and Efficacy of Albiglutide in Patients With Type 2 Diabetes","Diabetes Mellitus, Type 2","endocrine and metabolic","Biological: albiglutide|Drug: insulin glargine","biolog","GlaxoSmithKline","Both","Adult|Senior",779,"February 2009","November 2012","Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52",1.3475,"1",24155
"231","NCT01284517","Lurasidone HCI - A 6-week Phase 3 Study of Patients With Bipolar I Depression","Bipolar Depression","mental health","Drug: Lurasidone|Drug: Placebo","drug","Sunovion","Both","Adult|Senior",356,"November 2010","July 2011","Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Endpoint (Week 6)",1.353174155,"1",24139
"232","NCT00863798","Study Evaluating Desvenlafaxine Succinate Sustained Release In Adults With Major Depressive Disorder","Major Depressive Disorder","mental health","Drug: Desvenlafaxine Succinate Sustained-Release 10mg|Drug: Desvenlafaxine Succinate Sustained-Release 50 mg|Drug: placebo","drug","Wyeth is now a wholly owned subsidiary of Pfizer|Pfizer","Both","Adult|Senior",682,"April 2009","October 2011","Change From Baseline in HAM-D17 Total Score at Final On-therapy (FOT) Evaluation (Week 8 or ET)",1.3563,"1",24142
"233","NCT00552058","Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease","Crohn Disease","other","Biological: certolizumab pegol (CDP870, CZP)|Other: Placebo","biolog","UCB Pharma","Both","Adult|Senior",439,"March 2008","August 2009","Percentage of Subjects in Clinical Remission at Week 6",1.359462745,"1",24116
"234","NCT00385138","Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition.","Atherosclerosis|Acute Coronary Syndrome (ACS)","cardiovascular","Drug: Cangrelor|Drug: clopidogrel|Drug: Placebo bolus & placebo infusion|Drug: Placebo capsules - end of PCI|Drug: Placebo capsules - end of infusion","drug","The Medicines Company","Both","Adult|Senior",5364,"September 2006","August 2008","Incidence of All-cause Mortality， Myocardial Infarction (MI)， and Ischemia-driven Revascularization (IDR)",1.372203809,"1",24104
"235","NCT00992589","Safety and Efficacy of Rabeprazole in Infants With Gastroesophageal Erosive Reflux Disease (GERD)","Gastroesophageal Reflux","other","Drug: Rabeprazole sodium 5 mg|Drug: Rabeprazole sodium 10 mg|Drug: Placebo","drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Eisai Inc.","Both","Child",344,"November 2009","May 2012","Change From Baseline in Average Daily Frequency of Regurgitation (Double-blind Phase/ Baseline Observation Carried Forward)",1.3787,"1",24149
"236","NCT00676650","Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel Chemotherapy","Prostatic Neoplasms","cancer","Drug: Prednisone|Drug: sunitinib|Drug: Placebo|Drug: Prednisone","drug","Pfizer","Male","Adult|Senior",873,"July 2008","November 2012","Overall Survival (OS)",1.3793,"1",24155
"237","NCT00088166","XERECEPT® (hCRF) for Patients Requiring Dexamethasone to Treat Edema Associated With Brain Tumors","Brain Edema|Brain Tumor","cancer","Drug: hCRF|Drug: placebo hCRF","drug","Celtic Pharma Development Services|Neurobiological Technologies","Both","Adult|Senior",200,"May 2004","April 2008","The Proportion of Patients in Each Treatment Group Who Are Responders at Week 2 and Continue to be Responders at Week 5",1.415,"1",24100
"238","NCT00257192","Safety And Efficacy Of Ziprasidone In Adolescents With Schizophrenia","Schizophrenia","mental health","Drug: placebo|Drug: Ziprasidone oral capsules","drug","Pfizer","Both","Child",284,"April 2006","August 2008","Change From Baseline in Brief Psychiatric Rating Scale - Anchored (BPRS-A) Total Score at Week 6",1.429014729,"1",24104
"239","NCT01464190","A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients","Chronic Kidney Disease Requiring Chronic Dialysis","endocrine and metabolic","Drug: PA21 (2.5 g tablet containing 500 mg iron)|Drug: Sevelamer carbonate","drug","Vifor Inc.|Fresenius Medical Care North America","Both","Adult|Senior",659,"September 2011","January 2011","Change From Baseline and Levels at Each Time Point for Serum Phosphorus",1.445,"1",24133
"240","NCT00048724","Peg-Intron for Prevention of Disease Progress in Chronic Hepatitis C Patients With Cirrhosis (Study P02569)","Chronic Hepatitis C|Cirrhosis","other","Biological: peginterferon alfa-2b (SCH 54031)","biolog","Merck Sharp & Dohme Corp.","Both","Adult",631,"June 2002","April 2010","Time to Observation of the First Clinical Event Experienced by a Subject",1.461420785,"1",24124
"241","NCT00703781","Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery","Cataract","other","Drug: bromfenac ophthalmic solution|Drug: placebo","drug","Bausch & Lomb Incorporated","Both","Adult|Senior",126,"June 2008","June 2009","Number of Participants With Summed Ocular Inflammation Score (SOIS) of Zero",1.4676,"1",24114
"242","NCT00097695","Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema","Angioedema","cardiovascular","Drug: Icatibant|Drug: Placebo","drug","Shire","Both","Adult|Senior",84,"August 2004","May 2009","Time to Onset of Symptom Relief (TOSR)",1.468383798,"1",24113
"243","NCT00658567","A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis","Parkinson's Disease Psychosis","mental health","Drug: Pimavanserin tartrate (ACP-103)|Drug: Pimavanserin tartrate (ACP-103)|Drug: Pimavanserin tartrate (ACP-103)","drug","ACADIA Pharmaceuticals Inc.","Both","Adult|Senior",123,"March 2008","April 2012","Antipsychotic Efficacy",1.47,"1",24148
"244","NCT00679432","(CB-01-02/01) Randomized Placebo Controlled Trial of Budesonide-multi-matrix System (MMX™) 6 mg and 9 mg in Patients With Ulcerative Colitis","Ulcerative Colitis","other","Procedure: Blood sampling, endoscopy|Drug: budesonide-MMX® 6 mg|Drug: budesonide-MMX® 9 mg|Drug: Placebo|Drug: Asacol® 400 mg","drug","Salix Pharmaceuticals","Both","Adult|Senior",510,"June 2008","October 2010","Clinical and Endoscopic Remission.",1.4784,"1",24130
"245","NCT00468845","Study Of The Efficacy And Safety Of Pregabalin Compared To Placebo For Treatment Of Post-Surgical Pain From Hysterectomy","Pain, Postoperative","other","Drug: pregabalin (Lyrica)|Drug: pregabalin (Lyrica)|Drug: matched placebo","drug","Pfizer","Female","Adult|Senior",501,"June 2007","August 2012","Worst Pain Using the Modified Brief Pain Inventory - Short Form (m-BPI-sf)",1.484033626,"1",24152
"246","NCT00410202","Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lami","Hepatitis B, Chronic","other","Drug: Entecavir|Drug: Tenofovir|Drug: Adefovir|Drug: Lamivudine","drug","Bristol-Myers Squibb","Both","Child|Adult|Se",629,"March 2008","October 2008","Percentage of Participants With Hepatitis B Virus (HBV) Deoxyribonucleic Acid (DNA) < 50 IU/mL (Approximately 300 Copies/mL) by Polymerase Chain Reaction (PCR) at Week 48",1.500055603,"1",24106
"247","NCT01072630","Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder","Depression","mental health","Drug: Armodafinil|Drug: Placebo","drug","Cephalon|Teva Pharmaceutical Industries","Both","Adult",492,"March 2010","September 2008","Change From Baseline to Week 8 in the Total Score From the 30-Item Inventory of Depressive Symptomatology-Clinician-Rated (IDS-C30)",1.513313678,"1",24105
"248","NCT00918138","Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compare","Type 2 Diabetes","endocrine and metabolic","Drug: Saxagliptin|Drug: Metformin XR|Drug: Placebo matching Metformin XR|Drug: Metformin XR|Drug: Placebo matching Saxagliptin","drug","AstraZeneca","Both","Adult|Senior",219,"August 2009","September 2008","Change From Baseline in 24-Hour Mean Weighted Glucose (MWG) at Week 4",1.5228,"1",24105
"249","NCT01057693","Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy","Diabetic Neuropathy, Painful","mental health","Drug: pregabalin (Lyrica)|Drug: Placebo","drug","Pfizer","Both","Adult|Senior",665,"March 2010","August 2009","Change From Single-Blind Baseline in Mean Pain Score at Week 19 During Double-Blind Phase",1.546018914,"1",24116
"250","NCT00518089","A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis","Bacterial Conjunctivitis","other","Drug: Gatifloxacin 0.5% eye drops|Drug: placebo eye drops","drug","Allergan","Both","Child|Adult|Se",859,"February 2008","January 2010","",1.561,"1",24121
"251","NCT00036270","Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane","Breast Neoplasms","cancer","Drug: exemestane (Aromasin)|Drug: tamoxifen + exemestane","drug","Pfizer","Female","Adult|Senior",9779,"August 2001","January 2009","Disease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 2.75 Years",1.563223647,"1",24109
"252","NCT00082433","Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer","Cancer|Breast Cancer","cancer","Drug: Ixabepilone + Capecitabine|Drug: Capecitabine","drug","Bristol-Myers Squibb","Female","Adult|Senior",1221,"November 2003","June 2008","",1.570925305,"1",24102
"253","NCT00909181","Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence","Urge Urinary Incontinence|Urinary Frequency","other","Drug: Oxybutynin|Drug: Placebo","drug","Antares Pharma Inc.","Both","Adult|Senior",626,"March 2009","June 2008","Change From Baseline in Mean Weekly Frequency of Urinary Incontinence Episodes at Week 12",1.5888,"1",24102
"254","NCT00434148","Safety and Efficacy of Different Dose Levels of Pasireotide in Patients With de Novo, Persistent or Recurrent Cushing's Disease","Cushing's Disease","endocrine and metabolic","Drug: Pasireotide","drug","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior",165,"December 2006","March 2009","Proportion of mUFC (Urinary Free Cortisol) Responders by Randomized Dose Group",1.591,"1",24111
"255","NCT00312494","3-week Study to Evaluate Efficacy and Safety of Ziprasidone With Either Lithium or Divalproex in Acutely Manic Subjects","Bipolar Disorder","mental health","Drug: Placebo|Drug: Ziprasidone|Drug: Ziprasidone","drug","Pfizer","Both","Adult",680,"April 2006","January 2011","Change From Baseline to Week 3 in Young Mania Rating Scale (YMRS)",1.608617524,"1",24133
"256","NCT00418886","Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients","Non Small Cell Lung Cancer|Lung Cancer","cancer","Drug: Vandetanib|Drug: Pemetrexed","drug","AstraZeneca","Both","Adult|Senior",698,"January 2007","March 2009","Progression-Free Survival (PFS) in the Overall Population",1.609532291,"1",24111
"257","NCT00756977","BLI850 vs an Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy","Colon Cancer","cancer","Drug: BLI850|Drug: polyethylene glycol 3350 based bowel preparation","drug","Braintree Laboratories","Both","Adult|Senior",394,"August 2008","March 2009","Efficacy - Preparation Quality Using a 4 Point Scale",1.6147,"1",24111
"258","NCT00945945","A Study of Duloxetine in Patients With Osteoarthritis Knee Pain","Osteoarthritis Knee Pain","other","Drug: Duloxetine (DLX)|Drug: Placebo (PLA)","drug","Eli Lilly and Company","Both","Adult|Senior",424,"July 2009","November 2008","Change From Baseline to 13 Week Endpoint (Baseline Observation Carried Forward [BOCF]) in Brief Pain Inventory (BPI) ""24-Hour Average Pain"" Item (Question 3) of the BPI-Modified Short Form Score",1.6211,"1",24107
"259","NCT00909870","Pivotal Trial of Dermagraft(R) to Treat Venous Leg Ulcers","Venous Leg Ulcer","cardiovascular","Device: Dermagraft(R)|Device: Profore","device","Shire Regenerative Medicine, Inc.","Both","Adult|Senior",537,"June 2009","December 2010","Complete Healing of the Study Ulcer by Week 16.",1.6305,"1",24132
"260","NCT00733005","Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05528)(COMPLETED)","Allergic Rhinitis","other","Drug: Mometasone furoate nasal spray (MFNS)|Drug: Matching placebo nasal spray","drug","Merck Sharp & Dohme Corp.","Both","Child|Adult|Se",324,"July 2008","December 2011","The Change From Baseline in Average AM/PM PRIOR Nasal Congestion Score Over 15 Days.",1.6352,"1",24144
"261","NCT00168298","A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion","Macular Edema|Retinal Vein Occlusion","cardiovascular","Drug: 700 µg Dexamethasone|Drug: 350 µg Dexamethasone|Other: Sham Injection","drug","Allergan","Both","Adult|Senior",668,"November 2004","March 2011","Number of Patients With 15 or More Letter Improvement in Best Corrected Visual Acuity (BCVA) in the Study Eye",1.637,"1",24135
"262","NCT00920816","Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer","Kidney Neoplasms","cancer","Drug: Axitinib (AG-013736)|Drug: Sorafenib","drug","Pfizer","Both","Adult|Senior",492,"August 2009","January 2012","Progression Free Survival (PFS): First-Line Participants",1.6406,"1",24145
"263","NCT00548548","A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer","Adenocarcinoma","cancer","Drug: Bevacizumab|Drug: Capecitabine|Drug: Cisplatin|Drug: Placebo|Drug: 5-fluorouracil","drug","Genentech, Inc.|Hoffmann-La Roche|Chugai Pharmaceutical","Both","Adult|Senior",774,"September 2007","February 2009","Overall Survival",1.643884802,"1",24110
"264","NCT00435162","Dose Response of Valsartan on Sitting Systolic Blood Pressure in Children 6 Months - 5 Years of Age With High Blood Pressure","Hypertension","cardiovascular","Drug: Valsartan 0.25 mg/kg|Drug: Valsartan 1.0 mg/kg|Drug: Valsartan 4.0 mg/kg","drug","Novartis Pharmaceuticals|Novartis","Both","Child",74,"March 2007","October 2012","Change in Mean Sitting Systolic Blood Pressure (MSSBP) From Baseline to End of Period 1 (Week 6)",1.649721064,"1",24154
"265","NCT00684177","Retapamulin Versus Placebo in Secondarily-Infected Traumatic Lesions (SITL)","Secondarily-infected Abrasions|Secondarily-infected Lacerations|Secondarily-infected Su","other","Drug: Retapamulin Ointment, 1%|Drug: Placebo ointment","drug","GlaxoSmithKline","Both","Child|Adult|Se",508,"May 2008","November 2012","Number of Participants With Clinical Success and Failure at Follow-up (7-9 Days Post Therapy) for the Primary Efficacy Population",1.6546,"1",24155
"266","NCT00887978","Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension","Pulmonary Hypertension","cardiovascular","Drug: UT-15C SR|Drug: Placebo","drug","United Therapeutics","Both","Adult|Senior",310,"June 2009","May 2011","6-minute Walk Distance (6MWD)",1.7007,"1",24137
"267","NCT00410072","Entecavir Plus Tenofovir Combination Therapy Versus Entecavir Monotherapy in Naive Subjects With Chronic Hepatitis B","Hepatitis B, Chronic","other","Drug: Entecavir|Drug: Entecavir + Tenofovir","drug","Bristol-Myers Squibb","Both","Child|Adult|Se",669,"April 2007","June 2012","Percentage of Participants Who Achieved Hepatitis B Virus DNA (HBV DNA) Levels <50 IU/mL by Polymerase Chain Reaction (PCR) at Week 96",1.704970106,"1",24150
"268","NCT00531479","Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis","Aspergillosis","other","Drug: voriconazole|Drug: anidulafungin|Drug: voriconazole","drug","Pfizer","Both","Child|Adult|Se",459,"July 2008","May 2010","All-cause Mortality at Week 6 in Participants With Proven or Probable Invasive Aspergillosis",1.712524791,"1",24125
"269","NCT00531427","Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee","Chronic Pain|Osteoarthritis of the Knee","other","Drug: Buprenorphine|Drug: Placebo","drug","Purdue Pharma LP","Both","Adult|Senior",567,"September 2007","January 2009","""Average Pain Over the Last 24 Hours"" Score of the Study Knee at Week 12 of the Double Blind Phase.",1.720729063,"1",24109
"270","NCT01054885","Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease","Pulmonary Disease, Chronic Obstructive","respiratory","Drug: FF Inhalation Powder|Drug: FF/GW642444 Inhalation Powder|Drug: GW642444 Inhalation Powder|Drug: Placebo","drug","GlaxoSmithKline","Both","Adult|Senior",1226,"October 2009","December 2008","Change From Baseline in Weighted Mean FEV1 Over 0-4 Hours (h) Post-dose at Day 168",1.72238389,"1",24108
"271","NCT00283842","Study Evaluating Desvenlafaxine Succinate Sustained-release (DVS SR) in Adult Outpatients With Pain Associated With Diabetic Peripheral Neuropathy","Diabetic Neuropathies|Pain","mental health","Drug: DVS SR|Drug: Placebo","drug","Wyeth is now a wholly owned subsidiary of Pfizer","Both","Adult|Senior",408,"March 2006","August 2012","Change in Mean Pain Severity Score From Baseline to 13 Weeks",1.727934322,"1",24152
"272","NCT00231153","Study of Omiganan 1% Gel in Preventing Catheter Infections/Colonization in Patients With Central Venous Catheters","Infection","other","Drug: Omiganan 1% gel|Drug: Povidone-Iodine 10%","drug","Cadence Pharmaceuticals","Both","Child|Adult|Se",1859,"August 2005","November 2008","Local Catheter Site Infection (LCSI)",1.739197665,"1",24107
"273","NCT00415194","A Study for Patients With Head and Neck Cancer","Head and Neck Neoplasms","cancer","Drug: pemetrexed|Drug: cisplatin|Drug: placebo","drug","Eli Lilly and Company","Both","Adult|Senior",795,"December 2006","June 2012","Overall Survival (OS)",1.739197665,"1",24150
"274","NCT00550459","Effects of Titrated Oral Tolvaptan 15-60 mg Once Daily (QD) on Cognitive and Neurological Function in Elderly Hyponatremic Patients","Hyponatremia","endocrine and metabolic","Drug: Tolvaptan|Drug: Placebo","drug","Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka Pharmaceutical Co., Ltd.","Both","Adult|Senior",57,"August 2007","October 2011","Change From Baseline in the Neurocognitive Composite Score of Speed Domains (NCS-SD; Sum of All Correct Speed Domain Z-Scores)",1.750686071,"1",24142
"275","NCT00704847","Efficacy and Safety of Oral Salmon Calcitonin in Patients With Knee Osteoarthritis (OA 2 Study)","Osteoarthritis","other","Drug: Oral Salmon Calcitonin|Drug: Oral Salmon Calcitonin (Placebo)","drug","Nordic Bioscience A/S|Novartis","Both","Adult|Senior",1030,"June 2008","December 2010","Joint Space Width (JSW) in the Medial Tibia-femoral Knee Joint in the Signal Knee Measured by X-ray Change From Baseline Over 24 Months",1.7522,"1",24132
"276","NCT00534599","Generalized Anxiety Disorder Adjunct Study","Anxiety|Anxiety Disorders|Anxiety Neuroses|Anxiety States","mental health","Drug: Placebo|Drug: quetiapine fumarate XR","drug","AstraZeneca","Both","Adult",409,"August 2007","August 2009","Least Square Mean Change From Randomization to Week 8 in Hamilton Rating Scale for Anxiety (HAM-A) Total Score",1.756518004,"1",24116
"277","NCT00569192","A Study of 2 Doses of MAP0010 and Placebo in Asthmatic Children","Asthma","respiratory","Drug: 0.135mg MAP0010|Drug: 0.25mg MAP0010|Drug: Placebo","drug","Allergan|MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan","Both","Child",360,"December 2007","December 2012","Change From Baseline in Daytime Composite Symptom Score",1.773,"1",24156
"278","NCT00509873","A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis","Bacterial Conjunctivitis","other","Drug: Gatifloxacin 0.5% eye drops|Drug: placebo eye drops","drug","Allergan","Both","Child|Adult|Se",578,"August 2007","August 2011","Percentage of Patients With Clearing (Clinical Success) of Conjunctival Hyperemia and Conjunctival Discharge at Day 6",1.781,"1",24140
"279","NCT00647270","Study Comparing 80 mg of Adalimumab With Placebo, and Demonstrating the Non-inferiority of Monthly 80 mg Adalimumab Dosing Compared With 40 mg Adalimumab Every Other","Rheumatoid Arthritis","other","Drug: adalimumab|Drug: Placebo|Drug: adalimumab","drug","Abbott","Both","Adult|Senior",420,"December 2007","March 2011","The Number of Responders According to the American College of Rheumatology (ACR) 20 Response Criteria at Week 12 Involving the Comparison of Adalimumab 80 mg Monthly Dose Versus Placebo and Adalimumab 40 mg Every Other Week (Eow)",1.787,"1",24135
"280","NCT00325442","FREEDOM-C: Oral Treprostinil in Combination With an Endothelin Receptor Antagonist (ERA) and/or a Phosphodiesterase-5 (PDE-5) Inhibitor for the Treatment of Pulmonar","Pulmonary Hypertension","cardiovascular","Drug: Oral treprostinil (UT-15C) sustained release tablets|Drug: Placebo","drug","United Therapeutics","Both","Child|Adult|Se",354,"October 2006","December 2008","Six Minute Walk Distance (6MWD)",1.799118107,"1",24108
"281","NCT00527943","Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Particpants With Acute Coronary Syndrome (TRA•CER) (Study P","Atherosclerosis|Myocardial Ischemia|Myocardial Infarction","cardiovascular","Drug: Vorapaxar|Drug: Placebo","drug","Merck Sharp & Dohme Corp.|Duke Clinical Research Institute","Both","Adult|Senior",12944,"December 2007","December 2009","Kaplan-Meier Estimate of the Percentage of Participants Who Experienced Cardiovascular Death， Myocardial Infarction， Stroke， Recurrent Ischemia With Re-hospitalization， and/or Urgent Coronary Revascularization Within 2 Years From Randomization",1.799118107,"1",24120
"282","NCT00392288","Efficacy and Safety of Ciclesonide (CIC) Administered Twice Daily in Pediatric Patients With Asthma.","Asthma","respiratory","Drug: Ciclesonide|Drug: Ciclesonide|Drug: Placebo","drug","Nycomed|Sanofi","Both","Child",528,"September 2006","November 2011","Change From Baseline in Forced Expiratory Volume in One Second (FEV1) at Week 12.",1.809972834,"1",24143
"283","NCT00883168","A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies","Seasonal Allergic Rhinitis","other","Drug: Placebo|Drug: azelastineHcl|Drug: fluticasone propionate|Drug: azelastine Hcl/fluticasone propionate","drug","Meda Pharmaceuticals","Both","Child|Adult|Se",1791,"April 2009","March 2008","Change From Baseline in 12 Hour Reflective Total Nasal Symptom Score (rTNSS)",1.8115,"1",24099
"284","NCT00551135","Surgical Pain After Inguinal Hernia Repair (SPAIHR)","Pain, Postoperative|Hernia, Inguinal","other","Drug: Pregabalin|Drug: placebo|Drug: Pregabalin|Drug: Pregabalin","drug","Pfizer","Male","Child|Adult|Se",425,"January 2008","July 2012","Modified Brief Pain Inventory–Short Form (mBPI-sf): Worst Pain 24 Hours Post Surgery",1.833017289,"1",24151
"285","NCT00394212","Incisionless Treatment for Patients With Inadequate Weight Loss Following Roux-en-Y Gastric Bypass","Obesity","other","Device: Transoral Suturing|Other: Sham Endoscopy","device","C. R. Bard","Both","Adult|Senior",77,"November 2006","July 2008","Weight Loss (%)",1.838423669,"1",24103
"286","NCT00401973","Assessment of Safety and Efficacy of Therapy for the Prevention of Weight Gain Associated With Olanzapine","Schizophrenia|Schizoaffective Disorders","mental health","Drug: olanzapine|Drug: amantadine|Drug: metformin|Drug: zonisamide|Behavioral: Wellness education","drug","Eli Lilly and Company","Both","Adult",199,"November 2006","June 2009","Change From Baseline to Endpoint in Weight",1.845258117,"1",24114
"287","NCT00856973","Safety & Efficacy Study of Study Drug (Eszopiclone) in Children and Adolescents With Attention-deficit/Hyperactivity Disorder - Associated Insomnia","Insomnia|Attention Deficit Hyperactivity Disorder","mental health","Drug: eszopiclone|Drug: eszopiclone|Drug: Placebo","drug","Sunovion","Both","Child",486,"May 2009","September 2008","Change From Baseline to the End of the Double- Blind Treatment Period (Week 12) in Polysomnography (PSG) Defined Latency to Persistent Sleep (LPS).",1.8747,"1",24105
"288","NCT00564486","Analgesic Efficacy & Safety of Intravenous (IV) Acetaminophen Versus Placebo for the Treatment of Postop Pain","Pain","other","Drug: IV Placebo|Drug: IV Placebo|Drug: IV Acetaminophen|Drug: IV Acetaminophen","drug","Cadence Pharmaceuticals","Both","Adult|Senior",244,"November 2007","November 2008","Sum Pain Intensity Difference - Baseline to 24 Hours (SPID24)， 1 g IV Acetaminophen vs. Placebo (PI Was Measured at the Timepoints of T0， 1， 2， 3， 4， 5， 6， 7， 8， 9， 10， 11， 12， 14， 16， 18， 20， and 24 Hours.)",1.88,"1",24107
"289","NCT01044459","Long-term Safety, Tolerability and Efficacy of Aclidinium Bromide in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-35)","Chronic Obstructive Pulmonary Disease","respiratory","Drug: aclidinium bromide|Drug: aclidinium bromide","drug","Forest Laboratories| Almirall, S.A.","Both","Adult|Senior",605,"November 2009","February 2011","Change From Baseline in Morning Pre-dose (Trough) Forced Expiratory Volume in One Second (FEV1)",1.886,"1",24134
"290","NCT00707486","A Randomized, Self Controlled Clinical Study of Hemostatic Efficacy of the HemCon Dental Dressing","Tooth Extractions","other","Device: Hemcon Dental Dressing|Device: Gauze with Pressure and/or Gelfoam","device","HemCon Medical Technologies, Inc","Both","Child|Adult|Se",72,"June 2008","February 2010","Time to Hemostasis",1.887,"1",24122
"291","NCT00688519","Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis One of Two Phase 3 Studies","Psoriasis","other","Drug: U0267|Drug: Vehicle","drug","Stiefel, a GSK Company|GlaxoSmithKline","Both","Child|Adult|Se",336,"March 2008","June 2011","Number of Subjects With Treatment Success， Assessed Per the Investigator's Static Global Assessment (ISGA)",1.8957,"1",24138
"292","NCT00674739","Safety and Effectiveness Study of Imiquimod Creams in the Treatment of External Genital Warts","Genital Warts","other","Drug: Imiquimod|Drug: 3.75% imiquimod cream|Drug: placebo cream","drug","Graceway Pharmaceuticals, LLC","Both","Child|Adult|Se",470,"May 2008","September 2011","",1.9,"1",24141
"293","NCT00159913","A Randomized, Double-Blind, Placebo-Controlled Study of Sildenafil in Children With Pulmonary Arterial Hypertension.","Pulmonary Arterial Hypertension, Children","cardiovascular","Drug: Sildenafil citrate|Drug: Sildenafil citrate|Drug: Placebo|Drug: Sildenafil citrate","drug","Pfizer","Both","Child",235,"August 2003","October 2008","Percent Change From Baseline in Peak Volume of Oxygen (VO2) Consumed : Intent To Treat Population",1.911035648,"1",24106
"294","NCT00348283","Effects of Adalimumab on Mucosal Healing in Subjects With Crohn's Disease Involving the Colon","Crohn's Disease","other","Biological: adalimumab|Biological: placebo|Biological: adalimumab","biolog","Abbott","Both","Adult|Senior",135,"August 2006","June 2009","Number of Subjects Without Mucosal Ulceration at Week 12",1.911035648,"1",24114
"295","NCT00620282","The Effect of Liraglutide on Endothelial Function in Subjects With Type 2 Diabetes Mellitus","Diabetes|Diabetes Mellitus, Type 2","endocrine and metabolic","Drug: liraglutide|Drug: placebo|Drug: glimepiride","drug","Novo Nordisk A/S","Both","Adult|Senior",49,"February 2008","November 2012","Change in Acetylcholine (ACh)-Mediated Forearm Blood Flow (FBF)",1.9197,"1",24155
"296","NCT00264537","A Study of the Safety and Efficacy of Golimumab in Subjects With Rheumatoid Arthritis That Are Methotrexate-naive","Rheumatoid Arthritis","other","Drug: Placebo injections|Drug: Placebo capsules|Drug: Methotrexate capsules|Biological: Golimumab 50 mg injections|Biological: Golimumab 100 mg injections","biolog","Centocor, Inc.|Schering-Plough","Both","Adult|Senior",637,"December 2005","July 2010","Number of Participants Who Achieved American College of Rheumatology (ACR) 50 Response at Week 24",1.934920925,"1",24127
"297","NCT00578812","PCM Cervical Disc System","Radiculopathy|Myelopathy","mental health","Device: Anterior Cervical Discectomy and Fusion (ACDF)|Device: PCM Cervical Disc","device","NuVasive","Both","Adult",494,"January 2005","January 2010","Individual Patient Overall Success",1.938,"1",24121
"298","NCT00759681","ArterX Surgical Sealant, A Randomized Prospective Multicenter Trial","Vascular Disease","cardiovascular","Device: ArterX Surgical Sealant|Device: Gelfoam and Thrombin","device","Tenaxis Medical, Inc.","Both","Adult|Senior",217,"September 2008","February 2008","Immediate Sealing Evidenced by no Bleeding on Clamp Release.",1.96,"1",24098
"299","NCT00926029","Compare the Clinical Efficacy of Prototype Toothpastes","Dental Plaque","other","Drug: Fluoride|Drug: Triclosan, fluoride|Other: Metal salt","drug","Colgate Palmolive","Both","Adult",98,"January 2008","November 2009","Plaque Index",1.96,"1",24119
"300","NCT01024738","Study to Determine the Anti-plaque Efficacy of Commerical Toothpastes and an Oral Rinse","Dental Plaque","other","Drug: Fluoride|Drug: Triclosan, fluoride|Drug: Chlorhexidine Gluconate","drug","Colgate Palmolive","Both","Adult",22,"March 2008","November 2009","Plaque Index",1.96,"1",24119
"301","NCT01079130","Efficacy and Safety of Different Doses of Indacaterol","Asthma","respiratory","Drug: Indacaterol|Drug: Salmeterol|Drug: Placebo to Indacaterol|Drug: Placebo to Salmeterol","drug","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior",511,"February 2010","December 2010","Trough Forced Expiratory Volume in 1 Second (FEV1) After 2 Weeks of Treatment",1.977368428,"1",24132
"302","NCT00955747","Naturlose (D-Tagatose) Efficacy Evaluation Trial","Type 2 Diabetes","endocrine and metabolic","Drug: Tagatose|Drug: Sugar Substitute Splenda","drug","Robert Lodder|University of Kentucky|Spherix Incorporated","Both","Adult|Senior",494,"April 2007","March 2008","Change in Hemoglobin A1C Level From Baseline",2.0131,"1",24099
"303","NCT00864253","A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma","Malignant Melanoma","cancer","Drug: ABI-007|Drug: Dacarbazine","drug","Celgene Corporation|University of Arizona","Both","Adult|Senior",529,"April 2009","August 2010","Progression Free Survival (PFS) Based on a Blinded Radiology Assessment of Response Using Response Evaluation Criteria in Solid Tumors (RECIST) Guidelines",2.0141,"1",24128
"304","NCT00388726","E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer","Breast Cancer","cancer","Drug: E7389|Drug: Physician's Choice","drug","Eisai Inc.|Eisai Limited","Female","Adult|Senior",762,"October 2006","May 2012","Overall Survival",2.043530007,"1",24149
"305","NCT01017952","A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obs","Pulmonary Disease, Chronic Obstructive","respiratory","Drug: FF/GW642444 Inhalation Powder|Drug: GW642444 Inhalation Powder","drug","GlaxoSmithKline","Both","Adult|Senior",1635,"September 2009","July 2009","Annual Rate of Moderate and Severe COPD Exacerbations Expressed as Least Square Mean",2.0537,"1",24115
"306","NCT01053988","A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (CO","Pulmonary Disease, Chronic Obstructive","respiratory","Drug: FF/GW642444 Inhalation Powder|Drug: FF Inhalation Powder|Drug: GW642444 Inhalation Powder|Drug: Placebo","drug","GlaxoSmithKline","Both","Adult|Senior",1031,"October 2009","August 2008","Change From Baseline in Weighted Mean FEV1 Over 0-4 Hours Post-dose at Day 168",2.053748911,"1",24104
"307","NCT00312845","Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma","Non-Hodgkin's Lymphoma","cancer","Drug: Bortezomib + Rituximab|Drug: Rituximab","drug","Millennium Pharmaceuticals, Inc.|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Both","Adult|Senior",676,"March 2006","July 2008","Progression Free Survival",2.06418689,"1",24103
"308","NCT00927472","Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice","Pediculosis","other","Drug: Malathion gel 0.5%|Drug: Permethrin 1% rinse","drug","Taro Pharmaceuticals USA","Both","Child|Adult|Se",254,"August 2009","November 2008","Proportion of Index Subjects Free of Any of Lice 14 Days After Their Last Treatment.",2.0684,"1",24107
"309","NCT01120691","Effect of QVA149 Versus NVA237 and Tiotropium on Chronic Obstructive Pulmonary Disorder (COPD) Exacerbations","Chronic Obstructive Pulmonary Disease","respiratory","Drug: QVA149|Drug: NVA237|Drug: tiotropium|Drug: Salbutamol/albuterol","drug","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior",2224,"April 2010","September 2008","Rate of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Exacerbations in QVA149 and NVA237 Treatment Arms During the Treatment Period.",2.074854734,"1",24105
"310","NCT00856843","BLI800-303: An Efficacy Evaluation of 2 Different Bowel Cleansing Preparations in Adult Subjects","Colonoscopy","other","Drug: BLI800|Drug: Polyethylene glycol 3350 based bowel preparation","drug","Braintree Laboratories","Both","Adult|Senior",136,"February 2009","February 2008","Efficacy: Percentage of Patients With Successful Preparations Based on a 4 Point Scale",2.0749,"1",24098
"311","NCT01163032","Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder","Non-24-Hour Sleep-Wake Disorder","mental health","Drug: tasimelteon|Drug: Placebo","drug","Vanda Pharmaceuticals","Both","Adult|Senior",136,"August 2010","January 2009","Proportion of Patients Entrained as Assessed by Urinary aMT6",2.084551839,"1",24109
"312","NCT00789737","Welchol as Monotherapy for Type 2 Diabetes Mellitus","Type 2 Diabetes Mellitus","endocrine and metabolic","Drug: Welchol|Drug: Placebo","drug","Daiichi Sankyo Inc.","Both","Adult|Senior",357,"January 2009","January 2009","Percent Change in Hemoglobin A1c",2.0869,"1",24109
"313","NCT00996372","Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women","Sexual Dysfunctions, Psychological","mental health","Drug: flibanserin|Drug: placebo","drug","Sprout Pharmaceuticals, Inc","Female","Adult|Senior",949,"October 2009","January 2008","Change From Baseline in the Number of Satisfying Sexual Events",2.0884,"1",24097
"314","NCT01086384","Asthma Exacerbation Study","Asthma","respiratory","Drug: Fluticasone Furoate/GW642444|Drug: Fluticasone furoate","drug","GlaxoSmithKline","Both","Child|Adult|Se",2020,"February 2010","November 2008","Number of Participants With 1 or More Severe Asthma Exacerbations",2.096927429,"1",24107
"315","NCT00374907","A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise","Type 2 Diabetes","endocrine and metabolic","Drug: Saxagliptin|Drug: Placebo|Drug: Metformin (blinded)|Drug: Metformin (open-label)","drug","AstraZeneca","Both","Adult|Senior",156,"September 2006","September 2008","Insulin Secretion Rate Area Under the Curve (AUC) During Intravenous (IV)-Oral Hyperglycemic Clamp - Percent Change From Baseline at Week 12",2.108358399,"1",24105
"316","NCT00996164","Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder","Sexual Dysfunctions, Psychological","mental health","Drug: Flibanserin|Drug: Placebo","drug","Sprout Pharmaceuticals, Inc","Female","Adult",1090,"October 2009","March 2011","The Change From Baseline to Week 24 in the Score of the Female Sexual Function Index Desire Domain.",2.1185,"1",24135
"317","NCT00490971","A Study to Evaluate the Effectiveness and Safety of Extended-Release (ER) Paliperidone Compared With Placebo in Delaying the Recurrence of Symptoms in Bipolar I Diso","Bipolar Disorder","mental health","Drug: Olanzapine|Drug: Paliperidone ER|Drug: Placebo","drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Both","Adult",768,"May 2006","February 2010","Time to Recurrence of Any Mood Symptoms (Manic or Depressive) Associated With Bipolar I Disorder",2.12007169,"1",24122
"318","NCT01626118","Study of Indomethacin Capsules to Treat Pain Following Bunionectomy","Other Acute Postoperative Pain","other","Drug: Indomethacin|Drug: Indomethacin|Drug: Indomethacin|Drug: Placebo","drug","Iroko Pharmaceuticals, LLC","Both","Adult",373,"May 2012","October 2009","The Time-Weighted Summed Pain Intensity Difference Measured Using the 100-mm Visual Analogue Scale From 0 to 48 Hours After Trial Entry (VASSPID-48)",2.12007169,"1",24118
"319","NCT00347360","The COREG And Lisinopril Combination Therapy In Hypertensive Subjects (COSMOS) Trial","Hypertension","cardiovascular","Drug: lisinopril|Drug: carvedilol controlled release formulation","drug","GlaxoSmithKline","Both","Adult|Senior",654,"July 2006","August 2009","Change From Baseline to Week 6 in 24 Hour (hr) Mean Diastolic Blood Pressure",2.13,"1",24116
"320","NCT00065442","Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy","Prostate Cancer","cancer","Biological: Sipuleucel-T|Biological: APC-Placebo","biolog","Dendreon","Male","Adult|Senior",512,"July 2003","August 2009","Overall Survival",2.144410621,"1",24116
"321","NCT00704418","Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery","Cataract","other","Drug: Bromfenac|Drug: Placebo","drug","Bausch & Lomb Incorporated","Both","Adult|Senior",156,"June 2008","March 2009","Number of Participants With Summed Ocular Inflammation Score (SOIS) of Zero",2.1463,"1",24111
"322","NCT01018862","A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Children With Perennial Allergic Rhinitis","Perennial Allergic Rhinitis","other","Drug: Azelastine hydrochloride nasal spray 0.15%|Drug: Azelastine hydrochloride nasal spray 0.10%|Drug: Placebo","drug","Meda Pharmaceuticals","Both","Child",489,"November 2009","September 2010","Change From Baseline in 12-hour Reflective Total Nasal Symptom Score (TNSS) for the Entire 28-day Study Period Compared to Placebo",2.1587,"1",24129
"323","NCT00368277","A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly","Hypertension","cardiovascular","Drug: Aliskiren|Drug: Ramipril|Drug: Hydrochlorothiazide|Drug: Amlodipine","drug","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior",901,"September 2006","October 2010","Change From Baseline in Mean Sitting Systolic Blood Pressure to Week 12",2.169,"1",24130
"324","NCT01294787","Effect of QVA149 on Exercise Tolerance in Patients With Chronic Obstructive Pulmonary Disease (COPD)","COPD","respiratory","Drug: indacaterol and glycopyrronium bromide (QVA149)|Drug: placebo|Drug: tiotropium","drug","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior",85,"February 2011","December 2012","Exercise Tolerance Comparison Between QVA149 and Placebo Groups",2.169,"1",24156
"325","NCT00225732","Trial of Caldolor for Treatment of Pain in Post-Operative Adult Patients","Pain","other","Other: Normal saline as placebo comparator|Drug: Intravenous ibuprofen","drug","Cumberland Pharmaceuticals","Female","Adult|Senior",319,"January 2005","June 2012","Change in the Patient Demand for the Narcotic Analgesic， Morphine， Post Surgery",2.170090378,"1",24150
"326","NCT00712920","A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Perennial Allergies","Perennial Allergic Rhinitis","other","Drug: 0.15% azelastine hydrochloride|Drug: 0.1% azelastine hydrochloride|Drug: Placebo","drug","Meda Pharmaceuticals","Both","Child|Adult|Se",581,"January 2007","April 2008","Change From Baseline in 12-hour Reflective Total Nasal Symptom Score (AM and PM Combined) at 28 Days.",2.1701,"1",24100
"327","NCT00724126","Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)","Non-Constipation Irritable Bowel Syndrome","other","Drug: Rifaximin|Drug: Placebo","drug","Salix Pharmaceuticals","Both","Adult|Senior",637,"July 2008","April 2009","Proportion of Subjects Who Had Adequate Relief of Global IBS Symptoms for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie， Weeks 3 Through 6).",2.1701,"1",24112
"328","NCT00606489","Efficacy and Safety Study of Caldolor (Intravenous Ibuprofen) in Hospitalized Adult and Pediatric Burn Patients","Burns","other","Drug: Caldolor|Drug: Placebo","drug","Cumberland Pharmaceuticals","Both","Child|Adult|Se",61,"November 2007","April 2012","Temperature",2.187,"1",24148
"329","NCT00708123","In Situ Caries of Fluoride Toothpastes","Healthy Subjects|Partial Denture Wearers|Caries","other","Drug: Sodium fluoride toothpaste|Drug: Placebo toothpaste","drug","GlaxoSmithKline","Both","Adult|Senior",60,"November 2007","July 2012","Mean Percentage Surface Microhardness Recovery (%SMHR) of Enamel Specimens Exposed to NaF/Carbopol Toothpaste (1400 ppmF)， NaF Toothpaste (1350ppmF) Compared to NaMFP/NaF Toothpaste (1450ppmF)",2.2188,"1",24151
"330","NCT00662909","Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder","Urinary Bladder, Overactive","other","Drug: Mirabegron|Drug: Placebo","drug","Astellas Pharma Inc","Both","Adult|Senior",2149,"April 2008","May 2012","Change From Baseline to End of Treatment (Final Visit) in Mean Number of Incontinence Episodes Per 24 Hours",2.2262,"1",24149
"331","NCT01005719","Study to Compare Gastric Inhibition of Two Proton Pump Inhibitors (CL2008-18)(P07815)(COMPLETED)","Human Experimentation","other","Drug: Zegerid|Drug: Prevacid®","drug","Merck Sharp & Dohme Corp.","Both","Adult",63,"September 2009","April 2010","Achievement of Sustained Difference in Inhibition of Intragastric Acidity Based on Median pH Values Between the Two Active Study Treatments at Steady-state on Day 7",2.2539,"1",24124
"332","NCT01001234","A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents (MK-0462-082 AM7)","Migraine, Acute","mental health","Drug: rizatriptan|Drug: placebo|Drug: rizatriptan|Drug: placebo","drug","Merck Sharp & Dohme Corp.","Both","Child",1382,"November 2009","August 2009","Pain Freedom at 2 Hours Post Dose in Participants Between 12 and 17 Years of Age",2.2606,"1",24116
"333","NCT00635817","A Study of Leuprolide 11.25 mg and 30 mg Administered Every 3 Months to Treat Central Precocious Puberty","Puberty, Precocious","endocrine and metabolic","Drug: Leuprolide acetate 11.25 mg|Drug: Leuprolide acetate 30 mg","drug","Abbott","Both","Child",84,"June 2008","August 2008","Percentage of Participants With Suppression of Peak Stimulated Luteinizing Hormone (<4 mIU/mL) From Month 2 Through Month 6",2.2638,"1",24104
"334","NCT00090051","FCR Versus FC Alone in the Treatment of Chronic Lymphocytic Leukemia (CLL) in Relapsed Patients","Chronic Lymphocytic Leukemia","cancer","Drug: Rituximab|Drug: Fludarabine Phosphate|Drug: Cyclophosphamide","drug","Hoffmann-La Roche|Biogen Idec|Genentech, Inc.","Both","Adult|Senior",552,"July 2003","September 2009","Progression-free Survival (PFS) as Assessed by the Independent Review Committee (IRC)",2.29383462,"1",24117
"335","NCT00528372","A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise","Type 2 Diabetes","endocrine and metabolic","Drug: Dapagliflozin|Drug: Dapagliflozin placebo|Drug: Metformin","drug","Bristol-Myers Squibb|AstraZeneca","Both","Adult|Senior",1067,"September 2007","December 2010","Adjusted Mean Change From Baseline to Week 24 in Hemoglobin A1C (HbA1c) (Last Observation Carried Forward [LOCF]): Group 1",2.313411963,"1",24132
"336","NCT00783692","Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Crohn's Disease","Crohn's Disease","other","Drug: vedolizumab|Other: Placebo","drug","Millennium Pharmaceuticals, Inc.","Both","Adult|Senior",1116,"December 2008","February 2010","Induction Phase: Percentage of Participants Achieving Clinical Remission at Week 6",2.3152,"1",24122
"337","NCT00750139","Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Pedis","Tinea Pedis|Athlete's Foot","other","Drug: NAFT-500|Drug: Placebo 2-weeks|Drug: Naftin 1%|Drug: Placebo 4-weeks","drug","Merz Pharmaceuticals, LLC","Both","Child|Adult|Se",707,"August 2008","February 2012","Percentage of Subjects With Complete Cure at Week 6.",2.3263,"1",24146
"338","NCT00809965","An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome","Acute Coronary Syndrome|Myocardial Infarction|Myocardial Ischemia|Unstable Angina","cardiovascular","Drug: Rivaroxaban 2.5 mg|Drug: Rivaroxaban 5 mg|Drug: Placebo|Drug: Standard of care","drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Bayer","Both","Adult|Senior",15526,"November 2008","June 2009","The Percentage of Patients With the Composite Endpoint of Cardiovascular Death， Myocardial Infarction， or Stroke",2.3263,"1",24114
"339","NCT00615550","PREGNANT Short Cervix Trial","Preterm Delivery|Short Cervix|Short Uterine Cervical Length","other","Drug: progesterone|Drug: placebo","drug","Columbia Laboratories|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)","Female","Child|Adult",465,"March 2008","December 2012","Number of Participants With Birth <=32 6/7 Weeks Gestation.",2.326347874,"1",24156
"340","NCT00073528","Study Comparing GW572016 And Letrozole Versus Letrozole In Subjects With Advanced Or Metastatic Breast Cancer","Neoplasms, Breast","cancer","Drug: Lapatinib (GW572016)|Drug: Letrozole","drug","GlaxoSmithKline","Female","Adult|Senior",1286,"December 2003","July 2009","Number of Participants With Progression Free Survival (PFS) in the Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Her3 as Assessed by the Investigator",2.345530971,"1",24115
"341","NCT00113607","An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer","Ovarian Cancer","cancer","Drug: Trabectedin|Drug: DOXIL|Drug: Dexamethasone","drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|PharmaMar","Female","Adult|Senior",672,"April 2005","November 2008","Progression-Free Survival (PFS): Independent Radiologist Review",2.345530971,"1",24107
"342","NCT00478192","Study of Efficacy & Safety for 3 Infusion Regimens of IV Conivaptan in Subjects With Euvolemic or Hypervolemic Hyponatremia","Hyponatremia","endocrine and metabolic","Drug: Conivaptan|Drug: Placebo","drug","Cumberland Pharmaceuticals","Both","Adult|Senior",50,"April 2007","May 2009","Change in Serum Sodium From Baseline to the 48 Hour Assessment or Study Drug Discontinuation.",2.345530971,"1",24113
"343","NCT00626028","Comparison of Inhaled Nitric Oxide and Oxygen in Patient Reactivity During Acute Pulmonary Vasodilator Testing","Idiopathic Pulmonary Arterial Hypertension|Congenital Heart Disease With Pulmonary Hype","cardiovascular","Drug: Nitric Oxide for inhalation|Drug: Oxygen|Drug: Nitric Oxide plus Oxygen","drug","INO Therapeutics","Both","Child|Adult",136,"September 2004","April 2012","Reversible Pulmonary Hypertension (Vasoreactivity)as Defined by Hemodynamic Measurements",2.3534,"1",24148
"344","NCT00969709","Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder","Major Depressive Disorder","mental health","Drug: Levomilnacipran ER|Drug: Levomilnacipran ER|Drug: Levomilnacipran ER|Drug: Placebo","drug","Forest Laboratories","Both","Adult",724,"September 2009","June 2010","Change in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score",2.3535,"1",24126
"345","NCT00510146","Olanzapine Treatment of Patients With Bipolar I Disorder","Depression, Bipolar","mental health","Drug: Olanzapine|Drug: Placebo","drug","Eli Lilly and Company","Both","Adult",514,"August 2007","November 2008","Change From Baseline to Endpoint in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score (Acute Phase)",2.365618127,"1",24107
"346","NCT01275066","A Double-Blind Study to Evaluate the Efficacy and Safety of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)","MPS IV A","endocrine and metabolic","Drug: BMN 110 Weekly|Drug: Placebo|Drug: BMN 110 Every Other Week","drug","BioMarin Pharmaceutical","Both","Child|Adult|Se",177,"February 2011","February 2009","Change From Baseline in Endurance as Measured by the 6-minute Walk Test",2.378144623,"1",24110
"347","NCT00641056","Efficacy of Exenatide Once Weekly and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea (","Type 2 Diabetes Mellitus","endocrine and metabolic","Drug: Exenatide Once Weekly|Drug: Insulin Glargine","drug","AstraZeneca|Eli Lilly and Company","Both","Adult|Senior",467,"April 2008","August 2012","Change in HbA1c From Baseline to Week 26",2.3867,"1",24152
"348","NCT00344968","Fluocinolone Acetonide Implant Compared to Sham Injection in Patients With Diabetic Macular Edema","Diabetic Macular Edema","other","Drug: fluocinolone acetonide|Drug: Fluocinolone Acetonide|Procedure: Standard of care laser photocoagulation","drug","Alimera Sciences","Both","Adult|Senior",956,"September 2007","January 2012","Visual Acuity",2.402,"1",24145
"349","NCT00689481","Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis Two of Two Phase 3 Studies","Psoriasis","other","Drug: U0267 Foam|Drug: Vehicle foam","drug","Stiefel, a GSK Company|GlaxoSmithKline","Both","Child|Adult|Se",323,"March 2008","November 2008","Number of Subjects With Treatment Success， Assessed Per the Investigator's Static Global Assessment",2.4089,"1",24107
"350","NCT00966953","Development of Clinical Method to Determination Triclosan Retention in Plaque Following Brushing.","Gingival Diseases","other","Drug: Fluoride|Drug: Triclosan/Fluoride toothpaste|Drug: Fluoride|Drug: Fluoride|Other: antibacterial plant extract","drug","Colgate Palmolive","Both","Adult",25,"October 2007","February 2012","Plaque Index",2.4237,"1",24146
"351","NCT00769314","Phase 3 Clinical Study for the Treatment of Cold Sore","Herpes Labialis","other","Drug: Acyclovir Lauriad|Drug: Placebo","drug","Onxeo","Both","Adult|Senior",1727,"May 2007","April 2012","",2.4324,"1",24148
"352","NCT01702532","Nicotine Mouth Film for Craving Relief.","Smoking Cessation","other","Drug: Nicotine","drug","GlaxoSmithKline","Both","Adult|Senior",320,"September 2012","October 2010","The Change From Pre-dose Post-provocation in Craving Score at 50 Seconds",2.454705623,"1",24130
"353","NCT00577655","Chronic-Dose Safety and Efficacy Study of an Albuterol Metered Dose Inhaler (MDI) Inhaler Using a Hydrofluoroalkane (HFA) Propellant In Pediatric Asthmatics","Asthma","respiratory","Drug: Albuterol|Drug: Placebo","drug","Teva Branded Pharmaceutical Products, R&D Inc.","Both","Child",103,"August 2007","October 2011","Maximum Percent Change From Baseline",2.462427681,"1",24142
"354","NCT00525824","12-week Open-label, Phase IIIb Comparing Efficacy and Safety of Rosuvastatin (CRESTOR™) in Combination With Ezetimibe","Hypercholesterolemia|Coronary Heart Disease|Atherosclerosis","cardiovascular","Drug: Rosuvastatin   (Crestor)|Drug: Ezetimibe|Drug: Simvastatin","drug","AstraZeneca","Both","Adult|Senior",1743,"August 2007","December 2008","Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After 6 Weeks Combination Treatment",2.467,"1",24108
"355","NCT00249873","Atrial Fibrillation Clopidogrel Trial With Irbesartan for Prevention of Vascular Events (ACTIVE A)","Atrial Fibrillation|Vascular Risk","cardiovascular","Drug: clopidogrel (SR25990C)|Drug: placebo","drug","Sanofi|Bristol-Myers Squibb","Both","Adult|Senior",7554,"June 2003","June 2012","First Occurence of Any Component of the Composite of Stroke， Non-Central Nervous System (Non-CNS) Systemic Embolism， Myocardial Infarction or Vascular Death as Per Adjudication",2.475633576,"1",24150
"356","NCT00256204","A Randomized Placebo Controlled Study to Show That Rasagiline May Slow Disease Progression for Parkinson's Disease","Parkinson's Disease","mental health","Drug: Rasagiline Mesylate|Drug: Rasagiline Mesylate|Other: Placebo","drug","Teva Pharmaceutical Industries","Both","Adult|Senior",1174,"November 2005","March 2011","Change in Total Unified Parkinson's Disease Rating Scale (UPDRS) Score From Baseline",2.475633576,"1",24135
"357","NCT00325403","FREEDOM - M: Oral Treprostinil as Monotherapy for the Treatment of Pulmonary Arterial Hypertension (PAH)","Pulmonary Hypertension","cardiovascular","Drug: Oral treprostinil (UT-15C) Sustained Release Tablets|Other: Placebo","drug","United Therapeutics","Both","Child|Adult|Se",349,"October 2006","July 2008","Six Minute Walk Distance (6MWD)",2.497705474,"1",24103
"358","NCT00413010","Pregabalin in the Treatment of Patients With Generalized Anxiety Disorder (GAD).","Generalized Anxiety Disorder","mental health","Drug: pregabalin|Drug: placebo","drug","Pfizer","Both","Adult|Senior",356,"December 2006","November 2011","Change in Hamilton Anxiety Rating Scale (HAM-A) Total Scores",2.5,"1",24143
"359","NCT00889863","Flare Prevention Study of Canakinumab in Patients With Active Systemic Juvenile Idiopathic Arthritis (SJIA)","Systemic Juvenile Idiopathic Arthritis With Active Flare","other","Drug: canakinumab|Drug: placebo","drug","Novartis Pharmaceuticals|Pediatric Rheumatology International Trials Organization|Novartis","Both","Child|Adult",177,"July 2009","February 2009","Part I: Percentage of Patients Who Were on Steroids at Entry Into Part I and Who Were Able to Taper Steroid as Per Protocol in at Least 25% of the Patients Who Entered the Study Taking a Steroid",2.5092,"1",24110
"360","NCT00264810","RNS® System Pivotal Study","Epilepsy","mental health","Procedure: RNS® System implantation|Device: RNS® System responsive stimulation","device","NeuroPace","Both","Adult|Senior",240,"December 2005","September 2009","Acute SAE Rate",2.512144328,"1",24117
"361","NCT01064414","An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment","Diabetes Mellitus, Type 2|Renal Insufficiency","endocrine and metabolic","Drug: Canagliflozin|Drug: Placebo","drug","Janssen Research & Development, LLC","Both","Adult|Senior",272,"June 2010","June 2012","Change in HbA1c From Baseline to Week 26",2.512144328,"1",24150
"362","NCT00755417","Study of Gabapentin Extended Release (G-ER) in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women","Hot Flashes","endocrine and metabolic","Drug: Gabapentin Extended-Release (G-ER) 1200 mg|Drug: Gabapentin Extended-Release (G-ER) 1800 mg|Drug: Placebo","drug","Depomed","Female","Adult|Senior",541,"September 2008","August 2009","Change From Baseline in Average Daily Frequency of Hot Flashes After 4 Weeks of Treatment With Daily Doses of G-ER 1200 mg or G-ER 1800 mg Compared to Placebo",2.521,"1",24116
"363","NCT00105443","A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma","Carcinoma, Hepatocellular","cancer","Drug: Sorafenib (Nexavar, BAY43-9006)|Drug: Placebo","drug","Bayer","Both","Adult|Senior",602,"March 2005","June 2010","Overall Survival (OS)",2.522270522,"1",24126
"364","NCT00620022","The Effect of Indacaterol on Exercise Endurance in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease","Chronic Obstructive Pulmonary Disease","respiratory","Drug: Indacaterol 300 μg|Drug: Placebo","drug","Novartis","Both","Adult|Senior",90,"April 2008","December 2008","Exercise Duration Time Assessed by Constant-load Cycle Ergometry at the End of Each Treatment Period",2.5427,"1",24108
"365","NCT00660179","Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension","Pulmonary Arterial Hypertension","cardiovascular","Drug: macitentan (ACT-064992)|Drug: macitentan (ACT-064992)|Drug: placebo","drug","Actelion","Both","Child|Adult|Se",742,"May 2008","March 2011","Time to First Confirmed Morbidity or Mortality Event up to the End of Treatment (Kaplan-Meier Estimate of Patients Without a Morbidity or Mortality Event)",2.5491,"1",24135
"366","NCT00689104","Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder","Urinary Bladder, Overactive","other","Drug: Mirabegron|Drug: Tolterodine|Drug: Placebo to Mirabegron|Drug: Placebo to Tolterodine","drug","Astellas Pharma Inc","Both","Adult|Senior",2336,"April 2008","February 2012","Change From Baseline to End of Treatment (Final Visit) in Mean Number of Incontinence Episodes Per 24 Hours",2.5511,"1",24146
"367","NCT00795639","Sitaxsentan Efficacy And Safety Trial With A Randomized Prospective Assessment Of Adding Sildenafil (SR-PAAS)","Pulmonary Arterial Hypertension|Pulmonary Hypertension","cardiovascular","Drug: Sitaxsentan|Drug: Placebo","drug","Pfizer","Both","Child|Adult|Se",183,"December 2008","September 2009","Change From Baseline in Total Distance Walked During 6 Minute Walk Distance (6MWD) at Week 12",2.5622,"1",24117
"368","NCT00280566","Safety and Maintenance of Effect of Ziprasidone Plus a Mood Stabilizer in Bipolar I Disorder (Manic or Mixed)","Bipolar Mania|Bipolar Disorder","mental health","Drug: Placebo|Drug: Ziprasidone Oral Capsule","drug","Pfizer","Both","Adult|Senior",584,"December 2005","May 2012","Time to Intervention for a Mood Episode During Double Blind Period",2.562238076,"1",24149
"369","NCT00490919","Buprenorphine Transdermal System (BTDS) in Subjects With Moderate to Severe Chronic Low Back Pain","Low Back Pain","other","Drug: Buprenorphine transdermal  system|Drug: Placebo","drug","Purdue Pharma LP","Both","Adult|Senior",539,"June 2007","February 2010","Average Pain Over the Last 24 Hours Scores at Week 12 of the Double-blind Phase.",2.562238076,"1",24122
"370","NCT00731679","Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)","Non-Constipation Irritable Bowel Syndrome","other","Drug: Rifaximin|Drug: Placebo","drug","Salix Pharmaceuticals","Both","Adult|Senior",623,"July 2008","May 2011","Proportion of Subjects Who Had Adequate Relief of Global IBS Symptoms for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie， Weeks 3 Through 6).",2.5758,"1",24137
"371","NCT00457015","Efficacy Study of DX-88 (Ecallantide) to Treat Acute Attacks of Hereditary Angioedema (HAE)","Hereditary Angioedema","cardiovascular","Drug: ecallantide|Drug: Phosphate Buffer Saline (PBS), pH 7.0","drug","Dyax Corp.","Both","Child|Adult|Se",96,"April 2007","June 2008","Change From Baseline in Mean Symptom Complex Severity (MSCS) Score at 4 Hours Post-dose",2.575829304,"1",24102
"372","NCT00461292","Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder","Overactive Bladder","other","Biological: botulinum toxin Type A (200U)|Biological: botulinum toxin Type A (300U)|Other: Normal saline (Placebo); botulinum toxin Type A (200U)|Other: Normal saline (Placebo); botulinum toxin Type A (300U)","biolog","Allergan","Both","Adult|Senior",275,"May 2007","January 2009","Change From Baseline in Number of Weekly Episodes of Urinary Incontinence",2.575829304,"1",24109
"373","NCT00488631","An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis","Colitis, Ulcerative","other","Biological: Placebo|Biological: Golimumab 50 mg|Biological: Golimumab 100 mg|Biological: Golimumab 200 mg","biolog","Janssen Research & Development, LLC|Merck Sharp & Dohme Corp.","Both","Adult|Senior",1228,"September 2007","June 2012","Number of Participants in Clinical Response Through Week 54",2.575829304,"1",24150
"374","NCT00626392","Study to Evaluate the EFFECTS of Acetylsalicylic Acid (ASA) on Niaspan®-Induced Flushing in Subjects With Dyslipidemia","Dyslipidemia","cardiovascular","Drug: niacin extended-release (NER)|Drug: aspirin (ASA)|Drug: aspirin placebo (ASA Pbo)","drug","Abbott","Both","Adult|Senior",277,"February 2008","July 2011","Maximum Severity of Flushing Events During Week 1 of Niacin Extended-release (NER) Treatment",2.575829304,"1",24139
"375","NCT01072929","A Study to Evaluate the Efficacy and Safety of Armodafinil Treatment as Adjunctive Therapy in Adults With Major Depression Associated With Bipolar I Disorder","Depression","mental health","Drug: Armodafinil|Drug: Placebo","drug","Cephalon|Teva Pharmaceutical Industries","Both","Adult",433,"January 2010","February 2009","Change From Baseline to Week 8 in the Total Score From the 30-Item Inventory of Depressive Symptomatology-Clinician-Rated (IDS-C30)",2.586344242,"1",24110
"376","NCT00573170","TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults","Migraine Disorders|Migraine, Acute","mental health","Drug: TREXIMET®|Drug: Butalbital-containing Combination Medications (BCM)|Drug: placebo","drug","GlaxoSmithKline","Both","Adult",375,"February 2008","August 2008","Number of Participants With a Sustained Pain-free (SPF) Response From 2 to 24 Hours Post-dose",2.603,"1",24104
"377","NCT00683592","Randomized, Double-Blind, Placebo Controlled Study of Vilazodone's Efficacy, Safety, and Biomarkers of Response in Major Depressive Disorder (MDD)","Major Depressive Disorder","mental health","Drug: vilazodone|Drug: placebo","drug","Forest Laboratories","Both","Adult|Senior",481,"March 2008","November 2010","Change From Baseline to Week 8 in the MADRS (Montgomery-Asberg Depression Rating Scale) Total Score.",2.6121,"1",24131
"378","NCT00622700","Phase III Study With Teriflunomide Versus Placebo in Patients With First Clinical Symptom of Multiple Sclerosis","Multiple Sclerosis","mental health","Drug: Teriflunomide|Drug: Placebo","drug","Sanofi","Both","Adult",618,"February 2008","November 2010","Time to Conversion to Clinically Deﬁnite Multiple Sclerosis (CDMS)",2.6236,"1",24131
"379","NCT00761930","Compare the Clinical Efficacy of Prototype Toothpastes.","Gingival Diseases","other","Drug: Fluoride|Drug: Triclosan and fluoride|Drug: Herbal Ingredient and fluoride","drug","Colgate Palmolive","Both","Adult",103,"March 2008","July 2010","Dental Plaque",2.6261,"1",24127
"380","NCT00645671","Loteprednol Etabonate Ophthalmic Ointment vs. Vehicle in the Treatment of Inflammation Following Cataract Surgery","Ocular Inflammation","other","Drug: 0.5% Loteprednol Etabonate Ophthalmic Ointment|Drug: Vehicle of Loteprednol Etabonate Ophthalmic Ointment","drug","Bausch & Lomb Incorporated","Both","Adult|Senior",400,"March 2008","November 2008","Subjects With Complete Resolution of Anterior Chamber Cells and Flare. Grade=0.",2.6421,"1",24107
"381","NCT00724815","The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine","Migraine Disorders","mental health","Drug: NP101 - Sumatriptan iontophoretic transdermal patch|Drug: Placebo","drug","NuPathe Inc.","Both","Adult",530,"January 2009","March 2009","Pain Free at Two Hours",2.6517,"1",24111
"382","NCT00337571","Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)","Behavioral Symptoms|Autistic Disorder","mental health","Drug: Aripiprazole|Drug: Placebo","drug","Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka America Pharmaceutical","Both","Child",218,"June 2006","April 2010","Mean Change (Week 8 - Baseline) in the Autistic Behavior Checklist (ABC) Irritability Subscale Score",2.652069808,"1",24124
"383","NCT01089127","Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)","Chronic Obstructive Pulmonary Disease","respiratory","Drug: Indacaterol|Drug: Salmeterol 50 μg|Drug: Placebo to indacaterol|Drug: Placebo to salmeterol","drug","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior",552,"March 2010","May 2011","Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose at the End of the Study (Week 2 + 1 Day， Day 15)",2.652069808,"1",24137
"384","NCT00662558","A Six Week Study Of The Pain Relieving Effects Of Celecoxib 200 Mg Twice Daily Compared To Tramadol 50 Mg Four Times Daily In Patients With Chronic Low Back Pain","Low Back Pain","other","Drug: celecoxib|Drug: tramadol HCL","drug","Pfizer","Both","Adult|Senior",802,"January 2008","August 2008","Treatment Responders Based on the Numerical Rating Scale-Pain (NRS-Pain)",2.6521,"1",24104
"385","NCT00737672","GORE VIABAHN Endoprosthesis Versus Percutaneous Transluminal Angioplasty (PTA) to Revise AV Grafts in Hemodialysis","Renal Failure|Hemodialysis","other","Device: GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface|Procedure: Percutaneous Transluminal Angioplasty","device","W.L.Gore & Associates","Both","Adult|Senior",293,"September 2008","September 2010","Target Lesion Primary Patency at 6 Months",2.6521,"1",24129
"386","NCT01081912","Phase 3 Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Low Back Pain","Back Pain Lower Back Chronic","other","Drug: Placebo|Drug: Hydrocodone bitartrate","drug","Zogenix, Inc.","Both","Adult|Senior",510,"March 2010","September 2012","Mean Change in 24-hour Pain Intensity Ratings Scale (NRS).",2.68,"1",24153
"387","NCT00281697","A Study to Evaluate the Safety and Efficacy of Bevacizumab in Combination With Chemotherapy in Previously Treated Metastatic Breast Cancer (RIBBON 2)","Metastatic Breast Cancer","cancer","Drug: Bevacizumab|Drug: Placebo|Drug: Standard chemotherapy","drug","Genentech, Inc.","Both","Adult|Senior",684,"February 2006","May 2011","Progression-free Survival",2.687449447,"1",24137
"388","NCT00079937","Efficacy and Safety of Omalizumab in Children (6 - < 12 Years) With Moderate-severe, Inadequately Controlled Allergic Asthma","Asthma","respiratory","Drug: Omalizumab|Drug: Placebo|Drug: Fluticasone","drug","Novartis Pharmaceuticals|Novartis","Both","Child",628,"April 2004","May 2008","",2.696844261,"1",24101
"389","NCT00334958","Rufinamide Given as Adjunctive Therapy in Patients With Refractory Partial Seizures","Epilepsy","mental health","Drug: Placebo|Drug: Rufinamide","drug","Eisai Inc.","Both","Child|Adult|Se",356,"February 2006","April 2011","Percentage Change in Total Partial Seizure Frequency Per 28 Days During Maintenance Phase Relative to the Baseline Phase",2.696844261,"1",24136
"390","NCT00600886","Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly","Acromegaly","endocrine and metabolic","Drug: Pasireotide|Drug: Octreotide","drug","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior",358,"February 2008","March 2009","Compare the Proportion of Patients With a Reduction of Mean GH Level to <2.5 ug/L and the Normalization of IGF-1 Between the Two Teatments Groups",2.696844261,"1",24111
"391","NCT01430754","Withdrawal Study to Demonstrate the Maintenance Effect in the Treatment of Non-24-Hour Sleep-Wake Disorder","Non-24-Hour Sleep-Wake Disorder","mental health","Drug: tasimelteon|Drug: Placebo","drug","Vanda Pharmaceuticals","Both","Child|Adult|Se",20,"September 2011","April 2012","Maintenance of Entrainment (aMT6s) in Subjects With N24HSWD.",2.697,"1",24148
"392","NCT00885378","Efficacy and Safety Study of Saxagliptin + Metformin Immediate Release (IR) Versus Metformin IR Alone in Type 2 Diabetes Mellitus","Type 2 Diabetes Mellitus","endocrine and metabolic","Drug: Saxagliptin plus metformin IR|Drug: Placebo plus metformin IR","drug","AstraZeneca","Both","Adult|Senior",166,"May 2009","August 2010","",2.7317,"1",24128
"393","NCT01156571","A Clinical Trial Comparing Cangrelor to Clopidogrel Standard Therapy in Subjects Who Require Percutaneous Coronary Intervention (PCI) (CHAMPION PHOENIX)","Atherosclerosis|Percutaneous Coronary Intervention|Acute Coronary Syndrome","cardiovascular","Drug: cangrelor P2Y12 (platelet) inhibitor|Drug: Clopidogrel - 300 or 600 mg (study arm)|Drug: Clopidogrel 600 mg post cangrelor","drug","The Medicines Company","Both","Adult|Senior",11145,"September 2010","November 2010","The Composite Incidence of All-cause Mortality， Myocardial Infarction (MI)， Ischemia-driven Revascularization (IDR) and Stent Thrombosis (ST)",2.735318203,"1",24131
"394","NCT00099437","Comparison of Fulvestrant (FASLODEX™) 250 mg and 500 mg in Postmenopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer Progressing or Relapsing Af","Breast Cancer","cancer","Drug: Fulvestrant","drug","AstraZeneca","Female","Adult|Senior",834,"February 2005","March 2008","Time to Progression (TTP)",2.747781385,"1",24099
"395","NCT00614445","The Efficacy Of Diclectin® For Nausea And Vomiting Of Pregnancy","Nausea and Vomiting of Pregnancy","other","Drug: doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg|Drug: Placebo","drug","Duchesnay Inc.|Premier Research Group plc","Female","Adult|Senior",280,"January 2008","February 2009","Diclectin Versus Placebo for Treatment of Nausea and Vomiting of Pregnancy (NVP) as Measured by the Change in Pregnancy Unique-Quantification of Emesis (PUQE) Overall Score of Symptoms From Baseline (Day 1) to End of Study Visit (Day 15).",2.747781385,"1",24110
"396","NCT00732381","Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05529)","Allergic Rhinitis","other","Drug: Mometasone furoate nasal spray (MFNS)|Drug: Matching placebo nasal spray","drug","Merck Sharp & Dohme Corp.","Both","Child|Adult|Se",351,"August 2008","July 2010","The Change From Baseline in Average AM/PM PRIOR Nasal Congestion Score Over 15 Days",2.7478,"1",24127
"397","NCT01358526","Efficacy and Safety of Oxycodone/Naloxone Controlled-release Tablets (OXN) Compared to Placebo in Opioid-experienced Subjects With Moderate to Severe Chronic Low Bac","Low Back Pain","other","Drug: Oxycodone/Naloxone Controlled-release|Drug: Placebo","drug","Purdue Pharma LP","Both","Adult|Senior",1095,"May 2011","February 2011","The “Average Pain Over the Last 24 Hours” at Week 12 of the Double-blind Period",2.776190335,"1",24134
"398","NCT00470600","Efficacy and Safety Study of Caldolor (IV Ibuprofen) in Hospitalized Adult Orthopedic Patients","Pain","other","Drug: Caldolor|Other: Normal Saline","drug","Cumberland Pharmaceuticals","Both","Adult|Senior",185,"May 2007","March 2008","AUC-VAS With Movement (Post-operative Period， Hour-6-28)",2.777,"1",24099
"399","NCT00721968","Safety and Efficacy of the GTS400 Stent in Conjunction With Cataract","Open-angle Glaucoma","other","Device: Glaucoma Stent Surgery (GTS400 Stent)|Procedure: cataract surgery alone","device","Glaukos Corporation","Both","Adult|Senior",62,"March 2007","September 2008","Month 12 Intraocular Pressure ≤ 18 mmHg Without Topical Hypotensive Medications",2.7865,"1",24105
"400","NCT00069121","A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer","Colorectal Cancer","cancer","Drug: capecitabine [Xeloda]|Drug: Oxaliplatin|Drug: Oxaliplatin|Drug: Leucovorin|Drug: 5 FU","drug","Hoffmann-La Roche","Both","Adult|Senior",1886,"January 2003","October 2011","Disease-free Survival (DFS) [Number of Events]",2.797,"1",24142
"401","NCT01034462","Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder","Major Depressive Disorder","mental health","Drug: Levomilnacipran ER|Drug: Placebo","drug","Forest Laboratories","Both","Adult|Senior",442,"December 2009","March 2008","Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score",2.80064873,"1",24099
"402","NCT00666263","Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropathy","Multifocal Motor Neuropathy","mental health","Biological: Immune Globulin Intravenous (human), 10%|Biological: 0.25% human albumin solution (Placebo)","biolog","Baxter Healthcare Corporation","Both","Adult|Senior",50,"August 2008","January 2012","Grip Strength in the More Affected Hand",2.807,"1",24145
"403","NCT00868452","Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Add-on)","Bipolar Depression","mental health","Drug: lurasidone + (lithium or divalproex)|Drug: Placebo + (lithium or divalproex)","drug","Sunovion","Both","Adult|Senior",348,"April 2009","August 2012","Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Endpoint (Week 6)",2.807,"1",24152
"404","NCT00912964","A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder","Urinary Bladder, Overactive","other","Drug: Mirabegron|Drug: Placebo","drug","Astellas Pharma Inc","Both","Adult|Senior",2030,"April 2009","March 2010","Change From Baseline to End of Treatment (Final Visit) in Mean Number of Incontinence Episodes Per 24 Hours",2.807,"1",24123
"405","NCT00194077","Study of Aripiprazole (Abilify) in Children With Symptoms of Mania","Bipolar Disorder","mental health","Drug: Aripiprazole|Drug: Placebo","drug","University Hospital Case Medical Center|Bristol-Myers Squibb","Both","Child",60,"August 2004","October 2009","Time in Weeks to Discontinuation",2.807033768,"1",24118
"406","NCT00540514","Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer","Non-Small Cell Lung Carcinoma","cancer","Drug: Albumin-bound paclitaxel|Drug: Paclitaxel|Drug: Carboplatin","drug","Celgene Corporation","Both","Adult|Senior",1052,"November 2007","May 2009","Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment",2.807033768,"1",24113
"407","NCT00562159","Efficacy and Safety of Grass Sublingual Tablet in Adults (P05238 AM3)(COMPLETED)","Rhinoconjunctivitis|Rhinitis|Conjunctivitis|Allergy","other","Drug: Placebo|Biological: SCH 697243|Drug: Loratadine 10 mg Rescue Treatment|Drug: Olopatadine 0.1% Rescue Treatment|Drug: Mometasone 50 mcg Rescue Treatment|Drug: Prednisone 5 mg Rescue Treatment|Drug: Albuterol sulfate 108","biolog","Merck Sharp & Dohme Corp.","Both","Adult",439,"November 2007","November 2011","Participant Total Combined Symptom (TCS) Score Over the Entire Grass Pollen Season (GPS)",2.807033768,"1",24143
"408","NCT00396032","A Study of Tenecteplase for Restoration of Function in Dysfunctional Hemodialysis Catheters","Dysfunctional Hemodialysis Catheters","cardiovascular","Drug: placebo|Drug: tenecteplase","drug","Genentech, Inc.","Both","Child|Adult|Se",150,"October 2006","December 2011","Percentage of Subjects Who Had Treatment Success With Respect to Blood Flow Rate (BFR) at Visit 1",2.847963287,"1",24144
"409","NCT00500318","A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","Pulmonary Disease, Chronic Obstructive","respiratory","Drug: Aclidinium Bromide|Drug: Placebo","drug","Forest Laboratories| Almirall, S.A.","Both","Adult|Senior",181,"July 2007","March 2008","Change From Baseline in Exercise Endurance Time (ET)",2.862736264,"1",24099
"410","NCT01087762","Certolizumab Pegol in Subjects With Active Axial Spondyloarthritis","Spondyloarthropathies","other","Biological: CZP 200 mg Q2W|Biological: CZP 400 mg Q4W|Other: Placebo","biolog","UCB BIOSCIENCES GmbH|UCB Pharma","Both","Adult|Senior",325,"March 2010","March 2009","Assessment in Axial Spondyloarthritis International Society 20 % (ASAS20) Response Criteria at Week 12",2.878161739,"1",24111
"411","NCT01185301","Study to Determine the Effects of Different Doses of Methotrexate (MTX) When Taken With Adalimumab in Subjects With Early Rheumatoid Arthritis (RA)","Early Rheumatoid Arthritis","other","Biological: adalimumab|Drug: methotrexate","biolog","AbbVie (prior sponsor, Abbott)|AbbVie","Both","Adult|Senior",395,"October 2010","October 2012","Percentage of Participants With 28-Joint Disease Activity Score of C-reactive Protein (DAS28[CRP]) Low Disease Activity at Week 26",2.878161739,"1",24154
"412","NCT00827242","Study to Treat Patients Who Have Signs and Symptoms of Benign Prostatic Hyperplasia (BPH) With Tadalafil Daily","Benign Prostatic Hyperplasia","other","Drug: Placebo|Drug: tadalafil","drug","Eli Lilly and Company","Male","Adult|Senior",325,"January 2009","April 2008","Change From Baseline to 12 Weeks， International Prostate Symptom Score (IPSS)",2.8782,"1",24100
"413","NCT00895011","Research Evaluating an Investigational Medication for Erectile Dysfunction - Post-Prostatectomy","Erectile Dysfunction","other","Drug: Placebo|Drug: Avanafil|Drug: Avanafil","drug","VIVUS, Inc.","Male","Adult|Senior",298,"April 2009","November 2008","Change in Percentage of Sexual Attempts in Which Subjects Are Able to Maintain an Erection of Sufficient Duration to Have Successful Intercourse",2.8891,"1",24107
"414","NCT00524264","A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery","Cataract Extraction|Pain|Inflammation","other","Drug: ketorolac","drug","Allergan","Both","Adult|Senior",248,"October 2007","March 2008","Resolution of Post Operative Inflammation",2.891,"1",24099
"415","NCT00784277","A Study to Compare the Frequency of Constipation Symptoms With Tapentadol Immediate Release (IR) Treatment Versus Oxycodone IR Treatment in Patients With End-stage J","Joint Diseases|Arthritis|Osteoarthritis","other","Drug: oxycodone CR|Drug: oxycodone IR|Drug: Tapentadol ER (CG5503)|Drug: Tapentadol IR (CG5503)|Drug: Tapentadol IR (CG5503)|Drug: placebo|Drug: placebo","drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Grünenthal GmbH","Both","Adult|Senior",597,"October 2008","December 2009","5-Day Sum of Pain Intensity Difference (SPID5)",2.8943,"1",24120
"416","NCT00533273","Non-US Study of AA4500 (XIAFLEX™, Proposed Name) in the Treatment of Advanced Dupuytren's Disease","Advanced Dupuytren's Disease","other","Biological: collagenase clostridium histolyticum","biolog","Auxilium Pharmaceuticals","Both","Adult|Senior",66,"August 2007","May 2010","Reduction in Contracture to 5° or Less of the Primary Joint",2.908,"1",24125
"417","NCT00339183","Comparison of Treatment Effect of Chemotherapy With Panitumumab to Chemotherapy Alone","Metastatic Colorectal Cancer","cancer","Drug: Panitumumab|Drug: FOLFIRI","drug","Amgen","Both","Adult|Senior",1186,"May 2006","May 2010","Progression-free Survival (PFS)",2.911237726,"1",24125
"418","NCT00570739","Effects of Metformin Hydrochloride (HCl) in Combination With Colesevelam HCl, Compared to Metformin HCl Alone, in Patients With Type 2 Diabetes Mellitus and the Effe","Type 2 Diabetes Mellitus|Hypercholesterolemia|Pre-diabetes","endocrine and metabolic","Drug: Metformin HCl and Colesevelam Placebo|Drug: Metformin HCl tablets and Colesevelam tablets|Drug: Colesevelam placebo|Drug: Colesevelam","drug","Daiichi Sankyo Inc.","Both","Adult|Senior",502,"November 2007","January 2011","",2.920027944,"1",24133
"419","NCT00668525","Escitalopram in Adult Patients With Major Depressive Disorder","Major Depressive Disorder","mental health","Drug: Escitalopram|Drug: Placebo|Drug: Escitalopram","drug","Forest Laboratories","Both","Adult",877,"April 2008","November 2012","Change From Baseline in Total Montgomery Asberg Depression Rating Scale (MADRS) at 8 Weeks.",2.9286,"1",24155
"420","NCT00562302","Bio-Seal Biopsy Track Plug for Reducing Pneumothorax Rates Post Lung Biopsy Procedure","Pneumothorax","respiratory","Device: Bio-Seal Plug","device","Angiotech Pharmaceuticals","Both","Adult|Senior",339,"April 2005","May 2010","Incidence Rate of Treatment Success",2.938,"1",24125
"421","NCT00407745","A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury","Neuralgia|Spinal Cord Injuries","other","Drug: placebo|Drug: pregabalin","drug","Pfizer","Both","Adult|Senior",220,"January 2007","January 2012","Duration Adjusted Average Change (DAAC) of Mean Pain Score",2.947842552,"1",24145
"422","NCT00561470","Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Bas","Colorectal Neoplasms|Neoplasm Metastasis","cancer","Drug: Placebo|Drug: Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)|Drug: FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)","drug","Sanofi|Regeneron Pharmaceuticals|NSABP Foundation Inc","Both","Adult|Senior",1226,"November 2007","January 2009","Overall Survival (OS)",2.947842552,"1",24109
"423","NCT00772603","Evaluation of Efficacy and Safety of OXC XR as Adjunctive Therapy for Partial Seizures","Epilepsies, Partial","mental health","Drug: Placebo|Drug: 2400mg SPN-804|Drug: 1200mg SPN-804","drug","Supernus Pharmaceuticals, Inc.|Parexel","Both","Adult",366,"November 2008","October 2008","PCH(T)， ITT",2.9677,"1",24106
"424","NCT00781859","Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial.","Vitreomacular Adhesion","other","Drug: 125 µg Ocriplasmin|Drug: Placebo","drug","ThromboGenics","Both","Adult|Senior",326,"December 2008","March 2008","Proportion of Subjects With Nonsurgical Resolution of Focal Vitreomacular Adhesion at Day 28.",2.9677,"1",24099
"425","NCT00782340","A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa","Symptomatic Neurogenic Orthostatic Hypotension (NOH)|Non-diabetic Neuropathy|Primary Au","cardiovascular","Drug: Placebo|Drug: Droxidopa","drug","Chelsea Therapeutics|Chiltern International Inc.","Both","Adult|Senior",263,"September 2008","July 2010","Change in Orthostatic Hypotension Questionnaire Score (OHQ)",2.9677,"1",24127
"426","NCT00843024","Migraine Study in Adolescent Patients","Migraine Disorders","mental health","Drug: Sumatriptan and Naproxen Sodium|Drug: Placebo","drug","GlaxoSmithKline","Both","Child",589,"December 2008","May 2010","Number of Participants Who Were Pain Free at 2 Hours Post-dose",2.9677,"1",24125
"427","NCT00375492","Effect on Weight Loss of Exenatide Versus Placebo","Type 2 Diabetes Mellitus","other","Drug: exenatide|Drug: placebo","drug","AstraZeneca|Eli Lilly and Company","Both","Adult|Senior",196,"September 2006","December 2008","Change From Baseline in Body Weight",2.967737925,"1",24108
"428","NCT00397033","Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.","Schizoaffective Disorder|Psychotic Disorder","mental health","Drug: Paliperidone ER|Drug: Paliperidone ER|Drug: Placebo","drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Janssen, LP","Both","Adult",316,"November 2006","September 2008","Baseline Positive and Negative Symptoms of Schizophrenia (PANSS) Total Score",2.967737925,"1",24105
"429","NCT00988221","A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis","Juvenile Idiopathic Arthritis","other","Drug: Tocilizumab|Drug: Placebo","drug","Hoffmann-La Roche","Both","Child",188,"November 2009","November 2008","Percent of Patients With a Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology 30 (ACR30) Flare in Part II of the Study (Weeks 16-40)",2.9831,"1",24107
"430","NCT01377194","Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder","Major Depressive Disorder","mental health","Drug: Levomilnacipran ER|Drug: Levomilnacipran ER|Drug: Placebo","drug","Forest Laboratories","Both","Adult|Senior",568,"June 2011","May 2010","Change in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score - Mixed-effects Model for Repeated Measures (MMRM) Analysis.",2.999976993,"1",24125
"431","NCT00194012","Study of Aripiprazole (Abilify) Versus Placebo in Children With Subsyndromal Bipolar Disorder","Bipolar Disorder","mental health","Other: Placebo|Drug: Aripiprazole","drug","University Hospital Case Medical Center|Bristol-Myers Squibb","Both","Child",59,"August 2004","May 2011","Youth Mania Rating Scale (YMRS)",3,"1",24137
"432","NCT00506441","A Phase 3, Randomized, Double Blind, Placebo-Controlled, Multi-Center, Withdrawal Study of MCI-196 in CKD on Dialysis With Hyperphosphatemia","Chronic Kidney Disease|Dialysis|Hyperphosphatemia","endocrine and metabolic","Drug: MCI-196|Drug: Placebo","drug","Mitsubishi Tanabe Pharma Corporation","Both","Adult|Senior",245,"September 2007","October 2008","The Change in Serum Phosphorus From Week 12 to Week 16",3.028,"1",24106
"433","NCT01461369","Study of Diclofenac Capsules to Treat Osteoarthritis Pain","Osteoarthritis","other","Drug: Diclofenac|Drug: Diclofenac|Drug: Placebo","drug","Iroko Pharmaceuticals, LLC","Both","Adult|Senior",305,"October 2011","March 2008","Change From Baseline to Week 12 After Trial Entry in Osteoarthritis Pain Measured on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score.",3.035672367,"1",24099
"434","NCT00777023","Study of Gabapentin Extended Release (G-ER)in the Treatment of Vasomotor (Hot Flashes/Hot Flushes) Symptoms in Postmenopausal Women.","Hot Flashes","endocrine and metabolic","Drug: Gabapentin Extended-Release (G-ER) 1200 mg|Drug: Gabapentin Extended-Release (G-ER) 1800 mg|Drug: Placebo","drug","Depomed","Female","Adult|Senior",565,"October 2008","July 2012","Change From Baseline in Average Daily Frequency of Moderate or Severe Hot Flashes After 4 Weeks of Treatment",3.0357,"1",24151
"435","NCT00599521","Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%","Acne Vulgaris","other","Drug: Adapalene lotion 0.1%|Drug: Adapalene Lotion Vehicle","drug","Galderma","Both","Child|Adult|Se",1067,"November 2007","November 2009","Co-Primary Endpoint: Success Rate on Investigator's Global Assessment (IGA) From Baseline to Week 12",3.051,"1",24119
"436","NCT00734578","Efficacy and Safety of SPD503 in Combination With Psychostimulants","ADHD","mental health","Drug: SPD503-AM|Drug: SPD503-PM|Drug: Placebo","drug","Shire","Both","Child",461,"September 2008","January 2009","Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at Week 8 - Last Observation Carried Forward (LOCF)",3.0902,"1",24109
"437","NCT00750152","Multicenter Study of the Safety and Efficacy of NAFT-500 in Tinea Cruris","Tinea Cruris|Jock Itch","other","Drug: NAFT-500|Drug: Placebo","drug","Merz Pharmaceuticals, LLC","Both","Child|Adult|Se",334,"September 2008","October 2009","Percentage of Subjects",3.0902,"1",24118
"438","NCT00798967","Study of Teduglutide Effectiveness in Parenteral Nutrition (PN)-Dependent Short Bowel Syndrome (SBS) Subjects","Short Bowel Syndrome","other","Drug: teduglutide|Drug: placebo","drug","NPS Pharma|Nycomed","Both","Adult|Senior",86,"November 2008","July 2011","Responder",3.0902,"1",24139
"439","NCT00824291","Study Evaluating Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder","Depressive Disorder, Major","mental health","Drug: desvenlafaxine succinate sustained release|Genetic: Genotyping","drug","Wyeth is now a wholly owned subsidiary of Pfizer","Both","Adult|Senior",437,"February 2009","October 2010","Change From Baseline in Hamilton Depression Scale (HAM-D) at Week 12",3.0902,"1",24130
"440","NCT00902174","Imatinib (QTI571) in Pulmonary Arterial Hypertension","Pulmonary Arterial Hypertension","cardiovascular","Drug: imatinib mesylate|Drug: Placebo","drug","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior",202,"September 2009","April 2011","Difference in Six-minute Walk Distance Test (6MWD) Between Imatinib and Placebo at 24 Weeks",3.0902,"1",24136
"441","NCT00541450","A Study to Evaluate the Efficacy and Safety of Sitagliptin and MK0431A in Comparison to a Commonly Used Medication in Patients With Type 2 Diabetes (0431-068)(COMPLE","Type 2 Diabetes Mellitus","endocrine and metabolic","Drug: Comparator: sitagliptin phosphate (sitagliptin)|Drug: sitagliptin phosphate (+) metformin hydrochloride|Drug: Comparator: pioglitazone|Drug: Matching placebo to pioglitazone|Drug: Matching placebo to sitagliptin|Drug: M","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",492,"January 2008","April 2009","Change in Hemoglobin A1c (A1C) in the Sita/Met Fixed-Dose Combination (FDC) or Pioglitazone Groups at 40 Weeks",3.090232306,"1",24112
"442","NCT01163266","Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder","Depressive Disorder, Major","mental health","Drug: Vortioxetine|Drug: Placebo","drug","Takeda","Both","Adult|Senior",462,"July 2010","February 2011","Change From Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score",3.090232306,"1",24134
"443","NCT00662532","Antibiotic Study for Dental Implants","Periodontitis","other","Drug: Minocycline HCl","drug","OraPharma","Both","Adult|Senior",44,"April 2008","June 2008","Overall PD Reduction",3.106,"1",24102
"444","NCT00803634","Clevidipine in the Treatment of Blood Pressure in Patients With Acute Heart Failure (PRONTO)","Hypertension|Heart Failure","cardiovascular","Drug: Clevidipine|Drug: Standard of Care IV antihypertensive","drug","The Medicines Company","Both","Adult|Senior",117,"December 2008","June 2008","Time to First Achieve Initial Prespecified SBP Target Range and 15% Reduction From Baseline Within First 30 Minutes",3.1313,"1",24102
"445","NCT01000311","A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Mon","Meningococcal Disease","other","Biological: MenACWY-CRM|Biological: DTaP-IPV/Hib|Biological: HBV|Biological: PCV|Biological: MMR","biolog","Novartis Vaccines|Novartis","Both","Child",529,"November 2009","March 2010","Percentage of Subjects With hSBA Titer ≥1:8 Against Serogroup A， C， W and Y One Month After Toddler Vaccination of MenACWY-CRM",3.136,"1",24123
"446","NCT00101933","SANTE - Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy","Epilepsy","mental health","Device: Medtronic DBS Therapy for epilepsy|Device: Medtronic DBS Therapy for epilepsy","device","MedtronicNeuro","Both","Adult",157,"December 2003","February 2009","Primary Analysis: Change in Seizure Rate",3.138180768,"1",24110
"447","NCT00397189","Efficacy and Safety of Circadin® 2 mg in the Treatment of Primary Insomnia Patients","Primary Insomnia","mental health","Drug: Circadin|Drug: placebo circadin","drug","Neurim Pharmaceuticals Ltd.","Both","Adult|Senior",930,"October 2006","May 2011","The Change From Baseline in Subjective Sleep Latency.",3.152,"1",24137
"448","NCT00022672","A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® A","Breast Cancer","cancer","Drug: trastuzumab (Herceptin®)|Drug: anastrazole (Arimidex®)","drug","Hoffmann-La Roche|Genentech, Inc.","Female","Adult|Senior",208,"January 2001","September 2008","Progression Free Survival (PFS)",3.155906758,"1",24105
"449","NCT00357994","Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects","Advanced Parkinson's Disease","mental health","Drug: Levodopa carbidopa intestinal gel (LCIG)|Drug: Placebo gel|Drug: Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets|Drug: Placebo (PBO) oral capsules|Device: CADD-Legacy® 1400 ambulatory infusion","device","AbbVie (prior sponsor, Abbott)|Quintiles|AbbVie","Both","Adult|Senior",36,"January 2009","September 2008","Change From Baseline to Week 12 in Average Daily Normalized ""Off"" Time",3.174683527,"1",24105
"450","NCT00660387","Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects","Advanced Parkinson's Disease","mental health","Drug: Levodopa carbidopa intestinal gel (LCIG)|Drug: Placebo Gel|Drug: Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets|Drug: Placebo (PBO) oral capsules|Device: CADD-Legacy® 1400 ambulatory infusion","device","AbbVie (prior sponsor, Abbott)|Quintiles|AbbVie","Both","Adult|Senior",35,"December 2009","June 2008","Change From Baseline to Week 12 in Average Daily Normalized ""Off"" Time",3.1747,"1",24102
"451","NCT00735462","Phase 3 Study of Imiquimod Creams in the Treatment of External Genital Warts","Genital Warts","other","Drug: 2.5% imiquimod cream|Drug: 3.75% imiquimod cream|Drug: Placebo cream","drug","Graceway Pharmaceuticals, LLC","Both","Child|Adult|Se",511,"August 2008","April 2009","Proportion of Subjects Achieving Complete Clearance of All Warts (Baseline and New) at the End of Study.",3.1921,"1",24112
"452","NCT01451541","A Safety and Efficacy Study of Ciclesonide Nasal Aerosol in Subjects 6-11 Years With Perennial Allergic Rhinitis (PAR).","Perennial Allergic Rhinitis|PAR","other","Drug: Ciclesonide nasal aerosol 37 mcg|Drug: ciclesonide nasal aerosol 74 mcg|Drug: Placebo","drug","Sunovion","Both","Child",848,"October 2011","September 2008","The Change From Baseline in Average Daily Subject-reported AM and PM Reflective Total Nasal Symptom Scores (rTNSS) Averaged Weekly Over the First 6 Weeks of the Double-blind Treatment.",3.209,"1",24105
"453","NCT00549549","Celebrex In Acute Gouty Arthritis Study","Arthritis, Gouty","endocrine and metabolic","Drug: Indomethacin|Drug: Celecoxib|Drug: Celecoxib|Drug: Celecoxib","drug","Pfizer","Both","Adult|Senior",402,"February 2008","July 2011","Change From Baseline to Day 2 in Patient's Assessment of Pain Intensity",3.22,"1",24139
"454","NCT00765882","Phase III, Randomized, Double-Blind, Placebo-Controlled, Trial of Linaclotide Administered to Patients With Chronic Constipation","Chronic Constipation","other","Drug: Linaclotide 290 micrograms|Drug: Linaclotide 145 micrograms|Drug: Placebo","drug","Forest Laboratories|Ironwood Pharmaceuticals, Inc.","Both","Adult|Senior",633,"September 2008","February 2008","Complete Spontaneous Bowel Movement (CSBM) Overall Responder",3.2389,"1",24098
"455","NCT01010633","Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery","Inflammation|Pain","other","Drug: Vehicle of Loteprednol Etabonate|Drug: Loteprednol Etabonate","drug","Bausch & Lomb Incorporated","Both","Adult|Senior",406,"November 2009","July 2009","Resolution of Anterior Chamber Cells (ACC).",3.2591,"1",24115
"456","NCT00578331","Safety Study of Olopatadine Nasal Spray","Perennial Allergic Rhinitis","other","Drug: Olopatadine 0.6% nasal spray|Drug: Placebo Nasal Spray","drug","Alcon Research","Both","Child|Adult|Se",890,"December 2006","June 2009","Mean Response at Day 30 to the Patient-rated Relief Assessment Questionnaire",3.26,"1",24114
"457","NCT01028391","30-Week Extension to an Initial Combination Study (24 Weeks in Duration) of Sitagliptin With Pioglitazone (0431-064)","Type 2 Diabetes Mellitus","endocrine and metabolic","Drug: Sitagliptin 100 mg q.d.+ Pioglitazone 45 mg  q.d.|Drug: Pioglitazone 45 mg q.d. + Sitagliptin 100 mg placebo q.d.|Drug: Metformin","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",317,"September 2007","September 2008","Change From Baseline (i.e.， Week 0 of the 24-week Base Study) in Hemoglobin A1c (HbA1c) at Week 54",3.2667,"1",24105
"458","NCT01029652","Canakinumab in the Treatment of Acute Gout Flares and Prevention of New Flares in Patients Unable to Use Non-steroidal Anti-inflammatory Drugs (NSAIDs) and/or Colchi","Acute Gout","endocrine and metabolic","Drug: Canakinumab 150 mg|Drug: Triamcinolone acetonide 40 mg|Drug: Placebo to canakinumab|Drug: Placebo to triamcinolone acetonide","drug","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior",230,"December 2009","September 2008","Time to First New Flare",3.2733,"1",24105
"459","NCT00100659","PEDS-C: Pegylated Interferon +/- Ribavirin for Children With Hepatitis C","Chronic Hepatitis C","other","Drug: Pegylated Interferon/ribavirin","drug","National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Roche Pharma AG","Both","Child|Adult",114,"December 2004","July 2011","Sustained Viral Response (SVR)",3.283,"1",24139
"460","NCT00662675","A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency","Exocrine Pancreatic Insufficiency|Steatorrhea|Malabsorption Syndromes|Cystic Fibrosis","endocrine and metabolic","Drug: Pancrease MT 10.5, or MT 21|Drug: Placebo for Pancrease MT 10.5 or MT 21","drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Both","Child|Adult",40,"August 2008","September 2008","Change in the Coefficient of Fat Absorption (COA-fat Percent)",6.134,"1",24105
"461","NCT00690820","Study Investigating a Delayed-Release Pancrelipase in Patients With Pancreatic Exocrine Insufficiency (PEI) Due to Cystic Fibrosis (CF)","Cystic Fibrosis|Pancreatic Exocrine Insufficiency","endocrine and metabolic","Drug: Pancrelipase Delayed Release|Drug: Placebo Comparator","drug","Solvay Pharmaceuticals","Both","Child",17,"June 2008","April 2011","Coefficient of Fat Absorption (%)",7.544,"1",24136
"462","NCT00692913","A Study to Test the Effect of MK0217A on Vitamin D Inadequacy in Postmenopausal Women With Osteoporosis (0217A-262)","Osteoporosis","endocrine and metabolic","Drug: FOSAVANCE 5600 (Alendronate Sodium (+) cholecalciferol)|Dietary Supplement: Calcium Supplement 500 mg|Other: Referred-Care Model","drug","Merck Sharp & Dohme Corp.","Female","Adult|Senior",515,"June 2008","January 2009","Percentage of Participants With Serum Levels of 25-hydroxyvitamin D Below 20 ng/mL at Week 26",5.637,"1",24109
"463","NCT00700427","A Long Term Study of a Medication for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)","Attention Deficit Hyperactivity Disorder","mental health","Drug: atomoxetine hydrochloride|Drug: Placebo","drug","Eli Lilly and Company","Both","Adult",2017,"June 2008","December 2008","Percentage of Participants Who Maintain a Satisfactory Response During the Double-Blind Maintenance/Randomized Withdrawal Period",3.344,"1",24108
"464","NCT00703118","A Safety and Effectiveness Study of Telaprevir in Chronic, Genotype 1, Hepatitis C Patients That Failed Previous Standard Treatment","Hepatitis C, Chronic","other","Drug: Telaprevir|Drug: Peg-IFN-alfa-2a|Drug: Ribavirin|Drug: Placebo","drug","Tibotec BVBA|Tibotec Pharmaceutical Limited","Both","Adult|Senior",663,"October 2008","July 2009","Number of Participants With Sustained Virologic Response (SVR) 24 Weeks After the Last Planned Dose of Study Medication - SVR24 Planned",9.265,"1",24115
"465","NCT00704730","Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer","Thyroid Cancer","cancer","Drug: XL184|Drug: Placebo","drug","Exelixis","Both","Adult|Senior",330,"June 2008","June 2008","Progression-Free Survival (PFS)",6.995,"1",24102
"466","NCT00706849","Efficacy and Safety Study of ISIS 301012 (Mipomersen) as Add-on in Familial Hypercholesterolemic Patients With Coronary Artery Disease","Heterozygous Familial Hypercholesterolemia|Coronary Artery Disease","cardiovascular","Drug: mipomersen sodium|Drug: placebo","drug","Genzyme, a Sanofi Company|Isis Pharmaceuticals|Sanofi","Both","Adult|Senior",124,"July 2008","September 2008","Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at the Primary Efficacy Time Point",5.574,"1",24105
"467","NCT00722371","MK0431 and Pioglitazone Co-Administration Factorial Study in Patients With Type 2 Diabetes Mellitus (0431-102 AM2)","Type 2 Diabetes Mellitus","endocrine and metabolic","Drug: Sitagliptin phosphate|Drug: Pioglitazone hydrochloride|Drug: Matching placebo to sitagliptin|Drug: Matching placebo to pioglitazone|Drug: Metformin","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",1615,"September 2008","May 2010","Change From Baseline in Hemoglobin A1C (A1C) at Week 24",3.087,"1",24125
"468","NCT00728416","Study of Nasonex in the Relief of Nasal Congestion in Patients With Seasonal Allergic Rhinitis (Study P05583)","Allergic Rhinitis","other","Drug: Mometasone furoate nasal spray (MFNS)|Drug: Matching placebo nasal spray","drug","Merck Sharp & Dohme Corp.","Both","Child|Adult|Se",333,"August 2008","April 2008","Change From Baseline in Average AM/PM PRIOR Nasal Congestion Score Over 15 Days",5.063,"1",24100
"469","NCT00734162","Evaluation of Tenofovir Disoproxil Fumarate in Adolescents With Chronic Hepatitis B Infection","Hepatitis B Virus (HBV)","other","Drug: Tenofovir disoproxil fumarate (TDF)|Drug: Placebo","drug","Gilead Sciences","Both","Child",106,"September 2008","March 2010","Percentage of Participants With HBV Deoxyribonucleic Acid (DNA) < 400 Copies/mL at Week 72",9.487,"1",24123
"470","NCT00753688","Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy","Sarcoma, Soft Tissue","cancer","Drug: PAZOPANIB|Drug: Placebo","drug","GlaxoSmithKline","Both","Adult|Senior",369,"October 2008","December 2009","Progression-free Survival (PFS)",6.514,"1",24120
"471","NCT00755807","Duloxetine for Multiple Sclerosis Pain","Multiple Sclerosis","mental health","Drug: Duloxetine Hydrochloride (HCI)|Drug: Placebo","drug","Eli Lilly and Company","Both","Adult|Senior",239,"October 2008","April 2008","Change From Baseline in the Weekly 24-Hour Average Pain Scores at Week 6 (Acute Phase)",3.255,"1",24100
"472","NCT00765817","Addition Of Exenatide To Insulin Glargine In Type 2 Diabetes Mellitus","Type 2 Diabetes","endocrine and metabolic","Drug: placebo|Drug: exenatide","drug","AstraZeneca|Eli Lilly and Company","Both","Adult|Senior",261,"October 2008","April 2008","Change in Glycosylated Hemoglobin (HbA1c)",5.578,"1",24100
"473","NCT00767806","A Study for Patient With Chronic Low Back Pain","Chronic Low Back Pain","other","Drug: Duloxetine|Drug: Placebo","drug","Eli Lilly and Company","Both","Adult|Senior",401,"September 2008","July 2010","Change From Baseline to 12 Weeks in Brief Pain Inventory 24-hour Average Pain Score",3.101,"1",24127
"474","NCT00782184","Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED)","Hypercholesterolemia","cardiovascular","Drug: ezetimibe/simvastatin 10/40|Drug: atorvastatin 40 mg|Drug: atorvastatin 20 mg","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",250,"November 2008","October 2010","",4.78,"1",24130
"475","NCT00783263","A Study of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients With Hypercholesterolemia (MK0653-139)","Hypercholesterolemia","cardiovascular","Drug: Comparator: rosuvastatin 5 mg + ezetimibe 10 mg|Drug: Comparator: rosuvastatin 10 mg|Drug: Comparator: rosuvastatin 10 mg + ezetimibe 10 mg|Drug: Comparator: rosuvastatin 20 mg","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",440,"November 2008","June 2012","Percent Change From Baseline in LDL-Cholesterol (mg/dL) After 6 Weeks of Treatment",6.442,"1",24150
"476","NCT00789191","Effect of Detemir and Sitagliptin on Blood Glucose Control in Type 2 Diabetes","Diabetes|Diabetes Mellitus, Type 2","endocrine and metabolic","Drug: insulin detemir|Drug: sitagliptin|Drug: metformin|Drug: sulphonylurea","drug","Novo Nordisk A/S","Both","Adult|Senior",222,"November 2008","June 2009","HbA1c (Glycosylated Haemoglobin A1c)",4.9,"1",24114
"477","NCT00887224","Relapse Prevention Study Of Desvenlafaxine Succinate Sustained Release In Outpatients With Major Depressive Disorder","Major Depressive Disorder","mental health","Drug: Desvenlafaxine succinate sustained release 50 mg|Drug: Desvenlafaxine succinate sustained release 25 mg|Drug: Placebo","drug","Pfizer","Both","Adult|Senior",874,"June 2009","October 2011","Time to Relapse Following Randomization to the Double-blind (DB) Phase: Estimated Probability (Percent) of Relapse at DB Day 185",4.563,"1",24142
"478","NCT00900731","A Study to Compare the Lung Effect of Indacaterol and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)","Chronic Obstructive Pulmonary Disease","respiratory","Drug: Indacaterol 150 μg|Drug: Tiotropium 18 μg|Drug: Placebo to indacaterol|Drug: Placebo to tiotropium","drug","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior",1598,"June 2009","February 2011","Trough Forced Expiratory Volume in 1 Second (FEV1) at End of Treatment (Week 12)",0.707,"1",24134
"479","NCT00910520","Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence","Overactive Bladder","other","Biological: onabotulinumtoxinA|Drug: normal saline","biolog","Allergan","Both","Adult|Senior",548,"September 2009","June 2010","Change From Baseline in Number of Daily Episodes of Urinary Incontinence",6.811,"1",24126
"480","NCT00910845","Study of Botulinum Toxin Type A for the Treatment of Patients With Idiopathic Overactive Bladder With Urinary Incontinence","Overactive Bladder","other","Biological: onabotulinumtoxinA|Drug: normal saline","biolog","Allergan","Both","Adult|Senior",557,"September 2009","May 2010","Change From Baseline in Number of Daily Episodes of Urinary Incontinence",6.794,"1",24125
"481","NCT00916006","A Multi-center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)","Actinic Keratosis","other","Drug: PEP005 Gel|Drug: Vehicle Gel","drug","Peplin","Both","Adult|Senior",269,"June 2009","July 2012","Patients With Complete Clearance of Actinic Keratosis (AK) Lesions.",8.087,"1",24151
"482","NCT00929110","1-year Study to Assess the Efficacy, Safety, and Tolerability of Glycopyrronium Bromide (NVA237) in Chronic Obstructive Pulmonary Disease (COPD)","Chronic Obstructive Pulmonary Disease","respiratory","Drug: Glycopyrronium bromide|Drug: Placebo to glycopyrronium bromide|Drug: Tiotropium","drug","Novartis","Both","Adult|Senior",1066,"June 2009","May 2009","Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 12",4.405,"1",24113
"483","NCT00942604","A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations","Actinic Keratoses","other","Drug: PEP005 (ingenol mebutate) Gel|Drug: Vehicle gel","drug","Peplin","Both","Adult|Senior",203,"July 2009","November 2012","Proportion of Patients With Complete Clearance of Actinic Keratoses (AK) Lesions",6.914,"1",24155
"484","NCT00973479","An Effectiveness and Safety Study of Intravenous Golimumab in Patients With Active Rheumatoid Arthritis Despite Treatment With Methotrexate Therapy","Arthritis, Rheumatoid","other","Drug: Golimumab|Other: Placebo|Drug: methotrexate (MTX)","drug","Centocor, Inc.|Schering-Plough","Both","Adult|Senior",592,"September 2009","December 2011","Proportion of Participants With an American College of Rheumatology (ACR) 20 Response at Week 14",8.497,"1",24144
"485","NCT00997984","Tolerability and Efficacy of AM and PM Once Daily Dosing With Extended-release Guanfacine Hydrochloride in Children 6-12 With Attention-Deficit/Hyperactivity Disorde","Attention-Deficit/Hyperactivity Disorder","mental health","Drug: extended-release guanfacine hydrochloride (SPD503)|Drug: placebo|Drug: extended-release guanfacine hydrochloride","drug","Shire","Both","Child",340,"November 2009","March 2011","Change From Baseline in Attention-Deficit/Hyperactivity Disorder-Rating Scale-IV (ADHD-RS-IV) Total Score at Week 8 - Last Observation Carried Forward (LOCF)",6.503,"1",24135
"486","NCT01005901","A Study to Assess the Safety, Tolerability and Efficacy of NVA237 Versus Placebo","Chronic Obstructive Pulmonary Disease","respiratory","Drug: Glycopyrronium bromide|Drug: Placebo","drug","Novartis","Both","Adult|Senior",1324,"October 2009","September 2011","Trough Forced Expiratory Volume in 1 Second (FEV1) at 12 Weeks",6.01,"1",24141
"487","NCT01009086","A Study of the Safety and Effectiveness of Ustekinumab in Patients With Psoriatic Arthritis","Arthritis, Psoriatic","other","Drug: Placebo|Drug: Ustekinumab 45 mg|Drug: Ustekinumab 90 mg","drug","Janssen Research & Development, LLC","Both","Adult|Senior",615,"December 2009","January 2008","Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24.",4.333,"1",24097
"488","NCT01017120","A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne","Acne Vulgaris","other","Drug: Tazarotene Foam|Drug: Vehicle Foam","drug","Stiefel, a GSK Company|GlaxoSmithKline","Both","Child|Adult",742,"October 2009","December 2010","Absolute Change in Lesion Counts (LCs) From Baseline to Week 12",3.748,"1",24132
"489","NCT01017146","A Study to Evaluate the Safety and Efficacy of Tazarotene Foam, 0.1%, in Subjects With Common Facial Acne - W0260-301","Acne Vulgaris","other","Drug: Tazarotene foam|Drug: Vehicle Foam","drug","Stiefel, a GSK Company|GlaxoSmithKline","Both","Child|Adult",744,"October 2009","April 2010","Absolute Change in Lesion Counts (LCs) From Baseline to Week 12",4.535,"1",24124
"490","NCT01018680","A Study Comparing Duloxetine Versus Placebo in Patients Taking a Nonsteroidal Anti-inflammatory Drug (NSAID) for Knee Pain Due to Osteoarthritis","Osteoarthritis Knee Pain","other","Drug: Duloxetine|Drug: Placebo","drug","Eli Lilly and Company","Both","Adult|Senior",524,"November 2009","August 2012","Change From Baseline in the Weekly Mean of the 24-Hour Average Pain Score at 8 Weeks",5.85,"1",24152
"491","NCT01024608","Study in Adult and Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)","Seasonal Allergic Rhinitis|Hay Fever","other","Drug: Beclomethasone dipropionate|Drug: Placebo Nasal Aerosol","drug","Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Both","Child|Adult|Se",340,"December 2009","April 2008","Change From Baseline in Average Subject-Reported AM and PM Reflective Total Nasal Symptom Score (rTNSS) Over the Two-week Treatment Period",4.573,"1",24100
"492","NCT01033071","Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone Compared to Olmesartan Medoxomil and Hydrochlorothiazide in Participants With Moderate to Severe Hyper","Essential Hypertension","cardiovascular","Drug: Azilsartan medoxomil  and chlorthalidone|Drug: Azilsartan medoxomil  and chlorthalidone|Drug: Olmesartan medoxomil and hydrochlorothiazide","drug","Takeda","Both","Adult|Senior",1071,"January 2010","January 2009","Change From Baseline in Trough， Sitting， Clinic Systolic Blood Pressure.",4.516,"1",24109
"493","NCT00048568","A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate","Rheumatoid Arthritis","other","Drug: Abatacept|Drug: Methotrexate|Drug: Placebo","drug","Bristol-Myers Squibb","Both","Adult|Senior",1250,"December 2002","January 2009","Number of American College of Rheumatology 20 (ACR 20) Responders at Day 169",6.502,"1",24109
"494","NCT00049842","Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED)","Chronic Hepatitis C|Liver Fibrosis","other","Biological: peginterferon alfa-2b (SCH 54031)","biolog","Merck Sharp & Dohme Corp.","Both","Adult",540,"October 2002","April 2011","Fibrosis Response Status (ie， Improvement， no Change， or the Worsening of the Fibrosis Score in Participants With Baseline METAVIR Fibrosis Score of F2 or F3).",0.994,"1",24136
"495","NCT00094458","Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (S","Crohn Disease","other","Biological: infliximab infusion; AZA placebo caps|Other: infliximab (IFX) infusion; azathioprine (AZA) caps|Drug: infliximab (IFX) placebo infusion; azathioprine (AZA) caps","biolog","Centocor Ortho Biotech Services, L.L.C.|Schering-Plough","Both","Adult|Senior",508,"March 2005","February 2008","Corticosteriod-free Clinical Remission",5.17,"1",24098
"496","NCT00213135","A Safety and Efficacy Study of Oral Cladribine in Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)","Multiple Sclerosis, Relapsing-Remitting","mental health","Drug: Cladribine 5.25 mg/kg|Drug: Cladribine 3.5 mg/kg|Other: Placebo","drug","EMD Serono","Both","Adult",1326,"April 2005","November 2011","Annualized Qualifying Relapse Rate",7.262,"1",24143
"497","NCT00227370","Comparison of Oral Valganciclovir and Placebo for the Prevention of Cytomegalovirus (CMV) After Lung Transplantation","Cytomegalovirus Infections","other","Drug: valganciclovir|Other: Placebo","drug","Scott Palmer|Roche Pharma AG|Duke University","Both","Adult|Senior",136,"July 2003","January 2008","Incidence of CMV End Organ Disease",5.151,"1",24097
"498","NCT00276458","To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 20 mg (0653-079)(COMPLETED)","Hypercholesterolemia","cardiovascular","Drug: Comparator: atorvastatin|Drug: Comparator: Placebo|Drug: Comparator: ezetimibe|Drug: Comparator: Placebo.","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",196,"February 2006","May 2008","Percent Change From Baseline in Low Density Lipoprotein-Cholesterol (LDL-C) at Week 6",7.359,"1",24101
"499","NCT00307047","SPIRIT IV Clinical Trial: Clinical Evaluation of the XIENCE V® Everolimus Eluting Coronary Stent System","Coronary Artery Disease","cardiovascular","Device: XIENCE V® Everolimus Eluting Coronary Stent|Device: TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent","device","Abbott Vascular","Both","Adult|Senior",3687,"August 2006","August 2009","",3.351,"1",24116
"500","NCT00311376","Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Neurogenic Overactive Bladder","Overactive Bladder","other","Biological: botulinum toxin Type A (200U)|Biological: botulinum toxin Type A (300U)|Other: Normal Saline (Placebo); botulinum toxin Type A (200U)|Other: Normal Saline (Placebo); botulinum toxin Type A (300U)","biolog","Allergan","Both","Adult|Senior",416,"August 2006","May 2009","Change From Baseline in Number of Weekly Episodes of Urinary Incontinence",6.974,"1",24113
"501","NCT00314249","Study of Milnacipran for the Treatment of Fibromyalgia","Fibromyalgia","mental health","Drug: Placebo|Drug: Milnacipran 100mg","drug","Forest Laboratories|Cypress Bioscience, Inc.","Both","Adult|Senior",1025,"April 2006","April 2008","",3.982,"1",24100
"502","NCT00323284","A Study of the Trabecular Micro-bypass Stent in Combination With Cataract Surgery in Subjects With Open Angle Glaucoma","Open-Angle Glaucoma","other","Device: iStent plus Cataract Surgery|Procedure: Cataract surgery only","device","Glaukos Corporation","Both","Adult|Senior",240,"June 2005","April 2009","Efficacy",3.583,"1",24112
"503","NCT00328627","Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.","Type 2 Diabetes Mellitus","endocrine and metabolic","Drug: Alogliptin|Drug: Alogliptin placebo|Drug: Pioglitazone|Drug: Pioglitazone placebo","drug","Takeda","Both","Adult|Senior",1554,"May 2006","January 2010","Change From Baseline to Week 26 in Glycosylated Hemoglobin (HbA1c) (Grouped Analysis)",8.141,"1",24121
"504","NCT00332241","Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)","Autistic Disorder","mental health","Drug: Aripiprazole|Drug: Placebo","drug","Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka America Pharmaceutical","Both","Child",98,"June 2006","April 2011","Mean Change (Week 8 - Baseline) in the Autistic Behavior Checklist (ABC) Irritability Subscale Score",3.893,"1",24136
"505","NCT00340834","Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension Phase","Multiple Sclerosis","mental health","Drug: Fingolimod 1.25 mg|Drug: Fingolimod 0.5 mg|Drug: Interferon β-1a 30 µg","drug","Novartis","Both","Adult",1292,"May 2006","January 2010","Estimated Annualized Aggregate Relapse Rate (ARR) in the Core Phase of the Study",2.77,"1",24121
"506","NCT00358436","Efficacy and Safety of LAS 34273 in Patients With Moderate to Severe Stable Chronic Obstructive Pulmonary Disease(COPD)","Chronic Obstructive Pulmonary Disease","respiratory","Drug: Aclidinium bromide|Drug: Placebo","drug","Almirall, S.A.|Forest Laboratories","Both","Adult|Senior",804,"July 2006","July 2008","Trough FEV1 (L) at 28 Weeks on Treatment",3.597,"1",24103
"507","NCT00371137","A Safety and Efficacy Study of Xyrem® in Subjects With Fibromyalgia","Fibromyalgia","other","Drug: Xyrem®|Drug: Placebo","drug","Jazz Pharmaceuticals","Both","Adult|Senior",548,"August 2006","February 2009","Pain VAS (Visual Analog Scale) Response. Percentage of Subjects With a Greater Than or Equal to 30% Reduction in Pain VAS From Baseline (BOCF).",3.818,"1",24110
"508","NCT00381485","Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04431AM2)(COMPLETED)","Asthma","respiratory","Drug: Mometasone furoate/formoterol (MF/F) combination|Drug: Mometasone furoate/formoterol (MF/F) combination|Drug: Mometasone furoate MDI (MF MDI)","drug","Merck Sharp & Dohme Corp.|Novartis","Both","Child|Adult|Se",834,"July 2006","March 2012","Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 12 in Forced Expiratory Volume (Liters) in 1 Second (FEV1)",6.22,"1",24147
"509","NCT00383240","Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04334AM1)(COMPLETED)","Asthma","respiratory","Drug: mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID|Drug: Mometasone furoate MDI (MF MDI) 200 mcg|Drug: formoterol fumarate 10 mcg|Drug: Placebo","drug","Merck Sharp & Dohme Corp.|Novartis","Both","Child|Adult|Se",781,"September 2006","August 2009","Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 12 in Forced Expiratory Volume (Liters) in 1 Second (FEV1) for MF/F Versus MF",4.604,"1",24116
"510","NCT00383435","Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in COPD (Study P04229AM4)(COMPLETED)","Chronic Obstructive Pulmonary Disease (COPD)","respiratory","Drug: Mometasone furoate/formoterol (MF/F) combination|Drug: Mometasone furoate/formoterol (MF/F) combination|Drug: Mometasone furoate MDI (MF MDI)|Drug: Formoterol MDI|Drug: Placebo","drug","Merck Sharp & Dohme Corp.|Novartis","Both","Adult|Senior",1055,"October 2006","September 2011","Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 13 in Forced Expiratory Volume (Liters) in 1 Second (FEV1)",4.334,"1",24141
"511","NCT00383552","Effects of Mometasone Furoate/Formoterol Combination Versus Mometasone Furoate Alone in Persistent Asthmatics (Study P04073AM1)(COMPLETED)","Asthma","respiratory","Drug: Mometasone Furoate/Formoterol Fumarate Combination MDI 100/10 mcg BID|Drug: Mometasone Furoate MDI (MF MDI)|Drug: Formoterol Fumarate 10 mcg|Drug: Placebo","drug","Merck Sharp & Dohme Corp.|Novartis","Both","Child|Adult|Se",746,"September 2006","November 2010","Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 12 in Forced Expiratory Volume (Liters) in 1 Second (FEV1)",3.494,"1",24131
"512","NCT00383721","Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in Chronic Obstructive Pulmonary Disease (COPD) (Study P04230AM4)","Chronic Obstructive Pulmonary Disease (COPD)","respiratory","Drug: Mometasone furoate/formoterol (MF/F) combination|Drug: Mometasone furoate/formoterol (MF/F) combination|Drug: Mometasone furoate MDI (MF MDI)|Drug: Formoterol MDI|Drug: Placebo","drug","Merck Sharp & Dohme Corp.|Novartis","Both","Adult|Senior",1196,"September 2006","June 2008","Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 13 in Forced Expiratory Volume (Liters) in 1 Second (FEV1)",4.932,"1",24102
"513","NCT00386308","Efficacy and Safety Study of XP12B in Women With Menorrhagia","Menorrhagia|Heavy Menstrual Bleeding","other","Drug: Tranexamic acid tablets|Drug: Placebo tablets","drug","Ferring Pharmaceuticals","Female","Adult",196,"October 2006","November 2010","",6.555,"1",24131
"514","NCT00391872","A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome","Acute Coronary Syndrome","cardiovascular","Drug: Ticagrelor|Drug: Clopidogrel","drug","AstraZeneca","Both","Adult|Senior",18624,"October 2006","August 2008","Participants With Any Event From the Composite of Death From Vascular Causes， Myocardial Infarction (MI)， and Stroke",3.304,"1",24104
"515","NCT00395343","Sitagliptin Added-on to Insulin Study (0431-051)","Type 2 Diabetes Mellitus","endocrine and metabolic","Drug: sitagliptin phosphate|Drug: Comparator : placebo (unspecified)","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",641,"December 2006","February 2010","Change From Baseline in A1C at Week 24",7.84,"1",24122
"516","NCT00395512","Efficacy of Alogliptin With Pioglitazone (Actos®) in Subjects With Type 2 Diabetes Mellitus","Diabetes Mellitus","endocrine and metabolic","Drug: Alogliptin|Drug: Pioglitazone|Drug: Placebo","drug","Takeda","Both","Adult|Senior",655,"November 2006","May 2011","Change From Baseline to Week 26 in Glycosylated Hemoglobin (HbA1c)",4.989,"1",24137
"517","NCT00397631","Initial Combination With Pioglitazone Study (0431-064)","Type 2 Diabetes Mellitus","endocrine and metabolic","Drug: sitagliptin 100 mg q.d./pioglitazone 30 mg q.d|Drug: Comparator: placebo to match sitagliptin 100 mg q.d./pioglitazone 30 mg q.d.","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",520,"December 2006","March 2010","Change From Baseline in HbA1c (Hemoglobin A1C) at Week 24",7.268,"1",24123
"518","NCT00397839","The Effect Of Oral Ibandronate In Male Osteoporosis","Male Osteoporosis","endocrine and metabolic","Drug: Ibandronate|Drug: placebo","drug","Hoffmann-La Roche|GlaxoSmithKline","Male","Adult|Senior",135,"January 2007","August 2012","Mean Percent Change in BMD of the Lumbar Spine From Baseline to Month 12",4.285,"1",24152
"519","NCT00406367","IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Blepharospasm","Blepharospasm","other","Drug: incobotulinumtoxinA (Xeomin)|Drug: Placebo","drug","Merz Pharmaceuticals GmbH","Both","Adult|Senior",109,"October 2006","May 2009","Jankovic Rating Scale (JRS) Change From Baseline in the JRS Severity Subscore at Week 6 After Injection (Assessed by a Blinded Independent Rater)",4.9,"1",24113
"520","NCT00407030","IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Cervical Dystonia","Cervical Dystonia","other","Drug: incobotulinumtoxinA (Xeomin) (240 Units)|Drug: incobotulinumtoxinA (Xeomin) (120 Units)|Drug: Placebo","drug","Merz Pharmaceuticals GmbH","Both","Adult|Senior",233,"July 2006","December 2009","Change From Baseline in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) -Total Score at Week 4 After Injection of the Main Period - Xeomin (240 Units) Versus Placebo",5.88,"1",24120
"521","NCT00412373","Evaluation of Effectiveness and Safety of Flexible-dose Paliperidone Extended Release in Patients With Schizoaffective Disorder.","Schizoaffective Disorder|Psychotic Disorder","mental health","Drug: Placebo|Drug: Paliperidone ER|Drug: Paliperidone ER","drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Janssen, LP","Both","Adult",307,"December 2006","December 2008","Positive and Negative Symptoms of Schizophrenia (PANSS) Total Score at Baseline.",0.306,"1",24108
"522","NCT00419744","A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD","Chronic Obstructive Pulmonary Disease","respiratory","Drug: Budesonide/formoterol (SYMBICORT) pMDI|Drug: Formoterol Turbuhaler","drug","AstraZeneca","Both","Adult|Senior",1200,"January 2007","January 2008","Total Number of Chronic Obstructive Pulmonary Disease (COPD) Exacerbations Per Patient-treatment Year",4.182,"1",24097
"523","NCT00422734","Tadalafil Taken Daily Compared to Placebo on Improvement of Getting and Maintaining an Erection and Sexual Quality of Life","Impotence","other","Drug: tadalafil|Drug: Placebo","drug","Eli Lilly and Company|ICOS Corporation","Male","Adult|Senior",342,"November 2006","November 2008","Change From Baseline to Endpoint in the International Index of Erectile Function (IIEF)- Erectile Function Domain Score (Sum of IIEF Questions 1-5 and 15)",8.37,"1",24107
"524","NCT00423813","A Safety and Efficacy Study of Xyrem® (Sodium Oxybate) to Treat Fibromyalgia.","Fibromyalgia","other","Drug: placebo|Drug: Xyrem®","drug","Jazz Pharmaceuticals","Both","Adult|Senior",573,"December 2006","December 2012","Pain VAS (Visual Analog Scale) Response. Percentage of Subjects With a Greater Than or Equal to 30% Reduction in Pain VAS From Baseline (BOCF).",3.373,"1",24156
"525","NCT00433290","Duloxetine vs. Placebo in the Treatment of Osteoarthritis Knee Pain","Osteoarthritis Knee Pain","other","Drug: Duloxetine|Drug: Placebo","drug","Eli Lilly and Company","Both","Adult|Senior",256,"February 2007","July 2008","Change in Brief Pain Inventory (BPI) 24-hour Average Rating",3.1,"1",24103
"526","NCT00449176","A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) Extended Release (ER) in Patients With Moderate to Severe Chronic Low Back Pain","Low Back Pain","other","Drug: tapentadol (CG5503) ER|Drug: oxycodone CR|Drug: placebo","drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Grünenthal GmbH","Both","Adult|Senior",981,"February 2007","September 2008","Change From Baseline of the Average Pain Intensity Based on a 11-point Numerical Rating Scale (NRS) Over the Last Week of the Maintenance Period at Week 12.",4.211,"1",24105
"527","NCT00455520","A Safety and Efficacy Study for Tapentadol (CG5503) Extended Release for Patients With Painful Diabetic Peripheral Neuropathy","Diabetic Neuropathy","mental health","Drug: CG5503|Drug: placebo","drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Grünenthal GmbH","Both","Adult|Senior",395,"April 2007","March 2009","Change From Baseline (at Randomization) in Average Pain Intensity on an 11-point Numerical Rating Scale (NRS) Over the Last Week of the Double-blind Maintenance Period at Week 12",6.5,"1",24111
"528","NCT00456521","A Safety and Efficacy Study of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects Participating in an Intensive Behavior Modification Program","Obesity|Overweight","other","Drug: Naltrexone SR 32 mg/ bupropion SR 360 mg/ day|Drug: Placebo|Behavioral: Intensive group lifestyle modification counseling","drug","Orexigen Therapeutics, Inc","Both","Adult",793,"March 2007","April 2008","Co-primary: Body Weight- Mean Percent Change",6.112,"1",24100
"529","NCT00463606","A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With Dyslipidemia","Hypercholesterolemia|Dyslipidemia","cardiovascular","Drug: ABT-335 and rosuvastatin calcium|Drug: ABT-335|Drug: rosuvastatin calcium","drug","AstraZeneca","Both","Adult|Senior",760,"April 2007","April 2011","Mean Percent Change From Baseline to the Final Visit in High-density Lipoprotein Cholesterol (HDL-C) (Full Analysis Set)",5.657,"1",24136
"530","NCT00465985","Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome","Muckle Wells Syndrome","other","Drug: ACZ885|Drug: Placebo","drug","Novartis","Both","Child|Adult|Se",35,"April 2007","February 2008","Percent of Participants With Disease Flare in Part II (After 24 Weeks of the Double-blind Part)",8.34,"1",24098
"531","NCT00474630","A Safety and Efficacy Study Comparing Naltrexone SR/Bupropion SR and Placebo in Obese Subjects With Type 2 Diabetes","Obesity|Overweight|Diabetes Mellitus, Type 2","other","Drug: Naltrexone SR 32 mg/bupropion SR 360 mg/ day|Drug: Placebo|Behavioral: Ancillary therapy","drug","Orexigen Therapeutics, Inc","Both","Adult|Senior",505,"May 2007","September 2011","Co-primary: Body Weight- Mean Percent Change",6.065,"1",24141
"532","NCT00478205","Comparison of 23 mg Donepezil Sustained Release (SR) to 10 mg Donepezil Immediate Release (IR) in Patients With Moderate to Severe Alzheimer's Disease","Alzheimer's Disease","mental health","Drug: Aricept (donepezil SR 23 mg)|Drug: Aricept (donepezil IR 10 mg)","drug","Eisai Inc.|Eisai Limited","Both","Adult|Senior",1467,"June 2007","October 2009","Change From Baseline to Week 24 in SIB Total Score",2.504,"1",24118
"533","NCT00482729","MK0431A Comparative Study in Patients With Type 2 Diabetes (0431A-079)(COMPLETED)","Type 2 Diabetes Mellitus","endocrine and metabolic","Drug: sitagliptin phosphate (+) metformin hydrochloride|Drug: metformin","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",1246,"June 2007","December 2011","Change From Baseline in Hemoglobin A1c (A1C) at Week 18",6.533,"1",24144
"534","NCT00483704","Multiple Attacks Study to Compare the Efficacy and Safety of MK-0974 With Placebo for Acute Migraine (MK-0974-031)","Migraines","mental health","Drug: Telcagepant 140 mg|Drug: Talcagepant 280 mg|Drug: Placebo","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",1935,"August 2008","August 2009","Percentage of Participants Reporting Pain Freedom at 2 Hours Post-dose (First Migraine Attack)",5.323,"1",24116
"535","NCT00485758","Extended Niacin/Laropiprant in Patients With Type 2 Diabetes (0524A-069)","Diabetes Mellitus Type 2","endocrine and metabolic","Drug: ER niacin/laropiprant|Drug: Comparator : placebo (unspecified)","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",796,"July 2007","November 2008","Percent Change at Week (Wk) 12 Compared to Baseline (Bl) in Low-density Lipoprotein Cholesterol in Patients With Type 2 Diabetes When Compared to Placebo",9.944,"1",24107
"536","NCT00499863","Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD","ADHD","mental health","Drug: methylphenidate transdermal system (DAYTRANA)|Drug: Placebo","drug","Shire","Both","Child",217,"July 2007","January 2009","Change From Baseline in the Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at Endpoint",5.739,"1",24109
"537","NCT00510068","Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors","Advanced Neuroendocrine Tumors","cancer","Drug: Everolimus|Drug: Placebo","drug","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior",410,"July 2007","March 2012","Time to Progression Free Survival (PFS) Based as Per Investigator Using Kaplan-Meier Methodology",8.187,"1",24147
"538","NCT00516737","Study to Test Rizatriptan in the Early Treatment of Acute Migraine (0462-081)","Migraine","mental health","Drug: Comparator: rizatriptan benzoate|Drug: Comparator: Placebo","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",207,"October 2007","March 2009","Number of Participants Who Are Pain Free at 2 Hours Post-Dose",5.64,"1",24111
"539","NCT00524030","Efficacy And Safety Study Of Pregabalin (Lyrica) As Monotherapy In Patients With Partial Seizures","Epilepsies, Partial","mental health","Drug: pregabalin 600 mg/day|Drug: pregabalin 150 mg/day","drug","Pfizer","Both","Adult|Senior",161,"September 2007","March 2011","Percentage of Participants in the Pregabalin 600 mg/Day Treatment Group Discontinuing the Study Due to at Least 1 Pre-Defined Seizure Exit Criteria",6.318,"1",24135
"540","NCT00526474","Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737)","Atherosclerosis|Ischemia|Myocardial Infarction|Cerebrovascular Accident|Peripheral Arte","cardiovascular","Drug: Vorapaxar|Drug: Placebo","drug","Merck Sharp & Dohme Corp.|The Thrombolysis in Myocardial Infarction Study (TIMI) Group","Both","Adult|Senior",26449,"September 2007","May 2008","Kaplan-Meier Estimate of the Percentage of Participants Who Experienced Cardiovascular (CV) Death， Myocardial Infarction (MI)， Stroke， or Urgent Coronary Revascularization (UCR) Within 3 Years From Randomization",3.273,"1",24101
"541","NCT00527787","Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen","Gastric Ulcer","other","Drug: PN400 (VIMOVO)|Drug: Naproxen","drug","POZEN","Both","Adult|Senior",434,"September 2007","July 2008","Number of Participants With Gastric Ulcer Confirmed by Endoscopy",6.053,"1",24103
"542","NCT00532779","A Study of the Safety and Efficacy of Two Doses of Naltrexone SR/Bupropion SR and Placebo in Overweight and Obese Subjects","Obesity|Overweight","other","Drug: Naltrexone SR 16 mg/Bupropion SR 360 mg /day|Drug: Naltrexone SR 32 mg/Bupropion SR 360 mg /day|Drug: Placebo|Behavioral: Ancillary therapy","drug","Orexigen Therapeutics, Inc","Both","Adult",1742,"October 2007","August 2009","Co-primary: Body Weight- Mean Percent Change",8.666,"1",24116
"543","NCT00532935","MK0431A vs. Pioglitazone in Patients With Type 2 Diabetes Mellitus (0431A-066)","Type 2 Diabetes Mellitus","endocrine and metabolic","Drug: sitagliptin phosphate (+) metformin hydrochloride|Drug: Comparator: pioglitazone","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",517,"January 2008","June 2008","Change From Baseline in A1C at Week 32",4.848,"1",24102
"544","NCT00534248","Study to Evaluate the Safety and Effectiveness of Zostavax™ in Subjects 50 - 59 Years of Age (V211-022)","Shingles","other","Biological: Zoster Vaccine, Live (Zostavax™)|Biological: Comparator: Placebo","biolog","Merck Sharp & Dohme Corp.","Both","Adult",22439,"October 2007","March 2010","Incidence of Confirmed Herpes Zoster (HZ) Cases by Vaccination Group",5.345,"1",24123
"545","NCT00550550","Efficacy and Safety of Grass Sublingual Tablet in Children and Adolescents (P05239 AM3)(COMPLETED)","Rhinoconjunctivitis|Rhinitis|Conjunctivitis|Allergy","other","Drug: Placebo|Biological: SCH 697243|Drug: Loratadine Syrup 1 mg/mL Rescue Treatment|Drug: Loratadine 10 mg Rescue Treatment|Drug: Olopatadine 0.1% Rescue Treatment|Drug: Mometasone furoate 50 mcg Rescue Treatment|Drug: Albut","biolog","Merck Sharp & Dohme Corp.","Both","Child",345,"November 2007","October 2011","Participant Total Combined Symptom (TCS) Score Over the Entire Grass Pollen Season (GPS)",3.294,"1",24142
"546","NCT00567190","A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-positive Metastatic Breast Cancer (CLEOPA","Metastatic Breast Cancer","cancer","Drug: Pertuzumab|Drug: Placebo|Drug: Trastuzumab|Drug: Docetaxel","drug","Genentech, Inc.|Hoffmann-La Roche","Both","Adult|Senior",808,"February 2008","April 2008","Progression-free Survival (PFS) Determined by an Independent Review Facility",4.922,"1",24100
"547","NCT00568178","An Extension Study Designed to Assess Effects of Losartan on Proteinuria in Pediatric Populations (MK-0954-326 AM1,EXT1(AM2))","Proteinuria","other","Drug: Losartan Potassium|Other: Comparator: Placebo (Losartan)|Drug: Comparator: amlodipine besylate|Other: Comparator: Placebo (amlodipine besylate)|Other: Placebo (Losartan)|Drug: Enalapril Maleate","drug","Merck Sharp & Dohme Corp.","Both","Child",306,"June 2007","March 2012","Double-Blind Treatment Phase: Percent Change From Baseline in Urinary Protein/Creatinine (Pr/Cr) Ratio (gm/gm) at Week 12",5.635,"1",24147
"548","NCT00590577","Effectiveness and Safety of 3 Fixed Doses (25 mg eq., 100 mg eq., and 150 mg eq.) of Paliperidone Palmitate in Patients With Schizophrenia","Schizophrenia","mental health","Drug: Paliperidone palmitate 25 mg eq.|Drug: Paliperidone palmitate 150 mg eq.|Drug: Placebo|Drug: Paliperidone palmitate 100 mg eq.","drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Both","Adult|Senior",652,"March 2007","August 2009","Change in Positive and Negative Syndrome Scale (PANSS) Total Score From Baseline to Week 13 or the Last Post-baseline Assessment",4.9,"1",24116
"549","NCT00591253","Efficacy and Safety of Azilsartan Medoxomil in African American Participants With Essential Hypertension","Hypertension","cardiovascular","Drug: Azilsartan medoxomil|Drug: Azilsartan medoxomil|Drug: Placebo","drug","Takeda","Both","Adult|Senior",413,"October 2007","February 2009","Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.",3.3,"1",24110
"550","NCT00591578","Efficacy and Safety Comparison of Azilsartan Medoxomil to Valsartan in Participants With Essential Hypertension","Hypertension","cardiovascular","Drug: Azilsartan Medoxomil|Drug: Azilsartan Medoxomil|Drug: Valsartan","drug","Takeda","Both","Adult|Senior",984,"December 2007","December 2012","Change From Baseline in 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.",3.659,"1",24156
"551","NCT00603239","Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin","Type 2 Diabetes Mellitus","endocrine and metabolic","Drug: exenatide|Drug: placebo","drug","AstraZeneca|Eli Lilly and Company","Both","Adult|Senior",165,"January 2008","June 2008","Change in Glycosylated Hemoglobin (HbA1c)",4.625,"1",24102
"552","NCT00603798","Safety and Effectiveness Study of Imiquimod Creams for the Treatment of Actinic Keratoses (AKs)","Actinic Keratosis","other","Drug: Imiquimod cream|Drug: Placebo cream|Drug: Imiquimod cream","drug","Graceway Pharmaceuticals, LLC","Both","Adult|Senior",490,"January 2008","March 2009","Number of Participants With Complete Clearance of AK Lesions",6.919,"1",24111
"553","NCT00605176","Safety and Effectiveness Study of Imiquimod Creams for Treatment of Actinic Keratoses (AKs)","Actinic Keratoses","other","Drug: imiquimod cream|Drug: imiquimod cream|Drug: Placebo","drug","Graceway Pharmaceuticals, LLC","Both","Adult|Senior",479,"January 2008","July 2009","Number of Participants With Complete Clearance of AK Lesions",6.898,"1",24115
"554","NCT00607373","Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia","Lipid Metabolism, Inborn Errors|Hypercholesterolemia, Autosomal Dominant|Hyperlipidemia","cardiovascular","Drug: mipomersen|Drug: Placebo","drug","Genzyme, a Sanofi Company|Isis Pharmaceuticals|Sanofi","Both","Child|Adult|Se",51,"July 2007","June 2008","Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Primary Efficacy Time Point",3.985,"1",24102
"555","NCT00613938","A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy.","Arthralgia|Bunion|Hallux Valgus|Pain","other","Drug: Tapentadol (CG5503)|Drug: Tapentadol (CG5503)|Drug: oxycodone|Drug: placebo","drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Grünenthal GmbH","Both","Adult|Senior",901,"February 2008","July 2010","Sum of Pain Intensity Difference Over 48 Hours (SPID48)",5.244,"1",24127
"556","NCT00650078","Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra®) Therapy in Patients With Active Rheumatoid Arthritis","Rheumatoid Arthritis","other","Drug: MR prednisone|Drug: Placebo","drug","Horizon Pharma Ireland, Ltd., Dublin Ireland","Both","Adult|Senior",350,"March 2008","September 2008","ACR 20 Response Rate at Visit 4",3.304,"1",24105
"557","NCT01041859","A Study to Evaluate the Efficacy, Safety, and Tolerability of Tapentadol ER Compared With Placebo in Patients With Chronic, Painful Diabetic Peripheral Neuropathy","Diabetic Peripheral Neuropathy","mental health","Drug: Tapentadol extended release (ER)|Drug: Placebo","drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Grünenthal GmbH","Both","Adult|Senior",460,"December 2009","May 2011","Change From Double-Blind Baseline of the Average Pain Intensity Based on an 11-point Numerical Rating Scale(NRS) Over the Last Week of the Maintenance Period at Week 12",4.06,"1",24137
"558","NCT01063855","Concomitant Use of PriLigy in Men Treated for Erectile Dysfunction","Erectile Dysfunction|Sexual Dysfunction","other","Drug: Placebo|Drug: Dapoxetine|Drug: PDE5I (phosphodiesterase-5 inhibitor)","drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Male","Adult|Senior",495,"April 2010","October 2011","The Average Intravaginal Ejaculatory Latency Time (IELT) at Week 12",3.93,"1",24142
"559","NCT01066585","A Safety and Efficacy Study Comparing 0.5% Ivermectin Cream to a Vehicle Control in Subjects With Head Lice Infestation","Head Lice","other","Drug: Ivermectin Cream|Drug: vehicle control","drug","Topaz Pharmaceuticals Inc","Both","Child|Adult|Se",410,"March 2010","March 2009","Percentage of Index Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 15 Post-treatment With Either Ivermectin or Placebo (Vehicle Control)",9.061,"1",24111
"560","NCT01068600","Comparison of Efficacy of Indacaterol Versus Placebo Over 12 Weeks","Chronic Obstructive Pulmonary Disease","respiratory","Drug: Indacaterol|Drug: Placebo to indacaterol","drug","Novartis","Both","Adult|Senior",318,"January 2010","March 2008","Trough Forced Expiratory Volume in 1 Second (FEV1) After 12 Weeks of Treatment",6.383,"1",24099
"561","NCT01072149","A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Profiles of 3 Doses of Fluticasone Furoate (FF)/GW642444 Inhal","Pulmonary Disease, Chronic Obstructive","respiratory","Drug: Fluticasone Furoate (FF)/GW642444 Inhalation Powder|Device: placebo","device","GlaxoSmithKline","Both","Adult|Senior",54,"January 2010","May 2009","Time-adjusted Area Under the Curve (AUC) (i.e.， Weighted Mean) for 24-hour Serial Forced Expiratory Volume in One Second (FEV1) at the End of Each 28-day Treatment Period",8.457,"1",24113
"562","NCT01077362","A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents","Arthritis, Psoriatic","other","Drug: placebo|Drug: ustekinumab 45 mg|Drug: ustekinumab 90 mg","drug","Janssen Research & Development, LLC","Both","Adult|Senior",312,"March 2010","December 2010","Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24.",3.745,"1",24132
"563","NCT01081834","The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial","Diabetes Mellitus, Type 2","endocrine and metabolic","Drug: Canagliflozin|Drug: Placebo|Drug: Sitagliptin","drug","Janssen Research & Development, LLC","Both","Adult|Senior",678,"March 2010","December 2012","Change in HbA1c From Baseline to Week 26 (Main Study)",10,"1",24156
"564","NCT01087788","Certolizumab Pegol in Subjects With Adult Onset Active and Progressive Psoriatic Arthritis","Arthritis, Psoriatic","other","Biological: CZP 200 mg Q2W|Biological: CZP 400 mg Q4W|Other: Placebo","biolog","UCB BIOSCIENCES GmbH|UCB Pharma","Both","Adult|Senior",409,"March 2010","February 2010","American College of Rheumatology 20 (ACR20) Response at Week 12",6.06,"1",24122
"565","NCT01098747","Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental Pain","Pain","other","Drug: Novel Ibuprofen|Drug: Standard Ibuprofen|Drug: Standard Ibuprofen|Drug: Placebo","drug","Pfizer","Both","Child|Adult",335,"April 2010","December 2012","Time-weighted Sum of Pain Relief Rating and Pain Intensity Difference From 0-8 Hours (SPRID 0-8)",9.724,"1",24156
"566","NCT01106430","Comparison of Lisdexamfetamine Dimesylate With Atomoxetine HCl in Attention-Deficit/Hyperactivity Disorder (ADHD) Subjects With an Inadequate Response to Methylpheni","Attention-Deficit/Hyperactivity Disorder","mental health","Drug: Lisdexamfetamine Dimesylate|Drug: Atomoxetine Hydrochloride","drug","Shire","Both","Child",267,"June 2010","February 2009","Time to First Response",3.291,"1",24110
"567","NCT01106625","The CANTATA-MSU Trial (CANagliflozin Treatment And Trial Analysis - Metformin and SUlphonylurea)","Diabetes Mellitus, Type 2","endocrine and metabolic","Drug: Canagliflozin|Drug: Placebo|Drug: Metformin|Drug: Sulphonylruea","drug","Janssen Research & Development, LLC","Both","Adult|Senior",469,"May 2010","July 2009","Change in HbA1c From Baseline to Week 26",7.32,"1",24115
"568","NCT01106651","A Safety and Efficacy Study of Canagliflozin in Older Patients (55 to 80 Years of Age) With Type 2 Diabetes Mellitus","Diabetes Mellitus, Type 2","endocrine and metabolic","Drug: Canagliflozin 100 mg|Drug: Canagliflozin 300 mg|Drug: Antihyperglycemic agent(s)|Drug: Placebo","drug","Janssen Research & Development, LLC","Both","Adult|Senior",716,"June 2010","November 2008","Change in HbA1c From Baseline to Week 26",8.261,"1",24107
"569","NCT01106677","The CANTATA-D Trial (CANagliflozin Treatment and Trial Analysis - DPP-4 Inhibitor Comparator Trial)","Diabetes Mellitus, Type 2","endocrine and metabolic","Drug: Placebo|Drug: Canagliflozin|Drug: Sitagliptin|Drug: Metformin immediate release","drug","Janssen Research & Development, LLC","Both","Adult|Senior",1284,"May 2010","October 2012","Change in HbA1c From Baseline to Week 26",8.732,"1",24154
"570","NCT01106690","The CANTATA-MP Trial (CANagliflozin Treatment and Trial Analysis - Metformin and Pioglitazone)","Diabetes Mellitus, Type 2","endocrine and metabolic","Drug: Placebo|Drug: Canagliflozin|Drug: Sitagliptin|Drug: Metformin|Drug: Pioglitazone","drug","Janssen Research & Development, LLC","Both","Adult|Senior",344,"June 2010","September 2008","Change in HbA1c From Baseline to Week 26",6.526,"1",24105
"571","NCT01109173","Confirmatory Study Nepafenac 0.3%","Cataract","other","Drug: Nepafenac Ophthalmic Suspension, 0.3%|Drug: Nepafenac Ophthalmic Suspension, 0.1%|Other: Nepafenac Ophthalmic Suspension 0.3% Vehicle|Other: NEVANAC Vehicle","drug","Alcon Research","Both","Adult|Senior",2120,"June 2010","February 2012","Percentage of Patients Cured at Day 14",9.171,"1",24146
"572","NCT01115673","To Evaluate the Safety and Efficacy of Acetaminophen 650 mg and 1000mg in Dental Pain After Surgery","Pain","other","Drug: Acetaminophen|Drug: Placebo  Control","drug","McNeil Consumer Healthcare Division of McNEIL-PPC, Inc.|Johnson & Johnson Consumer and Personal Products Worldwide","Both","Child|Adult",540,"June 2010","April 2009","Overall Analgesic Efficacy – Sum of Pain Intensity Difference and Pain Relief Scores Over Six Hours (SPRID6)",9.428,"1",24112
"573","NCT01127581","Efficacy & Safety Study Comparing Misoprostol Vaginal Insert (MVI) Versus Dinoprostone Vaginal Insert (DVI) for Reducing Time to Vaginal Delivery","Reducing Time to Vaginal Delivery|Cervical Ripening|Induction of Labor","other","Drug: MVI 200|Drug: Dinoprostone Vaginal Insert (DVI)","drug","Ferring Pharmaceuticals","Female","Adult|Senior",1358,"September 2010","December 2011","Time to Vaginal Delivery During the First Hospital Admission",7.507,"1",24144
"574","NCT01129011","Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen","Gastric Ulcer","other","Drug: PN400 (VIMOVO)|Drug: Naproxen","drug","POZEN","Both","Adult|Senior",420,"September 2007","August 2011","Number of Participants With Gastric Ulcer Confirmed by Endoscopy",4.986,"1",24140
"575","NCT01134705","Study in Adult and Adolescent Subjects With PAR (Perennial Allergic Rhinitis)","Rhinitis, Allergic, Perennial","other","Drug: Beclomethasone dipropionate hydrofluoroalkane  HFA Nasal Aerosol|Drug: Placebo Nasal Aerosol","drug","Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Both","Child|Adult|Se",474,"May 2010","December 2011","Change From Baseline in Average AM and PM Reflective Total Nasal Symptom Score (rTNSS) Over the Six-week Treatment Period",4.573,"1",24144
"576","NCT01139762","A Study of Tadalafil Use With Finasteride in Men With Enlarged Prostates and Urinary Symptoms","Benign Prostatic Hyperplasia|Enlarged Prostate","other","Drug: Tadalafil|Drug: Placebo|Drug: Finasteride","drug","Eli Lilly and Company","Male","Adult|Senior",696,"September 2010","April 2010","Change in Total International Prostate Symptom Score (IPSS) From Baseline to 12 Weeks",3.213,"1",24124
"577","NCT01142193","Study to Evaluate the Safety and Effectiveness of USL255 in Patients With Refractory Partial-onset Seizures","Epilepsy","mental health","Drug: USL255|Drug: Placebo","drug","Upsher-Smith Laboratories","Both","Adult|Senior",249,"May 2010","January 2011","Percent Reduction From Baseline in Weekly (7 Day) Partial-onset Seizure Frequency During the Titration Plus Maintenance Phase Compared to Baseline.",3.777,"1",24133
"578","NCT01153009","Safety and Efficacy of Vortioxetine (Lu AA21004) in Adults With Major Depressive Disorder","Depressive Disorder, Major","mental health","Drug: Vortioxetine|Drug: Duloxetine|Drug: Placebo","drug","Takeda","Both","Adult|Senior",614,"June 2010","October 2009","Change From Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) Total Score",1.24,"1",24118
"579","NCT01154036","MK0653C in High Cardiovascular Risk Patients With High Cholesterol (Switch Study)(MK-0653C-162)","Hypercholesterolemia","cardiovascular","Drug: ezetimibe 10 mg|Drug: atorvastatin|Drug: Comparator: rosuvastatin","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",1547,"July 2010","September 2009","Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C) (Phase I)",6.382,"1",24117
"580","NCT01174004","A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis","Parkinson's Disease Psychosis","mental health","Drug: pimavanserin tartrate|Drug: placebo","drug","ACADIA Pharmaceuticals Inc.","Both","Adult|Senior",199,"July 2010","December 2008","Antipsychotic Efficacy",3.242,"1",24108
"581","NCT01197521","Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Not","Rheumatoid Arthritis","other","Drug: fostamatinib|Drug: fostamatinib|Drug: placebo, fostamatinib","drug","AstraZeneca","Both","Adult|Senior",923,"September 2010","December 2008","Proportion of Patients With ACR20 at Week 24， Comparison Between Fostamatinib and Placebo.",4.2,"1",24108
"582","NCT01216163","Study Evaluating A Novel Ibuprofen Formulation In The Treatment Of Dental Pain","Pain","other","Drug: Novel Ibuprofen|Drug: Acetaminophen|Drug: Placebo","drug","Pfizer","Both","Child|Adult",218,"October 2010","October 2011","Time-weighted Sum of Pain Relief Rating With Pain Intensity Difference From 0 to 6 Hours (SPRID 0-6)",7.549,"1",24142
"583","NCT01270971","Efficacy and Safety Evaluation of AN2690 Topical Solution to Treat Onychomycosis of the Toenail","Onychomycosis of Toenails","other","Drug: AN2690 Topical Solution, 5%|Drug: Solution Vehicle","drug","Anacor Pharmaceuticals, Inc.","Both","Adult|Senior",594,"December 2010","September 2012","Complete Cure (Completely Clear Nail and Negative Mycology) of Target Great Toenail at Week 52",4.498,"1",24153
"584","NCT01287117","A Study of the Efficacy and Safety of Omalizumab (Xolair) in Patients With Chronic Idiopathic Urticaria (CIU)/Chronic Spontaneous Urticaria (CSU) Who Remain Symptoma","Chronic Idiopathic Urticaria","other","Drug: Omalizumab|Drug: Placebo","drug","Genentech, Inc.","Both","Child|Adult|Se",319,"February 2011","November 2009","Change From Baseline to Week 12 in the Weekly Itch Severity Score",3.315,"1",24119
"585","NCT01289015","Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis","Tinea Pedis","other","Drug: NAFT-600 ( naftin 2 % gel )|Drug: Placebo","drug","Merz Pharmaceuticals, LLC","Both","Child|Adult|Se",855,"February 2011","April 2011","Complete Cure of Interdigital Tinea Pedis",7.046,"1",24136
"586","NCT01290341","Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis","Tinea Pedis","other","Drug: NAFT-600 (naftin 2 % gel)|Drug: Placebo","drug","Merz Pharmaceuticals, LLC","Both","Child|Adult|Se",860,"February 2011","April 2008","Complete Cure of Interdigital Tinea Pedis",9.038,"1",24100
"587","NCT01302119","Efficacy and Safety of AN2690 Topical Solution to Treat Onychomycosis of the Toenail","Onychomycosis of Toenails","other","Drug: AN2690 Topical Solution, 5%|Drug: Solution Vehicle","drug","Anacor Pharmaceuticals, Inc.","Both","Adult|Senior",604,"February 2011","July 2009","Complete Cure (Completely Clear Nail and Negative Mycology) of Target Great Toenail at Week 52",4.534,"1",24115
"588","NCT01307319","Study of an Investigational Nasal Aerosol or Placebo Nasal Aerosol in Children (Ages 6-11) With Seasonal Allergies","Seasonal Allergic Rhinitis|SAR","other","Drug: BDP HFA|Drug: Placebo nasal aerosol","drug","Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Both","Child",715,"March 2011","September 2008","",3.568,"1",24105
"589","NCT01313637","A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD","Pulmonary Disease, Chronic Obstructive","respiratory","Drug: GSK573719/GW642444 125/25mcg|Drug: GSK573719 125mcg|Drug: GW642444 25mcg|Drug: Placebo only","drug","GlaxoSmithKline","Both","Adult|Senior",1493,"March 2011","April 2009","Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24)",8.252,"1",24112
"590","NCT01313650","A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD","Pulmonary Disease, Chronic Obstructive","respiratory","Drug: 62.5/25mcg|Drug: 62.5mcg|Drug: 25mcg|Drug: Placebo","drug","GlaxoSmithKline","Both","Adult|Senior",1538,"March 2011","April 2009","Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24)",5.635,"1",24112
"591","NCT01316900","24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary Disease","Pulmonary Disease, Chronic Obstructive","respiratory","Drug: GSK573719/GW642444 125/25|Drug: GSK573719/GW642444 62.5/25|Drug: GW642444|Drug: tiotropium bromide","drug","GlaxoSmithKline","Both","Adult|Senior",846,"March 2011","February 2009","Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 169 (Week 24)",3.392,"1",24110
"592","NCT01339260","An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting","Chemotherapy-Induced Nausea and Vomiting","other","Drug: Netupitant and Palonosetron|Drug: Palonosetron|Drug: Dexamethasone","drug","Helsinn Healthcare SA|Parexel","Both","Adult|Senior",1455,"April 2011","June 2008","Percentage of Patients With Complete Response (CR) Defined as no Emesis， no Rescue Medication， at Cycle 1",7.438,"1",24102
"593","NCT01362491","Ibuprofen Sodium Tension Headache Study","Pain","other","Drug: Ibuprofen Sodium|Drug: Standard Ibuprofen|Drug: Placebo","drug","Pfizer","Both","Adult",226,"June 2011","February 2011","Time-weighted Sum of Pain Relief Rating and Pain Intensity Difference From 0-3 Hours (SPRID 0-3) for Ibuprofen Sodium Versus Placebo Tablet",7.392,"1",24134
"594","NCT01376245","A 24-week Study of Fluticasone Furoate/Vilanterol Inhalation Powder in Subjects of Asian Ancestry With COPD","Pulmonary Disease, Chronic Obstructive","respiratory","Drug: fluticasone furoate/vilanterol|Drug: Placebo","drug","GlaxoSmithKline","Both","Adult|Senior",646,"April 2011","February 2011","Mean Change From Baseline in Clinic Visit Pre-dose Trough FEV1 at Day 169",5.38,"1",24134
"595","NCT01387230","Evaluate the Efficacy and Safety of GSK573719 Delivered Via a Novel Dry Powder Inhaler in Subjects With COPD","Pulmonary Disease, Chronic Obstructive","respiratory","Drug: GSK573719|Drug: GSK573719|Other: Placebo","drug","GlaxoSmithKline","Both","Adult|Senior",206,"July 2011","April 2010","Change From Baseline (BL) in Trough Forced Expiratory Volume in One Second (FEV1) on Day 85",3.319,"1",24124
"596","NCT01462435","Study of Diclofenac Capsules to Treat Pain Following Bunionectomy","Other Acute Postoperative Pain","other","Drug: Diclofenac Test (lower dose)|Drug: Diclofenac Test (upper dose)|Drug: Celecoxib|Drug: Placebo","drug","Iroko Pharmaceuticals, LLC","Both","Adult",428,"October 2011","March 2010","The Time-Weighted Summed Pain Intensity Difference Measured Using the 100-mm Visual Analogue Scale From 0 to 48 Hours After Trial Entry (VASSPID-48)， ANCOVA Model.",3.654,"1",24123
"597","NCT01543685","Study of Indomethacin Capsules to Treat Pain Following Bunionectomy","Other Acute Postoperative Pain","other","Drug: Indomethacin|Drug: Indomethacin|Drug: Indomethacin|Drug: Celecoxib|Drug: Placebo","drug","Iroko Pharmaceuticals, LLC","Both","Adult",462,"February 2012","September 2010","The Time-Weighted Summed Pain Intensity Difference Measured Using the 100-mm Visual Analogue Scale From 0 to 48 Hours After Trial Entry (VASSPID-48)",3.409,"1",24129
"598","NCT01568892","Study Assessing Dolutegravir in HIV-1 Infected Subjects With Virus Resistant to Raltegravir and/or Elivitegravir","Infection, Human Immunodeficiency Virus","other","Drug: dolutegravir 50 mg twice daily|Drug: dolutegravir placebo twice daily|Drug: Open-label dolutegravir 50mg twice daily","drug","ViiV Healthcare|Shionogi|GlaxoSmithKline","Both","Adult|Senior",30,"April 2012","May 2010","Mean Change From Baseline in Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) at Day 8",6.315,"1",24125
"599","NCT00324155","Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma","Melanoma","cancer","Drug: Ipilimumab|Drug: Placebo|Drug: Dacarbazine","drug","Bristol-Myers Squibb|Medarex","Both","Adult|Senior",681,"August 2006","February 2008","",3.322,"1",24098
"600","NCT00563368","A Study Comparing Multiple Doses of VI-0521 With Placebo and Their Single-agent Constituents for Treatment of Obesity in Adults","Obesity","other","Drug: VI-0521|Drug: VI-0521|Drug: topiramate|Drug: topiramate|Drug: phentermine|Drug: phentermine|Drug: VI-0521","drug","VIVUS, Inc.|Medpace, Inc.","Both","Adult|Senior",756,"December 2007","February 2008","Percent Weight Loss From Baseline to Week 28",3.319,"1",24098
"601","NCT00615433","Lurasidone HCl A Phase 3 Study of Patients With Acute Schizophrenia","Schizophrenia","mental health","Drug: Lurasidone|Drug: Olanzapine|Drug: Placebo comparator|Drug: Lurasidone 40 mg tablets","drug","Sunovion","Both","Adult|Senior",478,"January 2008","November 2011","Change in Total PANSS (Positive and Negative Syndrome Scale)Score From Baseline to the End of the Double Blind Treatment Period.",3.36,"1",24143
"602","NCT00145327","Double-blind Extension of HORIZON Pivotal Fracture Trial (Zoledronic Acid in the Treatment of Postmenopausal Osteoporosis)","Osteoporosis","endocrine and metabolic","Drug: Zoledronic Acid|Drug: Placebo","drug","Novartis","Female","Senior",2456,"May 2005","March 2012","Percentage Change in Bone Mineral Density (BMD) of Femoral Neck at Year 6 Relative to Year 3",3.372,"1",24147
"603","NCT00382408","A Clinical Trial to Evaluate the Safety, Efficacy, and Immunogenicity of DR-5001","Respiratory Tract Diseases","respiratory","Biological: DR-5001|Other: Placebo","biolog","Duramed Research|Teva Pharmaceutical Industries","Both","Child|Adult|Se",4041,"September 2006","May 2012","Number of Participants With Throat Culture Positive for Wild Type-4 Adenovirus (ADV) Infection",3.373,"1",24149
"604","NCT00578929","Safety and Efficacy of Olopatadine HCl Nasal Spray in 6-11 Year Old Patients","Seasonal Allergic Rhinitis","other","Drug: Olopatadine Hydrochloride Nasal Spray 0.6%|Drug: Vehicle","drug","Alcon Research","Both","Child",2388,"September 2007","September 2009","Percent Change From Baseline in the Reflective Total Nasal Symptom Score (TNSS)",3.379,"1",24117
"605","NCT01315249","QVA149 Versus Fluticasone/Salmeterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)","Chronic Obstructive Pulmonary Disease (COPD)","respiratory","Drug: indacaterol and glycopyrronium (QVA149)|Drug: Placebo to fluticasone/salmeterol|Drug: fluticasone/salmeterol|Drug: Placebo to indacaterol and glycopyrronium (QVA149)","drug","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior",523,"March 2011","March 2012","Forced Expiratory Volume in 1 Second Area Under the Curve (FEV1 AUC) 0-12",3.468,"1",24147
"606","NCT01194830","Efficacy and Safety of Linagliptin (BI 1356) in Black/African Americans With Type 2 Diabetes With a MTT Sub-study","Diabetes Mellitus, Type 2","endocrine and metabolic","Drug: Linagliptin|Drug: Placebo","drug","Boehringer Ingelheim|Eli Lilly and Company","Both","Adult|Senior",234,"September 2010","July 2009","Change From Baseline in HbA1c (Glycosylated Hemoglobin) After 24 Weeks",3.480756404,"1",24115
"607","NCT00890682","Study of Postoperative Analgesia in Bunionectomy","Bunion|Hallux Valgus","other","Drug: SKY0402|Drug: Placebo","drug","Pacira Pharmaceuticals, Inc","Both","Adult|Senior",193,"April 2009","November 2008","Area Under the Curve (AUC) of the Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores",3.4808,"1",24107
"608","NCT00759148","Moxifloxacin AF Ophthalmic Solution for Treatment of Bacterial Conjunctivitis","Bacterial Conjunctivitis","other","Drug: Moxifloxacin eye drops|Drug: Moxifloxacin AF Ophthalmic Solution Vehicle (placebo)","drug","Alcon Research","Both","Child|Adult|Se",1179,"October 2008","December 2009","Clinical Cure of Bacterial Conjunctivitis",3.496,"1",24120
"609","NCT00794664","Safety and Efficacy of Mipomersen in Patients With Severe Hypercholesterolemia on a Maximally Tolerated Lipid-Lowering Regimen and Who Are Not on Apheresis","Hypercholesterolemia|Coronary Heart Disease","cardiovascular","Drug: Mipomersen|Drug: Placebo","drug","Genzyme, a Sanofi Company|Isis Pharmaceuticals|Sanofi","Both","Adult|Senior",58,"January 2009","August 2009","Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at Primary Efficacy Time Point",3.5009,"1",24116
"610","NCT00598832","Clinical Study to Test the Efficacy and Safety of Adapalene, 0.1%","Acne Vulgaris","other","Drug: Adapalene lotion 0.1%|Drug: Adapalene Lotion Vehicle","drug","Galderma","Both","Child|Adult|Se",1075,"November 2007","January 2011","Co-Primary Endpoint: Success Rate on Investigator's Global Assessment (IGA) From Baseline to Week 12",3.502,"1",24133
"611","NCT01353079","Efficacy and Safety Study Of Short Ragweed Pollen Sublingual-Oral Immunotherapy","Allergy","other","Biological: Short Ragweed Pollen Allergenic Extract|Biological: Placebo","biolog","Greer Laboratories","Both","Adult",429,"April 2011","October 2009","Scores on a Scale [Net Average Combined Daily Rhinoconjunctivitis Symptom (RSS) and Medication Scores]",3.523,"1",24118
"612","NCT00094653","MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma","Melanoma|Metastases","cancer","Drug: MDX-010 (anti-CTLA4) monoclonal antibody|Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine","biolog","Bristol-Myers Squibb","Both","Adult|Senior",1783,"September 2004","May 2011","Overall Survival (OS) (Time-to-Death) Difference Between MDX-010 in Combination With gp 100 Melanoma Peptide Vaccine Versus gp 100 Melanoma Peptide Vaccine Alone",3.540083799,"1",24137
"613","NCT00813488","Fentanyl Buccal Tablets Versus Immediate Release Oxycodone for Breakthrough Pain in Patients With Chronic Pain","Chronic Pain","other","Drug: Fentanyl Buccal Tablet|Drug: Immediate release oxycodone","drug","Cephalon|Teva Pharmaceutical Industries","Both","Adult|Senior",213,"December 2008","January 2010","Pain Intensity Difference (PID) at 15 Minutes Post-treatment (PID15)",3.5401,"1",24121
"614","NCT00948818","Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation","Irritable Bowel Syndrome Characterized by Constipation","other","Drug: Linaclotide 290 micrograms|Drug: Matching placebo","drug","Forest Laboratories|Ironwood Pharmaceuticals, Inc.","Both","Adult|Senior",803,"July 2009","January 2012","Abdominal Pain and Complete Spontaneous Bowel Movement (APC) Responder， 9 Out of 12 Weeks",3.5401,"1",24145
"615","NCT00988247","Long Term Safety and Efficacy Trial of Beclomethasone Dipropionate - Hydrofluoroalkane (BDP-HFA) 320 Mcg in Allergic Rhinitis","Rhinitis, Allergic, Perennial","other","Drug: Beclomethasone dipropionate|Drug: Placebo Nasal Aerosol","drug","Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Both","Child|Adult|Se",529,"October 2009","April 2009","Change From Baseline in Average Subject-Assessed 24-Hour Reflective Total Nasal Symptom Score (rTNSS) up to 30 Weeks",3.5872,"1",24112
"616","NCT00297102","Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The AURA Study (BY217/M2-124)","Chronic Obstructive Pulmonary Disease (COPD)","respiratory","Drug: Roflumilast|Drug: Placebo","drug","Takeda","Both","Adult|Senior",1523,"February 2006","February 2012","Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1)",3.615300007,"1",24146
"617","NCT01206387","Effects of Desoximetasone Spray 0.25% on Moderate to Severe Plaque Psoriasis","Psoriasis","other","Drug: Desoximetasone Spray 0.25%|Drug: placebo comparator","drug","Taro Pharmaceuticals USA","Both","Adult|Senior",120,"August 2010","November 2011","Clinical Success",3.615300007,"1",24143
"618","NCT01259492","Efficacy and Safety Study of Methylphenidate Hydrochloride Extended Release in Adults With Childhood-onset Attention Deficit/Hyperactivity Disorder (ADHD)","Attention Deficit/Hyperactivity Disorder","mental health","Drug: Placebo|Drug: Ritalin LA 20 mg|Drug: Ritalin LA 30 mg","drug","Novartis Pharmaceuticals|Novartis","Both","Adult",725,"November 2010","June 2008","Change From Baseline of Period 1 (Baseline 1) to End of Period 1 on Attention-Deficit/Hyperactivity Disorder Rating Scale (DSM-IV ADHD RS) Total Score by Treatment",3.615300007,"1",24102
"619","NCT00168324","A Study of the Safety and Efficacy of a New Treatment for Macular Edema Resulting From Retinal Vein Occlusion","Macular Edema|Retinal Vein Occlusion","cardiovascular","Drug: 700 µg Dexamethasone|Drug: 350 µg Dexamethasone|Other: Sham Injection","drug","Allergan","Both","Adult|Senior",599,"October 2004","December 2008","",3.623,"1",24108
"620","NCT00086580","Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients","B-Cell Chronic Lymphocytic Leukemia","cancer","Biological: FluCAM [Fludara + Campath]|Biological: fludarabine phosphate","biolog","Genzyme, a Sanofi Company|Sanofi","Both","Adult|Senior",335,"July 2004","October 2009","Kaplan-Meier Estimates for Progression-free Survival (PFS) Based on Independent Response Review Panel (IRRP) Assessment",3.657,"1",24118
"621","NCT00170950","Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension","Hypertension","cardiovascular","Drug: Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1|Drug: Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2|Drug: Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 a","drug","Novartis","Both","Adult|Senior",11506,"October 2003","October 2011","Time-to-event Analysis of Percentage of Patients With a Composite Cardiovascular (CV) Morbidity or Mortality Event",3.713,"1",24142
"622","NCT00790751","Research Evaluating an Investigational Medication for Erectile Dysfunction - General ED","Erectile Dysfunction","other","Drug: placebo|Drug: avanafil|Drug: avanafil|Drug: avanafil","drug","VIVUS, Inc.","Male","Adult|Senior",646,"November 2008","October 2011","Change in Percentage of Sexual Attempts in Which Subjects Were Able to Maintain an Erection of Sufficient Duration to Have Successful Intercourse",3.7168,"1",24142
"623","NCT00678392","Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer","Kidney Neoplasms","cancer","Drug: Axitinib (AG-013736)|Drug: Sorafenib","drug","Pfizer","Both","Adult|Senior",723,"September 2008","July 2009","Progression-Free Survival (PFS)",3.719,"1",24115
"624","NCT00678418","ALK21-013: Efficacy and Safety of Medisorb® Naltrexone (VIVITROL®) in Adults With Opioid Dependence","Opiate Dependence","mental health","Drug: VIVITROL® 380 mg|Drug: Placebo","drug","Alkermes, Inc.","Both","Adult|Senior",250,"June 2008","December 2012","Percentage (%) of Opioid-free Weeks Per Subject in Double-blind Period (Part A)",3.719,"1",24156
"625","NCT00294515","IMPACT Study: A Study of Valcyte (Valganciclovir) for Prevention of Cytomegalovirus Disease (CMV) in Kidney Allograft Recipients","Cytomegalovirus Infections","other","Drug: Valganciclovir|Drug: Valganciclovir","drug","Hoffmann-La Roche","Both","Child|Adult|Se",326,"March 2006","December 2009","Percentage of Patients Who Developed Cytomegalovirus (CMV) Disease up to Month 12 Post-transplant",3.586,"1",24120
"626","NCT00395876","A Study of Tenecteplase for Restoration of Function in Dysfunctional Central Venous Catheters","Dysfunctional Central Venous Access Catheters","cardiovascular","Drug: placebo|Drug: tenecteplase","drug","Genentech, Inc.","Both","Child|Adult|Se",100,"November 2006","July 2009","Percentage of Patients Who Had Restoration of Central Venous Catheter (CVC) Function Following a Single Administration of Study Drug",3.941,"1",24115
"627","NCT00474058","Randomized Evaluation of the 24-Hour Coverage: Efficacy of Rotigotine","Parkinson's Disease","mental health","Drug: Rotigotine|Other: Placebo","drug","UCB Pharma","Both","Adult|Senior",287,"May 2007","June 2010","Change in Early Morning UPDRS Part III Score",3.823,"1",24126
"628","NCT00514735","Tailored Treatment of Permanent Atrial Fibrillation","Atrial Fibrillation","cardiovascular","Procedure: Medtronic Cardiac Ablation System|Drug: Class I or III Antiarrhythmic Medications","proced","Medtronic Atrial Fibrillation Solutions","Both","Adult|Senior",210,"May 2007","March 2008","Chronic Effectiveness",4.493,"1",24099
"629","NCT00528879","A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled on Metformin Alone","Type 2 Diabetes","endocrine and metabolic","Drug: Dapagliflozin|Drug: Placebo|Drug: Metformin","drug","Bristol-Myers Squibb|AstraZeneca","Both","Adult|Senior",915,"September 2007","January 2009","Adjusted Mean Change From Baseline in Hemoglobin A1C (HbA1c) at Week 24 (Last Observation Carried Forward [LOCF])",3.762,"1",24109
"630","NCT00536484","Fesoterodine Flexible Dose Study","Overactive Bladder","other","Drug: Fesoterodine|Drug: Placebo","drug","Pfizer","Both","Adult|Senior",896,"August 2007","October 2010","Change in Mean Number of Micturition Episodes Per 24 Hours at Week 12 Relative to Baseline.",3.5,"1",24130
"631","NCT01098812","Clinical Evaluation of a 1-Piece Intraocular Lens","Cataract","other","Device: Tecnis ZCB00 IOL (control)|Device: Toric Intraocular lens","device","Abbott Medical Optics","Both","Adult|Senior",269,"March 2010","August 2008","Mean Percent Reduction in Cylinder",3.927,"1",24104
"632","NCT01280591","Evaluate Analgesic/Sedative Efficacy of Naproxen Sodium and Diphenhydramine in Patients With Postsurgical Dental Pain","Pain, Postoperative","other","Drug: Naproxen sodium 440 mg / DPH 50 mg (BAY98-7111)|Drug: Naproxen sodium 220 mg / DPH 50 mg (BAY98-7111)|Drug: Naproxen sodium 440 mg (BAYH6689)|Drug: DPH 50 mg","drug","Bayer","Both","Child|Adult",712,"October 2010","February 2009","Wake Time After Sleep Onset (WASO) Measured by Actigraphy",3.775,"1",24110
"633","NCT00892957","FS VH S/D 500 S-apr in Vascular Surgery","Hemostasis in Participants Receiving Peripheral Vascular Expanded Polytetrafluoroethyle","cardiovascular","Biological: Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr)|Other: Surgical gauze pads","biolog","Baxter Healthcare Corporation","Both","Child|Adult|Se",176,"July 2009","December 2008","Percentage of Participants Who Achieved Hemostasis at 4 Minutes Post Treatment Application.",3.7248,"1",24108
"634","NCT00809471","Research Evaluating an Investigational Medication for Erectile Dysfunction - Diabetic ED (REVIVE-D)","Erectile Dysfunction","other","Drug: placebo|Drug: avanafil|Drug: avanafil","drug","VIVUS, Inc.","Male","Adult|Senior",390,"December 2008","July 2010","Change in Percentage of Sexual Attempts in Which Subjects Were Able to Maintain an Erection of Sufficient Duration to Have Successful Intercourse",3.7889,"1",24127
"635","NCT00891462","Efficacy and Safety of Aclidinium Bromide for Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (LAS-MD-33)","Chronic Obstructive Pulmonary Disease","respiratory","Drug: Aclidinium bromide|Drug: Aclidinium bromide|Drug: Placebo","drug","Forest Laboratories| Almirall, S.A.","Both","Adult|Senior",561,"April 2009","August 2011","Change From Baseline in Morning Pre-dose Forced Expiratory Volume in 1 Second (FEV1)",3.8309,"1",24140
"636","NCT00630331","Efficacy Study of Two Influenza Vaccines and Placebo in Healthy Adult Subjects","Influenza","respiratory","Biological: Cell culture-derived influenza vaccine|Biological: Egg-derived influenza virus vaccine|Biological: Placebo","biolog","Novartis Vaccines|Novartis","Both","Adult",11404,"October 2007","July 2010","Number of Subjects With Culture-Confirmed Influenza Illness Caused by Vaccine-like Strains",3.84,"1",24127
"637","NCT00428597","A Study Of Sunitinib Compared To Placebo For Patients With Advanced Pancreatic Islet Cell Tumors","Carcinoma, Islet Cell|Carcinoma, Pancreas","cancer","Drug: sunitinib malate|Drug: Placebo","drug","Pfizer","Both","Adult|Senior",171,"June 2007","October 2011","Progression Free Survival (PFS)",3.850244437,"1",24142
"638","NCT00421928","Tapentadol (CG5503)","Osteoarthritis, Knee|Pain","other","Drug: oxycodone|Drug: placebo|Drug: tapentadol (CG5503)","drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.|Grünenthal GmbH","Both","Adult|Senior",1030,"January 2007","December 2009","Change From Baseline of the Average Pain Intensity Based on an 11-point Numerical Rating Scale(NRS) Over the Last Week of the Maintenance Period at Week 12.",3.889,"1",24120
"639","NCT00065507","Comparison of Entecavir to Adefovir in Chronic Hepatitis B Virus (HBV) Patients With Hepatic Decompensation","Hepatitis B","other","Drug: Entecavir (ETV)|Drug: Adefovir (ADV)","drug","Bristol-Myers Squibb","Both","Child|Adult|Se",195,"August 2003","October 2010","Change From Baseline in Hepatitis B Virus (HBV) DNA by Polymerase Chain Reaction (PCR) at Week 24",6.09,"1",24130
"640","NCT00089791","A Study to Evaluate Denosumab in the Treatment of Postmenopausal Osteoporosis","Osteoporosis","endocrine and metabolic","Drug: placebo|Drug: Denosumab","drug","Amgen","Female","Adult|Senior",7808,"August 2004","October 2008","Number of Participants With New Vertebral Fractures",9.011,"1",24106
"641","NCT00097500","Effects of Exenatide and Insulin Glargine in Subjects With Type 2 Diabetes","Type 2 Diabetes Mellitus","endocrine and metabolic","Drug: exenatide|Drug: Insulin glargine|Drug: Metformin","drug","AstraZeneca|Eli Lilly and Company","Both","Adult|Senior",69,"September 2004","March 2011","Beta-cell Function After 52 Weeks of Therapy",5.968,"1",24135
"642","NCT00106028","Safety and Efficacy of Risedronate in the Treatment of Osteogenesis Imperfecta in Children","Osteogenesis Imperfecta","other","Drug: risedronate sodium (Actonel)|Drug: Placebo","drug","Warner Chilcott","Both","Child",143,"November 2004","November 2010","",5.637,"1",24131
"643","NCT00113763","Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer","Colorectal Cancer|Metastases","cancer","Other: Best supportive care|Drug: Panitumumab","drug","Amgen","Both","Adult|Senior",463,"January 2004","August 2010","Progression-free Survival Time",6.018,"1",24128
"644","NCT00125164","Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency","Growth Disorders|Insulin-Like Growth Factor-1 Deficiency","other","Drug: rhIGF-1 (mecasermin, Tercica, Inc.)","drug","Ipsen","Both","Child",137,"March 2004","January 2010","Height Velocity During the First Year - Intent to Treat (ITT)Population",5.967,"1",24121
"645","NCT00179621","Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality","Myelodysplastic Syndromes","cancer","Drug: Lenalidomide 5 mg|Drug: Lenalidomide 10 mg|Drug: Placebo","drug","Celgene Corporation|ICON Clinical Research","Both","Adult|Senior",205,"July 2005","July 2009","Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for >= 26 Weeks (182 Days)",4.627,"1",24115
"646","NCT00239681","JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events","Elevated High-sensitivity C-Reactive Protein (hsCRP)","cardiovascular","Drug: Rosuvastatin|Other: Placebo","drug","AstraZeneca","Both","Adult|Senior",17802,"February 2003","September 2010","Time to Major Cardiac Event (Cardiovascular Death， Stroke， Myocardial Infarction， Hospitalization Due to Unstable Angina or Arterial Revascularization)",5.444,"1",24129
"647","NCT00285012","Smoking Cessation in Subjects With Mild-to-moderate Chronic Obstructive Pulmonary Disease (COPD).","Smoking Cessation","other","Drug: placebo|Drug: Varenicline Tartarate","drug","Pfizer","Both","Adult|Senior",504,"May 2006","May 2010","Number of Subjects With Four Week Continuous Quit Rate (CQR)",8.01,"1",24125
"648","NCT00288704","Rilonacept for Treatment of Cryopyrin-Associated Periodic Syndromes (CAPS)","Familial Cold Autoinflammatory Syndrome (FCAS)|Familial Cold Urticaria|Muckle-Wells Syn","other","Drug: rilonacept 160 mg|Drug: Placebo|Drug: rilonacept 160 mg","drug","Regeneron Pharmaceuticals","Both","Child|Adult|Se",104,"December 2005","August 2009","Change From Baseline to Week-6 (Part A) Endpoint in Mean Key Symptom Score (KSS)",5.461,"1",24116
"649","NCT00293059","Efficacy and Safety Study for the Treatment of Dysfunctional Uterine Bleeding","Metrorrhagia","other","Drug: Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)|Drug: Placebo","drug","Bayer","Female","Adult|Senior",190,"December 2005","March 2011","Proportion of Participants With no Dysfunctional Uterine Bleeding (DUB) Symptoms",5.705,"1",24135
"650","NCT00297115","Effect of Roflumilast on Exacerbation Rate in Patients With Chronic Obstructive Pulmonary Disease (COPD): The HERMES Study (BY217/M2-125)","Chronic Obstructive Pulmonary Disease (COPD)","respiratory","Drug: Roflumilast|Drug: Placebo","drug","Takeda","Both","Adult|Senior",1568,"March 2006","March 2010","Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1)",6.687,"1",24123
"651","NCT00312377","ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer","Non-small Cell Lung Cancer|Lung Cancer","cancer","Drug: Docetaxel|Drug: Vandetanib","drug","AstraZeneca","Both","Adult|Senior",1690,"May 2006","August 2011","Progression-Free Survival (PFS) in the Overall Population",4.076,"1",24140
"652","NCT00355134","Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple Sclerosis","Multiple Sclerosis","mental health","Drug: Fingolimod|Drug: Placebo","drug","Novartis","Both","Adult",1083,"June 2006","July 2011","Aggregate Annualized Relapse Rate (ARR) Estimate up to Month 24",5.376,"1",24139
"653","NCT00410124","RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafeni","Metastatic Renal Cell Carcinoma","cancer","Drug: RAD001|Drug: Placebo","drug","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior",416,"November 2006","September 2009","Progressive Free Survival (PFS) in Patients Who Receive RAD001 Plus Best Supportive Care(BSC) Versus Patients Who Receive Matching Placebo Plus BSC",8.203,"1",24117
"654","NCT00410761","An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer","Thyroid Cancer","cancer","Drug: ZD6474 (Vandetanib)","drug","AstraZeneca","Both","Adult|Senior",437,"November 2006","April 2011","Progression-Free Survival(PFS)",3.754,"1",24136
"655","NCT00414908","A Study to Investigate the Effect of Delayed Release Pancrelipase on Maldigestion in Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis and","Chronic Pancreatitis|Pancreatectomy|Pancreatic Exocrine Insufficiency","other","Drug: Pancrelipase delayed release capsule|Drug: Placebo Comparator","drug","Solvay Pharmaceuticals","Both","Adult|Senior",52,"October 2007","October 2009","Change of Coefficient of Fat Absorption (CFA) (%) Between Baseline and End of Double-blind (DB) Period.",5.017,"1",24118
"656","NCT00417079","XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer","Neoplasms|Prostatic Neoplasms","cancer","Drug: cabazitaxel (XRP6258) (RPR116258)|Drug: mitoxantrone|Drug: prednisone","drug","Sanofi","Male","Adult|Senior",755,"January 2007","March 2011","Overall Survival",4.104,"1",24135
"657","NCT00423046","Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age","Infections, Papillomavirus","other","Biological: GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM)|Biological: Gardasil ® (Merck & Co. Inc)|Biological: Placebo|Biological: Placebo","biolog","GlaxoSmithKline","Female","Adult",1106,"January 2007","October 2010","Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Neutralizing Antibodies",8.118,"1",24130
"658","NCT00430625","A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Gaucher Disease","Gaucher Disease, Type 1","endocrine and metabolic","Biological: VPRIV ®,","biolog","Shire","Both","Child|Adult|Se",25,"January 2007","December 2010","Change From Baseline to 12 Months in Hemoglobin Concentration for the 60 U/kg Treatment Group.",7.497,"1",24132
"659","NCT00434642","A Study of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Ovary, Peritoneal, or Fallopian Tube Carcinoma","Ovarian Cancer","cancer","Drug: Carboplatin|Drug: Gemcitabine|Drug: Bevacizumab|Drug: Placebo","drug","Genentech, Inc.","Female","Adult|Senior",484,"April 2007","October 2011","Progression Free Survival (PFS) as Determined by the Investigator， Per Response Evaluation Criteria for Solid Tumors (RECIST)",6.374,"1",24142
"660","NCT00439725","Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Dee","Venous Thromboembolism","cardiovascular","Drug: Rivaroxaban (Xarelto, BAY59-7939)|Drug: Placebo","drug","Bayer|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Both","Adult|Senior",1197,"February 2007","November 2010","Percentage of Participants With Symptomatic Recurrent Venous Thromboembolism [VTE] (i.e. the Composite of Recurrent Deep Vein Thrombosis [DVT] or Fatal or Non-fatal Pulmonary Embolism [PE]) Until the Intended End of Study Treatment",4.389,"1",24131
"661","NCT00441727","Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA)","Gastric Ulcer|Duodenal Ulcer","other","Drug: Esomeprazole 40 mg|Drug: Esomeprazole 20 mg|Drug: Placebo","drug","AstraZeneca","Both","Adult|Senior",2426,"February 2007","November 2010","Percentage of Participants Who Experienced the Occurence of Peptic Ulcer(s).",5.433,"1",24131
"662","NCT00444925","Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine for Overactive Bladder (OAB)","Overactive Bladder","other","Drug: fesoterodine fumarate|Drug: placebo|Drug: tolterodine tartrate","drug","Pfizer","Both","Adult|Senior",1712,"April 2007","April 2011","Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12 (End of Treatment).",1.296,"1",24136
"663","NCT00468481","Efficacy and Safety Study for an Oral Contraceptive Containing Folate","Neural Tube Defects|Contraception|Oral Contraceptives (OC)","other","Drug: Drospirenone/Ethinylestradiol/Methyltetrahydrofolate|Drug: Drospirenone/Ethinylestradiol (Yaz)","drug","Bayer","Female","Adult",385,"April 2007","February 2010","Red Blood Cell (RBC) Folate Level at 24 Weeks",7.372,"1",24122
"664","NCT00473330","A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RISE)","Diabetes Mellitus|Macular Edema","endocrine and metabolic","Drug: Ranibizumab|Drug: Sham injection","drug","Genentech, Inc.","Both","Adult|Senior",377,"June 2007","October 2010","Percentage of Patients Who Gained ≥ 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline at Month 24",4.536,"1",24130
"665","NCT00473382","A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RIDE)","Diabetes Mellitus|Macular Edema","endocrine and metabolic","Drug: Ranibizumab|Drug: Sham injection","drug","Genentech, Inc.","Both","Adult|Senior",382,"June 2007","October 2009","Percentage of Patients Who Gained ≥ 15 Letters in Their Best Corrected Visual Acuity (BCVA) Score From Baseline at Month 24",4.337,"1",24118
"666","NCT00482612","Study of the Safety and Effectiveness of Esmirtazapine in Participants With Chronic Primary Insomnia (P05706)","Insomnia","mental health","Drug: Esmirtazapine|Drug: Placebo","drug","Merck Sharp & Dohme Corp.","Both","Adult",526,"December 2006","October 2009","Average Total Sleep Time (TST) as Recorded Daily in the Sleep Diary During the 14-day In-treatment Period",3.42,"1",24118
"667","NCT00483652","Study of Fampridine-SR Tablets in Multiple Sclerosis Patients","Multiple Sclerosis","mental health","Drug: Fampridine-SR|Drug: Placebo","drug","Acorda Therapeutics","Both","Adult|Senior",240,"May 2007","April 2008","Responders Based Upon the Timed 25-Foot Walk [T25FW]",6.473,"1",24100
"668","NCT00485836","A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Central Retinal Vein Occlusion (CRUISE)","Macular Edema|Retinal Vein Occlusion","cardiovascular","Drug: Sham injection|Drug: Ranibizumab injection 0.3 mg|Drug: Ranibizumab injection 0.5 mg","drug","Genentech, Inc.","Both","Adult|Senior",392,"July 2007","November 2008","Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at 6 Months",5.931,"1",24107
"669","NCT00486018","A Study of the Efficacy and Safety of Ranibizumab Injection in Patients With Macular Edema Secondary to Branch Retinal Vein Occlusion (BRAVO)","Macular Edema|Retinal Vein Occlusion","cardiovascular","Drug: Ranibizumab injection 0.3 mg|Drug: Ranibizumab injection 0.5 mg|Drug: Sham injection","drug","Genentech, Inc.","Both","Adult|Senior",397,"July 2007","April 2008","Mean Change From Baseline in Best Corrected Visual Acuity (BCVA) Score at 6 Months",6.58,"1",24100
"670","NCT00500656","Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema (HAE)","Hereditary Angioedema","cardiovascular","Drug: Icatibant|Drug: Tranexamic Acid|Drug: Oral Placebo|Drug: S.C. Placebo","drug","Shire","Both","Adult|Senior",85,"March 2005","January 2008","Time to Onset of Symptom Relief.",4.044,"1",24097
"671","NCT00531817","A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis","Rheumatoid Arthritis","other","Drug: Tocilizumab|Drug: Placebo|Drug: Permitted DMARDs","drug","Hoffmann-La Roche","Both","Adult|Senior",619,"October 2007","August 2009","",5.623,"1",24116
"672","NCT00553358","Neo ALTTO (Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) Study","Neoplasms, Breast","cancer","Drug: Lapatinib|Biological: Trastuzumab|Drug: Paclitaxel","biolog","GlaxoSmithKline|Breast International Group|SOLTI Breast Cancer Research Group","Female","Adult|Senior",455,"January 2008","May 2010","Number of Participants With Pathological Complete Response (pCR) at the Time of Surgery",3.926,"1",24125
"673","NCT00561821","Efficacy and Safety Study of Org 50081 (Esmirtazapine) in Elderly Participants (P05709)","Insomnia|Sleep Initiation and Maintenance Disorders|Mental Disorders|Dyssomnias|Sleep D","mental health","Drug: Esmirtazapine|Drug: Placebo","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",538,"November 2007","June 2008","Average Wake Time After Sleep Onset Measured by Polysomnography",6.066,"1",24102
"674","NCT00567164","Efficacy and Safety of Two Flexible Extended Regimens of BAY86-5300 (SH T00186D) in Comparison With the Conventional Regimen of YAZ","Contraception|Ovulation Inhibition|Contraceptives, Oral","other","Drug: EE20/DRSP (BAY86-5300)|Drug: EE20/DRSP (BAY86-5300)|Drug: EE20/DRSP (YAZ, BAY86-5300)","drug","Bayer","Female","Adult",1887,"October 2007","July 2009","Pearl Index",0.45,"1",24115
"675","NCT00586664","Efficacy and Safety Study of Bepotastine Besilate Ophthalmic Solution in Allergic Conjunctivitis","Allergic Conjunctivitis","other","Drug: Bepreve (bepotastine besilate ophthalmic solution) 1.5%|Drug: placebo comparator|Drug: Bepotastine Besilate Ophthalmic Solution 1.0%","drug","Bausch & Lomb Incorporated","Both","Child|Adult|Se",130,"October 2007","March 2008","Ocular Itching",8.434,"1",24099
"676","NCT00603291","BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus","Obesity","other","Drug: Lorcaserin 10 mg QD|Drug: Lorcaserin 10 mg BID|Drug: Matching Placebo","drug","Arena Pharmaceuticals","Both","Adult",604,"December 2007","April 2008","Co-primary Endpoint- Proportion (%) of Patients Achieving > or = 5% Weight Loss From Baseline to Week 52",5.284,"1",24100
"677","NCT00609466","A Trial to Evaluate CG5503 Efficacy and Safety in Acute Pain After Bunionectomy","Bunionectomy|Pain|Postoperative Pain|Acute Pain","other","Drug: CG5503  IR|Drug: Morphine|Drug: Placebo","drug","Grünenthal GmbH|Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Both","Adult|Senior",291,"September 2007","July 2011","Sum of Pain Intensity Differences Relative to the Baseline Pain Intensity.",3.988,"1",24139
"678","NCT00611026","Clinical Trial to Evaluate the Efficacy and Safety of Fesoterodine in Comparison to Tolterodine Extended Release(ER)in Patients With Overactive Bladder.","Overactive Bladder","other","Drug: Tolterodine ER|Drug: Placebo|Drug: Fesoterodine","drug","Pfizer","Both","Adult|Senior",2417,"February 2008","June 2008","Change From Baseline in Mean Number of Urgency Urinary Incontinence (UUI) Episodes Per 24 Hours at Week 12",2.689,"1",24102
"679","NCT01037218","Treatment of Erectile Dysfunction II","Erectile Dysfunction","other","Drug: Udenafil|Drug: Placebo","drug","Warner Chilcott","Male","Adult|Senior",601,"September 2009","September 2008","Change in Erectile Function Domain Assessed by International Index of Erectile Function (IIEF)， Baseline to Final Visit/Week 12， mITT (Modified Intent-to-Treat)， LOCF (Last Observation Carried Forward)",3.92,"1",24105
"680","NCT01037244","Treatment of Erectile Dysfunction I","Erectile Dysfunction","other","Drug: Udenafil|Drug: Placebo","drug","Warner Chilcott","Male","Adult|Senior",618,"September 2009","January 2008","Change in Erectile Function Domain Assessed by International Index of Erectile Function (IIEF)， Baseline to Final Visit/Week 12， mITT (Modified Intent-to-Treat)， LOCF (Last Observation Carried Forward)",5.845,"1",24097
"681","NCT01042977","Efficacy and Safety in Patients With Type 2 Diabetes Mellitus and Cardiovascular Disease","Type 2 Diabetes Mellitus|Cardiovascular Disease|Inadequate Glycaemic Control","cardiovascular","Drug: Dapagliflozin|Drug: Placebo","drug","AstraZeneca|Bristol-Myers Squibb","Both","Adult|Senior",964,"March 2010","September 2008","Adjusted Mean Change in HbA1c Levels",8.18,"1",24105
"682","NCT01060072","Evaluation of Loteprednol Etabonate Versus Vehicle for the Treatment of Inflammation and Pain Following Cataract Surgery","Inflammation|Pain","other","Drug: Loteprednol etabonate|Drug: Vehicle of Loteprednol Etabonate","drug","Bausch & Lomb Incorporated","Both","Adult|Senior",407,"February 2010","July 2010","Resolution of Anterior Chamber Cells.",4.253,"1",24127
"683","NCT01074125","A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease","Hyperphosphatemia|End-Stage Renal Disease","endocrine and metabolic","Drug: ferric citrate","drug","Keryx Biopharmaceuticals|Collaborative Study Group (CSG)","Both","Adult|Senior",154,"May 2010","August 2008","Change in Serum Phosphorus From Baseline to End of Treatment",4.247,"1",24104
"684","NCT01080300","Breeze3:Study of Gabapentin Extended Release in the Treatment of Vasomotor Symptoms(Hot Flashes)in Postmenopausal Women","Hot Flashes","endocrine and metabolic","Drug: Gabapentin Extended Release|Drug: Placebo","drug","Depomed","Female","Adult|Senior",600,"August 2010","July 2010","Evaluate Efficacy of G-ER at 1800mg Daily Compared With Placebo in Reducing the Average Daily Frequency of Moderate to Severe Hot Flashes at Weeks 4 & 12 of the Efficacy Treatment Period， Compared With Baseline.",5.466,"1",24127
"685","NCT01101841","24-Week Efficacy & Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms","Hot Flashes","endocrine and metabolic","Drug: Brisdelle (paroxetine mesylate)|Drug: Placebo capsules","drug","Noven Therapeutics","Female","Adult|Senior",570,"March 2010","May 2008","Mean Change From Baseline in Hot Flash Frequency at Week 4 and Week 12.",4.06,"1",24101
"686","NCT01172938","Efficacy and Safety Study of Apremilast to Treat Active Psoriatic Arthritis","Psoriatic Arthritis","other","Drug: Apremilast|Drug: Placebo","drug","Celgene Corporation","Both","Adult|Senior",504,"June 2010","March 2009","Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 16",4.004,"1",24111
"687","NCT01217944","Efficacy and Safety of Ranibizumab in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia","Pathological Myopia","other","Drug: Ranibizumab|Drug: Verteporfin PDT|Drug: Sham Ranibizumab|Drug: Sham verteporfin PDT","drug","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior",277,"October 2010","October 2008","Average Change From Baseline to Month 1 Through Month 3 on Visual Acuity of the Study Eye",3.908,"1",24106
"688","NCT01226459","Clinical Trial in Females for Female Pattern Hair Loss","Androgenetic Alopecia","other","Drug: 5% Minoxidil Topical Foam|Drug: Vehicle Topical Foam","drug","Johnson & Johnson Healthcare Products Division of McNEIL-PPC, Inc.|Johnson & Johnson Consumer and Personal Products Worldwide","Female","Adult|Senior",404,"September 2010","February 2008","Target Area Hair Count",4.459,"1",24098
"689","NCT01232569","A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthriti","Rheumatoid Arthritis","other","Drug: Tocilizumab 162 mg|Drug: Placebo","drug","Hoffmann-La Roche","Both","Adult|Senior",656,"March 2011","June 2008","Percentage of Patients With an American College of Rheumatology 20 (ACR20) Response at Week 24",7.709,"1",24102
"690","NCT01271712","Study of Regorafenib as a 3rd-line or Beyond Treatment for Gastrointestinal Stromal Tumors (GIST)","Gastrointestinal Stromal Tumors","cancer","Drug: Regorafenib (Stivarga, BAY73-4506)|Drug: Placebo|Drug: Best supportive care","drug","Bayer","Both","Adult|Senior",199,"January 2011","October 2008","Progression-free Survival",6.975,"1",24106
"691","NCT01361308","Efficacy/Safety Study of Brisdelle™ (Formerly Known as Mesafem) in the Treatment of Vasomotor Symptoms (VMS)","Postmenopausal Symptoms","endocrine and metabolic","Drug: Brisdelle (paroxetine mesylate)|Drug: Placebo capsules","drug","Noven Therapeutics","Female","Adult|Senior",614,"May 2011","April 2008","Mean Change in Frequency of Moderate to Severe VMS From Baseline at Week 4 and Week 12.",3.833,"1",24100
"692","NCT01479764","Study of Sugammadex Versus Usual Care on Incidence of Residual Blockade at Post Anesthesia Care Unit Admission (P07981)","Surgical Procedures, Elective","other","Drug: Sugammadex|Drug: Neostigmine|Drug: Glycopyrrolate","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",154,"December 2011","January 2008","Incidence of Residual Neuromuscular Blockade (NMB) as Defined by a Train-of-Four (TOF) Ratio <0.9 at Post Anesthesia Care Unit (PACU) Entry",7.634,"1",24097
"693","NCT01592851","Clinical Efficacy of a Toothpaste in Providing Relief From the Pain of Dentinal Hypersensitivity","Dentine Hypersensitivity","other","Drug: Stannous Fluoride|Drug: Sodium Monofluorophosphate","drug","GlaxoSmithKline","Both","Adult",113,"April 2012","June 2008","Change From Baseline in Evaporative Air Sensitivity Pain Response on a Schiff Sensitivity Scale at Day 14",8.134,"1",24102
"694","NCT01592864","The Efficacy of a Dentifrice in Providing Relief From the Pain of Dentinal Hypersensitivity","Dentine Hypersensitivity","other","Drug: Stannous Fluoride|Drug: Sodium Monofluorophosphate","drug","GlaxoSmithKline","Both","Adult",120,"March 2012","August 2009","Mean Change From Baseline in Evaporative Air Sensitivity Pain Response on a Schiff Sensitivity Scale at Week 8",3.92,"1",24116
"695","NCT01607411","A Clinical Study to Evaluate Experimental Children's Toothpastes in an In-Situ Caries Model","Dental Caries","other","Drug: Fluoride|Drug: Placebo","drug","GlaxoSmithKline","Both","Child",55,"February 2012","January 2008","Percentage Surface Microhardness Recovery of Test Dentifrices Relative to Placebo Dentifrice",5.506,"1",24097
"696","NCT01641237","Effect of Fluoride in a Dentifrice on Remineralization of Erosive Lesions","Enamel Erosion","other","Drug: sodium fluoride|Drug: no added fluoride in a silica base","drug","GlaxoSmithKline","Both","Adult",72,"March 2012","April 2009","Percentage Surface Microhardness Recovery (%SMHR) Dose Response Relationship",5.034,"1",24112
"697","NCT01998880","CLL11: A Study of Rituximab With Chlorambucil or Chlorambucil Alone in Patients With Previously Untreated Chronic Lymphocytic Leukemia (Stage 1b)","Lymphocytic Leukemia, Chronic","cancer","Drug: obinutuzumab|Drug: rituximab|Drug: chlorambucil","drug","Hoffmann-La Roche|German CLL Study Group|Genentech, Inc.","Both","Adult|Senior",787,"December 2009","May 2008","Progression-free Survival (PFS)",7.013,"1",24101
"698","NCT00649389","Safety and Efficacy Study of a Triple Combination Therapy in Subjects With Hypertension","Hypertension","cardiovascular","Drug: Olmesartan medoxomil|Drug: Amlodipine|Drug: Hydrochlorothiazide","drug","Daiichi Sankyo Inc.","Both","Adult|Senior",2500,"May 2008","May 2008","Change From Baseline to Week 12 in Seated Diastolic Blood Pressure (SeDBP).",6.594,"1",24101
"699","NCT00655356","Safety and Efficacy Study of Isolagen Therapy in the Treatment of Nasolabial Fold Wrinkles","Bilateral Nasolabial Fold Wrinkles","other","Biological: Autologous Human Fibroblasts (azficel-T)|Biological: Placebo","biolog","Fibrocell Technologies, Inc.","Both","Adult|Senior",218,"November 2006","August 2008","Subject Wrinkle Assessment Responders",4.652,"1",24104
"700","NCT00675792","Comparison of Sugammadex Administered at 1-2 Post Tetanic Counts (PTCs) or Better With Neostigmine Administered as Per Standard of Care to Reverse Rocuronium-Induced","Anesthesia","mental health","Drug: Sugammadex|Drug: Neostigmine|Drug: Rocuronium","drug","Merck Sharp & Dohme Corp.","Both","Adult",100,"May 2008","December 2008","Residual Neuromuscular Blockade Evidenced by T4/T1 Ratio at the Time of Tracheal Extubation",5.832,"1",24108
"701","NCT00697515","Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)","ADHD","mental health","Drug: LDX|Drug: Placebo","drug","Shire","Both","Adult",142,"July 2008","February 2008","Permanent Product Measure of Performance (PERMP) Total Score Over the Treatment Day in the Crossover Phase",5.88,"1",24098
"702","NCT00705432","Safety and Efficacy of Boceprevir in Previously Untreated Subjects With Chronic Hepatitis C Genotype 1 (Study P05216AM2) (COMPLETED)","Hepatitis C, Chronic","other","Biological: Peginterferon alfa-2b (PEG)|Drug: Ribavirin (RBV)|Drug: Placebo|Drug: Boceprevir","biolog","Merck Sharp & Dohme Corp.","Both","Adult|Senior",1472,"August 2008","October 2008","Sustained Virologic Response (SVR) Rate",6.951,"1",24106
"703","NCT00705783","Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia","Schizophrenia","mental health","Drug: Aripiprazole depot|Drug: Placebo depot","drug","Otsuka Pharmaceutical Development & Commercialization, Inc.","Both","Adult",843,"July 2008","June 2009","Time to Exacerbation of Psychotic Symptoms/Impending Relapse",6.796,"1",24114
"704","NCT00707057","Ibuprofen Extended-Release Dental Pain Study","Pain|Post-Operative Pain|Third Molar Extraction","other","Drug: Ibuprofen 600 mg Extended-Release Tablets|Drug: Placebo","drug","SCOLR Pharma, Inc.|AAIPharma|Jean Brown Research","Both","Child|Adult",256,"June 2008","June 2009","Analgesic Efficacy， as Measured by the Sum of Pain Intensity Differences (SPID) Scale",8.032,"1",24114
"705","NCT00708500","Boceprevir in Subjects With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/Ribavirin (Study P05101AM3)(COMPLETED)","Hepatitis C, Chronic","other","Drug: Boceprevir (SCH 503034)|Biological: Pegylated interferon alfa-2b (SCH 54031)|Drug: Ribavirin (SCH 18908)|Drug: Boceprevir placebo","biolog","Merck Sharp & Dohme Corp.","Both","Adult|Senior",404,"August 2008","November 2008","Sustained Virologic Response (SVR) Rate in the Full Analysis Set (FAS) Population.",6.265,"1",24107
"706","NCT00725985","Oral Cladribine in Early Multiple Sclerosis (MS)","Multiple Sclerosis","mental health","Drug: Cladribine|Drug: Cladribine|Drug: Placebo|Drug: Rebif® new formulation (RNF)","drug","EMD Serono","Both","Adult",617,"December 2008","March 2009","Time to Clinically Definite Multiple Sclerosis (CDMS) Conversion Represented by Kaplan-Meier Estimates of the Cumulative Percentage of Participants With CDMS",4.428,"1",24111
"707","NCT00727857","Efficacy and Safety of Pioglitazone and Metformin Combination Therapy in Treating Type 2 Diabetes Mellitus.","Diabetes Mellitus","endocrine and metabolic","Drug: Pioglitazone and metformin|Drug: Pioglitazone|Drug: Metformin","drug","Takeda","Both","Adult|Senior",600,"June 2007","August 2008","Percent Change From Baseline in Glycosylated Hemoglobin",4.682,"1",24104
"708","NCT00730015","Trial of Linaclotide in Patients With Chronic Constipation","Chronic Constipation","other","Drug: Matching Placebo|Drug: Linaclotide","drug","Ironwood Pharmaceuticals, Inc.|Forest Laboratories","Both","Adult|Senior",643,"August 2008","May 2008","Complete Spontaneous Bowel Movement (CSBM) Overall Responder",4.905,"1",24101
"709","NCT00742391","A Multicenter Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel When Used to Treat Actinic Keratoses (AKs) on the Non Head Locations","Actinic Keratoses","other","Drug: PEP005 (ingenol mebutate) Gel|Drug: Vehicle gel","drug","Peplin","Both","Adult|Senior",255,"September 2008","February 2010","Patients With Complete Clearance of Actinic Keratosis (AKs)",5.244,"1",24122
"710","NCT00748098","Polysomnography Study of GSK1838262 Extended Release Tablets Versus Placebo in RLS and Associated Sleep Disturbance","Restless Legs Syndrome|Restless Legs Syndrome (RLS)","mental health","Drug: GSK1838262 Extended Release Tablets|Drug: Placebo","drug","XenoPort, Inc.","Both","Adult|Senior",136,"October 2008","April 2008","Adjusted Mean Change From Baseline in Wake Time During Sleep (WTDS) at Week 4/10 Measured by Polysomnography (PSG) (Sleep Study) Using Last Observation Carried Forward (LOCF)",5.286,"1",24100
"711","NCT00751179","Rocuronium Plus Sugammadex Versus Succinylcholine Alone in Participants Undergoing Short Surgical Procedures (19.4.319)(P05700 AM2)(COMPLETED)","Neuromuscular Blockade","mental health","Drug: rocuronium|Drug: sugammadex|Drug: succinylcholine","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",161,"November 2008","April 2011","Change From Baseline in Plasma Potassium Levels at 5 Minutes After Treatment With Rocuronium or Succinylcholine",6.032,"1",24136
"712","NCT00751881","An Efficacy Study of Teriflunomide in Patients With Relapsing Multiple Sclerosis","Multiple Sclerosis","mental health","Drug: Placebo (for teriflunomide)|Drug: Teriflunomide","drug","Sanofi","Both","Adult",1169,"August 2008","December 2011","Annualized Relapse Rate (ARR): Poisson Regression Estimate",3.805,"1",24144
"713","NCT00758498","Study of the Effect of Armodafinil Treatment in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag Disorder","Excessive Sleepiness","mental health","Drug: armodafinil|Drug: armodafinil|Drug: placebo","drug","Cephalon|Teva Pharmaceutical Industries","Both","Adult",427,"September 2008","October 2008","Mean Sleep Latency (Minutes) From the Multiple Sleep Latency Test (MSLT)- Average of Four Scheduled Naps Across Days 1 and 2",7.017,"1",24106
"714","NCT01006980","A Study of RO5185426 in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)","Malignant Melanoma","cancer","Drug: RO5185426|Drug: dacarbazine","drug","Hoffmann-La Roche","Both","Adult|Senior",677,"January 2010","May 2009","Overall Survival",4.916,"1",24113
"715","NCT01019694","Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease","Pulmonary Disease, Chronic Obstructive","respiratory","Drug: Combivent CFC-MDI|Drug: Combivent Respimat 20/100 mcg|Drug: Atrovent HFA 42 mcg + Albuterol HFA 200 mcg","drug","Boehringer Ingelheim","Both","Adult|Senior",470,"November 2009","October 2009","Performance Domain Score From the Patient Satisfaction and Preference Questionnaire (PASAPQ) at Week 48",5.241,"1",24118
"716","NCT01031680","Efficacy and Safety in Patients With Type 2 Diabetes Mellitus, Cardiovascular Disease and Hypertension","Type 2 Diabetes Mellitus|Cardiovascular Disease|Hypertension|Inadequate Glycaemic Contr","cardiovascular","Drug: Dapagliflozin|Drug: Placebo","drug","AstraZeneca|Bristol-Myers Squibb","Both","Adult|Senior",922,"February 2010","January 2010","Adjusted Mean Change in HbA1c Levels",9.725,"1",24121
"717","NCT00853970","Efficacy Study of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery","Pain|Inflammation","other","Drug: Bromfenac Ophthalmic Solution|Drug: Placebo Comparator","drug","Bausch & Lomb Incorporated","Both","Adult|Senior",299,"February 2009","September 2009","Summed Ocular Inflammation Score (SOIS) of Zero",4.016,"1",24117
"718","NCT01370525","Efficacy of Esomeprazole in Patients With Frequent Heartburn","Heartburn","other","Drug: Esomeprazole","drug","AstraZeneca","Both","Adult|Senior",340,"August 2011","May 2011","Percentage of Heartburn Free 24 Hour Days During 14 Days of Randomized Treatment",3.928,"1",24137
"719","NCT00868699","Lurasidone - A 6-week Study of Patients With Bipolar I Depression (Monotherapy)","Bipolar Depression","mental health","Drug: lurasidone|Drug: lurasidone|Drug: Placebo","drug","Sunovion","Both","Adult|Senior",505,"April 2009","September 2008","Mean Change From Baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at Endpoint (Week 6)",3.9316,"1",24105
"720","NCT00548340","VEC-162 Study in Adult Patients With Primary Insomnia","Primary Insomnia","mental health","Drug: VEC-162 20 mg|Drug: Placebo|Drug: VEC-162 50 mg","drug","Vanda Pharmaceuticals","Both","Adult",322,"November 2007","March 2008","Average Change From Baseline - Latency to Persistent Sleep (LPS)",3.943,"1",24099
"721","NCT00855582","A Study in the Treatment of Erectile Dysfunction and Benign Prostate Hyperplasia","Erectile Dysfunction|Benign Prostatic Hyperplasia","other","Drug: Tadalafil|Drug: Placebo","drug","Eli Lilly and Company","Male","Adult|Senior",606,"March 2009","April 2009","Change From Baseline in Total International Prostate Symptom Score (IPSS) at Week 12 Endpoint (5 mg)",3.9655,"1",24112
"722","NCT00826280","Caffeine's Effect on Regadenoson Administration With Single Photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)","Coronary Artery Disease (CAD)","cardiovascular","Drug: regadenoson|Drug: overencapsulated caffeine|Radiation: technetium|Drug: placebo","drug","Astellas Pharma Inc","Both","Adult|Senior",347,"March 2009","September 2009","Change in Number of Reversible Defects",3.9676,"1",24117
"723","NCT00890721","Study of Pain Control in Hemorrhoidectomy","Hemorrhoid","other","Drug: SKY0402|Drug: Placebo","drug","Pacira Pharmaceuticals, Inc","Both","Adult|Senior",189,"May 2009","July 2009","The Area Under the Curve (AUC) of the Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores Through 72 Hours for Subjects Receiving SKY0402 vs. Placebo.",3.9722,"1",24115
"724","NCT01001208","The Efficacy and Safety of Adding Methotrexate to Etanercept in Psoriasis","Psoriasis","other","Drug: Methotrexate|Drug: Etanercept|Drug: Placebo","drug","Amgen|Immunex Corporation","Both","Adult|Senior",478,"November 2009","July 2008","PASI 75 Response at Week 24",4.0004,"1",24103
"725","NCT00789373","A Study of Induction and Maintenance Treatment of Advanced Non-squamous Non-Small Cell Lung Cancer","Non-Small Cell Lung Cancer","cancer","Drug: Pemetrexed|Drug: Cisplatin|Drug: Placebo|Drug: Pemetrexed|Other: Best Supportive Care","drug","Eli Lilly and Company","Both","Adult|Senior",939,"November 2008","July 2008","Investigator-assessed Objective Progression-free Survival (PFS)",4.0128,"1",24103
"726","NCT00818883","Efficacy and Safety of Azilsartan Medoxomil and Chlorthalidone in Participants With Moderate to Severe Hypertension","Essential Hypertension","cardiovascular","Drug: Azilsartan medoxomil and chlorthalidone|Drug: Azilsartan medoxomil and hydrochlorothiazide","drug","Takeda","Both","Adult|Senior",609,"February 2009","March 2009","Change From Baseline in Trough， Sitting， Clinic Systolic Blood Pressure",4.0652,"1",24111
"727","NCT00824473","A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies","Seasonal Allergic Rhinitis","other","Drug: Placebo|Drug: 0.15% azelastine hydrochloride","drug","Meda Pharmaceuticals","Both","Child|Adult|Se",506,"December 2008","October 2008","Change From Baseline in 12-hour Reflective Total Nasal Symptom Score(rTNSS)for the Entire 14-day Study Period Compared to Placebo (AM and PM Combined)at 14 Days",4.0701,"1",24106
"728","NCT00736879","Safety and Efficacy of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes","Type 2 Diabetes Mellitus","endocrine and metabolic","Drug: Dapagliflozin|Drug: Placebo","drug","Bristol-Myers Squibb|AstraZeneca","Both","Adult|Senior",497,"September 2008","May 2009","Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 Last Observation Carried Forward (LOCF) - All Randomized Participants",4.1268,"1",24113
"729","NCT00960440","Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors","Arthritis, Rheumatoid","other","Drug: CP-690,550|Drug: CP-690,550|Drug: Placebo|Drug: CP-690,550|Drug: Placebo|Drug: CP-690,550","drug","Pfizer","Both","Adult|Senior",399,"October 2009","March 2011","Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 3",4.1344,"1",24135
"730","NCT00844649","Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas","Metastatic Pancreatic Cancer","cancer","Drug: Albumin-bound paclitaxel|Drug: Gemcitabine","drug","Celgene Corporation","Both","Adult|Senior",861,"May 2009","August 2011","Overall Survival (OS)",4.1706,"1",24140
"731","NCT00122382","Remission and Joint Damage Progression in Early Rheumatoid Arthritis","Rheumatoid Arthritis","other","Drug: Abatacept|Drug: placebo|Drug: methotrexate","drug","Bristol-Myers Squibb","Both","Adult|Senior",1052,"July 2005","June 2010","",4.174,"1",24126
"732","NCT00789828","Efficacy and Safety of Everolimus (RAD001) in Patients of All Ages With Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis Complex (TSC)(EXIST-1)","Tuberous Sclerosis|Subependymal Giant Cell Astrocytoma","other","Drug: Everolimus|Drug: Placebo","drug","Novartis Pharmaceuticals|Novartis","Both","Child|Adult|Se",118,"August 2009","June 2010","Subependymal Giant Cell Astrocytomas (SEGA) Response Rate",4.1893,"1",24126
"733","NCT00105196","A Study of Aripiprazole in Patients With Major Depressive Disorder","Major Depressive Disorder","mental health","Drug: Aripiprazole+ ADT|Drug: Placebo+ ADT","drug","Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka America Pharmaceutical","Both","Adult",349,"March 2005","July 2010","Mean Change in the Montgomery Åsberg Depression Rating Scale (MADRS)",4.275,"1",24127
"734","NCT00808132","Study Evaluating The Effects Of Bazedoxifene/Conjugated Estrogens On Endometrial Safety And Postmenopausal Osteoporosis","Menopause|Osteoporosis","endocrine and metabolic","Drug: bazedoxifene 20 mg/ conjugated estrogens 0.45 mg|Drug: bazedoxifene 20 mg/ conjugated estrogens 0.625 mg|Drug: bazedoxifene 20 mg|Drug: conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg|Drug: Placebo","drug","Pfizer","Female","Adult",1886,"January 2009","March 2012","Percentage of Participants With Endometrial Hyperplasia at Month 12: Main Study",4.2831,"1",24147
"735","NCT00853385","A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis","Rheumatoid Arthritis","other","Drug: CP 690,550|Drug: CP-690,550|Other: Placebo|Other: Placebo|Biological: Biologic TNFi","biolog","Pfizer","Both","Adult|Senior",717,"May 2009","August 2011","Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 6",4.2918,"1",24140
"736","NCT00909727","Study of Ivacaftor in Cystic Fibrosis Subjects Aged 6 to 11 Years With the G551D Mutation","Cystic Fibrosis","respiratory","Drug: Ivacaftor|Drug: Placebo","drug","Vertex Pharmaceuticals Incorporated|Cystic Fibrosis Foundation Therapeutics","Both","Child",52,"August 2009","November 2011","Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 24",4.3103,"1",24143
"737","NCT00521456","A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery","Cataract Extraction","other","Drug: ketorolac eye drops","drug","Allergan","Both","Adult|Senior",263,"October 2007","July 2010","Resolution of Post Operative Inflammation",4.333,"1",24127
"738","NCT00337727","Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)(0869-130)(COMPLETED)","Chemotherapy-Induced Nausea and Vomiting","other","Drug: aprepitant|Drug: Comparator: ondansetron|Drug: Comparator: dexamethasone|Drug: Comparator: fosaprepitant dimeglumine|Drug: Comparator; Placebo (unspecified)|Drug: Comparator; Placebo (unspecified)","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",848,"January 2007","July 2012","Number of Patients Who Reported No Vomiting",4.351,"1",24151
"739","NCT00097786","Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications","Diabetes Mellitus, Type 2","endocrine and metabolic","Drug: Valsartan 160 mg + nateglinide 60 mg|Drug: Valsartan 160 mg + nateglinide placebo|Drug: Nateglinide 60 mg + valsartan placebo|Drug: Valsartan placebo + nateglinide placebo","drug","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior",9306,"January 2002","September 2011","Percentage of Patients Reaching the Endpoint: Progression to Diabetes - Valsartan Versus Non-valsartan",4.383,"1",24141
"740","NCT01097616","Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study A (MK-4305-028)","Primary Insomnia","mental health","Drug: Suvorexant High Dose (HD)|Drug: Suvorexant Low Dose (LD)|Drug: Comparator: Placebo","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",1023,"May 2010","November 2011","Suvorexant HD Versus Placebo: Change From Baseline in Mean Subjective Total Sleep Time (sTSTm) at Month 1",5.122,"1",24143
"741","NCT01097629","Safety and Efficacy Study of Suvorexant in Participants With Primary Insomnia - Study B (MK-4305-029)","Primary Insomnia","mental health","Drug: Suvorexant High Dose (HD)|Drug: Suvorexant Low Dose (LD)|Drug: Comparator: Placebo","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",1020,"May 2010","October 2011","Suvorexant HD Versus Placebo: Change From Baseline in Mean Subjective Total Sleep Time (sTSTm) at Month 1",6.443,"1",24142
"742","NCT00649428","Safety and Efficacy Study of Isolagen TherapyTM in the Treatment of Nasolabial Fold Wrinkles","Bilateral Nasolabial Fold Wrinkles","other","Biological: Autologous Human Fibroblast (azficel-T)|Biological: Placebo","biolog","Fibrocell Technologies, Inc.","Both","Adult|Senior",203,"October 2006","November 2011","Subject Wrinkle Assessment Responders",4.4172,"1",24143
"743","NCT00655863","Efficacy of Alogliptin and With Pioglitazone in Patients With Type 2 Diabetes.","Diabetes Mellitus","endocrine and metabolic","Drug: Alogliptin and Pioglitazone|Drug: Alogliptin|Drug: Placebo","drug","Takeda","Both","Adult|Senior",71,"July 2007","May 2011","Change From Baseline in Postprandial Incremental Area Under the Curve for Total Triglycerides at Week 16.",4.4294,"1",24137
"744","NCT00821093","Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD)","Chronic Obstructive Pulmonary Disease (COPD)","respiratory","Drug: Indacaterol 150 µg|Drug: Salmeterol 50 µg|Drug: Placebo to indacaterol|Drug: Placebo to salmeterol","drug","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior",1123,"January 2009","January 2011","Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Time) Area Under the Curve (AUC) From 5 Minutes to 11 Hours 45 Minutes Post-dose at the End of the Study (Week 12， Day 84)",4.4428,"1",24133
"745","NCT00282971","A Clinical Trial Assessing The Impact Of Inhaled Insulin On Glucose Control In Patients With Type 2 Diabetes Mellitus","Diabetes Mellitus Type 2","endocrine and metabolic","Other: Standard of Care|Drug: Inhaled Insulin (Exubera)","drug","Pfizer","Both","Adult|Senior",354,"March 2006","March 2012","Percentage Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 24",4.455,"1",24147
"746","NCT01370538","Efficacy of Esomeprazole in Patients With Frequent Heartburn","Heartburn","other","Drug: Esomeprazole","drug","AstraZeneca","Both","Adult|Senior",341,"August 2011","September 2008","Percentage of Heartburn Free 24 Hour Days During 14 Days of Randomized Treatment",4.555,"1",24105
"747","NCT00783718","Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis","Ulcerative Colitis","other","Drug: vedolizumab|Other: Placebo","drug","Millennium Pharmaceuticals, Inc.","Both","Adult|Senior",895,"January 2009","October 2010","Induction Phase: Percentage of Participants With a Clinical Response at Week 6",4.5659,"1",24130
"748","NCT00790192","Lurasidone HCL - A 6-week Phase 3 Study of Patients With Acute Schizophrenia.","Schizophrenia","mental health","Drug: Lurasidone|Drug: Lurasidone|Drug: Quetiapine XR|Drug: Placebo","drug","Sunovion","Both","Adult|Senior",488,"October 2008","February 2012","Primary Efficacy Endpoint: Mean Change in Total PANSS Score From Baseline to the End of the Double Blind Phase",4.568,"1",24146
"749","NCT00757588","Safety and Efficacy of Saxagliptin Plus Insulin With or Without Metformin","Type 2 Diabetes","endocrine and metabolic","Drug: Saxagliptin, 5 mg + insulin|Drug: Placebo  + insulin","drug","AstraZeneca","Both","Adult|Senior",455,"November 2008","December 2012","Adjusted Mean Change From Baseline in A1C Levels (Last Observation Carried Forward [LOCF])",4.6067,"1",24156
"750","NCT00856544","A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications","Arthritis, Rheumatoid","other","Drug: CP-690,550|Drug: CP-690,550|Drug: Placebo|Drug: Placebo","drug","Pfizer","Both","Adult|Senior",795,"May 2009","March 2012","Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 6",4.6198,"1",24147
"751","NCT01010971","Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis (SAR) to Mounta","Seasonal Allergic Rhinitis","other","Drug: Ciclesonide HFA 160 μg|Drug: Ciclesonide HFA 80 μg|Drug: Placebo","drug","Sunovion","Both","Child|Adult|Se",671,"December 2009","September 2012","Change From Baseline in Daily Subject-reported AM and PM Reflective TNSS Averaged Over the Two-week Treatment Period.",4.6493,"1",24153
"752","NCT00938717","Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)","Irritable Bowel Syndrome With Constipation","other","Drug: Linaclotide or Matching Placebo","drug","Ironwood Pharmaceuticals, Inc.|Forest Laboratories","Both","Adult|Senior",805,"July 2009","November 2012","Abdominal Pain and Complete Spontaneous Bowel Movement (APC) Responder， 9 Out of 12 Weeks",4.6711,"1",24155
"753","NCT00660829","A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies","Seasonal Allergic Rhinitis","other","Drug: Placebo|Drug: 0.15% Azelastine Hydrochloride","drug","Meda Pharmaceuticals","Both","Child|Adult|Se",536,"December 2007","November 2012","Change From Baseline in 12-hour Reflective Total Nasal Symptom Score (TNSS) (AM and PM Combined)at 14 Days",4.6735,"1",24155
"754","NCT01535560","Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa","Acute Otitis Externa","other","Drug: AL-60371, 0.3% otic suspension|Drug: AL-60371 Vehicle","drug","Alcon Research","Both","Child|Adult|Se",589,"April 2012","January 2011","Proportion of Patients With Clinical Cures at the Day 11 (TOC) Visit",4.674,"1",24133
"755","NCT00790400","Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyom","Tuberous Sclerosis Complex (TSC)|Lymphangioleiomyomatosis (LAM)","cancer","Drug: Everolimus (RAD001)|Drug: Placebo","drug","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior",118,"April 2009","November 2012","Angiomyolipoma Response Rate as Per Central Radiology Review (Double-blind Period)",4.7555,"1",24155
"756","NCT00637273","A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes","Type 2 Diabetes Mellitus","endocrine and metabolic","Drug: exenatide once weekly|Drug: sitagliptin|Drug: pioglitazone|Drug: placebo tablet|Drug: placebo once weekly","drug","AstraZeneca|Eli Lilly and Company","Both","Adult|Senior",514,"January 2008","October 2012","Change in HbA1c From Baseline to Week 26",4.8092,"1",24154
"757","NCT00790023","Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis","Seasonal Allergic Rhinitis","other","Drug: 80 mcg Ciclesonide|Drug: 160 mcg Ciclesonide|Drug: Placebo","drug","Sunovion","Both","Child|Adult|Se",707,"November 2008","November 2011","Change From Baseline in Daily Subject-reported AM and PM Reflective Total Nasal Symptom Score (rTNSS) Averaged Over the Two-week Treatment Period.",4.8484,"1",24143
"758","NCT00699153","Loteprednol Etabonate in an Ophthalmic Base vs Vehicle for the Treatment of Inflammation Following Cataract Surgery","Ocular Inflammation","other","Drug: Loteprednol Etabonate|Drug: Vehicle of Ophthalmic Loteprednol Etabonate","drug","Bausch & Lomb Incorporated","Both","Adult|Senior",400,"June 2008","November 2011","Participants With Complete Resolution of Anterior Chamber Cells and Flare. Grade=0",4.9347,"1",24143
"759","NCT00761150","Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)","Chronic Low Back Pain","other","Drug: ABT-712|Drug: Placebo","drug","AbbVie (prior sponsor, Abbott)|AbbVie","Both","Adult|Senior",308,"September 2008","December 2012","Change From Double-blind (DB) Baseline to Final Assessment in Chronic Lower Back Pain (CLBP) Intensity by Visual Analog Scale (VAS)",4.938,"1",24156
"760","NCT00638690","Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy","Prostatic Neoplasms","cancer","Drug: Placebo|Drug: Abiraterone acetate|Drug: Prednisone/prednisolone","drug","Cougar Biotechnology, Inc.","Male","Adult|Senior",1195,"May 2008","July 2011","Overall Survival",4.9408,"1",24139
"761","NCT01202188","A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)","Chronic Obstructive Pulmonary Disease (COPD)","respiratory","Drug: indacaterol and glycopyrronium (QVA149)|Drug: glycopyrronium (NVA237)|Drug: indacaterol (QAB149)|Drug: tiotropium|Drug: placebo","drug","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior",2144,"September 2010","March 2012","Trough Forced Expiratory Volume In One Second (FEV1) After 26 Weeks of Treatment",4.95,"1",24147
"762","NCT00883740","Effects Of Pregabalin (Lyrica) On Sleep Maintenance In Subjects With Fibromyalgia","Fibromyalgia|Sleep Disorders","mental health","Drug: Pregabalin|Drug: Placebo","drug","Pfizer","Both","Adult|Senior",119,"June 2009","March 2012","Wake After Sleep Onset (WASO) at Weeks 5 and 11",4.978,"1",24147
"763","NCT00091442","A Study of Docetaxel Monotherapy or DOXIL and Docetaxel in Patients With Advanced Breast Cancer","Breast Cancer","cancer","Drug: Docetaxel|Drug: DOXIL","drug","Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","Female","Adult|Senior",751,"September 2004","April 2012","",4.98,"1",24148
"764","NCT00829166","An Open-label Study of Trastuzumab Emtansine (T-DM1) vs Capecitabine + Lapatinib in Patients With HER2-positive Locally Advanced or Metastatic Breast Cancer","Breast Cancer","cancer","Drug: Trastuzumab emtansine [Kadcyla]|Drug: Lapatinib|Drug: Capecitabine","drug","Hoffmann-La Roche","Both","Adult|Senior",991,"February 2009","November 2012","Progression-free Survival (PFS) Assessed by an Independent Review Committee",4.9837,"1",24155
"765","NCT00859898","Study of Dapagliflozin in Combination With Metformin XR to Initiate the Treatment of Type 2 Diabetes","Type 2 Diabetes Mellitus","endocrine and metabolic","Drug: Dapagliflozin|Drug: Metformin XR|Drug: Metformin XR|Drug: dapagliflozin matching Placebo|Drug: metformin HCl Modified Release matching Placebo","drug","Bristol-Myers Squibb|AstraZeneca","Both","Adult|Senior",1093,"April 2009","March 2012","Adjusted Mean Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 (Last Observation Carried Forward) - Randomized Treated Participants",5.0189,"1",24147
"766","NCT00797797","Study of Milnacipran Added to Pregabalin for Treatment of Fibromyalgia","Fibromyalgia","mental health","Drug: No Treatment Added|Drug: Milnacipran Added","drug","Forest Laboratories","Both","Adult|Senior",364,"November 2008","September 2012","Patient Global Impression of Change (PGIC) Responder Rate at End of Study",5.0678,"1",24153
"767","NCT00907426","Safety and Efficacy Study of Bimatoprost to Treat Hypotrichosis of the Eyelashes After Application to the Eyelid Margin","Hypotrichosis","other","Drug: Bimatoprost 0.03% solution|Drug: Vehicle solution","drug","Allergan","Both","Adult|Senior",368,"August 2009","February 2012","Percentage of Treatment Responders at Month 4",5.0941,"1",24146
"768","NCT01356602","Safety and Efficacy of Canakinumab Prefilled Syringes in Frequently Flaring Acute Gouty Arthritis Patients","Acute Gouty Arthritis","endocrine and metabolic","Drug: Canakinumab pre-filled syringe|Drug: Canakinumab lyophilized powder|Drug: Triamcinolone Acetonide|Drug: Placebo","drug","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior",397,"May 2011","February 2012","Pain Intensity on a 0-100 mm Visual Analog Scale (VAS) Between the Canakinumab 150 mg PFS and Triamcinolone Acetonide 40 mg Groups",5.114,"1",24146
"769","NCT00932893","An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Invol","Carcinoma, Non-Small-Cell Lung","cancer","Drug: PF-02341066|Drug: Pemetrexed|Drug: Docetaxel","drug","Pfizer","Both","Adult|Senior",347,"September 2009","June 2012","Progression-Free Survival (PFS)",5.1834,"1",24150
"770","NCT00974311","Safety and Efficacy Study of MDV3100 in Patients With Castration-Resistant Prostate Cancer Who Have Been Previously Treated With Docetaxel-based Chemotherapy","Castration-Resistant Prostate Cancer","cancer","Drug: Enzalutamide|Drug: Placebo","drug","Medivation, Inc.|Astellas Pharma Inc","Male","Adult|Senior",1199,"September 2009","October 2012","Overall Survival",5.194,"1",24154
"771","NCT00846365","Efficacy and Safety of Azilsartan Medoxomil Plus Chlorthalidone in Participants With Moderate to Severe Hypertension","Essential Hypertension","cardiovascular","Drug: Azilsartan medoxomil and chlorthalidone|Drug: Azilsartan medoxomil and chlorthalidone|Drug: Olmesartan medoxomil-hydrochlorothiazide","drug","Takeda","Both","Adult|Senior",1085,"March 2009","January 2011","Change From Baseline to Week 8 in Trough， Sitting， Clinic Systolic Blood Pressure.",5.1983,"1",24133
"772","NCT01367249","Efficacy of Bromfenac Ophthalmic Solution in Patients Undergoing Cataract Surgery","Pain|Inflammation|Cataract","other","Drug: Bromfenac Ophthalmic Solution|Drug: Placebo","drug","Bausch & Lomb Incorporated","Both","Adult|Senior",440,"May 2011","September 2008","Ocular Inflammation",5.2,"1",24105
"773","NCT00687908","Adapalene-Benzoy Peroxide (BPO) Gel in the Treatment of Acne Vulgaris as a 6-month Maintenance","Acne","other","Drug: Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel|Drug: Vehicle Gel","drug","Galderma","Both","Child|Adult",243,"November 2008","December 2009","Maintenance Success for Total Lesions at Week 24",5.3185,"1",24120
"774","NCT00981045","Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function","Iron Deficiency Anemia|Impaired Renal Function","other","Drug: Ferric Carboxymaltose (FCM)|Drug: Iron Sucrose (Venofer)","drug","Luitpold Pharmaceuticals","Both","Adult|Senior",2561,"August 2009","November 2009","Mean Change From Baseline to the Highest Observed Hemoglobin Any Time From Baseline to End of Study.",5.3205,"1",24119
"775","NCT00963508","Efficacy, Safety and Tolerability of a Novel Malathion Formulation in Patients 2 Years and Older With Head Lice","Pediculosis","other","Drug: Malathion gel 0.5%|Drug: Permethrin 1% rinse (Nix Crème)","drug","Taro Pharmaceuticals USA","Both","Child|Adult|Se",403,"August 2009","February 2008","Proportion of Index Subjects Free of Any Lice 14 Days After Their Last Treatment in the Modified ITT (LOCF)",5.3432,"1",24098
"776","NCT00095147","Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis","Rheumatoid Arthritis","other","Drug: Abatacept (ABA) + Methotrexate (MTX), double-blind (DB)|Drug: Infliximab (INF) + MTX, DB|Drug: Placebo (PLA) + MTX, DB|Drug: PLA + MTX switched to ABA+ MTX, DB|Drug: ABA, open-label (OL)","drug","Bristol-Myers Squibb","Both","Adult|Senior",431,"February 2005","November 2008","DB; Adjusted Mean Change From Baseline to Day 197 in Disease Activity Score (DAS) 28 Score (Erythrocyte Sedimentation Rate [ESR]) For ABA Versus PLA (Last Observation Carried Forward [LOCF] Analysis)",5.364,"1",24107
"777","NCT00174785","A Trial With Dronedarone to Prevent Hospitalization or Death in Patients With Atrial Fibrillation","Atrial Fibrillation|Atrial Flutter","cardiovascular","Drug: dronedarone (SR33589)|Drug: placebo","drug","Sanofi","Both","Senior",4628,"June 2005","March 2012","First Hospitalization for Cardiovascular Reason or Death From Any Cause",5.374,"1",24147
"778","NCT00740792","A Study Evaluating the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies","Seasonal Allergic Rhinitis","other","Drug: azelastine HCl/fluticasone propionate|Drug: azelastine Hcl|Drug: fluticasone propionate|Drug: placebo","drug","Meda Pharmaceuticals","Both","Child|Adult|Se",776,"August 2008","October 2011","Change From Baseline in 12 Hour Reflective Total Nasal Symptom Score (rTNSS)",5.3772,"1",24142
"779","NCT00812006","A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis","Migraine","mental health","Drug: rizatriptan benzoate|Drug: Comparator: placebo","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",108,"March 2009","November 2009","Pain Relief (PR)",5.5753,"1",24119
"780","NCT00845065","Boceprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Participants With Chronic Hepatitis C Genotype 1 Who Failed Prior Treatment With Peginterferon/","Hepatitis C, Chronic","other","Drug: Boceprevir|Other: Placebo|Biological: Peginterferon alfa-2a|Drug: Ribavirin","biolog","Merck Sharp & Dohme Corp.","Both","Adult|Senior",202,"February 2009","March 2010","Sustained Virologic Response (SVR) Rate in Full Analysis Set (FAS) Population.",5.7144,"1",24123
"781","NCT00305604","Study of Sitagliptin in Older Type 2 Diabetics (0431-047)(COMPLETED)","Type 2 Diabetes","endocrine and metabolic","Drug: sitagliptin phosphate|Drug: Comparator: Placebo","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",206,"March 2006","May 2010","Change From Baseline in HbA1c (Hemoglobin A1c) at Week 24",5.717,"1",24125
"782","NCT00943826","A Study of Avastin® (Bevacizumab) in Combination With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Glioblastoma","Glioblastoma","cancer","Drug: bevacizumab [Avastin®]|Drug: Placebo|Drug: temozolomide|Radiation: Radiation therapy","drug","Hoffmann-La Roche","Both","Adult|Senior",921,"June 2009","October 2008","Co-Primary: Progression-free Survival (PFS) as Assessed by Investigator",5.7718,"1",24106
"783","NCT00660517","A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies","Seasonal Allergic Rhinitis","other","Drug: MP29-02|Drug: azelastine Hcl|Drug: fluticasone propionate|Drug: placebo","drug","Meda Pharmaceuticals","Both","Child|Adult|Se",607,"December 2007","November 2011","Change From Baseline in 12 Hour Reflective Total Nasal Symptom Score (rTNSS)",5.7884,"1",24143
"784","NCT00299130","A Study to Evaluate Rituximab in Combination With Methotrexate Compared to Methotrexate Alone in Patients With Rheumatoid Arthritis","Rheumatoid Arthritis","other","Drug: Folate|Drug: Methotrexate|Drug: Methylprednisolone|Drug: Placebo|Drug: Rituximab","drug","Genentech, Inc.|Roche Pharma AG","Both","Adult|Senior",511,"October 2005","August 2009","Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24",5.793,"1",24116
"785","NCT00048581","Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the P","Rheumatoid Arthritis","other","Drug: Abatacept|Drug: Placebo|Drug: Abatacept","drug","Bristol-Myers Squibb","Both","Adult|Senior",738,"December 2002","November 2009","Double-blind Period (DB); Number of Participants With American College of Rheumatology (ACR) 20 Response at Day 169",5.86,"1",24119
"786","NCT00862251","Ezetimibe/Simvastatin (MK-0653A) Versus Rosuvastatin Versus Doubling Statin Dose in Participants With Cardiovascular Disease and Diabetes Mellitus (MK-0653A-133)(COM","Cardiovascular Disorder|Diabetes Mellitus","cardiovascular","Drug: ezetimibe (+) simvastatin|Drug: simvastatin 40 mg or atorvastatin 20 mg|Drug: Rosuvastatin|Drug: atorvastatin 10 mg or simvastatin 20 mg","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",808,"April 2009","July 2010","Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) After Switching to Treatment With Ezetimibe/Simvastatin vs Doubling the Dose of Statin (Simvastatin or Atorvastatin).",5.9649,"1",24127
"787","NCT00651118","A Study to Evaluate the Safety and Effectiveness of a Nasal Spray to Treat Seasonal Allergies","Seasonal Allergic Rhinitis","other","Drug: Placebo|Drug: azelastine Hcl|Drug: azelastineHcl /  fluticasone propionate|Drug: fluticasone propionate","drug","Meda Pharmaceuticals","Both","Child|Adult|Se",832,"March 2008","February 2011","Change From Baseline in 12-hour Reflective Total Nasal Symptom Score (rTNSS)",5.9867,"1",24134
"788","NCT00830947","Effect of Cyclic Loading (Vibration) on Orthodontic Tooth Movement","Malocclusion","other","Device: OrthoAccel Device|Device: Sham Device","device","OrthoAccel Technologies Inc.","Both","Child|Adult",45,"February 2009","July 2008","The Rate of Orthodontic Movement of a Maxillary Canine Tooth Being Distalized to Close an Extraction Space.",5.9891,"1",24103
"789","NCT00846586","Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease","Chronic Obstructive Pulmonary Disease (COPD)","respiratory","Drug: Indacaterol 150 μg|Drug: Tiotropium 18 μg|Drug: Placebo to indacaterol","drug","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior",1134,"March 2009","December 2010","Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 8 Hours Post-dose at the End of Treatment (Week 12)",6.0052,"1",24132
"790","NCT01068158","A Study Comparing the Safety and Efficacy of 0.5% Ivermectin Cream to Placebo in Lice Infested Subjects","Head Lice","other","Drug: 0.5% Ivermectin Cream|Drug: Placebo control","drug","Topaz Pharmaceuticals Inc","Both","Child|Adult|Se",371,"March 2010","August 2012","Percentage of Index Participants Who Were Lice-Free by Day 2 That Were Maintained Through Day 15 Post-treatment With Either Ivermectin or Placebo (Vehicle Control)",6.008,"1",24152
"791","NCT00889330","Safety and Efficacy Study of a Eye Drop for Eye Allergy","Allergic Conjunctivitis","other","Drug: alcaftadine|Drug: Placebo","drug","Vistakon Pharmaceuticals","Both","Child|Adult|Se",60,"April 2009","March 2008","Ocular Itching at Visit 3 (Day 0) at 7 Minutes Following Allergen Challenge， 16 Hours After Treatment Instillation.",6.0163,"1",24099
"792","NCT00763321","Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)","Chronic Low Back Pain","other","Drug: ABT-712|Drug: Placebo","drug","AbbVie (prior sponsor, Abbott)|AbbVie","Both","Adult|Senior",287,"September 2008","June 2010","Change From Double-blind (DB) Baseline to Final Assessment in Chronic Lower Back Pain (CLBP) Intensity by Visual Analog Scale (VAS)",6.0331,"1",24126
"793","NCT00812955","""Safety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol (\""Bad Cholesterol\"") and Triglyc","Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia","cardiovascular","Drug: ABT-143|Drug: simvastatin","drug","AstraZeneca","Both","Adult|Senior",474,"November 2008","January 2008","Mean Percent Change From Baseline to the Final Visit in Low-density Lipoprotein Cholesterol (LDL-C) (Full Analysis Set)",6.1135,"1",24097
"794","NCT00991276","Polysomnography Study Of Pregabalin And Pramipexole Versus Placebo In Patients With Restless Legs Syndrome And Associated Sleep Disturbance","Restless Legs Syndrome","mental health","Drug: pregabalin|Drug: placebo|Drug: pramipexole","drug","Pfizer","Both","Adult|Senior",85,"December 2009","August 2009","Wake After Sleep Onset (WASO)",6.1872,"1",24116
"795","NCT00683800","Study Evaluating The Safety And Efficacy Of Desvenlafaxine Succinate For Vasomotor Symptoms In Menopausal Women","Vasomotor Symptoms","other","Drug: desvenlafaxine succinate (DVS) SR|Drug: Placebo","drug","Pfizer","Female","Adult|Senior",2186,"June 2008","August 2010","Change From Baseline in the Average Daily Number of Moderate to Severe Hot Flushes at Week 4",6.225,"1",24128
"796","NCT00075218","A Study To Assess The Safety And Efficacy Of SU11248 In Patients With Gastrointestinal Stromal Tumor(GIST)","Gastrointestinal Stromal Tumor","cancer","Drug: Placebo|Drug: SU011248","drug","Pfizer","Both","Adult|Senior",361,"December 2003","October 2009","Time to Tumor Progression (TTP) as Assessed by Imaging Studies at End of Double-blind Treatment Phase",6.259,"1",24118
"797","NCT00806026","Long Term Study Of Pregabalin In Idiopathic Restless Legs Syndrome Patients","Idiopathic Restless Legs Syndrome","mental health","Drug: placebo and pregabalin|Drug: pramipexol|Drug: pramipexol|Drug: Pregabalin|Drug: pramipexol|Drug: pramipexol","drug","Pfizer","Both","Adult|Senior",731,"December 2008","August 2008","Restless Legs Syndrome (RLS) Symptom Severity",6.3,"1",24104
"798","NCT00083889","SU011248 Versus Interferon-Alfa As First-Line Systemic Therapy For Patients With Metastatic Renal Cell Carcinoma","Carcinoma, Renal Cell","cancer","Drug: Interferon-alfa|Drug: SU011248","drug","Pfizer","Both","Adult|Senior",750,"August 2004","June 2008","Progression-Free Survival (PFS)， Core Radiology Assessment",6.302,"1",24102
"799","NCT01087801","A Study of Synthetic Human Secretin (ChiRhoStim®) Administered Intravenously to Stimulate Exocrine Pancreas Fluid Secretion for Collection Via Endoscope and Laborat","Pancreatic Disease","other","Drug: ChiRhoStim|Drug: Placebo","drug","ChiRhoClin, Inc.","Both","Adult|Senior",64,"October 2007","March 2009","Endoscopic Sample",6.341,"1",24111
"800","NCT00642460","A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)","Juvenile Idiopathic Arthritis","other","Drug: tocilizumab [RoActemra/Actemra]|Drug: Placebo|Drug: Non-steroidal anti-inflammatory drugs (NSAIDs)|Drug: methotrexate|Drug: corticosteroids","drug","Hoffmann-La Roche","Both","Child",112,"May 2008","November 2010","Part I: Percentage of Participants With ≥30% Improvement in Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) Core Set and Absence of Fever",6.3744,"1",24131
"801","NCT00705575","Efficacy and Safety of the Combination Aliskiren (300 mg) and Hydrochlorothiazide (25mg) to Aliskiren (300mg) Monotherapy in Patients With Staged II Hypertension","Hypertension","cardiovascular","Drug: Aliskiren/hydrochlorothiazide (HCTZ) (300/25 mg)|Drug: Aliskiren (300 mg)","drug","Novartis","Both","Adult|Senior",688,"June 2008","November 2008","Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 12)",6.4839,"1",24107
"802","NCT01072448","12-week Efficacy of Indacaterol","Chronic Obstructive Pulmonary Disease","respiratory","Drug: Indacaterol 75 μg|Drug: Placebo to indacaterol","drug","Novartis","Both","Adult|Senior",323,"January 2010","March 2008","Trough Forced Expiratory Volume in 1 Second (FEV1) 24 Hours Post-dose at the End of the Study (Week 12 + 1 Day， Day 85)",6.527,"1",24099
"803","NCT00717236","Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis","Rheumatoid Arthritis","other","Drug: Certolizumab pegol (CZP)|Other: Placebo","drug","UCB Pharma","Both","Adult|Senior",1648,"July 2008","October 2011","American College of Rheumatology 20% (ACR20) Response at Week 12",6.579,"1",24142
"804","NCT00506389","A Six Week, Double-Blind Randomized, Efficacy and Safety, Sleep Lab Trial With Esmirtazapine (Org 50081) (P05707)","Insomnia","mental health","Drug: Esmirtazapine|Drug: Placebo","drug","Merck Sharp & Dohme Corp.|Parexel","Both","Adult",419,"June 2007","January 2011","Average Wake Time After Sleep Onset (WASO) During the In-Treatment Period",6.656,"1",24133
"805","NCT00984867","Dapagliflozin DPPIV Inhibitor add-on Study","Type 2 Diabetes","endocrine and metabolic","Drug: Dapagliflozin|Drug: Placebo","drug","AstraZeneca|Bristol-Myers Squibb","Both","Adult|Senior",833,"October 2009","October 2010","Adjusted Mean Change in HbA1c Levels",6.6667,"1",24130
"806","NCT01297920","Three Month Efficacy/Safety Study With a 3-Month Safety Extension of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% or Brimonidine 0.2%","Open-Angle Glaucoma|Ocular Hypertension","other","Drug: Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|Drug: Brinzolamide ophthalmic suspension, 1%|Drug: Brimonidine tartrate ophthalmic solution, 0.2%","drug","Alcon Research","Both","Adult|Senior",1062,"March 2011","February 2010","Mean Intraocular Pressure (IOP) at Each Assessment Timepoint (8 AM， +2 h， +7 h， and +9 h) at Month 3",6.711,"1",24122
"807","NCT00623636","Phase 3 Study of MAP0004 in Adult Migraineurs","Migraine Disorders","mental health","Drug: MAP0004|Drug: Placebo","drug","Allergan|MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan","Both","Adult",902,"July 2008","November 2009","Number of Subjects With Pain Relief at 2 Hours From Time of First Dose",6.7622,"1",24119
"808","NCT01389284","Evaluate Efficacy and Safety of Extended Release (ER) Naproxen Sodium","Pain, Postoperative","other","Drug: Naproxen Sodium ER (BAYH6689)|Drug: Naproxen Sodium IR (Aleve, BAYH6689)|Drug: Naproxen Sodium ER Placebo|Drug: Naproxen Sodium IR Placebo","drug","Bayer","Both","Child|Adult|Se",300,"June 2011","July 2008","Summed， Time-weighted Pain Intensity Difference From 0 to 24 Hours Postdose (SPID0-24)",6.824,"1",24103
"809","NCT00838903","Efficacy and Safety of Albiglutide in Treatment of Type 2 Diabetes","Diabetes Mellitus, Type 2","endocrine and metabolic","Biological: albiglutide|Drug: sitagliptin|Drug: glimepiride|Drug: metformin|Biological: placebo albiglutide|Drug: placebo sitagliptin|Drug: placebo glimepiride","biolog","GlaxoSmithKline","Both","Adult|Senior",1049,"February 2009","April 2009","Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 104",6.86,"1",24112
"810","NCT00885352","Sitagliptin (MK-0431) vs. Placebo in Patients With Inadequate Glycemic Control on Metformin With Pioglitazone (MK-0431-128)","Type 2 Diabetes Mellitus","endocrine and metabolic","Drug: Sitagliptin|Drug: Comparator: Placebo|Drug: Pioglitazone|Drug: Metformin|Drug: Glipizide","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",313,"April 2009","July 2008","Change From Baseline in Hemoglobin A1c (A1C) at Week 26",6.8818,"1",24103
"811","NCT00631657","A 6-Month Efficacy and Safety Study of Org 50081 in Adult Patients With Chronic Primary Insomnia (21106/P05701/MK-8265-002)","Sleep Initiation and Maintenance Disorders|Mental Disorders|Dyssomnias|Sleep Disorders|","mental health","Drug: Esmirtazapine|Drug: Placebo","drug","Merck Sharp & Dohme Corp.","Both","Adult",460,"March 2008","October 2008","Change From Baseline in Total Sleep Time (TST) - 6-Month Treatment Period",6.941963636,"1",24106
"812","NCT00419094","Conversion to Monotherapy Study With Keppra XR for Partial Seizures","Epilepsy","mental health","Drug: Keppra XR|Drug: Keppra XR","drug","UCB Pharma","Both","Child|Adult|Se",228,"August 2007","May 2008","The Cumulative Exit Rate at 112 Days After the Beginning of the Previous Antiepileptic Drug (AED) Tapering Phase",6.985,"1",24101
"813","NCT00953147","A 6 Month Safety and Efficacy Study of Once Daily Ciclesonide Hydrofluoroalkane (HFA) in the Treatment of Perennial Allergic Rhinitis (PAR) in Subjects 12 Years and","Allergic Rhinitis|Perennial Allergic Rhinitis","other","Drug: Ciclesonide HFA 80 mcg|Drug: Ciclesonide HFA 160 mcg|Drug: Placebo","drug","Sunovion","Both","Child|Adult|Se",1110,"August 2009","December 2009","Change From Baseline in Daily Subject-reported AM and PM Reflective TNSS (rTNSS) Averaged Over the First 6 Weeks of Double-blind Treatment",6.9956,"1",24120
"814","NCT00847626","Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension","Hypertension","cardiovascular","Drug: Azilsartan medoxomil and chlorthalidone|Drug: Azilsartan medoxomil and chlorthalidone|Drug: Azilsartan medoxomil and chlorthalidone|Drug: Azilsartan medoxomil and chlorthalidone|Drug: Azilsartan medoxomil and chlorthali","drug","Takeda","Both","Adult|Senior",1711,"January 2009","April 2008","Change From Baseline to Week 8 in Trough， Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitoring (Pooled Analysis)",7.28,"1",24100
"815","NCT00943072","Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)","Macular Edema Secondary to Central Retinal Vein Occlusion","cardiovascular","Biological: VEGF Trap-Eye 2.0mg|Drug: Sham","biolog","Regeneron Pharmaceuticals|Bayer","Both","Adult|Senior",189,"July 2009","October 2008","Percentage of Participants Who Gained at Least 15 Letters in BCVA at Week 24 as Measured by ETDRS Letter Score",7.3411,"1",24106
"816","NCT00729469","Efficacy and Safety of Ospemifene in the Treatment of Moderate to Severe Vaginal Dryness and Vaginal Pain Associated With Sexual Activity","Atrophy|Vaginal Diseases","other","Drug: Ospemifene 60 mg|Drug: Placebo|Drug: Non-hormonal vaginal lubricant","drug","Shionogi|Hormos Medical|QuatRx Pharmaceuticals|Shionogi Inc.","Female","Adult|Senior",919,"July 2008","July 2008","Change From Baseline to Week 12 in Percentage of Parabasal Cells in the Maturation Index of the Vaginal Smear (Dryness Strata)",7.352,"1",24103
"817","NCT00474526","A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants","Meningitis, Meningococcal","other","Biological: Meningococcal ACWY Conjugate Vaccine|Biological: DTaP-IPV-HBV|Biological: Hib|Biological: Rotavirus|Biological: Pneumococcal 7-valent Conjugate Vaccine|Biological: HAV|Biological: MMR-V|Biological: DTaP","biolog","Novartis Vaccines|Novartis","Both","Child",4545,"March 2007","June 2008","Percentage of Subjects With hSBA Titer >=1:8 - US Subjects",7.399,"1",24102
"818","NCT01189747","Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines","Lateral Canthus Rhytides|Crow's Feet Lines","other","Biological: onabotulinumtoxinA|Drug: normal saline","biolog","Allergan","Both","Adult|Senior",446,"October 2010","September 2008","Percentage of Responders Based on Composite Facial Wrinkle Scale Assessment of Crow's Feet Line Severity at Maximum Smile",7.399,"1",24105
"819","NCT00508742","Study Evaluating the Impact of a 13-valent Pneumococcal Conjugate Vaccine on Nasopharyngeal Colonization","Pneumococcal Infections","other","Biological: 13-valent Pneumococcal Conjugate Vaccine|Biological: 7 valent pneumococcal conjugate vaccine","biolog","Pfizer","Both","Child",1866,"December 2007","July 2008","Percentage of Participants With a New Acquisition of Serotype 6A' (6A + 6C) or 19A Combined 1 Month After the Infant Series to 24 Months of Age",7.409,"1",24103
"820","NCT00314574","A Study of Omalizumab (Xolair) in Subjects With Moderate to Severe Persistent Asthma (EXTRA)","Asthma","respiratory","Drug: omalizumab  (Xolair)|Drug: placebo|Drug: corticosteroids|Drug: long-acting beta-agonists","drug","Genentech, Inc.","Both","Child|Adult|Se",850,"December 2005","June 2008","Rate of Asthma Exacerbations Over the 48 Week Treatment Period",7.463,"1",24102
"821","NCT01007435","A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis","Rheumatoid Arthritis","other","Drug: Tocilizumab|Drug: Placebo to tocilizumab|Drug: Methotrexate|Drug: Placebo to methotrexate","drug","Hoffmann-La Roche","Both","Adult|Senior",1162,"October 2009","May 2008","Percentage of Participants With a Disease Activity Score 28 (DAS28) Remission Response at Week 24",7.5916,"1",24101
"822","NCT00877383","Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease","Chronic Obstructive Pulmonary Disease (COPD)","respiratory","Drug: Indacaterol 150 μg|Drug: Tiotropium 18 μg|Drug: Placebo to indacaterol","drug","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior",1142,"April 2009","April 2008","Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) From 5 Minutes to 8 Hours Post-dose at the End of the Study (Week 12， Day 84)",7.5994,"1",24100
"823","NCT00696384","A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension","Hypertension","cardiovascular","Drug: Azilsartan medoxomil|Drug: Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications.|Drug: Placebo","drug","Takeda","Both","Adult|Senior",418,"June 2007","August 2008","Change From Double-blind Baseline (Week 26) in Sitting Clinic Diastolic Blood Pressure to Week 32",7.6244,"1",24104
"824","NCT00814307","A Phase 3 Study Comparing 2 Doses of CP-690,550 vs. Placebo for Treatment of Rheumatoid Arthritis","Arthritis, Rheumatoid","other","Drug: CP-690,550|Drug: CP-690,550|Drug: Placebo|Drug: Placebo","drug","Pfizer","Both","Adult|Senior",611,"February 2009","June 2011","Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 3",7.7135,"1",24138
"825","NCT00401193","Efficacy and Safety of XP12B in Women With Menorrhagia","Menorrhagia|Heavy Menstrual Bleeding","other","Drug: Tranexamic acid tablets|Drug: Tranexamic acid tablets|Drug: Placebo tablets","drug","Ferring Pharmaceuticals","Female","Adult",304,"November 2006","February 2008","Mean Reduction From Baseline in Menstrual Blood Loss (MBL)",7.835,"1",24098
"826","NCT00915551","A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)","Actinic Keratosis","other","Drug: PEP005 (Ingenol Mebutate) gel, 0.015%|Drug: Vehicle Gel","drug","Peplin","Both","Adult|Senior",278,"June 2009","July 2009","Complete Clearance of Actinic Keratoses (AK) Lesions",7.9284,"1",24115
"827","NCT01297517","Efficacy and Safety Study of Brinzolamide 1%/Brimonidine 0.2% vs. Brinzolamide 1% and Brimonidine 0.2%","Open-Angle Glaucoma|Ocular Hypertension","other","Drug: Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|Drug: Brinzolamide ophthalmic suspension, 1%|Drug: Brimonidine tartrate ophthalmic solution, 0.2%","drug","Alcon Research","Both","Adult|Senior",1001,"February 2011","August 2008","Mean IOP at Month 3 for Each Assessment Timepoint (8 AM， + 2 h， + 7 h， and + 9 h)",7.938,"1",24104
"828","NCT01072188","Clinical Efficacy of 10% Arginine Bicarbonate Prophylaxis Paste","Hypersensitivity","other","Device: Arginine/Calcium Carbonate|Device: Nupro - Fluoride Free","device","Colgate Palmolive","Both","Adult|Senior",45,"July 2008","September 2009","Hypersensitivity to Touch (Tactile)",8.012,"1",24117
"829","NCT00982007","Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)","Iron Deficiency Anemia","endocrine and metabolic","Drug: Ferric Carboxymaltose (FCM)|Drug: Ferrous Sulfate Tablets|Drug: IV Iron (standard of care)|Drug: Ferric Carboxymaltose (FCM)","drug","Luitpold Pharmaceuticals","Both","Adult|Senior",997,"September 2009","May 2012","To Assess the Mean Increase From Baseline to the Highest Observed Hemoglobin Value Between Baseline and Day 35 or Time of Intervention for Patients Taking FCM as Compared to That for Patients Taking Ferrous Sulfate.",8.0766,"1",24149
"830","NCT00847613","A 2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate","Arthritis, Rheumatoid","other","Drug: CP-690,550|Drug: CP-690,550|Drug: CP-690,550|Drug: CP-690,550|Drug: Placebo|Drug: CP-690,550|Drug: Placebo|Drug: CP-690,550","drug","Pfizer","Both","Adult|Senior",800,"March 2009","April 2009","Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Month 6",8.1715,"1",24112
"831","NCT00931385","Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Foradil in Patients With Chronic Obstructive Pulmonary Disease","Pulmonary Disease, Chronic Obstructive","respiratory","Drug: BI 1744|Drug: bi1744|Drug: Placebo|Drug: Foradil","drug","Boehringer Ingelheim","Both","Adult|Senior",99,"June 2009","September 2010","FEV1 Area Under Curve 0-12 h (AUC 0-12h) Response After Six Weeks of Treatment",8.2222,"1",24129
"832","NCT01189760","Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines","Facial Rhytides|Crow's Feet Lines|Glabellar Lines","other","Biological: onabotulinumtoxinA 24 U|Biological: onabotulinumtoxinA 44 U|Drug: normal saline","biolog","Allergan","Both","Adult|Senior",917,"September 2010","August 2009","Percentage of Responders Based on Composite Facial Wrinkle Scale Assessment of Crow's Feet Line Severity at Maximum Smile",8.409,"1",24116
"833","NCT00627926","A Phase 3 Study of Telaprevir in Combination With Pegasys® and Copegus® in Treatment-Naive Subjects With Genotype 1 Hepatitis C Virus (HCV)","Hepatitis C","other","Biological: Pegylated Interferon Alfa 2a|Drug: Telaprevir|Drug: Ribavirin|Other: Placebo","biolog","Vertex Pharmaceuticals Incorporated|Tibotec Pharmaceutical Limited","Both","Adult|Senior",1095,"March 2008","August 2008","",8.4573,"1",24104
"834","NCT00839527","A Study to Determine the Safety and Efficacy of Albiglutide in Subjects With Type 2 Diabetes","Diabetes Mellitus, Type 2","endocrine and metabolic","Drug: placebo to match albiglutide|Biological: albiglutide|Drug: metformin|Drug: glimepiride|Drug: pioglitazone|Drug: placebo to match pioglitazone","biolog","GlaxoSmithKline","Both","Adult|Senior",685,"February 2009","July 2008","Change From Baseline (BL) in Glycosylated Hemoglobin (HbA1c) at Week 52",8.526,"1",24103
"835","NCT00696241","Efficacy and Safety of Azilsartan Medoxomil in Participants With Essential Hypertension","Hypertension","cardiovascular","Drug: Azilsartan medoxomil and olmesartan|Drug: Azilsartan medoxomil and olmesartan|Drug: Azilsartan medoxomil and olmesartan|Drug: Olmesartan|Drug: Placebo","drug","Takeda","Both","Adult|Senior",1275,"June 2007","August 2008","Change From Baseline in the 24-hour Mean Systolic Blood Pressure Measured by Ambulatory Blood Pressure Monitoring.",8.7246,"1",24104
"836","NCT00655629","Vardenafil Orodispersible Tablet (ODT) Versus Placebo in Males With Erectile Dysfunction, 50% of Whom Are to be 65 Years or Older.","Erectile Dysfunction","other","Drug: Vardenafil ODT (STAXYN, BAY38-9456)|Drug: Placebo","drug","Bayer|GlaxoSmithKline|Schering-Plough","Male","Adult|Senior",339,"April 2008","November 2010","Change From Baseline in International Index of Erectile Function (IIEF-EF Sub-Score) at 12 Weeks or Last Observation Carried Forward (LOCF)",8.836,"1",24131
"837","NCT00623480","Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatm","Hemophilia A","cardiovascular","Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)","biolog","Bayer","Male","Child|Adult",84,"March 2008","January 2011","Bleeding Frequency (Number of Total Bleeds)",8.889339403,"1",24133
"838","NCT00891202","A Study of Eliglustat Tartrate (Genz-112638) in Patients With Gaucher Disease (ENGAGE)","Gaucher Disease, Type 1","endocrine and metabolic","Drug: Eliglustat tartrate|Drug: Placebo","drug","Genzyme, a Sanofi Company|Sanofi","Both","Child|Adult|Se",40,"November 2009","August 2008","Percent Change From Baseline in Spleen Volume (in Multiples of Normal [MN]) at Week 39 of the Primary Analysis Period With Eliglustat Tartrate Treatment as Compared to Placebo",8.9642,"1",24104
"839","NCT01479374","Efficacy and Safety of AL-4943A Ophthalmic Solution in Patients With Allergic Conjunctivitis Using the Conjunctival Allergen Challenge (CAC) Model","Allergic Conjunctivitis","other","Drug: AL-4943A ophthalmic solution|Drug: AL-4943A vehicle|Drug: Olopatadine hydrochloride ophthalmic solution, 0.2%","drug","Alcon Research","Both","Adult|Senior",397,"January 2012","February 2008","Mean Ocular Itching at Onset of Action",8.973,"1",24098
"840","NCT00763269","The Efficacy of a Toothpaste to Reduce Sensitivity","Dentin Hypersensitivity","other","Drug: Triclosan, Silicon dioxide, fluoride|Drug: Triclosan, fluoride","drug","Colgate Palmolive","Both","Child|Adult|Se",626,"September 2008","June 2009","Hypersensitivity Tactile(Yeaple Probe)",9.0237,"1",24114
"841","NCT00894647","Safety and Effectiveness Study of Actinic Keratosis Treatment Following Cryosurgery","Actinic Keratosis","other","Drug: imiquimod cream|Drug: placebo cream","drug","Graceway Pharmaceuticals, LLC","Both","Adult|Senior",247,"May 2009","May 2009","Change From Baseline in Percentage of Lesion Count",9.1833,"1",24113
"842","NCT00852540","Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA","Impetigo|Secondarily-infected Traumatic Lesions|Skin Infections, Bacterial","other","Drug: Retpamulin Ointment, 1%|Drug: Linezolid","drug","Stiefel, a GSK Company|GlaxoSmithKline","Both","Child|Adult|Se",410,"April 2009","March 2008","Number of Participants Achieving Clinical Response at Follow-up Who Had Methicillin-resistant Staphlococcus Aureus (MRSA) as a Baseline Pathogen",9.6977,"1",24099
"843","NCT00133224","Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients","Prostate Cancer","cancer","Biological: Immunotherapy allogeneic GM-CSF secreting cellular vaccine|Drug: Chemotherapy (","biolog","Cell Genesys","Male","Adult|Senior",408,"July 2005","June 2009","",-2.669342092,"-1",24114
"844","NCT00395070","A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma","Metastatic Melanoma","cancer","Biological: Allovectin-7®|Drug: Dacarbazine (DTIC)|Drug: Temozolomide (TMZ)","biolog","Vical","Both","Adult|Senior",390,"October 2006","May 2010","",-2.575829304,"-1",24125
"845","NCT00600925","A Study of an Antibiotic Implant in General Surgical Subjects at Higher Risk for Surgical Wound Infection","Colorectal Surgery|Surgical Wound Infection","other","Drug: gentamicin-collagen sponge dipped in saline","drug","Innocoll Technologies|Duke University|Premier Research Group plc","Both","Adult|Senior",600,"January 2008","December 2009","",-2.5751,"-1",24120
"846","NCT00722852","Study of Safety and Efficacy of Diractin® for the Treatment of Osteoarthritis (OA) of the Knee","Osteoarthritis of the Knee","other","Drug: ketoprofen in Diractin®|Drug: Placebo","drug","IDEA AG","Both","Adult|Senior",555,"June 2008","November 2009","",-2.290367878,"-1",24119
"847","NCT01130246","VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome","Acute Coronary Syndrome","cardiovascular","Drug: A-002, varespladib methyl|Drug: Placebo","drug","Anthera Pharmaceuticals","Both","Adult|Senior",5189,"May 2010","June 2008","",-1.750686071,"-1",24102
"848","NCT01006252","A Study of Tasisulam Versus Paclitaxel as Treatment for Metastatic Melanoma","Melanoma","cancer","Drug: Tasisulam|Drug: Paclitaxel","drug","Eli Lilly and Company","Both","Adult|Senior",323,"December 2009","June 2010","",-1.550589875,"-1",24126
"849","NCT00738387","A Study of ASA404 or Placebo in Combination With Docetaxel in Second-line Treatment for (Stage IIIb/IV) Non-small Cell Lung Cancer","Non-Small Cell Lung Cancer","cancer","Drug: ASA404|Drug: Placebo|Drug: docetaxel","drug","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior",900,"December 2008","February 2008","",-1.468383798,"-1",24098
"850","NCT00893867","Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke","Acute Ischemic Stroke","cardiovascular","Drug: DP-b99|Drug: Placebo","drug","D-Pharm Ltd.","Both","Adult|Senior",446,"December 2009","October 2009","",-1.464710203,"-1",24118
"851","NCT00547651","AMR PH GL 2007 CL001 Phase 3 Trial in Patients With Small Cell Lung Cancer After Failure of First-Line Chemotherapy","Small Cell Lung Cancer","cancer","Drug: Amrubicin|Drug: Topotecan","drug","Celgene Corporation","Both","Adult|Senior",637,"September 2007","April 2010","",-1.3722,"-1",24124
"852","NCT00382811","OVATURE (OVArian TUmor REsponse) A Phase III Study of Weekly Carboplatin With and Without Phenoxodiol in Patients With Platinum-Resistant, Recurrent Epithelial Ovari","Fallopian Tube Cancer|Peritoneal Neoplasms|Ovarian Ca","cancer","Drug: phenoxodiol|Drug: carboplatin","drug","MEI Pharma, Inc.","Female","Adult|Senior",142,"October 2006","March 2010","",-1.036433389,"-1",24123
"853","NCT01097018","Perifosine Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Refractory Advanced Colorectal Cancer","Colorectal Cancer","cancer","Drug: Capecitabine|Drug: Perifosine|Drug: Placebo","drug","AEterna Zentaris","Both","Adult|Senior",468,"April 2010","May 2011","",-1.004785806,"-1",24137
"854","NCT00625664","Larotaxel + Cisplatin Versus Gemcitabine + Cisplatin in First Line Treatment of Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer","Urinary Bladder Neoplasms","cancer","Drug: larotaxel (XRP9881)|Drug: gemcitabine|Drug: cisplatin","drug","Sanofi","Both","Adult|Senior",337,"February 2008","September 2010","",-0.974113877,"-1",24129
"855","NCT01296620","Ulimorelin Study of Efficacy and Safety (ULISES 008)","Gastrointestinal Dysmotility","other","Drug: Ulimorelin Intravenously (IV)|Drug: Ulimorelin Invtravenously (IV)|Drug: 5% dextrose","drug","Tranzyme, Inc.|Norgine","Both","Adult|Senior",330,"February 2011","November 2010","",-0.974113877,"-1",24131
"856","NCT00347412","Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer","Non Small Cell Lung Cancer","cancer","Drug: Paclitaxel and Carboplatin|Drug: NOV-002 Injection in combination with Carboplatin vs","drug","Cellectar Biosciences, Inc.","Both","Adult|Senior",880,"November 2006","September 2011","",-0.887146559,"-1",24141
"857","NCT00566657","Efficacy and Safety of XRP0038/NV1FGF in Critical Limb Ischemia Patients With Skin Lesions","Peripheral Vascular Diseases","cardiovascular","Biological: riferminogene pecaplasmid|Biological: Placebo (for riferminogene pecaplasmid)","biolog","Sanofi","Both","Adult|Senior",525,"November 2007","September 2011","",-0.706302563,"-1",24141
"858","NCT00130208","Effect of Sulodexide in Early Diabetic Nephropathy","Diabetic Nephropathy","endocrine and metabolic","Drug: Sulodexide","drug","Keryx Biopharmaceuticals|Collaborative Study Group (CSG)","Both","Adult|Senior",1000,"August 2005","April 2012","",-0.67448975,"-1",24148
"859","NCT00658515","A Study of RO4607381 in Stable Coronary Heart Disease Patients With Recent Acute Coronary Syndrome","Coronary Heart Disease","cardiovascular","Drug: dalcetrapib|Drug: Evidence-based medical care for Acute Coronary Syndrome|Drug: Place","drug","Hoffmann-La Roche","Both","Adult|Senior",15865,"April 2008","August 2012","",-0.6433,"-1",24152
"860","NCT00174837","TRACE: Tirapazamine-Radiation And Cisplatin Evaluation","Head and Neck Squamous Cell Carcinoma","cancer","Drug: Tirapazamine (SR259075)|Drug: cisplatin","drug","Sanofi|Groupe Oncologie Radiotherapie Tete et Cou","Both","Adult|Senior",317,"April 2005","August 2011","",-0.628006014,"-1",24140
"861","NCT00829374","Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil","Alzheimer's Disease","mental health","Drug: Dimebon|Drug: Dimebon|Drug: Placebo comparator","drug","Medivation, Inc.|Pfizer","Both","Adult|Senior",1003,"March 2009","May 2012","",-0.612812991,"-1",24149
"862","NCT00334828","ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients With Severe Sepsis","Severe Sepsis","other","Drug: eritoran tetrasodium|Drug: Placebo","drug","Eisai Inc.","Both","Adult|Senior",2000,"June 2006","January 2012","",-0.53883603,"-1",24145
"863","NCT00321412","Safety and Efficacy of AST-120 in Mild to Moderate Crohn's Patients With Fistulas","Inflammatory Bowel Disease|Intestinal Fistula","other","Drug: AST-120","drug","Ocera Therapeutics","Both","Adult|Senior",191,"March 2006","December 2011","",-0.524400513,"-1",24144
"864","NCT00716547","Safety and Efficacy of Two Dosages of Diractin® in Osteoarthritis (OA)","Osteoarthritis of the Knee","other","Drug: ketoprofen in Diractin®|Drug: ketoprofen in Diractin®|Drug: Placebo|Drug: celecoxib","drug","IDEA AG","Both","Adult|Senior",1399,"May 2008","October 2012","",-0.448212281,"-1",24154
"865","NCT00707304","Safety and Efficacy of Talactoferrin in Previously Treated Patients With Non-small Cell Lung Cancer","Non Small Cell Lung Cancer","cancer","Drug: Talactoferrin|Drug: Placebo","drug","Agennix","Both","Adult|Senior",742,"November 2008","May 2012","",-0.439913166,"-1",24149
"866","NCT00417209","Larotaxel Compared To Continuous Administration of 5-FU in Advanced Pancreatic Cancer Patients Previously Treated With A Gemcitabine-Containing Regimen","Pancreatic Neoplasms","cancer","Drug: larotaxel (XRP9881)|Drug: 5-Fluorouracil","drug","Sanofi","Both","Adult|Senior",408,"December 2006","May 2012","",-0.398855066,"-1",24149
"867","NCT00262106","Trial to Evaluate PRO 2000/5 Gels for the Prevention of Vaginally Acquired HIV Infection","HIV Infections|Gonorrhea|Chlamydial Infections|Genita","other","Drug: PRO 2000/5|Drug: Placebo","drug","Endo Pharmaceuticals|Medical Research Council|Department for International Development, United Kingdom","Female","Child|Adult|Se",9404,"October 2005","May 2012","",-0.371856089,"-1",24149
"868","NCT01095250","Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis","Uveitis","other","Biological: AIN457|Biological: AIN457|Biological: AIN457|Biological: Placebo","biolog","Novartis","Both","Adult|Senior",31,"April 2010","May 2012","",-0.3383,"-1",24149
"869","NCT00089856","GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer","Prostate Cancer","cancer","Biological: Immunotherapy with allogeneic prostate vaccine|Drug: Chemotherapy (Taxotere and","biolog","Cell Genesys","Male","Adult|Senior",626,"July 2004","August 2012","",-0.279319034,"-1",24152
"870","NCT00662597","ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer","Non-Small Cell Lung Cancer","cancer","Drug: ASA404|Drug: Placebo|Drug: carboplatin|Drug: Paclitaxel","drug","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior",1285,"April 2008","April 2009","",-0.087844838,"-1",24112
"871","NCT00444626","A Study to Compare the Safety and Effectiveness of a Non-FDA Approved Device (DGE) and an FDA Approved Device for the Correction of Nasolabial Folds (NLFs)","Facial Wrinkles at the Nasolabial Folds","other","Device: Dermal Gel Extra (DGE)|Device: Restylane","device","Genzyme, a Sanofi Company|Mentor Worldwide, LLC","Both","Adult|Senior",140,"May 2007","July 2008","",0,"1",24103
"872","NCT00631319","A Double-blind Study of Controlled Release OROS Hydromorphone Compared to Placebo in Patients With Chronic OA Pain","Chronic Pain","other","Drug: OROS HYDROMORPHONE","drug","Mallinckrodt","Both","Adult|Senior",200,"February 2008","September 2008","",0,"1",24105
"873","NCT01208129","Safety and Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails","Onychomycosis","other","Drug: NAB001|Drug: Placebo control","drug","Promius Pharma, LLC","Both","Adult|Senior",458,"September 2010","December 2008","",0,"1",24108
"874","NCT01208168","Safety & Efficacy of NAB001 in the Treatment of Mild to Moderate Onychomycosis of the Toenails","Onychomycosis","other","Drug: NAB001|Drug: Vehicle alone","drug","Promius Pharma, LLC","Both","Adult|Senior",468,"September 2010","May 2010","",0,"1",24125
"875","NCT01577537","A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis","Bacterial Vaginosis","other","Drug: 1% SPL7013 Gel|Drug: Placebo","drug","Starpharma Pty Ltd","Female","Child|Adult|Se",251,"March 2012","August 2010","",0,"1",24128
"876","NCT00523211","Vicriviroc in HIV-Treatment Experienced Subjects (Study P04405AM5)","HIV Infections|Acquired Immunodeficiency Syndrome","other","Drug: Vicriviroc|Drug: Placebo","drug","Merck Sharp & Dohme Corp.","Both","Child|Adult|Se",506,"July 2007","October 2008","",0.003759951,"1",24106
"877","NCT00715637","Phase III Randomized Study of Amonafide (AS1413) and Cytarabine Versus Daunorubicin and Cytarabine in Patients With Secondary Acute Myeloid Leukemia (AML)- the ACCED","Secondary Acute Myeloid Leukemia (Secondary AML, sAML","cancer","Drug: Daunorubicin and Cytarabine|Drug: Amonafide and Cytarabine","drug","Antisoma Research","Both","Adult|Senior",420,"June 2007","April 2010","",0.005013278,"1",24124
"878","NCT00254904","Randomized Trial of Gemcitabine/Cisplatin + PF-3512676 vs Gemcitabine/Cisplatin Alone in Patients With Advanced NSCLC","Carcinoma, Non-Small-Cell Lung","cancer","Drug: Cisplatin|Drug: Gemcitabine|Drug: PF-3512676|Drug: Cisplatin|Drug: Gemcitabine + Cisp","drug","Pfizer","Both","Adult|Senior",839,"November 2005","July 2011","",0.025068908,"1",24139
"879","NCT01120301","Efficacy and Safety Trial of Transcranial Laser Therapy Within 24 Hours From Stroke Onset (NEST-3)","Acute Ischemic Stroke","cardiovascular","Device: NeuroThera® Laser System","device","PhotoThera, Inc","Both","Adult|Senior",1000,"September 2010","August 2008","",0.0831,"1",24104
"880","NCT01351675","Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes","Renal Insufficiency, Chronic|Diabetes Mellitus, Type","cardiovascular","Drug: Placebo|Drug: Bardoxolone Methyl: 20 mg","drug","Reata Pharmaceuticals, Inc.","Both","Adult|Senior",2185,"June 2011","August 2009","",0.100433721,"1",24116
"881","NCT00464269","Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures","Epilepsy","mental health","Other: Placebo|Drug: Brivaracetam|Drug: Brivaracetam|Drug: Brivaracetam","drug","UCB Pharma","Both","Child|Adult|Se",400,"September 2007","February 2009","",0.144633812,"1",24110
"882","NCT00128102","Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (0683-014 AM5, EXT1)","Mesothelioma|Lung Cancer","cancer","Drug: vorinostat|Drug: Placebo","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",662,"June 2005","July 2009","",0.176374165,"1",24115
"883","NCT00675623","A Safety and Efficacy Study of Oral Dimebon in Patients With Mild-To-Moderate Alzheimer's Disease","Alzheimer's Disease","mental health","Drug: Dimebon|Drug: Dimebon|Drug: Placebo","drug","Medivation, Inc.","Both","Adult|Senior",598,"May 2008","December 2009","",0.176374165,"1",24120
"884","NCT01281189","Phase 3 Study of Dexpramipexole in ALS","Amyotrophic Lateral Sclerosis","mental health","Drug: Dexpramipexole|Drug: Placebo","drug","Knopp Biosciences","Both","Adult|Senior",943,"March 2011","April 2012","",0.176374165,"1",24148
"885","NCT00411645","Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus (CMV) Disease in Stem Cell Transplant Recipients","Cytomegalovirus Infections","other","Drug: maribavir|Other: placebo","drug","Shire","Both","Adult|Senior",613,"December 2006","February 2009","",0.205,"1",24110
"886","NCT00600483","Safety and Efficacy of an Antibiotic Implant in Cardiac Surgical Subjects at Higher Risk for Sternal Wound Infection","Cardiac Surgery|Sternal Wound Infection","other","Drug: gentamicin-collagen sponge dipped in saline","drug","Innocoll Technologies|Duke University|Premier Research Group plc","Both","Adult|Senior",1502,"December 2007","December 2010","",0.2147,"1",24132
"887","NCT00458276","Study of the Efficacy and Safety of Tezosentan in Patients With Pre-operative Pulmonary Hypertension, Due to Left Heart Disease, Undergoing Open Heart Surgery","Heart Diseases|Hypertension, Pulmonary","cardiovascular","Drug: tezosentan|Drug: placebo","drug","Actelion","Both","Adult|Senior",274,"April 2007","April 2011","",0.21726735,"1",24136
"888","NCT00574132","Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Non-Carrier)","Alzheimer's Disease","mental health","Drug: Bapineuzumab 0.5 mg/kg|Drug: Placebo Control|Drug: Bapineuzumab 1.0 m/kg","drug","JANSSEN Alzheimer Immunotherapy Research & Development, LLC|Pfizer","Both","Adult|Senior",1331,"December 2007","May 2011","",0.2533,"1",24137
"889","NCT00348140","Rosiglitazone (Extended Release Tablets) As Adjunctive Therapy In Subjects With Mild To Moderate Alzheimer's Disease","Alzheimer's Disease","mental health","Drug: Rosiglitazone Extended Release 2mg|Drug: Rosiglitazone Extended Release 8mg|Other: Pl","drug","GlaxoSmithKline","Both","Adult|Senior",1450,"July 2006","September 2009","",0.253347103,"1",24117
"890","NCT00676143","Study Evaluating the Safety and Efficacy of Bapineuzumab in Alzheimer Disease Patients","Alzheimer Disease","mental health","Drug: bapineuzumab|Drug: placebo","drug","Pfizer","Both","Adult|Senior",1099,"May 2008","October 2011","",0.253347103,"1",24142
"891","NCT00401375","Study of Intravenous (IV) Methylnaltrexone Bromide (MNTX) in the Treatment of Post-Operative Ileus (POI).","Post-Operative Ileus (POI)","other","Drug: Methylnaltrexone|Drug: Placebo","drug","Salix Pharmaceuticals|Wyeth is now a wholly owned subsidiary of Pfizer","Both","Adult|Senior",515,"October 2006","February 2012","",0.261,"1",24146
"892","NCT01032915","Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis","Non-infectious Uveitis","other","Biological: AIN457|Biological: AIN457|Biological: AIN457|Drug: Placebo","biolog","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior",124,"February 2010","February 2008","",0.2843,"1",24098
"893","NCT00924989","A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma","Adrenocortical Carcinoma","cancer","Drug: OSI-906|Other: Placebo","drug","Astellas Pharma Inc","Both","Adult|Senior",139,"September 2009","July 2010","",0.292374896,"1",24127
"894","NCT00625612","Study of Denufosol Tetrasodium Inhalation Solution in Patients With Cystic Fibrosis (CF) Lung Disease","Cystic Fibrosis","respiratory","Drug: Denufosol Tetrasodium (INS37217) Inhalation Solution|Drug: Placebo","drug","Merck Sharp & Dohme Corp.","Both","Child|Adult|Se",466,"February 2008","July 2010","",0.329205984,"1",24127
"895","NCT00087022","Monoclonal Antibody Therapy (Rencarex®) in Treating Patients Who Have Undergone Surgery for Non-metastatic Kidney Cancer","Kidney Cancer","cancer","Biological: girentuximab|Other: placebo","biolog","Wilex","Both","Adult|Senior",864,"July 2004","November 2009","",0.331853346,"1",24119
"896","NCT00789633","A Phase 3 Study to Compare Efficacy and Safety of Masitinib in Combination With Gemcitabine, to Placebo in Combination With Gemcitabine, in Treatment of Patients Wit","Pancreatic Cancer","cancer","Drug: masitinib (AB1010)|Drug: placebo","drug","AB Science","Both","Adult|Senior",320,"November 2008","December 2010","",0.331853346,"1",24132
"897","NCT01155466","A Placebo- and Active Controlled Study of Preladenant in Subjects With Moderate to Severe Parkinson's Disease (Study P04938)","Parkinson Disease","mental health","Drug: Preladenant 2 mg tablet|Drug: Preladenant 5 mg tablet|Drug: Preladenant 10 mg tablet|","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",778,"July 2010","June 2010","",0.341,"1",24126
"898","NCT00518895","Trial of Dacarbazine With or Without Genasense in Advanced Melanoma","Melanoma","cancer","Drug: dacarbazine plus Genasense|Drug: dacarbazine plus placebo","drug","Genta Incorporated","Both","Adult|Senior",300,"July 2007","November 2009","",0.345125531,"1",24119
"899","NCT00601172","A Study Of IV Casopitant For The Prevention Of Chemotherapy Induced Nausea And Vomiting.","Nausea and Vomiting|Nausea and Vomiting, Chemotherapy","other","Drug: Casopitant|Drug: Dexamethasone and Ondansetron|Drug: Placebo","drug","GlaxoSmithKline","Both","Adult|Senior",710,"March 2008","February 2009","",0.3487,"1",24110
"900","NCT00133952","Effect of Ruboxistaurin on Clinically Significant Macular Edema","Diabetic Macular Edema","cardiovascular","Drug: Ruboxistaurin|Drug: Placebo","drug","Eli Lilly and Company","Both","Adult|Senior",308,"August 2005","December 2009","",0.353117972,"1",24120
"901","NCT00350948","Phase 3 Randomized Study of Telcyta + Doxorubicin Versus Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer","Ovarian Neoplasms","cancer","Drug: Telcyta|Drug: Liposomal Doxorubicin","drug","Telik","Female","Adult|Senior",244,"May 2006","March 2011","",0.353117972,"1",24135
"902","NCT01327976","ReCharge Clinical Trial","Obesity|Overweight","other","Device: Active, implantable, intra abdominal vagal blocking medical device (Maestro RC2 Sys","device","EnteroMedics","Both","Adult",234,"May 2011","September 2012","",0.371856089,"1",24153
"903","NCT00263042","Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes","Cardiovascular Disease","cardiovascular","Drug: rimonabant (SR141716)|Drug: placebo","drug","Sanofi","Both","Adult|Senior",18695,"December 2005","February 2008","",0.412463129,"1",24098
"904","NCT00467402","Efficacy, Safety and Tolerability of Agomelatine in the Prevention of Relapse of Major Depressive Disorder","Major Depressive Disorder","mental health","Drug: agomelatine|Drug: placebo","drug","Novartis","Both","Adult|Senior",644,"April 2007","March 2011","",0.430268965,"1",24135
"905","NCT00539981","Immunogenicity, Safety, Reactogenicity, Efficacy, Effectiveness and Lot Consistency of FluBlok","Influenza","other","Biological: Influenza Vaccine, recombinant hemagglutinin, FluBlok","biolog","Protein Sciences Corporation","Both","Adult",4648,"September 2007","March 2008","",0.4612,"1",24099
"906","NCT00575055","Bapineuzumab in Patients With Mild to Moderate Alzheimer's Disease (ApoE4 Carrier)","Alzheimer's Disease","mental health","Drug: Bapineuzumab 0.5 mg/kg|Drug: Placebo Control|Drug: Bapineuzumab 1.0 m/kg","drug","JANSSEN Alzheimer Immunotherapy Research & Development, LLC|Pfizer","Both","Adult|Senior",1121,"December 2007","February 2011","",0.4677,"1",24134
"907","NCT01090310","Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis Study","Non-infectious Uveitis","other","Biological: AIN457|Biological: AIN457|Biological: AIN457|Drug: Placebo","biolog","Novartis","Both","Adult|Senior",70,"August 2010","March 2011","",0.525,"1",24135
"908","NCT00216060","Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy","Metastatic Prostate Cancer","endocrine and metabolic","Drug: Risedronate|Drug: Placebo","drug","Hoosier Cancer Research Network|Sanofi|Walther Cancer Institute","Male","Adult|Senior",60,"October 2003","November 2010","",0.527278791,"1",24131
"909","NCT00254891","Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer","Carcinoma, Non-Small-Cell Lung","cancer","Drug: PF-3512676 + Paclitaxel + Carboplatin|Drug: Paclitaxel + Carboplatin","drug","Pfizer","Both","Adult|Senior",828,"November 2005","March 2008","",0.582841507,"1",24099
"910","NCT00474370","Vicriviroc in HIV-Treatment Experienced Subjects (Study P04889AM8)(COMPLETED)","HIV Infections|Acquired Immunodeficiency Syndrome","other","Drug: Vicriviroc|Drug: Placebo","drug","Merck Sharp & Dohme Corp.","Both","Child|Adult|Se",400,"May 2007","October 2008","",0.596262318,"1",24106
"911","NCT00397345","TroVax Renal Immunotherapy Survival Trial","Clear Cell Renal Carcinoma","cancer","Biological: Trovax","biolog","Oxford BioMedica","Both","Adult|Senior",700,"September 2006","October 2009","",0.597760126,"1",24118
"912","NCT00463242","A Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Agomelatine (25 or 50 mg) in the Treatment of Major Depressive Disorder (MDD)","Major Depressive Disorder","mental health","Drug: Agomelatine|Drug: paroxetine|Drug: placebo","drug","Novartis","Both","Adult|Senior",501,"March 2007","September 2011","",0.614325886,"1",24141
"913","NCT00391612","EASE Trial: Exhale Airway Stents for Emphysema","Emphysema","respiratory","Device: Exhale® Drug-Eluting Stent|Device: Sham control","device","Broncus Technologies","Both","Adult|Senior",450,"May 2006","November 2011","",0.618,"1",24143
"914","NCT01110902","Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder (MDD)","Major Depressive Disorder","mental health","Drug: Agomelatine (AGO178C)|Drug: Placebo","drug","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior",589,"May 2010","July 2008","",0.629533262,"1",24103
"915","NCT00074906","Venticute in Patients With Pneumonia or Aspiration of Gastric Contents and Intubation/Ventilation/Oxygenation Impairment (BY2001/M1-007)","Pneumonia","respiratory","Drug: Venticute","drug","Takeda","Both","Child|Adult|Se",1200,"November 2003","December 2009","",0.643345405,"1",24120
"916","NCT00831441","Phase III Acute Coronary Syndrome","Acute Coronary Syndrome","cardiovascular","Drug: Apixaban|Drug: Placebo","drug","Bristol-Myers Squibb|Pfizer|Duke University","Both","Adult|Senior",10848,"March 2009","October 2009","",0.658837693,"1",24118
"917","NCT00389779","DORADO-AC - Optimized Doses of Darusentan as Compared to an Active Control in Resistant Hypertension","Hypertension","cardiovascular","Drug: Darusentan|Drug: Guanfacine|Drug: Darusentan Placebo","drug","Gilead Sciences","Both","Adult|Senior",849,"September 2006","February 2008","",0.678,"1",24098
"918","NCT00141011","Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke","Stroke|Cerebral Ischemia|Brain Infarction","cardiovascular","Drug: Ancrod (Viprinex)|Drug: Placebo","drug","Neurobiological Technologies","Both","Adult|Senior",277,"September 2005","October 2011","",0.722479052,"1",24142
"919","NCT00228176","Atherosclerosis Underlying Development Assessed by Intima-Media Thickness in Patients on Rimonabant (Auditor)","Carotid Artery Plaque|Arteriosclerosis|Obesity|Metabo","cardiovascular","Drug: rimonabant (SR141716)|Drug: placebo","drug","Sanofi","Both","Adult|Senior",661,"August 2005","December 2011","",0.722479052,"1",24144
"920","NCT00613002","Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women","Hypoactive Sexual Desire Disorder","mental health","Drug: testosterone gel|Drug: placebo gel","drug","BioSante Pharmaceuticals","Female","Adult",597,"December 2006","July 2010","",0.734,"1",24127
"921","NCT00995709","Phase III Study in Refractory Behcet's Disease","Behcet Disease","cardiovascular","Drug: AIN457|Drug: AIN457|Drug: Placebo","drug","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior",117,"October 2009","April 2010","",0.7638,"1",24124
"922","NCT00863772","Tanezumab and Nerve Function In Arthritis Patients","Osteoarthritis","other","Biological: tanezumab|Biological: tanezumab|Other: Placebo","biolog","Pfizer","Both","Adult|Senior",220,"May 2009","January 2011","",0.782365165,"1",24133
"923","NCT00119717","Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke (SENTIS)","Cerebrovascular Accident","cardiovascular","Device: NeuroFlo™ catheter|Other: Control","device","CoAxia","Both","Adult|Senior",515,"June 2005","February 2010","",0.829184525,"1",24122
"924","NCT00106691","Prostate Cancer Prevention Study for Men With High Grade PIN (Prostatic Intraepithelial Neoplasia)","Preneoplastic Conditions|Prostatic Intraepithelial Ne","cancer","Drug: Toremifene 20 mg|Drug: Placebo","drug","GTx","Male","Adult|Senior",1590,"January 2005","September 2010","",0.859617364,"1",24129
"925","NCT01285570","Ulimorelin Study of Efficacy and Safety (ULISES 007)","Gastrointestinal Dysmotility","other","Drug: Ulimorelin Intravenously (IV)|Drug: Ulimorelin Intravenously (IV)|Drug: 5% dextrose i","drug","Tranzyme, Inc.|Norgine","Both","Adult|Senior",332,"January 2011","February 2008","",0.915365088,"1",24098
"926","NCT00328692","PROTECT-1: A Study of the Selective A1 Adenosine Receptor Antagonist KW-3902 for Patients Hospitalized With Acute HF and Volume Overload to Assess Treatment Effect o","Heart Failure, Congestive","cardiovascular","Drug: rolofylline|Drug: Comparator: Placebo (unspecified)","drug","NovaCardia, Inc.|Merck Sharp & Dohme Corp.","Both","Adult|Senior",932,"August 2006","October 2012","",0.934589291,"1",24154
"927","NCT00940095","Clazosentan in Aneurysmal Subarachnoid Hemorrhage","Aneurysmal Subarachnoid Hemorrhage","cardiovascular","Drug: Clazosentan|Drug: Clazosentan|Drug: Placebo","drug","Actelion","Both","Adult|Senior",577,"July 2009","June 2011","",0.954165253,"1",24138
"928","NCT00855920","Study Utilizing Rilonacept in Gout Exacerbations","Acute Gout Flare","endocrine and metabolic","Drug: rilonacept|Drug: indomethacin|Other: placebo|Other: placebo","drug","Regeneron Pharmaceuticals","Both","Adult|Senior",225,"March 2009","February 2009","",0.974113877,"1",24110
"929","NCT01368978","Pediatric Diabetics Type 1 Using InsuPatch","Type 1 Diabetes Mellitus","endocrine and metabolic","Device: InsuPatch","device","Insuline Medical Ltd.","Both","Child",27,"December 2009","February 2009","",1.036433389,"1",24110
"930","NCT00938652","A Phase 3, Multi-Center Study of Gemcitabine/Carboplatin, With or Without BSI-201, in Patients With ER-, PR-, and Her2-Negative Metastatic Breast Cancer","Breast Cancer","cancer","Drug: gemcitabine/carboplatin|Drug: Iniparib","drug","Sanofi","Female","Adult|Senior",519,"July 2009","May 2009","",1.080319341,"1",24113
"931","NCT00428090","Rosiglitazone (Extended Release Tablets) As Monotherapy In Subjects With Mild To Moderate Alzheimer's Disease","Alzheimer's Disease","mental health","Drug: Rosiglitazone","drug","GlaxoSmithKline","Both","Adult|Senior",862,"February 2007","March 2009","",1.09846842,"1",24111
"932","NCT00366795","Satavaptan for the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver","Ascites|Liver Cirrhosis","other","Drug: satavaptan (SR121463B)|Drug: placebo","drug","Sanofi","Both","Adult|Senior",241,"August 2006","August 2010","",1.103062556,"1",24128
"933","NCT00379470","Effect of NovoTTF-100A in Recurrent Glioblastoma Multiforme (GBM)","Recurrent Glioblastoma Multiforme","cancer","Device: NovoTTF-100A","device","NovoCure Ltd.","Both","Adult|Senior",236,"September 2006","February 2012","",1.103062556,"1",24146
"934","NCT00399919","Safety and Efficacy of Propionyl-L-Carnitine in the Treatment of Peripheral Arterial Disease (Intermittent Claudication)","Peripheral Vascular Diseases|Intermittent Claudicatio","cardiovascular","Drug: Propionyl-L-Carnitine|Drug: PLC","drug","Sigma-Tau Research, Inc.|Colorado Prevention Center","Both","Adult|Senior",69,"April 2006","June 2010","",1.131130901,"1",24126
"935","NCT00091676","Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma","Non-Hodgkins Lymphoma","cancer","Biological: FNHLId1|Biological: KLH + GM-CSF","biolog","Biovest International","Both","Adult|Senior",629,"January 2000","December 2008","",1.135896221,"1",24108
"936","NCT00718224","Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Elective Knee Replacement Surgery","Venous Thromboembolism","cardiovascular","Drug: Semuloparin sodium|Drug: Enoxaparin|Drug: Placebo","drug","Sanofi","Both","Adult|Senior",1150,"July 2008","July 2012","",1.165046922,"1",24151
"937","NCT00905372","Effect of LY2062430 on the Progression of Alzheimer's Disease","Alzheimer's Disease","mental health","Drug: LY2062430|Drug: Placebo","drug","Eli Lilly and Company","Both","Adult|Senior",1000,"May 2009","May 2010","",1.174986792,"1",24125
"938","NCT01577238","A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis","Bacterial Vaginosis","other","Drug: 1% SPL7013 Gel|Drug: Placebo","drug","Starpharma Pty Ltd","Female","Child|Adult|Se",250,"March 2012","November 2009","",1.185,"1",24119
"939","NCT00522834","Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma","Melanoma","cancer","Drug: Elesclomol (STA-4783)|Drug: Paclitaxel","drug","Synta Pharmaceuticals Corp.","Both","Adult|Senior",630,"August 2007","November 2010","",1.200358858,"1",24131
"940","NCT00562016","Protect II, A Prospective, Multicenter Randomized Controlled Trial","Coronary Artery Disease","cardiovascular","Device: IMPLELLA LP 2.5|Device: IABP Intra-aortic balloon pump","device","Abiomed Inc.","Both","Adult|Senior",452,"October 2007","September 2012","",1.20812288,"1",24153
"941","NCT00477490","Efficacy and Safety of Desmopressin Melt for the Treatment of Nocturia","Nocturia","other","Drug: desmopressin acetate|Drug: Placebo|Drug: desmopressin acetate|Drug: desmopressin acet","drug","Ferring Pharmaceuticals","Both","Adult|Senior",754,"May 2007","March 2012","",1.21,"1",24147
"942","NCT00657501","Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women","Hypoactive Sexual Desire Disorder","mental health","Drug: testosterone gel|Drug: placebo gel","drug","BioSante Pharmaceuticals","Female","Adult",575,"March 2008","November 2011","",1.242641419,"1",24143
"943","NCT00358878","Cirrhotic Ascites Treatment With Satavaptan in Patients With Ascites Due to Cirrhosis of the Liver (CATS)","Ascites|Liver Cirrhosis","other","Drug: satavaptan (SR121463B)|Drug: placebo","drug","Sanofi","Both","Adult|Senior",463,"July 2006","June 2010","",1.270237622,"1",24126
"944","NCT00740623","A Study of the Effectiveness, Safety, and Tolerability of Carisbamate as Add-On Therapy in Patients With Partial Onset Seizures.","Epilepsy, Partial, Motor|Epilepsy, Complex Partial|Ep","mental health","Drug: Carisbamate|Drug: placebo|Drug: Carisbamate","drug","SK Life Science","Both","Child|Adult|Se",547,"January 2009","July 2011","",1.2816,"1",24139
"945","NCT00262990","Patupilone Versus Doxorubicin in Patients With Ovarian, Primary Fallopian, or Peritoneal Cancer","Ovarian Cancer|Fallopian Tube Cancer|Peritoneal Neopl","cancer","Drug: EPO906 (Patupilone)|Drug: doxorubicin","drug","Novartis Pharmaceuticals|Novartis","Female","Adult|Senior",829,"November 2005","July 2009","",1.295928846,"1",24115
"946","NCT00597428","Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone","Opioid-Induced Bowel Dysfunction","other","Drug: Lubiprostone|Drug: Placebo","drug","Sucampo Pharmaceuticals, Inc.|Takeda|Sucampo Pharma Americas, LLC","Both","Adult|Senior",443,"August 2007","July 2011","",1.341,"1",24139
"947","NCT01724008","The Efficacy of a Dentifrice in Providing Relief From Dentinal Hypersensitivity","Dentine Hypersensitivity","other","Drug: Stannous Fluoride|Drug: Sodium Monofluorophosphate","drug","GlaxoSmithKline","Both","Adult",120,"March 2012","March 2010","",1.350049829,"1",24123
"948","NCT00359437","Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver","Ascites|Liver Cirrhosis","other","Drug: satavaptan (SR121463B)|Drug: placebo","drug","Sanofi","Both","Adult|Senior",501,"July 2006","July 2009","",1.372203809,"1",24115
"949","NCT00721760","Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery","Venous Thromboembolism","cardiovascular","Drug: Enoxaparin sodium|Drug: Semuloparin sodium|Drug: Placebo","drug","Sanofi","Both","Adult|Senior",1003,"July 2008","March 2008","",1.372203809,"1",24099
"950","NCT00976937","24-week Study Comparing Lixisenatide to Sitagliptin as add-on to Metformin in Obese Type 2 Diabetic Patients Younger Than 50 Years","Type 2 Diabetes Mellitus","endocrine and metabolic","Drug: Lixisenatide (AVE0010)|Drug: Lixisenatide Placebo|Device: Pen auto-injector|Drug: Sit","device","Sanofi","Both","Adult",319,"August 2009","November 2008","",1.3735,"1",24107
"951","NCT01085812","Relapse-Prevention Study With F2695 SR in Patients With Major Depressive Disorder","Depression|Major Depressive Disorder","mental health","Drug: F2695 SR|Drug: Placebo","drug","Forest Laboratories","Both","Adult",348,"March 2010","October 2009","",1.388,"1",24118
"952","NCT01239030","Efficacy and Safety of Methylphenidate HCl ER Capsules in Children and Adolescents With ADHD","Attention Deficit Hyperactivity Disorder|ADHD","mental health","Drug: Methylphenidate Hydrochloride Extended Release Capsules","drug","Rhodes Pharmaceuticals, L.P.","Both","Child|Adult",236,"November 2010","October 2010","",1.434,"1",24130
"953","NCT01052012","Bupivacaine Effectiveness and Safety in SABER™ Trial","Postoperative Pain|Abdominal Surgery","other","Drug: SABER™-Bupivacaine|Drug: Bupivacaine HCl|Drug: SABER™-Placebo","drug","Durect|Nycomed|Hospira, Inc.","Both","Adult|Senior",305,"December 2009","March 2008","",1.450209883,"1",24099
"954","NCT00411099","Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder","Major Depressive Disorder","mental health","Drug: agomelatine|Drug: placebo","drug","Novartis","Both","Adult|Senior",508,"December 2006","March 2012","",1.518,"1",24147
"955","NCT00257205","CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy","Melanoma","cancer","Drug: dacarbazine|Drug: CP-675,206|Drug: temozolomide","drug","AstraZeneca","Both","Adult|Senior",655,"March 2006","February 2008","",1.526039611,"1",24098
"956","NCT00409188","Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)","Non-small Cell Lung Cancer","cancer","Biological: Tecemotide (L-BLP25)|Biological: Placebo","biolog","EMD Serono|Merck KGaA","Both","Adult|Senior",1513,"January 2007","June 2008","",1.542302919,"1",24102
"957","NCT00522041","A Study to Determine the Effect of Nitroglycerin Ointment on the Pain Associated With Chronic Anal Fissures","Fissure in Ano|Pain","other","Drug: nitroglycerin 0.4%|Drug: Placebo","drug","Prostrakan Pharmaceuticals","Both","Adult|Senior",247,"August 2007","September 2009","",1.563223647,"1",24117
"958","NCT01110889","Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder","Major Depressive Disorder","mental health","Drug: Agomelatine (AGO178C)|Drug: Agomelatine (AGO178C)|Drug: Placebo","drug","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior",582,"May 2010","March 2011","",1.567490864,"1",24135
"959","NCT00479687","SUPARTZ Versus Placebo in Osteoarthritis of the Shoulder","Osteoarthritis of the Shoulder","other","Device: SUPARTZ|Device: Phosphate Buffered Saline","device","Bioventus LLC","Both","Adult|Senior",256,"May 2007","June 2008","",1.589267557,"1",24102
"960","NCT00368251","Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease in Adolescents and Adults","Unverricht-Lundborg Disease","mental health","Drug: Brivaracetam|Drug: Brivaracetam|Other: Placebo","drug","UCB Pharma","Both","Child|Adult|Se",56,"November 2006","November 2011","",1.621082251,"1",24143
"961","NCT00486668","A Study of AC Followed by a Combination of Paclitaxel Plus Trastuzumab or Lapatinib or Both Given Before Surgery to Patients With Operable HER2 Positive Invasive Bre","Invasive Breast Cancer","cancer","Drug: doxorubicin|Drug: cyclophosphamide|Drug: paclitaxel|Drug: trastuzumab|Drug: lapatinib","drug","NSABP Foundation Inc|GlaxoSmithKline","Female","Adult|Senior",529,"July 2007","March 2010","",1.669592577,"1",24123
"962","NCT00419705","Effectiveness and Safety Trial of a New Ischemic Stroke Treatment Within 24 Hours From Stroke Onset (NEST-2)","Ischemic Stroke","cardiovascular","Device: NeuroThera® Laser System","device","PhotoThera, Inc","Both","Adult|Senior",660,"December 2006","June 2010","",1.674664889,"1",24126
"963","NCT01262677","Once-A-Day Pregabalin For Partial Seizures","Partial Seizures|Epilepsies, Partial","mental health","Drug: pregabalin|Drug: pregabalin|Drug: pregabalin|Drug: pregabalin|Drug: pregabalin|Drug:","drug","Pfizer","Both","Adult|Senior",334,"January 2011","May 2009","",1.691716714,"1",24113
"964","NCT00330473","A Concordance Study Comparing Insulin Treatments in Patients With Type 2 Diabetes","Diabetes Mellitus, Type 2","endocrine and metabolic","Drug: Human Insulin Inhalation Powder|Drug: Insulin","drug","Eli Lilly and Company","Both","Adult|Senior",1019,"June 2006","April 2009","",1.695,"1",24112
"965","NCT00465491","Study of Picoplatin Efficacy After Relapse","Small Cell Lung Cancer","cancer","Drug: picoplatin|Other: best supportive care|Other: Best Supportive Care","drug","Poniard Pharmaceuticals","Both","Adult|Senior",399,"April 2007","June 2009","",1.700696461,"1",24114
"966","NCT00090519","Reduction in the Occurrence of Center-Involved Diabetic Macular Edema","Diabetic Retinopathy","cardiovascular","Drug: ruboxistaurin|Drug: placebo","drug","Eli Lilly and Company","Both","Adult|Senior",737,"February 2004","June 2011","",1.744913081,"1",24138
"967","NCT00656578","Efficacy and Safety Study of 4975 to Manage Pain of Bunionectomy","Pain","other","Drug: 4975|Drug: Placebo","drug","Anesiva, Inc.","Both","Adult|Senior",300,"March 2008","May 2010","",1.812,"1",24125
"968","NCT00626197","A Study to Evaluate Ocrelizumab in Patients With Nephritis Due to Systemic Lupus Erythematosus (BELONG)","Lupus Nephritis|Systemic Lupus Erythematosus","other","Drug: corticosteroids|Drug: cyclophosphamide|Drug: mycophenolate mofetil|Drug: ocrelizumab|","drug","Genentech, Inc.|Roche Pharma AG","Both","Child|Adult|Se",369,"February 2008","May 2008","",1.8453,"1",24101
"969","NCT00630812","Long Term Administration of Inhaled Mannitol in Cystic Fibrosis","Cystic Fibrosis","respiratory","Drug: inhaled mannitol|Drug: Placebo comparator","drug","Pharmaxis|ethica Clinical Research Inc.|Europe: KasaConsult bvba, Hoegaarden, Belgium|Argentina: Resolution Latin America; Buenos Aires, Argentina","Both","Child|Adult|Se",318,"September 2008","May 2011","",1.888193337,"1",24137
"970","NCT00709436","Safety and Efficacy of Repeated Doses of PMI-150 (Intranasal Ketamine) in Acute Post-operative Pain Following Orthopedic Surgery","Pain, Postoperative","other","Drug: PMI-150 (intranasal ketamine)|Drug: Placebo","drug","Hospira, Inc.","Both","Adult|Senior",250,"June 2008","September 2008","",1.934920925,"1",24105
"971","NCT00861614","Study of Immunotherapy to Treat Advanced Prostate Cancer","Prostate Cancer","cancer","Drug: Ipilimumab|Drug: Placebo","drug","Bristol-Myers Squibb","Male","Adult|Senior",796,"May 2009","November 2009","",1.934920925,"1",24119
"972","NCT00599716","Safety and Efficacy Assessment of Vismed® (Sodium Hyaluronate) for the Treatment of Dry Eye Syndrome","Dry Eye Disease","other","Drug: sodium hyaluronate|Drug: vehicle","drug","Lantibio|River Plate Biotechnology, Inc.|Rx Development Resources, LLC","Both","Adult|Senior",300,"December 2006","September 2009","",1.959963985,"1",24117
"973","NCT00357279","Study of Denufosol Inhalation Solution in Patients With Mild Cystic Fibrosis Lung Disease","Cystic Fibrosis","respiratory","Drug: denufosol tetrasodium (INS37217) Inhalation Solution|Drug: Placebo - 0.9% w/v sodium","drug","Merck Sharp & Dohme Corp.","Both","Child|Adult|Se",352,"July 2006","April 2009","",1.986300204,"1",24112
"974","NCT00404742","A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis","Uveitis, Posterior|Uveitis, Intermediate|Panuveitis","other","Drug: Placebo|Drug: LX211|Drug: LX211|Drug: LX211","drug","Lux Biosciences, Inc.","Both","Child|Adult|Se",232,"January 2007","July 2010","",1.99539331,"1",24127
"975","NCT00492596","The AttenueX IntraVesical System for the Treatment of Female Stress Urinary Incontinence","Urinary Incontinence, Stress","other","Device: AttenueX IntraVesical System|Procedure: Sham Procedure","device","Solace Therapeutics, Inc.","Female","Adult|Senior",166,"June 2006","March 2010","",1.99539331,"1",24123
"976","NCT00393991","Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma","Asthma","respiratory","Drug: Fluticasone propionate/formoterol fumarate 100/10|Drug: Fluticasone propionate 100|Dr","drug","SkyePharma AG","Both","Child|Adult|Se",475,"July 2006","February 2008","",2.004654462,"1",24098
"977","NCT00665223","A Study of Treatment With ACR16 in Patients With Huntington's Disease","Huntington's Disease","mental health","Drug: ACR16|Drug: Placebo","drug","Teva Pharmaceutical Industries","Both","Adult|Senior",437,"April 2008","March 2011","",2.0335,"1",24135
"978","NCT01030783","A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma","Advanced Renal Cell Carcinoma","cancer","Drug: tivozanib (AV-951)|Drug: Sorafenib","drug","AVEO Pharmaceuticals, Inc.","Both","Adult|Senior",517,"December 2009","June 2012","",2.033520149,"1",24150
"979","NCT01229566","Efficacy Study to Treat Subjects With Severe Hypertriglyceridemia","Severe Hypertriglyceridemia","cardiovascular","Drug: AKR-963","drug","Trygg Pharma,  Inc.","Both","Adult|Senior",240,"October 2010","December 2010","",2.043530007,"1",24132
"980","NCT00447564","Safety and Efficacy of Probuphine in the Treatment of Opioid Dependence","Opioid Dependence","mental health","Drug: Probuphine|Drug: placebo","drug","Titan Pharmaceuticals","Both","Adult",163,"October 2006","September 2011","",2.053748911,"1",24141
"981","NCT00577304","A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon","Raynaud's Disease|Raynaud's Disease Secondary to Scle","cardiovascular","Drug: Nitroglycerin|Drug: Topical AmphiMatrix","drug","MediQuest Therapeutics","Both","Child|Adult|Se",200,"December 2007","January 2012","",2.053748911,"1",24145
"982","NCT00605683","MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist","Idiopathic Parkinson's Disease","mental health","Drug: Safinamide (as add-on therapy)|Drug: Safinamide (as add-on therapy)|Drug: Safinamide","drug","Newron","Both","Adult|Senior",679,"November 2007","November 2010","",2.053748911,"1",24131
"983","NCT00904683","Effect of LY2062430 on the Progression of Alzheimer's Disease","Alzheimer's Disease","mental health","Drug: LY2062430|Drug: Placebo","drug","Eli Lilly and Company","Both","Adult|Senior",1040,"May 2009","November 2009","",2.053748911,"1",24119
"984","NCT00864097","Analgesic Efficacy And Safety of Tanezumab Added On To Diclofenac SR In Patients With Osteoarthritis Of The Knee Or Hip","Osteoarthritis","other","Biological: tanezumab|Drug: diclofenac|Biological: tanezumab|Drug: diclofenac|Biological: t","biolog","Pfizer","Both","Adult|Senior",607,"August 2009","September 2009","",2.06418689,"1",24117
"985","NCT00765700","Ketoprofen 10% Cream for Treatment of Pain Associated With Mild to Moderate Acute Soft Tissue Injury","Sprain|Strain|Acute Soft Tissue Injury","other","Drug: Topical Ketoprofen 10% Cream|Drug: Topical Placebo Cream","drug","Imprimis Pharmaceuticals, Inc.|Cato Research","Both","Adult|Senior",364,"September 2008","January 2010","",2.074854734,"1",24121
"986","NCT00643383","A Two-Arm Study Comparing the Analgesic Efficacy and Safety of Acetaminophen and Tramadol Combination BID  Versus Placebo for the Treatment of Acute Low Back Pain","Acute Low Back Pain","other","Drug: Combination drug (Acetaminophen + Tramadol)|Drug: Placebo","drug","Labopharm Inc.","Both","Adult|Senior",277,"March 2008","May 2010","",2.0749,"1",24125
"987","NCT01298219","Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone (OPAL)","Opioid-induced Bowel Dysfunction","other","Drug: Lubiprostone|Drug: Placebo","drug","Sucampo Pharmaceuticals, Inc.|Takeda|Sucampo Pharma Americas, LLC","Both","Adult|Senior",447,"December 2010","October 2010","",2.108358399,"1",24130
"988","NCT00660959","Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Oral Lixivaptan Capsules in Subject With Euvolemic Hyponatremi","Hyponatremia With Normal Extracellular Fluid Volume","endocrine and metabolic","Drug: lixivaptan|Drug: placebo","drug","CardioKine Inc.|Cardiokine Biopharma, LLC|Biogen Idec","Both","Adult|Senior",106,"April 2008","August 2009","",2.12007169,"1",24116
"989","NCT00260156","A Clinical Study to Assess the Effect of Vildagliptin on Beta Cell Function in Drug Naive Patients With Type 2 Diabetes","Diabetes Mellitus, Type 2","endocrine and metabolic","Drug: vildagliptin|Drug: placebo","drug","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior",59,"November 2005","September 2008","",2.170090378,"1",24105
"990","NCT00681356","Safety and Efficacy Study of 4975 in Patients Undergoing Total Knee Replacement","Total Knee Arthroplasty (Replacement)","other","Drug: 4975, 15 and 5 mg|Drug: Placebo Comparator|Drug: 4975 - 5 mg","drug","Anesiva, Inc.","Both","Adult|Senior",214,"September 2007","April 2011","",2.170090378,"1",24136
"991","NCT00925301","Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease","Fabry Disease","cardiovascular","Drug: migalastat hydrochloride|Drug: Placebo","drug","Amicus Therapeutics","Both","Child|Adult|Se",67,"August 2009","August 2011","",2.170090378,"1",24140
"992","NCT00255983","A Trial to Evaluate the Efficacy and Safety of Faropenem Medoxomil In the Treatment of Chronic Bronchitis","Chronic Bronchitis","respiratory","Drug: Faropenem medoxomil|Drug: placebo","drug","Replidyne|INC Research Limited","Both","Adult|Senior",491,"December 2005","November 2009","",2.184847908,"1",24119
"993","NCT01223937","Investigation of the Superiority Effect of Desmopressin to Placebo in Terms of Night Voids Reduction in Nocturia Adult Female Patients","Nocturia","other","Drug: Desmopressin|Drug: Placebo","drug","Ferring Pharmaceuticals","Female","Adult|Senior",263,"November 2010","May 2012","",2.197286377,"1",24149
"994","NCT00268879","Investigation of the Safety and Efficacy of Renzapride in Constipation Predominant Irritable Bowel Syndrome (IBS)","Irritable Bowel Syndrome","other","Drug: Renzapride","drug","Alizyme","Female","Adult",1821,"December 2005","February 2010","",2.211517809,"1",24122
"995","NCT00863304","Tanezumab in Osteoarthritis of the Hip or Knee (2)","Osteoarthritis","other","Biological: tanezumab 10 mg|Biological: tanezumab 5 mg|Drug: naproxen|Other: placebo","biolog","Pfizer","Both","Adult|Senior",849,"May 2009","April 2009","",2.218,"1",24112
"996","NCT00605215","BRAVO Study: Laquinimod Double Blind Placebo Controlled Study in RRMS Patients With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)","Multiple Sclerosis","mental health","Drug: laquinimod|Drug: placebo|Drug: Interferon β-1a (Avonex®)","drug","Teva Pharmaceutical Industries","Both","Adult",1331,"April 2008","June 2010","",2.2262,"1",24126
"997","NCT00206323","A Randomized, Placebo-Controlled, Tourette Syndrome Study.","Tourette Syndrome","mental health","Drug: Topiramate (drug)","drug","Baylor College of Medicine|Ortho-McNeil Janssen Scientific Affairs, LLC","Both","Child|Adult",16,"September 2004","May 2008","",2.227707898,"1",24101
"998","NCT00612170","A 14-week, Multi-center Study of [S,S]-Reboxetine in Patients With Fibromyalgia.","Fibromyalgia","other","Drug: [S,S]-Reboxetine|Drug: Placebo|Drug: [S,S]-Reboxetine|Drug: [S,S]-Reboxetine","drug","Pfizer","Both","Adult|Senior",1129,"December 2007","September 2009","",2.2414,"1",24117
"999","NCT00406588","SLV308 for Treatment of Patients With Parkinson's Disease Experiencing Motor Fluctuations","Advanced Stage Parkinson's Disease","mental health","Drug: Levodopa (Pardoprunox)|Drug: Placebo Comparator","drug","Solvay Pharmaceuticals","Both","Adult|Senior",295,"March 2007","March 2012","",2.299086992,"1",24147
"1000","NCT00088530","BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)","Lymphoma, Non-Hodgkin","cancer","Drug: pixantrone, cyclophosphamide, vincristine, rituximab, prednisone|Drug: Vinorelbine, O","drug","CTI BioPharma","Both","Adult|Senior",140,"July 2004","August 2008","",2.307984475,"1",24104
"1001","NCT01271933","Study Of A Controlled Release Formulation Of Pregabalin In Fibromyalgia Patients","Fibromyalgia","other","Drug: pregabalin|Drug: placebo","drug","Pfizer","Both","Adult|Senior",777,"March 2011","March 2011","",2.307984475,"1",24135
"1002","NCT01332253","Safety and Efficacy of Intravenous Ibuprofen for Treatment of Pain in Pediatric Patients Undergoing Tonsillectomy","Tonsillectomy","other","Drug: Intravenous ibuprofen|Other: Normal Saline","drug","Cumberland Pharmaceuticals","Both","Child",161,"July 2011","April 2011","",2.307984475,"1",24136
"1003","NCT01045161","To Assess the Long-term Safety, Efficacy and Tolerability of Inhaled Aclidinium Bromide in the Treatment of Moderate-to-severe Chronic Obstructive Pulmonary Disease","Chronic Obstructive Pulmonary Disease","respiratory","Drug: Aclidinium bromide|Drug: Aclidinium bromide|Drug: Placebo","drug","Forest Laboratories| Almirall, S.A.","Both","Adult|Senior",544,"December 2009","April 2010","",2.325,"1",24124
"1004","NCT00639743","PEITHO Pulmonary Embolism Thrombolysis Study","Pulmonary Embolism","cardiovascular","Drug: placebo ( group B)|Drug: tenecteplase (group A)","drug","Assistance Publique - Hôpitaux de Paris|German Federal Ministry of Education and Research|Boehringer Ingelheim","Both","Adult|Senior",1005,"November 2007","March 2011","",2.3263,"1",24135
"1005","NCT00392054","First Line Radiofrequency Ablation Versus Antiarrhythmic Drugs for Atrial Fibrillation Treatment (The RAAFT Study)","Atrial Fibrillation","cardiovascular","Procedure: Pulmonary Vein Isolation performed by Catheter Ablation|Drug: Conventional Antia","proced","Population Health Research Institute|Johnson & Johnson","Both","Adult|Senior",127,"August 2006","May 2010","",2.326347874,"1",24125
"1006","NCT00674661","Corneal Collagen Cross-Linking for Ectasia (CXL)","Ectasia","other","Drug: riboflavin ophthalmic solution|Device: UVA Irradiation","device","Avedro, Inc.","Both","Child|Adult|Se",179,"December 2007","December 2010","",2.326347874,"1",24132
"1007","NCT00960869","Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Develop","Gastric Ulcer","other","Drug: PA32540|Drug: EC Aspirin 325","drug","POZEN","Both","Adult|Senior",519,"October 2009","October 2008","",2.326347874,"1",24106
"1008","NCT01846442","Topical DHEA Against Vaginal Atrophy","Vaginal Atrophy","other","Drug: Placebo|Drug: DHEA (0.25%)|Drug: DHEA (0.5%)|Drug: DHEA (1.0%)","drug","EndoCeutics Inc.","Female","Adult|Senior",218,"June 2007","February 2009","",2.326347874,"1",24110
"1009","NCT00820027","Study of MK-0663/Etoricoxib in Postorthopedic Knee Replacement Surgery Pain (MK-0663-098)","Pain, Postoperative","other","Drug: Etoricoxib 90 mg|Drug: Etoricoxib 120 mg|Drug: Ibuprofen 600 mg|Drug: Matching Placeb","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",776,"December 2008","September 2011","",2.365618127,"1",24141
"1010","NCT00733902","Tanezumab in Osteoarthritis of the Knee","Arthritis|Osteoarthritis","other","Biological: tanezumab|Biological: tanezumab|Biological: tanezumab|Biological: Placebo","biolog","Pfizer","Both","Adult|Senior",697,"September 2008","July 2012","",2.432379059,"1",24151
"1011","NCT01166542","Efficacy Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin in Platinum-Refractory Head and Neck Cancers","Carcinoma, Squamous Cell of the Head and Neck","cancer","Biological: REOLYSIN|Drug: Carboplatin|Drug: Paclitaxel|Drug: Placebo","biolog","Oncolytics Biotech","Both","Adult|Senior",167,"June 2010","March 2012","",2.442151952,"1",24147
"1012","NCT00319501","Efficacy and Safety of Vanquix for the Management of Selected, Refractory, Patients With Epilepsy Who Require Intermittent Caregiver Medical Intervention to Control","Seizures|Epilepsies, Partial|Epilepsy, Complex Partia","mental health","Drug: Placebo|Drug: Vanquix Auto-Injector (Diazepam Injection)","drug","Pfizer","Both","Child|Adult|Se",234,"January 2006","December 2008","",2.512144328,"1",24108
"1013","NCT00411242","Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder","Major Depressive Disorder (MDD)","mental health","Drug: agomelatine|Drug: placebo","drug","Novartis","Both","Adult|Senior",503,"December 2006","February 2010","",2.575829304,"1",24122
"1014","NCT00773747","Study of Vorinostat (MK-0683) an HDAC Inhibitor, or Placebo in Combination With Bortezomib in Patients With Multiple Myeloma (MK-0683-088 AMN)","Multiple Myeloma","cancer","Drug: vorinostat|Drug: bortezomib|Drug: placebo to vorinostat","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",637,"December 2008","July 2010","",2.575829304,"1",24127
"1015","NCT01016808","Comparison of the Efficacy and Safety of Q8003 Versus Its Individual Components in Bunionectomy Patients","Moderate to Severe Postoperative Pain","other","Drug: Q8003|Drug: Morphine sulfate|Drug: Oxycodone HCl","drug","QRxPharma Inc.","Both","Adult|Senior",522,"December 2009","August 2008","",2.575829304,"1",24104
"1016","NCT01621399","Safety and Efficacy Study to Treat Bacterial Vaginosis","Bacterial Vaginosis","other","Drug: Product 55394|Drug: Placebo Vehicle (non-treatment)","drug","Medicis Global Service Corporation","Female","Adult|Senior",651,"May 2012","March 2012","",2.575829304,"1",24147
"1017","NCT00335166","SLV 308 and Pramipexole for Treatment of Patients With Early Parkinson Disease","Early Stage Parkinson Disease","mental health","Drug: Pardaprunox|Drug: pramipexole|Drug: Placebo Comparator","drug","Solvay Pharmaceuticals","Both","Adult|Senior",330,"November 2006","March 2009","",2.612054141,"1",24111
"1018","NCT00641329","CLONICEL (Clonidine Sustained Release) as Add-on to Stimulant Medication in 6 to 17 Yr-olds With ADHD","ADHD","mental health","Drug: CLONICEL (clonidine HCl sustained release)|Drug: Placebo","drug","Addrenex Pharmaceuticals, Inc.","Both","Child",198,"February 2008","February 2009","",2.6121,"1",24110
"1019","NCT00430742","An Investigational Drug Study to Assess Weight Loss in Patients With Type 2 Diabetes Mellitus (0364-011)(TERMINATED)","Obesity Type 2 Diabetes Mellitus|Type 2 Diabetes Mell","other","Drug: Taranabant|Drug: Comparator: Placebo","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",600,"November 2006","March 2012","",2.613,"1",24147
"1020","NCT01048242","Treatment of Insomnia in Elderly Sleep Apnea Patients With Ramelteon (TAK 375)","Insomnia|Obstructive Sleep Apnea","mental health","Drug: rozerem|Drug: Placebo","drug","University of Pennsylvania|Takeda","Both","Adult|Senior",29,"July 2006","March 2011","",2.652,"1",24135
"1021","NCT00383422","Study Comparing Arzoxifene With Raloxifene in Women After Menopause With Osteoporosis","Osteoporosis, Postmenopausal","endocrine and metabolic","Drug: Arzoxifene|Drug: Raloxifene","drug","Eli Lilly and Company","Female","Adult|Senior",320,"October 2006","December 2010","",2.652069808,"1",24132
"1022","NCT00404612","A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis","Uveitis, Posterior|Uveitis, Intermediate|Panuveitis","other","Drug: Placebo|Drug: LX211|Drug: LX211|Drug: LX211","drug","Lux Biosciences, Inc.","Both","Child|Adult|Se",218,"January 2007","April 2012","",2.652069808,"1",24148
"1023","NCT00627640","Safinamide in Idiopathic Parkinson's Disease (IPD) With Motor Fluctuations, as add-on to Levodopa","Idiopathic Parkinson's Disease","mental health","Drug: Safinimide 50-100 mg/day|Drug: Matching Placebo","drug","Newron","Both","Adult|Senior",549,"February 2009","May 2011","",2.6521,"1",24137
"1024","NCT00578955","Comparative Study of AzaSite Plus Compared to AzaSite Alone and Dexamethasone Alone to Treat Subjects With Blepharoconjunctivitis","Blepharoconjunctivitis","other","Drug: 1% Azithromycin and 0.1% Dexamethasone|Drug: 1% Azithromycin|Drug: 0.1% Dexamethasone","drug","InSite Vision","Both","Child|Adult|Se",417,"December 2007","April 2009","",2.6968,"1",24112
"1025","NCT00420589","A Weight Maintenance Study in Obese Patients (0364-012)(TERMINATED)","Obesity","other","Drug: taranabant|Drug: Comparator: placebo","drug","Merck Sharp & Dohme Corp.","Both","Adult",1000,"October 2006","April 2012","",2.696844261,"1",24148
"1026","NCT00529373","A Study of MK-0822 in Postmenopausal Women With Osteoporosis to Assess Fracture Risk (MK-0822-018)","Postmenopausal Osteoporosis","endocrine and metabolic","Drug: Odanacatib|Drug: Placebo for Odanacatib|Dietary Supplement: Vitamin D3","drug","Merck Sharp & Dohme Corp.","Female","Adult|Senior",16716,"September 2007","February 2011","",2.696844261,"1",24134
"1027","NCT01421498","Safety and Efficacy Study of SAR 1118 to Treat Dry Eye","Dry Eye|Keratoconjunctivitis Sicca","other","Drug: Lifitegrast","drug","Shire","Both","Adult|Senior",588,"August 2011","March 2012","",2.696844261,"1",24147
"1028","NCT00676507","Phase III Lucanix™ Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy","Lung Neoplasm|Carcinoma Non-small Cell Lung Cancer St","cancer","Biological: Lucanix™|Other: Placebo Comparator","biolog","NovaRx Corporation","Both","Adult|Senior",506,"July 2008","January 2010","",2.7016,"1",24121
"1029","NCT00830063","Tanezumab In Osteoarthritis Of The Knee (2)","Arthritis|Osteoarthritis","other","Biological: tanezumab 10 mg|Biological: tanezumab 5 mg|Drug: naproxen|Other: placebo","biolog","Pfizer","Both","Adult|Senior",848,"May 2009","August 2010","",2.722,"1",24128
"1030","NCT00394199","Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone & Formoterol Administered Alone in Patients With Asthma","Asthma","respiratory","Drug: Fluticasone propionate/Formoterol Fumarate 100/10|Drug: Fluticasone propionate 100|Dr","drug","SkyePharma AG","Both","Child|Adult|Se",357,"June 2006","January 2008","",2.747781385,"1",24097
"1031","NCT01221597","Study of AA4500 in the Treatment of Peyronie's Disease","Peyronie's Disease","other","Biological: AA4500","biolog","Auxilium Pharmaceuticals","Male","Adult|Senior",418,"September 2010","September 2012","",2.753287825,"1",24153
"1032","NCT00628680","A Multi-Centered, Two-Arm, Randomized Study Comparing the Effects of AAT-023 (Zuragen) Solution, and Heparin on the Incidence of Catheter Related Blood Stream Infect","End Stage Renal Disease","cardiovascular","Device: AAT-023 solution (Zuragen)|Drug: Heparin","device","Ash Access Technology","Both","Adult|Senior",415,"July 2006","January 2008","",2.807,"1",24097
"1033","NCT00961350","A Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PA32540 or Enteric Coated Aspirin 325 mg in Subjects Who Are at Risk for Devel","Gastric Ulcer","other","Drug: PA32540|Drug: EC Aspirin 325","drug","POZEN","Both","Adult|Senior",530,"October 2009","December 2011","",2.807033768,"1",24144
"1034","NCT01104766","Safety and Efficacy of Cariprazine in Patients With Schizophrenia","Schizophrenia","mental health","Drug: Cariprazine|Drug: Cariprazine|Drug: Aripiprazole|Drug: Placebo","drug","Forest Laboratories|Gedeon Richter Ltd.","Both","Adult",617,"April 2010","January 2011","",2.847963287,"1",24133
"1035","NCT00396448","Effect of 2-year Administration of CP-945,598 on Weight Loss Efficacy and Safety.","Obesity","other","Drug: CP-945,598 Treatment B|Drug: CP-945,598 Treatment A|Drug: Placebo","drug","Pfizer","Both","Adult|Senior",1253,"February 2007","March 2008","",2.855271888,"1",24099
"1036","NCT00595946","Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone","Opioid-Induced Bowel Dysfunction","other","Drug: Lubiprostone|Drug: Placebo","drug","Sucampo Pharmaceuticals, Inc.|Takeda|Sucampo Pharma Americas, LLC","Both","Adult|Senior",441,"August 2007","March 2009","",2.8782,"1",24111
"1037","NCT01397461","Efficacy and Safety of Ozenoxacin 1% Cream Versus Placebo in the Treatment of Patients With Impetigo","Impetigo","other","Drug: ozenoxacin placebo|Drug: retapamulin 1% ointment|Drug: ozenoxacin 1% cream","drug","Ferrer Internacional S.A.","Both","Child|Adult|Se",465,"March 2012","March 2011","",2.967737925,"1",24135
"1038","NCT01104779","Safety and Efficacy of Cariprazine in Schizophrenia","Schizophrenia","mental health","Drug: Cariprazine|Drug: Cariprazine|Drug: Placebo","drug","Forest Laboratories|Gedeon Richter Ltd.","Both","Adult",459,"April 2010","July 2009","",2.978143684,"1",24115
"1039","NCT01048866","A Study of Flurbiprofen 8.75 mg Lozenge in Patients With Pharyngitis","Pharyngitis","other","Drug: Placebo|Drug: Flurbiprofen","drug","Reckitt Benckiser LLC","Both","Adult|Senior",300,"November 2009","August 2008","",3.073,"1",24104
"1040","NCT00355849","Evaluate the Efficacy and Safety of Insulin in Patients With Type 2 Diabetes","Diabetes Mellitus, Type 2","endocrine and metabolic","Drug: Human Insulin Inhalation Powder|Drug: Insulin Glargine","drug","Eli Lilly and Company|Alkermes, Inc.","Both","Adult|Senior",555,"August 2006","October 2010","",3.090232306,"1",24130
"1041","NCT00509145","Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)","Multiple Sclerosis","mental health","Drug: Laquinimod|Other: Placebo","drug","Teva Pharmaceutical Industries","Both","Adult",1106,"December 2007","October 2008","",3.090232306,"1",24106
"1042","NCT01462812","Safety and Efficacy Study of a Single Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine","Migraine Headache","mental health","Drug: Sumatriptan|Drug: Placebo","drug","Optinose US Inc.","Both","Adult",230,"January 2011","May 2010","",3.090232306,"1",24125
"1043","NCT00560183","Efficacy and Safety of Q8003 in the Management of Post-bunionectomy Pain","Postoperative Pain","other","Drug: Q8003 (morphine sulfate and oxycodone hydrochloride)|Drug: Placebo","drug","QRxPharma Inc.","Both","Adult|Senior",256,"November 2007","February 2008","",3.138180768,"1",24098
"1044","NCT00572572","Aprepitant + a 5HT3 + Dexamethasone in Patients With Germ Cell Tumors","Germ Cell Tumors","other","Drug: Aprepitant|Drug: Placebo","drug","Hoosier Cancer Research Network|Merck Sharp & Dohme Corp.","Male","Child|Adult|Se",71,"December 2007","April 2009","",2.859,"1",24112
"1045","NCT00649025","A Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™) With Fluticasone or Flovent to Treat Moderate to Severe Asthma in","Asthma","respiratory","Drug: FlutiForm 250/10|Drug: SKP-Fluticasone|Drug: Flovent Fluticasone HFA","drug","SkyePharma AG|Abbott|MDS Pharma Services","Both","Child|Adult|Se",438,"March 2008","July 2012","",3.757,"1",24151
"1046","NCT00657904","Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer","Non-metastatic Prostate Cancer","cancer","Drug: Bicalutamide|Drug: Placebo","drug","AstraZeneca","Male","Adult|Senior",3618,"August 1995","July 2012","",4.67,"1",24151
"1047","NCT00691964","Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis","Plaque Psoriasis","other","Biological: ABT-874|Biological: etanercept|Drug: placebo","biolog","AbbVie (prior sponsor, Abbott)|Paragon Biomedical|AbbVie","Both","Adult|Senior",347,"May 2008","December 2012","",5.542,"1",24156
"1048","NCT01069692","Placebo Versus SBR759 in Lowering Phosphate in Dialysis Patients","Hyperphosphatemia|Chronic Kidney Disease","endocrine and metabolic","Drug: SBR759A|Drug: SBR759A|Drug: SBR759A|Drug: SBR759A|Drug: SBR759A","drug","Novartis","Both","Adult|Senior",115,"February 2010","June 2009","",5.245,"1",24114
"1049","NCT00088010","Effects of Arzoxifene on Bone Fractures and Incidence of Breast Cancer","Osteoporosis, Postmenopausal","cancer","Drug: Arzoxifene|Drug: Placebo","drug","Eli Lilly and Company","Female","Adult|Senior",9369,"June 2004","June 2010","",3.884,"1",24126
"1050","NCT00099853","Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes","Diabetes Mellitus, Type 2","endocrine and metabolic","Drug: Vildagliptin|Drug: pioglitazone|Drug: Placebo","drug","Novartis Pharmaceuticals|Novartis","Both","Adult|Senior",362,"May 2004","June 2008","",3.536,"1",24102
"1051","NCT00121108","MEDI-524 (Motavizumab) for the Prevention of Respiratory Syncytial Virus (RSV) Disease Among Native American Indian Infants in the Southwestern United States","Healthy","respiratory","Biological: MEDI-524|Other: Placebo","biolog","MedImmune LLC","Both","Child",2127,"November 2004","September 2012","",8.338,"1",24153
"1052","NCT00270504","Memokath® 044TW Stent for Treatment of Urethral Stricture","Urethral Stricture","other","Device: Memokath stenting","device","Pnn Medical DK","Male","Adult|Senior",92,"December 2002","October 2012","",3.09,"1",24154
"1053","NCT00289900","Lipid Efficacy and Safety in Patients With Mixed Hyperlipidemia (MK-0524B-024)","Mixed Hyperlipidemia","cardiovascular","Drug: Comparator: MK0524B|Drug: Comparator: Atorvastatin","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",2355,"January 2006","December 2008","",7.187,"1",24108
"1054","NCT00298038","A 6-month Efficacy, Safety and Tolerability Study of Rifaximin In Preventing Hepatic Encephalopathy","Hepatic Encephalopathy","endocrine and metabolic","Drug: Rifaximin","drug","Salix Pharmaceuticals","Both","Adult|Senior",299,"December 2005","July 2011","",4.037,"1",24139
"1055","NCT00384605","An Investigational Drug Study to Assess Weight Loss in Obese and Overweight Patients (0364-037)(TERMINATED)","Obesity","other","Drug: taranabant|Drug: placebo","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",1000,"October 2006","December 2009","",5.277,"1",24120
"1056","NCT00393952","New Combination Inhaler (FlutiForm HFA MDI 100/10 µg and 250/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo in Patients With Moderate to","Asthma","respiratory","Drug: Fluticasone propionate/Formoterol fumarate 250/10|Drug: Placebo|Drug: Fluticasone pro","drug","SkyePharma AG","Both","Child|Adult|Se",557,"June 2006","November 2012","",3.398,"1",24155
"1057","NCT00428948","Tolvaptan Phase 3 Efficacy and Safety Study in ADPKD","Polycystic Kidney Disease, Autosomal Dominant","other","Drug: tolvaptan|Drug: Placebo","drug","Otsuka Pharmaceutical Development & Commercialization, Inc.|Otsuka Pharmaceutical Co., Ltd.","Both","Adult",1445,"January 2007","November 2008","",8.82,"1",24107
"1058","NCT00485589","A Study of Ocrelizumab in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Are Naive to Methotrexate (FILM)","Rheumatoid Arthritis","other","Drug: methotrexate|Drug: ocrelizumab|Drug: placebo","drug","Genentech, Inc.|Roche Pharma AG","Both","Adult|Senior",613,"June 2007","September 2010","",3.291,"1",24129
"1059","NCT00557921","Clopidogrel and the Optimization of Gastrointestinal Events (COGENT-1)","Acute Coronary Syndrome|Myocardial Infarction|Coronar","cardiovascular","Drug: CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin|Drug: Plavix (clopidogrel 7","drug","Cogentus Pharmaceuticals","Both","Adult|Senior",5000,"December 2007","February 2008","",3.428,"1",24098
"1060","NCT00578695","THE BALANCE Study: Treatment of Hyponatremia Based on Lixivaptan in NYHA Class III/IV Cardiac Patient Evaluation","Hyponatremia","endocrine and metabolic","Drug: lixivaptan|Drug: Placebo","drug","CardioKine Inc.|Cardiokine Biopharma, LLC|Biogen Idec","Both","Adult|Senior",652,"January 2007","June 2012","",3,"1",24150
"1061","NCT00656305","ExAblate (Magnetic Resonance-guided Focused Ultrasound Surgery) Treatment of Metastatic Bone Tumors for the Palliation of Pain","Bone Metastases|Multiple Myeloma","cancer","Device: ExAblate 2000|Device: Sham","device","InSightec","Both","Adult|Senior",147,"March 2008","March 2009","",5.444,"1",24111
"1062","NCT00709904","Evaluation of AVE5026 as Compared to Placebo for the Extended Prophylaxis of Venous Thromboembolism in Patients Having Undergone Hip Fracture Surgery","Venous Thromboembolism","cardiovascular","Drug: Open-label Semuloparin sodium|Drug: Placebo (for Semuloparin sodium)|Drug: Semulopari","drug","Sanofi","Both","Adult|Senior",469,"June 2008","October 2012","",3.668,"1",24154
"1063","NCT00710580","Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis","Moderate to Severe Plaque Psoriasis","other","Biological: ABT-874|Biological: etanercept|Drug: placebo","biolog","AbbVie (prior sponsor, Abbott)|Paragon Biomedical|AbbVie","Both","Adult|Senior",350,"July 2008","February 2008","",7.989,"1",24098
"1064","NCT00829829","PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1","Intercritical Gout","endocrine and metabolic","Drug: rilonacept|Drug: rilonacept|Drug: rilonacept","drug","Regeneron Pharmaceuticals","Both","Adult|Senior",241,"February 2009","June 2011","",4.446,"1",24138
"1065","NCT00876798","A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Tolerability of Oral Lixivaptan Capsules in Subjects With Euvolemic Hypo","Euvolemic Hyponatremia","endocrine and metabolic","Drug: Lixivaptan|Drug: Placebo","drug","CardioKine Inc.|Cardiokine Biopharma, LLC|Biogen Idec","Both","Adult|Senior",206,"June 2009","July 2012","",4,"1",24151
"1066","NCT00985621","Tanezumab In Osteoarthritis Of The Hip Or Knee","Osteoarthritis","other","Biological: tanezumab 10 mg|Biological: tanezumab 5 mg|Drug: oxycodone|Other: placebo","biolog","Pfizer","Both","Adult|Senior",600,"October 2009","October 2010","",2.949,"1",24130
"1067","NCT01049334","A Study of Flurbiprofen 8.75 mg Lozenge in Patient With Pharyngitis","Pharyngitis","other","Drug: Placebo|Drug: Flurbiprofen","drug","Reckitt Benckiser LLC","Both","Adult|Senior",300,"November 2009","October 2012","",4.096,"1",24154
"1068","NCT01058668","Safety and Efficacy of Cariprazine for Bipolar I Disorder","Mania|Bipolar I Disorder","mental health","Drug: Cariprazine low dose|Drug: Cariprazine high dose|Drug: Placebo","drug","Forest Laboratories|Gedeon Richter Ltd.","Both","Adult",507,"January 2010","December 2011","",5.198,"1",24144
"1069","NCT01328093","A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients","Schizophrenia","mental health","Drug: LY2140023|Drug: Aripiprazole","drug","Eli Lilly and Company","Both","Adult",670,"April 2011","December 2012","",3.328,"1",24156
"1070","NCT01342315","Topical Antifungal Treatment for Tinea Cruris","Tinea Cruris","other","Drug: 33525|Drug: Placebo","drug","Medicis Global Service Corporation","Both","Child|Adult|Se",483,"May 2011","May 2011","",4.375,"1",24137
"1071","NCT01358240","Safety and Efficacy of Econazole Nitrate Foam 1% and Foam Vehicle in Subjects With Tinea Pedis","Tinea Pedis|Athlete's Foot","other","Drug: Econazole Nitrate Foam 1%|Drug: Vehicle Foam|Drug: Econazole Nitrate Cream 1%|Other:","drug","AmDerma|AmDerma Pharmaceuticals, LLC","Both","Child|Adult|Se",336,"June 2011","April 2009","",3.926,"1",24112
"1072","NCT01396785","Topical Antifungal Treatment for Tinea Pedis","Tinea Pedis","other","Drug: 33525|Drug: Placebo","drug","Medicis Global Service Corporation","Both","Child|Adult|Se",321,"July 2011","July 2011","",5.459,"1",24139
"1073","NCT01396811","Topical Antifungal Treatment for Tinea Pedis","Tinea Pedis","other","Drug: 33525|Drug: Placebo","drug","Medicis Global Service Corporation","Both","Child|Adult|Se",322,"July 2011","December 2008","",3.015,"1",24108
"1074","NCT00375401","A Long-Term Study To Examine The Effects Of CP-945,598 On Weight Loss And Safety","Obesity","other","Drug: CP-945,598 Treatment A|Drug: CP-945,598 Treatment B|Drug: Placebo","drug","Pfizer","Both","Adult|Senior",2536,"October 2006","December 2012","",3.352794781,"1",24156
"1075","NCT01142089","Study to Evaluate Safety and Efficacy of Rifamycin SV Multi-Matrix System (MMX) for the Treatment of Traveler's Diarrhea (TD)","Traveler's Diarrhea","other","Drug: Placebo|Drug: Rifamycin SV MMX","drug","Salix Pharmaceuticals","Both","Adult|Senior",264,"May 2010","November 2008","",3.352794781,"1",24107
"1076","NCT00800605","Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection","Influenza","other","Biological: Vero cell-derived, trivalent, seasonal influenza vaccine|Biological: Placebo: P","biolog","Baxter Healthcare Corporation","Both","Adult",7252,"December 2008","September 2009","",3.354,"1",24117
"1077","NCT00616993","Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601-004)","Inflammation","other","Drug: Difluprednate|Other: Placebo","drug","Sirion Therapeutics, Inc.","Both","Child|Adult|Se",120,"January 2008","May 2008","",3.4316,"1",24101
"1078","NCT01221623","Study of AA4500 in the Treatment of Peyronie's Disease","Peyronie's Disease","other","Biological: AA4500","biolog","Auxilium Pharmaceuticals","Male","Adult|Senior",418,"September 2010","April 2012","",3.480756404,"1",24148
"1079","NCT00262678","Efficacy and Safety of Sublingual Fentanyl Tablets in Treatment of Breakthrough Pain in Cancer Patients.","Pain|Cancer","other","Drug: EN3267","drug","Prostrakan Pharmaceuticals","Both","Child|Adult|Se",NA,"December 2005","July 2011","",3.540083799,"1",24139
"1080","NCT01058096","Safety and Efficacy of Cariprazine for Mania","Bipolar Disorder|Mania","mental health","Drug: Cariprazine|Drug: Placebo","drug","Forest Laboratories|Gedeon Richter Ltd.","Both","Adult",323,"January 2010","February 2008","",3.540083799,"1",24098
"1081","NCT00697099","Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery","Venous Thromboembolism","cardiovascular","Drug: Semuloparin sodium|Drug: Enoxaparin sodium|Drug: Placebo","drug","Sanofi","Both","Adult|Senior",2326,"June 2008","July 2008","",3.6153,"1",24103
"1082","NCT00504127","Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Knee","Osteoarthritis","other","Drug: Naproxcinod 375 mg bid|Drug: Naproxcinod 750 mg bid|Drug: Naproxen 500 mg bid|Drug: p","drug","NicOx","Both","Adult|Senior",1020,"April 2007","August 2009","",3.615300007,"1",24116
"1083","NCT00955825","Study of Efficacy and Safety of 300 IR Sublingual Immunotherapy (SLIT) Tablets in Adult Patients With Allergic Grass Pollen Rhinoconjunctivitis","Grass Pollen-related Allergic Rhinoconjunctivitis","other","Biological: Grass pollen allergen extract|Drug: Placebo tablet","biolog","Stallergenes","Both","Adult",473,"October 2008","December 2009","",3.615300007,"1",24120
"1084","NCT00694382","Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy","Venous Thromboembolism|Cancer","cardiovascular","Drug: Semuloparin sodium|Drug: Placebo (for semuloparin)","drug","Sanofi","Both","Adult|Senior",3212,"June 2008","June 2008","",3.7151,"1",24102
"1085","NCT00715624","GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin","Diabetes Mellitus, Type 2","endocrine and metabolic","Drug: Lixisenatide (AVE0010)|Drug: Placebo|Drug: Basal Insulin|Drug: Metformin|Device: Pen","device","Sanofi","Both","Adult|Senior",496,"July 2008","October 2009","",3.719016485,"1",24118
"1086","NCT01102244","A Study to Evaluate the Clinical Efficacy and Safety of Tobradex® ST Compared to Azasite® in the Treatment of Subjects With Moderate to Severe Chronic Blepharitis","Blepharitis","other","Drug: Tobradex ST|Drug: Azasite","drug","Alcon Research","Both","Adult|Senior",122,"April 2010","June 2011","",3.719016485,"1",24138
"1087","NCT01216618","Evaluation of the Effect of the InsuPatch Device on Insulin Pharmacokinetics in Clamp Studies","Diabetes Mellitus, Insulin-Dependent","endocrine and metabolic","Device: InsuPatch","device","Insuline Medical Ltd.","Both","Adult",55,"October 2010","March 2008","",3.846126145,"1",24099
"1088","NCT00538239","Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6)","Metastatic Soft-Tissue Sarcomas|Metastatic Bone Sarco","cancer","Drug: ridaforolimus|Drug: Placebo","drug","Merck Sharp & Dohme Corp.|Ariad Pharmaceuticals","Both","Child|Adult|Se",711,"October 2007","November 2011","",3.8791,"1",24143
"1089","NCT00253968","Efficacy and Safety of Eplivanserin Treatment for Sleep Maintenance Insomnia","Sleep Initiation and Maintenance Disorders|Insomnia","mental health","Drug: eplivanserin (SR46349)|Drug: placebo","drug","Sanofi","Both","Adult|Senior",967,"November 2005","August 2009","",4.546,"1",24116
"1090","NCT00330369","DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension","Hypertension","cardiovascular","Drug: Darusentan|Drug: Darusentan Placebo","drug","Gilead Sciences","Both","Adult|Senior",352,"June 2006","December 2008","",3.875,"1",24108
"1091","NCT00391196","A 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic Patients","Obesity","other","Drug: Placebo|Drug: CP-945,598|Drug: CP-945,598 Treatment B","drug","Pfizer","Both","Adult|Senior",975,"November 2006","November 2008","",5.513,"1",24107
"1092","NCT00406419","A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Continuing Methotrexate Treatment (STAGE)","Rheumatoid Arthritis","other","Drug: methotrexate|Drug: ocrelizumab|Drug: ocrelizumab|Drug: placebo","drug","Genentech, Inc.|Roche Pharma AG","Both","Adult|Senior",1015,"December 2006","September 2011","",5.602,"1",24141
"1093","NCT00476996","A Study of Ocrelizumab Compared to Placebo in Patients With Active Rheumatoid Arthritis Who Don't Have a Response to Anti-TNF-α Therapy (SCRIPT)","Rheumatoid Arthritis","other","Drug: leflunomide|Drug: methotrexate|Drug: ocrelizumab|Drug: ocrelizumab|Drug: placebo","drug","Genentech, Inc.|Roche Pharma AG","Both","Adult|Senior",840,"May 2007","July 2010","",5.221,"1",24127
"1094","NCT00556959","Study Evaluating the Safety and Efficacy of CLONICEL® to Treat Children and Adolescents With Attention Deficit Hyperactivity Disorder (ADHD)","Attention Deficit Disorder With Hyperactivity","mental health","Drug: high dose clonidine HCl sustained release|Drug: low dose clonidine HCl sustained rele","drug","Addrenex Pharmaceuticals, Inc.","Both","Child",236,"October 2007","November 2010","",4.37,"1",24131
"1095","NCT00712673","GLP-1 Receptor Agonist Lixisenatide (Morning or Evening) in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin","Diabetes Mellitus, Type 2","endocrine and metabolic","Drug: Lixisenatide (AVE0010)|Drug: Placebo|Device: Pen auto-injector|Drug: Metformin","device","Sanofi","Both","Adult|Senior",680,"June 2008","June 2010","",4.704,"1",24126
"1096","NCT00744367","A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Plus Pioglitazone.","Diabetes Mellitus, Type 2","endocrine and metabolic","Drug: metformin|Drug: pioglitazone|Drug: placebo|Drug: taspoglutide|Drug: taspoglutide","drug","Hoffmann-La Roche","Both","Adult|Senior",326,"October 2008","February 2010","",7.417,"1",24122
"1097","NCT00744926","A Study of Taspoglutide Versus Placebo for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise.","Diabetes Mellitus, Type 2","endocrine and metabolic","Drug: placebo|Drug: taspoglutide|Drug: taspoglutide","drug","Hoffmann-La Roche","Both","Adult|Senior",373,"August 2008","January 2012","",9.293,"1",24145
"1098","NCT00763451","GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin","Diabetes Mellitus, Type 2","endocrine and metabolic","Drug: Lixisenatide (AVE0010)|Drug: Placebo|Device: Pen auto-injector|Drug: Metformin","device","Sanofi","Both","Adult|Senior",484,"September 2008","July 2009","",4.9,"1",24115
"1099","NCT00763815","GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Pioglitazone","Diabetes Mellitus Type 2","endocrine and metabolic","Drug: Lixisenatide (AVE0010)|Drug: Placebo|Device: Pen auto-injector|Drug: Pioglitazone|Dru","device","Sanofi","Both","Adult|Senior",484,"September 2008","October 2010","",6.456,"1",24130
"1100","NCT00823992","A Study of Taspoglutide Versus Placebo for the Treatment of Obese Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin Monotherapy","Diabetes Mellitus, Type 2","endocrine and metabolic","Drug: placebo|Drug: taspoglutide","drug","Hoffmann-La Roche","Both","Adult|Senior",305,"January 2009","February 2010","",8.485,"1",24122
"1101","NCT00880620","A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease","Parkinson's Disease","mental health","Drug: placebo|Drug: IPX066|Drug: IPX066|Drug: IPX066","drug","IMPAX Laboratories, Inc.","Both","Adult|Senior",381,"April 2009","May 2012","",5.439,"1",24149
"1102","NCT00958438","PREventative Study Against URate-Lowering Drug-Induced Gout Exacerbations (PRE-SURGE 2)","Gout","endocrine and metabolic","Drug: placebo|Drug: rilonacept|Drug: rilonacept","drug","Regeneron Pharmaceuticals","Both","Adult|Senior",244,"July 2009","January 2011","",4.573,"1",24133
"1103","NCT00974974","A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).","Parkinson's Disease","mental health","Drug: IPX066|Drug: regular carbidopa-levodopa","drug","IMPAX Laboratories, Inc.","Both","Adult|Senior",471,"September 2009","September 2008","",3.799,"1",24105
"1104","NCT00975286","24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine","Type 2 Diabetes Mellitus","endocrine and metabolic","Drug: Lixisenatide (AVE0010)|Drug: Placebo|Drug: Insulin glargine|Device: Pen auto-injector","device","Sanofi","Both","Adult|Senior",446,"October 2009","December 2008","",4.48,"1",24108
"1105","NCT01130493","A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066","Parkinson's Disease","mental health","Drug: IPX066|Drug: Carbidopa/Levodopa/Entacapone","drug","IMPAX Laboratories, Inc.","Both","Adult|Senior",74,"May 2010","November 2009","",2.268,"1",24119
"1106","NCT01211834","Efficacy and Safety of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis","Rheumatoid Arthritis","other","Drug: tocilizumab|Drug: DMARDs|Drug: Placebo|Drug: DMARDs","drug","JW Pharmaceutical","Both","Adult|Senior",90,"October 2009","March 2008","",4.645,"1",24099
"1107","NCT01229449","Ibuprofen/Acetaminophen Versus Nurofen Plus® and Panadeine® Extra Dental Pain Study","Post-operative Pain","other","Drug: Ibuprofen/acetaminophen|Drug: Ibuprofen/acetaminophen (higher dose)|Drug: Nurofen Plu","drug","Reckitt Benckiser LLC|Worldwide Clinical Trials Ltd.|Premier Research Group plc|ACM Laboratories|Aptuit Inc.|Clearcut Clinical Consulting","Both","Child|Adult|Se",678,"January 2009","December 2012","",7.015,"1",24156
"1108","NCT01257451","Safety and Efficacy of Galvus in Elderly Type 2 Diabetes Patients","Type 2 Diabetes Mellitus","endocrine and metabolic","Drug: Vildagliptin|Drug: Placebo","drug","Novartis Pharmaceuticals|Novartis","Both","Senior",431,"December 2010","May 2009","",4.28,"1",24113
"1109","NCT01262456","Investigation of the Superiority Effect of Orally Disintegrating Desmopressin Tablets to Placebo in Terms of Night Voids Reduction in Nocturia Adult Males Patients","Nocturia","other","Drug: Desmopressin|Drug: Desmopressin|Drug: Placebo","drug","Ferring Pharmaceuticals","Male","Adult|Senior",392,"February 2011","April 2012","",3.626,"1",24148
"1110","NCT01269463","Time Course of Response to Methylphenidate HCl ER Capsules in Children 6 to 12 Years With ADHD in Classroom Setting","Attention Deficit Hyperactivity Disorder|ADHD","mental health","Drug: Methylphenidate Hydrochloride Extended Release Capsules|Drug: Placebo","drug","Rhodes Pharmaceuticals, L.P.","Both","Child",27,"December 2010","December 2012","",3.890591886,"1",24156
"1111","NCT00541489","Efficacy and Safety Study of Naproxcinod in Subjects With Osteoarthritis of the Hip","Osteoarthritis|Osteoarthritis, Hip","other","Drug: Naproxcinod|Drug: Naproxen|Drug: Placebo","drug","NicOx","Both","Adult|Senior",800,"June 2007","June 2009","",4.083,"1",24114
"1112","NCT00643851","An Efficacy & Safety Study of BMS-512148 in Combination With Metformin Extended Release Tablets","Type 2 Diabetes","endocrine and metabolic","Drug: Dapagliflozin|Drug: Metformin XR","drug","AstraZeneca","Both","Adult|Senior",600,"June 2008","April 2011","",6.742,"1",24136
"1113","NCT00657709","Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infan","Meningococcal Disease","other","Biological: Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1)|Biological: Serogroup B m","biolog","Novartis Vaccines|Novartis","Both","Child",3630,"March 2008","February 2008","",3.92,"1",24098
"1114","NCT00809354","Long-Term Analgesic Efficacy And Safety Of Tanezumab Alone Or In Combination With Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Versus NSAIDs Alone In Patients With","Osteoarthritis|Arthritis","other","Drug: NSAID|Biological: tanezumab|Biological: tanezumab|Biological: tanezumab|Drug: NSAID|B","biolog","Pfizer","Both","Adult|Senior",2720,"February 2009","September 2011","",4.412,"1",24141
"1115","NCT00782431","Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older","Influenza","other","Biological: Vero cell derived, trivalent, seasonal influenza vaccine|Biological: Licensed e","biolog","Baxter Healthcare Corporation","Both","Adult|Senior",3195,"November 2008","December 2008","",5.5313,"1",24108
"1116","NCT00817063","Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema","Eczema","other","Drug: alitretinoin|Drug: Placebo","drug","Stiefel, a GSK Company|Basilea Pharmaceutica|GlaxoSmithKline","Both","Adult|Senior",600,"January 2009","October 2009","",5.9894,"1",24118
"1117","NCT00051129","Anecortave Acetate in Subfoveal Choroidal Neovascularization (CNV) Due to Wet Age-Related Macular Degeneration (AMD)","Macular Degeneration|Maculopathy, Age-Related|Age-Rel","cardiovascular","Drug: Anecortave Acetate 15 mg sterile suspension|Other: Anecortave Acetate Vehicle","drug","Alcon Research","Both","Adult|Senior",291,"January 2007","February 2010","",NA,"?",24122
"1118","NCT00089804","Study of LJP 394 in Lupus Patients With History of Renal Disease","Lupus Erythematosus, Systemic|Lupus Nephritis","other","Drug: abetimus sodium (LJP 394) and/or placebo solution|Drug: abetimus sodium (LJP 394)|Dru","drug","La Jolla Pharmaceutical Company","Both","Child|Adult|Se",943,"October 2004","March 2009","",NA,"?",24111
"1119","NCT00102973","TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer","Ovarian Neoplasms","cancer","Drug: TLK286 in Combination with Carboplatin|Drug: Doxorubicin HCl Liposome Injection","drug","Telik","Female","Adult|Senior",244,"December 2004","June 2012","",NA,"?",24150
"1120","NCT00109538","Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)","Myelodysplastic Syndromes|Leukemia, Myelomonocytic, C","cancer","Drug: Lonafarnib|Other: Placebo","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",47,"May 2005","October 2008","",NA,"?",24106
"1121","NCT00131391","A Study of MK0364 in Obese Patients (0364-014)","Obesity","other","Drug: Comparator: taranabant|Drug: Comparator: placebo","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",2400,"July 2005","October 2009","",NA,"?",24118
"1122","NCT00226759","Efficacy and Safety of OMS103HP in Patients Undergoing Allograft Anterior Cruciate Ligament (ACL) Reconstruction","Knee Injuries","other","Drug: OMS103HP|Drug: Vehicle","drug","Omeros Corporation","Both","Child|Adult",321,"November 2004","March 2011","",NA,"?",24135
"1123","NCT00226772","Efficacy and Safety of OMS103HP in Patients Undergoing Autograft Anterior Cruciate Ligament (ACL) Reconstruction","Knee Injuries","other","Drug: OMS103HP|Drug: Vehicle","drug","Omeros Corporation","Both","Child|Adult",326,"June 2005","October 2011","",NA,"?",24142
"1124","NCT00231296","Safety and Efficacy of CryoCor™ Cryoablation for PAF","Atrial Fibrillation","cardiovascular","Device: Cardiac cryoablation system|Drug: Medical management","device","Boston Scientific Corporation","Both","Adult|Senior",174,"November 2004","February 2012","",NA,"?",24146
"1125","NCT00286078","Treatment for Migraines With an Implantable Device","Migraine","mental health","Device: Precision","device","Boston Scientific Corporation","Both","Adult|Senior",179,"February 2006","September 2011","",NA,"?",24141
"1126","NCT00294619","Treatment of Adults With Growth Hormone Deficiency","Pituitary Disorders|Adult Growth Hormone Deficiency","endocrine and metabolic","Drug: growth hormone","drug","LG Life Sciences|BioPartners GmbH","Both","Adult|Senior",147,"April 2006","January 2008","",NA,"?",24097
"1127","NCT00299325","VIsceral Fat Reduction Assessed by CT-scan On RImonabAnt","Metabolic Syndrome","endocrine and metabolic","Drug: Rimonabant|Drug: Placebo","drug","Sanofi","Both","Adult|Senior",254,"March 2006","August 2010","",NA,"?",24128
"1128","NCT00299507","Anecortave Acetate in Patients With Exudative Age-related Macular Degeneration (AMD)","Macular Degeneration","other","Drug: Anecortave Acetate Sterile Suspension, 30 mg/mL|Drug: Anecortave Acetate Sterile Susp","drug","Alcon Research","Both","Adult|Senior",240,"March 2005","August 2012","",NA,"?",24152
"1129","NCT00305188","Evaluation of the Efficacy of Xaliproden (SR57746A) in Preventing the Neurotoxicity of Oxaliplatin / 5FU/LV Chemotherapy.","Metastases|Colorectal Neoplasms|Colorectal Carcinoma","cancer","Drug: xaliproden (SR57746A)|Drug: Placebo|Drug: oxaliplatin","drug","Sanofi","Both","Adult|Senior",879,"December 2005","July 2008","",NA,"?",24103
"1130","NCT00308685","Chronic-dose Safety and Efficacy Study of a Bronchodilator Inhaler in Pediatric Asthmatics","Asthma","respiratory","Drug: Albuterol 90mcg","drug","Teva Branded Pharmaceutical Products, R&D Inc.|Teva Pharmaceutical Industries","Both","Child",100,"July 2007","July 2011","",NA,"?",24139
"1131","NCT00322218","Study Comparing the Zevalin Regimen With no Further Treatment in DLBCL Patients Who Are in Complete Remission After CHOP-R","Lymphoma, Large Cell, Diffuse","cancer","Drug: Zevalin Therapeutic Regimen|Other: Observation","drug","CTI BioPharma|Bayer","Both","Adult|Senior",400,"May 2006","October 2009","",NA,"?",24118
"1132","NCT00325650","Rimonabant In Prediabetic Subjects To Delay Onset Of Type 2 Diabetes (RAPSODI)","Prediabetic State","endocrine and metabolic","Drug: rimonabant (SR141716)|Drug: placebo","drug","Sanofi","Both","Adult|Senior",2420,"May 2006","January 2008","",NA,"?",24097
"1133","NCT00335244","Intravenous L-Citrulline to Treat Children Undergoing Heart Bypass Surgery","Heart Defects, Congenital|Hypertension, Pulmonary","cardiovascular","Drug: L-citrulline|Drug: Placebo of intravenous L-citrulline","drug","Asklepion Pharmaceuticals, LLC|Vanderbilt University","Both","Child",77,"May 2006","June 2012","",NA,"?",24150
"1134","NCT00336713","A 24-52-week Study to Evaluate the Long-term Efficacy and Safety of Saredutant in Patients With Depression (MAGENTA)","Depressive Disorder","mental health","Drug: Saredutant (SR48968C)|Drug: Placebo","drug","Sanofi","Both","Adult|Senior",430,"May 2006","July 2008","",NA,"?",24103
"1135","NCT00355355","A Phase 3 Study of Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC)","Carcinoma, Hepatocellular|Liver Neoplasms","cancer","Drug: Talaporfin sodium|Device: Interstitial Light Emitting Diodes|Procedure: Percutaneous","device","Light Sciences Oncology","Both","Adult|Senior",208,"July 2006","August 2012","",NA,"?",24152
"1136","NCT00360243","6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NA","Sexual Dysfunctions, Psychological","mental health","Drug: flibanserin|Drug: flibanserin|Drug: flibanserin|Drug: placebo","drug","Sprout Pharmaceuticals, Inc","Female","Adult",1392,"July 2006","May 2008","",NA,"?n",24101
"1137","NCT00390533","An Eight-week Study to Evaluate the Efficacy and Safety of 2 Doses of Saredutant in Patients With Generalized Anxiety Disorder","Generalized Anxiety","mental health","Drug: Saredutant|Drug: Placebo","drug","Sanofi","Both","Adult|Senior",428,"September 2006","May 2009","",NA,"?",24113
"1138","NCT00392106","High Intensity Focused Ultrasound (HIFU) Ablation System Study","Atrial Fibrillation","cardiovascular","Drug: propafenone|Drug: flecainide|Drug: dofetilide|Drug: sotolol|Device: Pulmonary vein ab","device","ProRhythm, Inc.","Both","Adult|Senior",240,"April 2006","April 2010","",NA,"?",24124
"1139","NCT00404885","A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis","Uveitis, Anterior|Panuveitis","other","Drug: Placebo|Drug: LX211|Drug: LX211|Drug: LX211","drug","Lux Biosciences, Inc.","Both","Child|Adult|Se",108,"January 2007","August 2008","",NA,"?n",24104
"1140","NCT00415142","An Eight-week Study Evaluating the Efficacy of a 100mg Dose of Saredutant Once Daily, in Elderly Patients With Major Depressive Disorder","Depressive Disorder","mental health","Drug: saredutant (SR48968)|Drug: placebo|Drug: escitalopram","drug","Sanofi","Both","Adult",393,"December 2006","October 2009","",NA,"?",24118
"1141","NCT00417118","An Eight-week Study to Evaluate the Efficacy and Safety of Saredutant in Patients With Generalized Anxiety Disorder","Generalized Anxiety","mental health","Drug: Saredutant|Drug: Escitalopram|Drug: Placebo","drug","Sanofi","Both","Adult|Senior",365,"December 2006","April 2010","",NA,"?",24124
"1142","NCT00426985","Efficacy and Safety of Ketoprofen Topical Patch 20% in the Treatment of Pain Associated With Shoulder, Elbow or Knee Tendonitis or Bursitis","Tendonitis|Bursitis","other","Drug: Ketoprofen Topical Patch 20%","drug","Endo Pharmaceuticals","Both","Adult|Senior",330,"January 2007","August 2011","",NA,"?",24140
"1143","NCT00438867","Angiogenesis in Women With Angina Pectoris Who Are Not Candidates for Revascularization","Angina Pectoris","cardiovascular","Genetic: Ad5FGF-4|Genetic: Placebo","biolog","Cardium Therapeutics","Female","Adult|Senior",300,"May 2007","November 2012","",NA,"?",24155
"1144","NCT00440310","Phase 3 Trial of Litx™ Plus Chemotherapy vs. Chemotherapy Only Treating Colorectal Cancer Patients With Recurrent Liver Metastases","Liver Metastases|Colorectal Neoplasms|Neoplasm Metast","cancer","Drug: Talaporfin sodium|Procedure: Percutaneous placement of device in liver metastases|Dev","device","Light Sciences Oncology","Both","Adult|Senior",483,"February 2007","April 2008","",NA,"?",24100
"1145","NCT00442416","A Study of Subcutaneous Mircera for the Treatment of Anemia in Peritoneal Dialysis Patients.","Anemia","other","Drug: Epoetin alfa|Drug: methoxy polyethylene glycol-epoetin beta [Mircera]","drug","Hoffmann-La Roche","Both","Adult|Senior",80,"February 2007","September 2008","",NA,"?",24105
"1146","NCT00443690","Placebo-Controlled Randomized Study of KW-3902 for Subjects Hospitalized With Worsening Renal Function and Heart Failure Requiring IV Therapy","Heart Failure, Congestive","cardiovascular","Drug: rolofylline|Drug: Comparator: Placebo (unspecified)","drug","NovaCardia, Inc.|Merck Sharp & Dohme Corp.","Both","Adult|Senior",480,"August 2007","November 2008","",NA,"?",24107
"1147","NCT00447187","Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk","Corneal Diseases|Cornea Transplant","other","Drug: LX201|Other: Placebo","drug","Lux Biosciences, Inc.","Both","Adult|Senior",368,"April 2007","April 2011","",NA,"?n",24136
"1148","NCT00447642","Study to Assess LX201 for Prevention of Corneal Allograft Rejection or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetr","Corneal Transplantation|Corneal Graft Rejection","other","Drug: LX201|Other: Placebo","drug","Lux Biosciences, Inc.","Both","Adult|Senior",122,"April 2007","April 2008","",NA,"?n",24100
"1149","NCT00454168","Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission","Leukemia","cancer","Biological: PR1 leukemia peptide vaccine|Biological: sargramostim|Other: placebo","biolog","The Vaccine Company|National Cancer Institute (NCI)","Both","Adult|Senior",244,"May 2005","June 2011","",NA,"?",24138
"1150","NCT00459745","A Study to Evaluate Daily Pravastatin, Fenofibrate or Pravafen in the Treatment of Combined Hyperlipidemia","Combined Hyperlipidemia","cardiovascular","Drug: Pravafen (combination of Pravastatin and Fenofibrate)","drug","Shionogi Inc.|Integrium","Both","Adult|Senior",481,"April 2007","July 2012","",NA,"?",24151
"1151","NCT00461591","Trial of Single-Dose Intravesical EOquin® as a Surgical Adjuvant Instilled in the Early Postoperative Period in Patients Undergoing TUR-BT","Bladder Cancer","cancer","Drug: EOquin®","drug","Spectrum Pharmaceuticals, Inc","Both","Adult|Senior",802,"April 2007","July 2012","",NA,"?",24151
"1152","NCT00464061","Efficacy an Safety of Volinanserin on Sleep Maintenance Insomnia With a Sub-study on Stable Type II Diabetes Mellitus","Sleep Initiation and Maintenance Disorders","endocrine and metabolic","Drug: volinanserin (M100907)|Drug: placebo","drug","Sanofi","Both","Adult|Senior",1847,"April 2007","July 2008","",NA,"?",24103
"1153","NCT00464243","Efficacy and Safety of Volinanserin on Sleep Maintenance Insomnia - Polysomnographic Study","Sleep Initiation and Maintenance Disorders","mental health","Drug: volinanserin (M100907)|Drug: placebo","drug","Sanofi","Both","Adult|Senior",604,"April 2007","March 2008","",NA,"?",24099
"1154","NCT00479882","MK0524B Lipid Study (0524B-063)","Primary Hypercholesterolemia|Mixed Dyslipidemia","cardiovascular","Drug: MK0524B|Drug: niacin (+) laropiprant|Drug: Comparator: simvastatin","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",2370,"June 2007","January 2012","",NA,"?",24145
"1155","NCT00486512","Chemoprevention of Colorectal Adenomas","Adenomatous Polyps","other","Drug: aspirin, 1,25-dihydroxycholecalciferol, calcium|Drug: placebo","drug","Colotech A/S","Both","Adult|Senior",1000,"June 2007","June 2012","",NA,"?n",24150
"1156","NCT00488267","Efficacy of ThermoProfen in Patients With Mild to Moderate Pain Associated With Osteoarthritis of the Knee","Osteoarthritis","other","Drug: ThermoProfen™ (Matrix Transdermal Ketoprofen/CHADD™ System)|Drug: Placebo Matrix/","drug","ZARS Pharma Inc.","Both","Adult|Senior",679,"June 2007","November 2010","",NA,"?",24131
"1157","NCT00488839","IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis","Multiple Sclerosis","mental health","Drug: Baclofen|Drug: Baclofen|Drug: Baclofen|Drug: Placebo","drug","IMPAX Laboratories, Inc.","Both","Adult|Senior",173,"June 2007","August 2009","",NA,"?s",24116
"1158","NCT00495885","Efficacy and Safety of M100907 on Sleep Maintenance Insomnia With a Sub-study in Stable Type II Diabetes Mellitus","Sleep Initiation and Maintenance Disorders","endocrine and metabolic","Drug: volinanserin (M100907)|Drug: Placebo","drug","Sanofi","Both","Adult|Senior",848,"June 2007","January 2009","",NA,"?",24109
"1159","NCT00515320","Study of Fluoxetine in Autism","Autistic Disorder","mental health","Drug: Fluoxetine|Drug: Placebo","drug","Neuropharm|Autism Speaks","Both","Child",158,"August 2007","November 2011","",NA,"?n",24143
"1160","NCT00519142","Mitiglinide in Combination With Metformin vs. Metformin Alone in Patients With Type 2 Diabetes Mellitus","Diabetes Mellitus, Type 2","endocrine and metabolic","Drug: placebo for mitiglinide|Drug: mitiglinide|Drug: mitiglinide","drug","Elixir Pharmaceuticals","Both","Adult|Senior",367,"August 2007","June 2010","",NA,"?",24126
"1161","NCT00531622","An Eight-Week Study of Saredutant and Escitalopram as Combination Treatment for Major Depressive Disorder","Major Depressive Disorder","mental health","Drug: saredutant (SR48968)|Drug: escitalopram|Drug: placebo","drug","Sanofi","Both","Adult",615,"September 2007","December 2008","",NA,"?",24108
"1162","NCT00532311","Efficacy of Lapaquistat Acetate Co-Administered With Statins in Subjects With Hypercholesterolemia","Hypercholesterolemia","cardiovascular","Drug: Lapaquistat acetate and stable statin therapy|Drug: Stable statin therapy","drug","Takeda","Both","Adult|Senior",411,"July 2007","September 2008","",NA,"?",24105
"1163","NCT00542685","A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder","Generalized Anxiety Disorder","mental health","Drug: PD 0332334|Drug: Placebo|Drug: PD 0332334|Drug: PD 0332334","drug","Pfizer","Both","Adult",551,"October 2007","July 2012","",NA,"?",24151
"1164","NCT00543374","Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease","Crohn's Disease","other","Drug: Placebo|Drug: PROCHYMAL adult human mesenchymal stem cells","drug","Mesoblast International Sàrl|Mesoblast, Ltd.","Both","Adult|Senior",98,"October 2007","May 2008","",NA,"?",24101
"1165","NCT00546507","Study Evaluating the Efficacy and Safety of Topical Diclofenac Spray in Osteoarthritis of the Knee: Trial I","Osteoarthritis","other","Drug: TDS-943 (topical diclofenac sodium 4% spray)|Drug: celecoxib|Other: placebo","drug","Mika Pharma GmbH","Both","Adult|Senior",650,"October 2007","November 2011","",NA,"?",24143
"1166","NCT00546780","A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse","Multiple Myeloma","cancer","Drug: Tanespimycin|Drug: Bortezomib","drug","Bristol-Myers Squibb","Both","Adult|Senior",31,"February 2008","January 2008","",NA,"?",24097
"1167","NCT00546832","Study Evaluating the Efficacy and Safety of Topical Diclofenac Spray in Osteoarthritis of the Knee: Trial II","Osteoarthritis","other","Drug: TDS-943 (topical diclofenac sodium 4% spray)|Drug: celecoxib|Other: placebo","drug","Mika Pharma GmbH","Both","Adult|Senior",650,"October 2007","April 2010","",NA,"?",24124
"1168","NCT00562497","Efficacy and Safety of Prochymal™ Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute GVHD","Graft Versus Host Disease","other","Drug: Prochymal|Other: Placebo","drug","Mesoblast International Sàrl|Mesoblast, Ltd.","Both","Adult|Senior",184,"September 2007","November 2011","",NA,"?n",24143
"1169","NCT00564421","Safety and Efficacy Study of Epinastine Nasal Spray in Subjects With Seasonal Allergic Rhinitis","Seasonal Allergic Rhinitis","other","Drug: epinastine nasal spray, low concentration, low dose volume|Drug: placebo nasal spray|","drug","Merck Sharp & Dohme Corp.","Both","Child|Adult|Se",798,"November 2007","December 2008","",NA,"?n",24108
"1170","NCT00566345","Efficacy Study of an Investigational Influenza Vaccine (Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection (CCII)","Influenza","other","Biological: Inactivated seasonal influenza vaccine (split virus, Vero cell-derived)|Biologi","biolog","Baxter Healthcare Corporation","Both","Adult",3670,"November 2007","May 2009","",NA,"?",24113
"1171","NCT00577161","Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL","Non-Hodgkin's Lymphoma","cancer","Drug: fludarabine and rituximab|Drug: fludarabine, rituximab, pixantrone","drug","CTI BioPharma","Both","Adult|Senior",300,"September 2007","April 2008","",NA,"?",24100
"1172","NCT00578474","A Phase III Study of an Otic Formulation in Acute Otitis Media With Tympanostomy Tubes","Acute Otitis Media","other","Drug: Moxidex otic solution|Drug: Ofloxacin otic solution|Device: Tympanostomy tubes","device","Alcon Research","Both","Child",911,"December 2005","February 2010","",NA,"?",24122
"1173","NCT00579189","Phase III Study of an Otic Formulation in Acute Otitis Media With Tympanostomy Tubes","Acute Otitis Media","other","Drug: Moxidex otic solution|Drug: Moxifloxacin otic solution|Device: Tympanostomy tubes","device","Alcon Research","Both","Child",776,"January 2006","July 2012","",NA,"?",24151
"1174","NCT00596583","DY001: Safety and Effectiveness of DYME as an Agent for Selective Staining of the Anterior Capsule During Cataract Surgery","Mature Cataracts","other","Drug: DYME|Drug: DYME","drug","Aqumen Biopharmaceuticals, N.A.","Both","Adult|Senior",300,"April 2007","July 2012","",NA,"?",24151
"1175","NCT00598806","Phase 3 Trial of Single-Dose Intravesical EOquin® as a Surgical Adjuvant for Noninvasive Bladder Cancer","Bladder Cancer","cancer","Drug: EOquin® (Apaziquone)","drug","Spectrum Pharmaceuticals, Inc","Both","Adult|Senior",813,"September 2007","June 2011","",NA,"?",24138
"1176","NCT00600288","Study of the Effect of Diquafosol Tetrasodium Ophthalmic Solution, 2% Versus Placebo in Dry Eye Subjects (P08634)","Dry Eye Disease","other","Drug: diquafosol tetrasodium Ophthalmic Solution, 2%|Drug: Non-preserved saline solution (P","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",261,"January 2008","July 2012","",NA,"?",24151
"1177","NCT00603577","Role of Xaliproden on Recovery Rate From Severe Neuropathy in Patients Who Have Completed Adjuvant Chemotherapy With Oxaliplatin Based Regimens","Colorectal Neoplasms","mental health","Drug: placebo|Drug: xaliproden","drug","Sanofi","Both","Adult|Senior",102,"January 2008","January 2012","",NA,"?",24145
"1178","NCT00616070","Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601-003)","Inflammation","other","Drug: Difluprednate|Other: Placebo","drug","Sirion Therapeutics, Inc.","Both","Child|Adult|Se",120,"December 2007","November 2011","",NA,"?",24143
"1179","NCT00618098","Study of OCTAPLEX and FFP in Patients Under Vit K Therapy Antagonist Needing Urgent Surgery or Invasive Procedures","Reversal of Anticoagulant Treatment","cardiovascular","Drug: prothrombin complex concentrate|Biological: Fresh Frozen Plasma","biolog","Octapharma","Both","Adult|Senior",200,"April 2008","February 2012","",NA,"?",24146
"1180","NCT00629551","An Eight-Week Study of Saredutant and Paroxetine as Combination Treatment for Major Depressive Disorder","Depressive Disorder, Major","mental health","Drug: saredutant (SR48968)|Drug: paroxetine|Drug: placebo","drug","Sanofi","Both","Adult",820,"February 2008","May 2008","",NA,"?",24101
"1181","NCT00631111","Study Evaluating the Efficacy of an Ibuprofen Effervescent Tablet in the Treatment of Post-Surgical Dental Pain","Pain","other","Drug: effervescent ibuprofen tablets|Drug: effervescent Aspirin plus Vitamin C tablets|Drug","drug","Wyeth is now a wholly owned subsidiary of Pfizer","Both","Child|Adult",270,"November 2007","December 2010","",NA,"?",24132
"1182","NCT00636480","Preoperative Skin Preparation Evaluation","Topical Antisepsis","other","Drug: Chlorhexidine gluconate|Drug: ChloraPrep One Step|Drug: Sterile saline","drug","CareFusion","Both","Child|Adult|Se",60,"October 2007","September 2009","",NA,"?",24117
"1183","NCT00655291","Efficacy of XP20B Following Bunionectomy Surgery","Acute Pain","other","Drug: XP20B|Drug: Placebo","drug","Xanodyne Pharmaceuticals","Both","Adult",190,"April 2008","April 2012","",NA,"?",24148
"1184","NCT00658008","A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)","Generalized Anxiety Disorder","mental health","Drug: PD 0332334|Drug: PD 0332334|Drug: PD 0332334|Drug: Paroxetine|Drug: Placebo","drug","Pfizer","Both","Adult",501,"April 2008","December 2011","",NA,"?",24144
"1185","NCT00658372","A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)","Generalized Anxiety Disorder","mental health","Drug: PD 0332334|Drug: PD 0332334|Drug: Paroxetine|Drug: Placebo","drug","Pfizer","Both","Adult",360,"May 2008","January 2008","",NA,"?",24097
"1186","NCT00658632","Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Mild to Moderate Erosive Gastroesophageal Reflux Disease (GERD)","Gastroesophageal Reflux Disease (GERD)","other","Drug: Rabeprazole sodium|Drug: Esomeprazole","drug","Eisai Inc.","Both","Adult|Senior",1320,"February 2008","September 2011","",NA,"?",24141
"1187","NCT00658762","A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)","Generalized Anxiety Disorder","mental health","Drug: PD 0332334|Drug: PD 0332334|Drug: paroxetine|Drug: Placebo","drug","Pfizer","Both","Adult",286,"May 2008","March 2010","",NA,"?",24123
"1188","NCT00661245","Transoral Gastroplasty for the Treatment of Morbid Obesity","Obesity","other","Device: TOGA|Device: Control","device","Satiety, Inc.","Both","Adult",275,"July 2008","October 2012","",NA,"?",24154
"1189","NCT00673920","A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy","Rheumatoid Arthritis","other","Drug: methotrexate|Drug: ocrelizumab|Drug: placebo","drug","Genentech, Inc.|Roche Pharma AG","Both","Adult|Senior",314,"April 2008","February 2008","",NA,"?",24098
"1190","NCT00680472","HKT-500 in Adult Patients With Shoulder Pain","Pain","other","Drug: HKT-500 & Ketoprofen Topical Patch|Drug: placebo","drug","Hisamitsu Pharmaceutical Co., Inc.","Both","Adult|Senior",368,"April 2008","February 2009","",NA,"?",24110
"1191","NCT00680784","HKT-500 in Adult Patients With Ankle Sprain","Ankle Sprain","other","Drug: HKT-500 & Ketoprofen Topical Patch|Drug: placebo","drug","Hisamitsu Pharmaceutical Co., Inc.","Both","Adult|Senior",260,"April 2008","January 2008","",NA,"?",24097
"1192","NCT00685113","A Clinical Trial to Evaluate the Efficacy and Safety of DR-3001 in Women With Overactive Bladder","Overactive Bladder","other","Drug: DR-3001|Drug: DR-3001|Drug: Placebo","drug","Duramed Research|Teva Pharmaceutical Industries","Female","Adult|Senior",1104,"May 2008","March 2009","",NA,"?",24111
"1193","NCT00688376","Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment","Attention Impairment","mental health","Drug: Donepezil hydrochloride|Drug: Placebo","drug","Eisai Inc.|Eisai Limited","Both","Child",300,"August 2008","July 2008","",NA,"?",24103
"1194","NCT00698581","A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onse","Epilepsy","mental health","Drug: Brivaracetam|Drug: Brivaracetam","drug","UCB Pharma","Both","Child|Adult|Se",88,"August 2008","November 2008","",NA,"?n",24107
"1195","NCT00699283","A Double-blind, Randomized Conversion to Monotherapy Study to Evaluate the Efficacy and Safety of Brivaracetam in Subjects (≥ 16 to 75 Years Old) With Partial Onse","Epilepsy","mental health","Drug: Brivaracetam|Drug: Brivaracetam","drug","UCB Pharma","Both","Child|Adult|Se",62,"August 2008","January 2012","",NA,"?n",24145
"1196","NCT00718965","Evaluation of Efficacy and Safety of AVE5530 in Patients With Primary Hypercholesterolemia","Hypercholesterolemia","cardiovascular","Drug: AVE5530|Drug: Placebo","drug","Sanofi","Both","Adult|Senior",826,"July 2008","October 2008","",NA,"?n",24106
"1197","NCT00729027","Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing Statins in Patients With Primary Hypercholesterolemia","Hypercholesterolemia","cardiovascular","Drug: AVE5530|Drug: AVE5530|Drug: placebo","drug","Sanofi","Both","Adult|Senior",1015,"July 2008","February 2008","",NA,"?",24098
"1198","NCT00738699","An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer","Ovarian Cancer","cancer","Drug: MORAb-003 (farletuzumab)|Drug: 0.9% Saline","drug","Morphotek","Female","Adult|Senior",417,"September 2008","November 2012","",NA,"?",24155
"1199","NCT00741715","Evaluation of Efficacy and Safety of AVE5530 Co-administered With Atorvastatin in Primary Hypercholesterolemia","Hypercholesterolemia","cardiovascular","Drug: AVE5530|Drug: atorvastatin|Drug: placebo","drug","Sanofi","Both","Adult|Senior",1736,"August 2008","May 2012","",NA,"?",24149
"1200","NCT00748124","PleuraSeal Pivotal Study (US)","Open Thoracotomy","other","Device: PleuraSeal Sealant System|Procedure: Standard Tissue Closure Techniques","device","Integra LifeSciences Corporation","Both","Adult|Senior",230,"August 2008","June 2012","",NA,"?",24150
"1201","NCT00750633","A Phase III Study of an Otic Formulation in Acute Otitis Externa","Acute Otitis Externa","other","Drug: Moxidex otic solution|Drug: Moxifloxacin otic solution|Drug: Dexamethasone phosphate","drug","Alcon Research","Both","Child|Adult|Se",990,"June 2008","May 2010","",NA,"?",24125
"1202","NCT00752050","Safety and Efficacy Study of Repeat Treatment With PurTox® Botulinum Toxin Type A for Frown Lines Between the Eyebrows","Glabellar Rhytides|Frown Lines Between the Eyebrows","other","Drug: Mentor Purified Toxin Botulinum Toxin Type A|Drug: Preservative-free Saline","drug","Mentor Worldwide, LLC|Synteract, Inc.","Both","Adult|Senior",699,"November 2007","February 2008","",NA,"?",24098
"1203","NCT00752297","Safety and Efficacy Study of PurTox® Botulinum Toxin Type A to Treat Frown Lines Between the Eyebrows","Glabellar Rhytides","other","Drug: Preservative-free Saline|Drug: Mentor Purified Toxin","drug","Mentor Worldwide, LLC|Quintiles","Both","Adult|Senior",402,"June 2007","March 2012","",NA,"?",24147
"1204","NCT00755781","Study of Cyclosporine Inhalation Solution (CIS) in Improving Bronchiolitis Obliterans Syndrome-Free Survival Following Lung Transplantation","Lung Transplant","respiratory","Drug: Cyclosporine Inhalation Solution (CIS)","drug","APT Pharmaceuticals, Inc.","Both","Adult|Senior",284,"September 2008","July 2008","",NA,"?",24103
"1205","NCT00766688","Evaluation of Safety and Efficacy of AVE5530 as add-on to Ongoing High Doses of Statins in Patients With Primary Severe Hypercholesterolemia","Hypercholesterolemia","cardiovascular","Drug: AVE5530|Drug: Placebo","drug","Sanofi","Both","Adult|Senior",643,"October 2008","February 2012","",NA,"?",24146
"1206","NCT00769886","Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Allergic Conjunctivitis.","Allergic Conjunctivitis","other","Drug: Ketotifen/naphazoline|Drug: Ketotifen|Drug: Naphazoline|Drug: Vehicle","drug","Bausch & Lomb Incorporated","Both","Child|Adult|Se",144,"October 2008","December 2011","",NA,"?",24144
"1207","NCT00770133","Ketotifen/Naphazoline Ophthalmic Solution in the Conjunctival Allergen Challenge Model of Acute Allergic Conjunctivitis.","Allergic Conjunctivitis","other","Drug: Ketotifen/naphazoline|Drug: Naphazoline|Drug: Ketotifen|Drug: Vehicle","drug","Bausch & Lomb Incorporated","Both","Child|Adult|Se",133,"February 2010","February 2009","",NA,"?",24110
"1208","NCT00773279","Efficacy, Safety and Preference Study of a Insulin Pen PDS290 vs. a Novo Nordisk Marketed Insulin Pen in Diabetics","Diabetes|Diabetes Mellitus, Type 1|Diabetes Mellitus,","endocrine and metabolic","Device: FlexTouch®|Device: FlexPen®","device","Novo Nordisk A/S","Both","Adult|Senior",242,"September 2008","March 2009","",NA,"?",24111
"1209","NCT00792727","HKT-500 in Adult Patients With Osteoarthritis (OA) Knee Pain","Osteoarthritis of the Knee","other","Drug: ketaprofen","drug","Hisamitsu Pharmaceutical Co., Inc.","Both","Adult|Senior",380,"September 2007","December 2012","",NA,"?",24156
"1210","NCT00801723","(CB-01-02/04) Extension Study of Budesonide Multi-Matrix System (MMX) 6 mg in Maintenance Of Remission In Patients With Ulcerative Colitis.","Ulcerative Colitis","other","Drug: Budesonide MMX 6 mg Tablet|Drug: Placebo Tablet","drug","Salix Pharmaceuticals","Both","Adult|Senior",123,"December 2008","December 2011","",NA,"?n",24144
"1211","NCT00836199","NicVAX/Placebo as an Aid for Smoking Cessation","Smoking Cessation|Smoking|Tobacco Cessation","other","Biological: NicVAX vaccine|Biological: Placebo vaccine","biolog","Nabi Biopharmaceuticals|National Institute on Drug Abuse (NIDA)","Both","Adult",1000,"October 2009","March 2011","",NA,"?n",24135
"1212","NCT00838526","Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)","Gastroesophageal Reflux Disease (GERD)","other","Drug: Rabeprazole ER|Drug: Ranitidine","drug","Eisai Inc.","Both","Adult|Senior",240,"August 2008","June 2008","",NA,"?",24102
"1213","NCT00839306","Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)","Gastroesophageal Reflux Disease (GERD)","other","Drug: Rabeprazole ER|Drug: Ranitidine","drug","Eisai Inc.","Both","Adult|Senior",240,"August 2008","November 2010","",NA,"?",24131
"1214","NCT00841126","Phase III Study to Investigate the Safety and Efficacy of Fermagate and Lanthanum Carbonate","Chronic Kidney Failure","other","Drug: Magnesium iron hydroxycarbonate|Drug: Lanthanum carbonate|Drug: Placebo","drug","Ineos Healthcare Limited","Both","Adult|Senior",657,"July 2009","June 2012","",NA,"?",24150
"1215","NCT00844662","Phase III Study to Investigate the Safety and Efficacy of Fermagate and Sevelamer Hydrochloride","Chronic Kidney Failure","other","Drug: Fermagate|Drug: Sevelamer hydrochloride","drug","Ineos Healthcare Limited","Both","Adult|Senior",1000,"July 2009","April 2008","",NA,"?",24100
"1216","NCT00849667","Efficacy and Safety of MORAb-003 in Subjects With Platinum-sensitive Ovarian Cancer in First Relapse","Ovarian Cancer","cancer","Drug: MORAb-003 (farletuzumab)|Drug: MORAb-003 (farletuzumab)|Drug: 0.9% Saline","drug","Morphotek","Female","Adult|Senior",1100,"April 2009","December 2010","",NA,"?n",24132
"1217","NCT00850239","Safety and Efficacy Study of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin","Type 2 Diabetes Mellitus","endocrine and metabolic","Drug: dutogliptin|Drug: placebo","drug","Phenomix|Forest Laboratories","Both","Adult|Senior",700,"May 2009","October 2008","",NA,"?",24106
"1218","NCT00865280","Study the Safety and Efficacy of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)","Skin Diseases, Infectious","other","Drug: PTK 0796|Drug: linezolid","drug","Paratek Pharmaceuticals Inc|Novartis Pharmaceuticals","Both","Adult|Senior",143,"March 2009","July 2008","",NA,"?",24103
"1219","NCT00865488","Evaluation of Adhexil Safety and Efficacy in Prevention and/or Reduction of Adhesions in Gynecological Surgery","Ovarian Cysts|Endometriosis|Adhesions","other","Biological: ADHEXIL","biolog","OMRIX Biopharmaceuticals","Female","Adult",80,"May 2009","March 2009","",NA,"?",24111
"1220","NCT00869063","Diclofenac Patch for the Treatment of Acute Pain Due to Mild to Moderate Wrist Sprain, Strain or Contusion","Acute Pain","other","Drug: Diclofenac Sodium Patch|Drug: Matching Placebo Patch","drug","Cerimon Pharmaceuticals|PPD","Both","Child|Adult|Se",214,"February 2009","October 2010","",NA,"?",24130
"1221","NCT00869180","Diclofenac Patch for Treatment of Acute Pain Due to Mild to Moderate Ankle Sprain","Acute Pain|Ankle Sprain","other","Drug: Diclofenac Sodium|Drug: Matching Placebo Patch","drug","Cerimon Pharmaceuticals|PPD","Both","Child|Adult|Se",219,"February 2009","June 2009","",NA,"?",24114
"1222","NCT00877279","Multicenter Study of the Safety and Efficacy of Dermal Filler, Belotero® Soft","Facial Wrinkles","other","Device: CosmoDerm1|Device: Belotero Soft","device","Merz Pharmaceuticals, LLC","Both","Adult|Senior",64,"November 2007","January 2008","",NA,"?",24097
"1223","NCT00881452","A Trial of CM-AT in Children With Autism","Autism","mental health","Drug: CM-AT|Drug: Placebo","drug","Curemark","Both","Child",182,"May 2009","December 2010","",NA,"?s",24132
"1224","NCT00893113","An Efficacy Study to Evaluate Alfuzosin to Treat Men With Erectile Dysfunction and Mild Lower Urinary Tract Symptoms","Erectile Dysfunction|Lower Urinary Tract Symptoms","other","Drug: Alfuzosin|Drug: Alfuzosin","drug","Chesapeake Urology Research Associates|Sanofi","Male","Adult|Senior",55,"June 2009","October 2009","",NA,"?",24118
"1225","NCT00911534","Comparing the Efficacy, Safety, and Tolerability of Rabeprazole ER 50 mg With Placebo in Subjects With Symptomatic Gastroesophageal Reflux Disease (sGERD)","Symptomatic Gastroesophageal Reflux Disease (sGERD)","other","Drug: rabeprazole sodium|Drug: Placebo","drug","Eisai Inc.","Both","Adult|Senior",304,"January 2009","August 2010","",NA,"?",24128
"1226","NCT00920582","Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus","Type 1 Diabetes Mellitus","endocrine and metabolic","Drug: Teplizumab (MGA031)|Drug: Placebo","drug","MacroGenics|Eli Lilly and Company","Both","Child|Adult",254,"September 2009","August 2008","",NA,"?",24104
"1227","NCT00927641","HKT-500 in the Treatment of Adult Patients With Ankle Sprain","Ankle Sprain","other","Drug: ketoprofen|Other: Placebo","drug","Hisamitsu Pharmaceutical Co., Inc.","Both","Adult|Senior",240,"July 2009","January 2008","",NA,"?",24097
"1228","NCT00930436","Evaluation of Sodium Bicarbonate to Reduce the Incidence of Contrast Induced Chronic Kidney Injury in Patients With Kidney Disease","Contrast Induced Kidney Injury.","other","Drug: sodium bicarbonate","drug","MD Scientific","Both","Adult|Senior",391,"January 2010","April 2008","",NA,"?",24100
"1229","NCT00931866","Diclofenac Patch for Treatment of Acute Pain Due to Mild to Moderate Soft Tissue Injuries (TAPED)","Acute Pain|Soft Tissue Injury","mental health","Drug: Diclofenac Sodium|Drug: Matching Placebo Patch","drug","Cerimon Pharmaceuticals|PPD","Both","Adult|Senior",407,"April 2009","January 2012","",NA,"?",24145
"1230","NCT00934427","Study of a Topical Formulation for the Treatment and Prevention of Raynaud's Phenomenon Symptoms","Raynaud Disease","cardiovascular","Drug: 0.9% nitroglycerin in TAM cream|Drug: vehicle cream","drug","MediQuest Therapeutics","Both","Adult|Senior",100,"June 2009","April 2011","",NA,"?",24136
"1231","NCT00937378","Treatment of Patients With Nocturia (Non-PK Study)","Nocturia","other","Drug: SER120|Drug: Placebo","drug","Serenity Pharmaceuticals, Inc.","Both","Adult|Senior",326,"June 2009","November 2009","",NA,"?",24119
"1232","NCT00937859","Treatment of Patients With Nocturia","Nocturia","other","Drug: SER120|Drug: Placebo","drug","Serenity Pharmaceuticals, Inc.","Both","Adult|Senior",301,"June 2009","June 2010","",NA,"?",24126
"1233","NCT00939237","Trial of Lycopene/Ateronon for Secondary Prevention of Coronary Heart Disease","Coronary Heart Disease","cardiovascular","Drug: Ateronon|Drug: Placebo","drug","Brigham and Women's Hospital|CamNutra Ltd.|Cambridge Theranostics Ltd","Both","Adult|Senior",213,"July 2009","September 2012","",NA,"?",24153
"1234","NCT00939900","Efficacy of Zoledronic Acid in Preventing Collapse of the Osteonecrotic Femoral Head","Avascular Necrosis of Femoral Head","other","Drug: zoledronic acid (aclasta)","drug","Seoul National University Bundang Hospital|Novartis Korea Ltd.","Both","Adult",110,"July 2009","January 2010","",NA,"?",24121
"1235","NCT00947557","Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Glimepiride With or Without Metformin","Diabetes Mellitus, Type II","endocrine and metabolic","Drug: Dutogliptin|Drug: Placebo","drug","Forest Laboratories|Phenomix","Both","Adult|Senior",677,"July 2009","April 2009","",NA,"?",24112
"1236","NCT00954590","A Safety and Efficacy Study Evaluating Dimebon (Latrepirdine) in Patients With Moderate to Severe Alzheimer's Disease","Moderate to Severe Alzheimer","mental health","Drug: Dimebon (latrepirdine)|Drug: Placebo","drug","Medivation, Inc.|Pfizer","Both","Adult|Senior",89,"October 2009","May 2010","",NA,"?",24125
"1237","NCT00955799","Efficacy, Safety, Tolerability of Neramexane in Patients With Subjective Tinnitus","Subjective Tinnitus","mental health","Drug: Neramexane mesylate|Drug: Placebo","drug","Merz Pharmaceuticals GmbH","Both","Adult|Senior",455,"September 2009","November 2010","",NA,"?",24131
"1238","NCT00961675","FST-201 in the Treatment of Acute Otitis Externa","Acute Otitis Externa","other","Drug: FST201 (dexamethasone 0.1% with povidone-iodine 1%)|Drug: Ciprodex (Ciprofloxacin 0.3","drug","Foresight Biotherapeutics","Male","Adult|Senior",70,"August 2009","December 2010","",NA,"?",24132
"1239","NCT00970424","Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Pioglitazone","Diabetes Mellitus, Type II","endocrine and metabolic","Drug: Placebo|Drug: Dutogliptin","drug","Forest Laboratories|Phenomix","Both","Adult|Senior",252,"August 2009","March 2011","",NA,"?",24135
"1240","NCT00987272","Study of Olopatadine HCl Ophthalmic Solutions Compared to Vehicle Using the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis in Japanese","Allergic Conjunctivitis","other","Drug: Olopatadine Hydrochloride Ophthalmic Solution, 0.2%|Drug: Olopatadine Hydrochloride O","drug","Alcon Research","Both","Adult|Senior",267,"October 2009","December 2011","",NA,"?",24144
"1241","NCT00989001","A Phase 3b Study of Vernakalant Injection in Patients With Recent Onset Symptomatic Atrial Fibrillation (AF)(MK-6621-045)","Atrial Fibrillation","cardiovascular","Drug: Vernakalant|Drug: Placebo","drug","Cardiome Pharma","Both","Adult|Senior",217,"October 2009","October 2012","",NA,"?",24154
"1242","NCT01016262","Efficacy and Safety Study of MAX-002 Suppository Versus Placebo in Mild to Moderate Ulcerative Proctitis","Ulcerative Proctitis","other","Drug: MAX-002|Drug: Placebo|Drug: Canasa®","drug","Axcan Pharma","Both","Adult|Senior",549,"September 2009","March 2012","",NA,"?",24147
"1243","NCT01018173","A Study of Taspoglutide in Patients With Inadequately Controlled Diabetes Mellitus Type 2 and Cardiovascular Disease","Diabetes Mellitus, Type 2","cardiovascular","Drug: placebo|Drug: taspoglutide","drug","Hoffmann-La Roche","Both","Adult|Senior",2118,"January 2010","April 2012","",NA,"?",24148
"1244","NCT01059682","A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease","Cardiovascular Disease","cardiovascular","Drug: dalcetrapib|Drug: Placebo","drug","Hoffmann-La Roche","Both","Adult|Senior",936,"January 2010","January 2012","",NA,"?",24145
"1245","NCT01064024","Evaluate the Safety and Efficacy of Phenazopyridine Hydrochloride Tablets, USP 200 mg vs. Placebo","Pain|Urinary Tract Infections","other","Drug: Phenazopyridine Hydrochloride|Drug: Placebo","drug","Amneal Pharmaceuticals, LLC|Oxford Pharmaceutical Resources, Inc.|Sristek Clinical Research|Biostudy Solutions, LLC","Female","Adult|Senior",233,"December 2009","January 2012","",NA,"?",24145
"1246","NCT01071902","Safety and Efficacy of Moxidex Otic","Acute Otitis Media","other","Drug: Moxidex otic solution|Drug: Moxifloxacin otic solution|Other: Vehicle|Device: Tympano","device","Alcon Research","Both","Child",400,"February 2010","January 2009","",NA,"?",24109
"1247","NCT01102114","A Second Study of NicVAX/Placebo as an Aid for Smoking Cessation","Smoking Cessation","other","Biological: NicVAX Vaccine|Biological: Placebo Vaccine","biolog","Nabi Biopharmaceuticals","Both","Adult",1000,"March 2010","June 2012","",NA,"?n",24150
"1248","NCT01145807","TDT 067 Onychomycosis Study","Onychomycosis","other","Drug: TDT067|Drug: Placebo|Drug: Transfersome","drug","Celtic Pharma Development Services|PPD","Both","Adult|Senior",738,"April 2010","May 2009","",NA,"?",24113
"1249","NCT01161615","MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Tendonitis and Bursitis of the Shoulder","Acute Tendonitis|Bursitis","other","Drug: MRX-7EAT","drug","IL Pharma Inc.|MEDRx Co., Ltd.","Both","Child|Adult|Se",350,"July 2010","March 2008","",NA,"?",24099
"1250","NCT01180634","MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis","Cystic Fibrosis","respiratory","Drug: MP-376 (Levofloxacin solution for Inhalation)|Drug: Placebo","drug","Mpex Pharmaceuticals|Aptalis Pharma","Both","Child|Adult|Se",330,"November 2010","March 2012","",NA,"?n",24147
"1251","NCT01188564","Efficacy, Safety and Immunogenicity Study of Recombinant Human C1 Inhibitor for the Treatment of Acute HAE Attacks","Hereditary Angioedema","cardiovascular","Drug: rhC1INH|Drug: Placebo (Saline)","drug","Pharming Technologies B.V.","Both","Child|Adult|Se",75,"January 2011","December 2008","",NA,"?",24108
"1252","NCT01198002","A Rheumatoid Arthritis Study in Patients on a Background Treatment of Methotrexate","Rheumatoid Arthritis","other","Drug: LY2127399|Drug: Placebo every 2 weeks|Drug: Placebo every 4 weeks","drug","Eli Lilly and Company","Both","Adult|Senior",990,"December 2010","July 2011","",NA,"?n",24139
"1253","NCT01198834","MRX-7EAT Etodolac-Lidocaine Topical Patch in the Treatment of Ankle Sprains","Ankle Sprains","other","Drug: MRX-7EAT|Drug: Placebo|Drug: Lidocaine|Drug: Etodolac","drug","IL Pharma Inc.|MEDRx Co., Ltd.","Both","Child|Adult|Se",600,"September 2010","June 2009","",NA,"?",24114
"1254","NCT01202760","A Rheumatoid Arthritis Study in Patients","Rheumatoid Arthritis","other","Drug: LY2127399|Drug: Placebo every 4 weeks|Drug: Placebo every 2 weeks","drug","Eli Lilly and Company","Both","Adult|Senior",1002,"January 2011","December 2008","",NA,"?n",24108
"1255","NCT01205048","Emervel Classic Lidocaine Versus Juvederm® Ultra in Treatment of Moderate to Severe Facial Wrinkles and Folds","Skin Wrinkling","other","Device: Emervel Classic Lidocaine|Device: Juvederm® Ultra","device","Galderma","Both","Adult|Senior",171,"September 2010","August 2009","",NA,"?",24116
"1256","NCT01205061","Emervel Deep Lidocaine vs. Juvederm® Ultra Plus in Treatment of Moderate to Severe Facial Wrinkles and Folds","Skin Wrinkling","other","Device: Emervel Deep Lidocaine|Device: Juvederm® Ultra Plus","device","Galderma","Both","Adult|Senior",162,"September 2010","November 2010","",NA,"?",24131
"1257","NCT01212471","A Dose Ranging Study to Evaluate Safety and Efficacy of Bromfenac Ophthalmic Solution in Dry Eye Disease","Dry Eye Syndrome","other","Drug: Bromfenac Ophthalmic Solution A|Drug: Bromfenac Ophthalmic Solution B|Drug: Placebo C","drug","Bausch & Lomb Incorporated","Both","Adult|Senior",840,"September 2010","February 2011","",NA,"?",24134
"1258","NCT01230125","Mapracorat Ophthalmic Suspension for the Treatment of Ocular Inflammation Following Cataract Surgery","Cataract","other","Drug: Mapracorat|Drug: Vehicle","drug","Bausch & Lomb Incorporated","Both","Adult|Senior",250,"November 2010","June 2010","",NA,"?",24126
"1259","NCT01235754","Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)","Hypoactive Sexual Desire Disorder","mental health","Drug: transdermal testosterone gel 1%|Drug: placebo gel","drug","BioSante Pharmaceuticals","Female","Adult|Senior",626,"October 2010","June 2011","",NA,"?",24138
"1260","NCT01243983","Efficacy and Safety of Voclosporin to Treat Active Noninfectious Uveitis","Noninfectious Uveitis","other","Drug: LX211","drug","Lux Biosciences, Inc.","Both","Adult|Senior",155,"February 2011","October 2010","",NA,"?",24130
"1261","NCT01256450","Efficacy and Safety Study of BEMA Buprenorphine in Subjects With Low Back Pain","Pain|Low Back Pain","other","Drug: BEMA Buprenorphine|Drug: BEMA Placebo","drug","Endo Pharmaceuticals","Both","Adult|Senior",334,"December 2010","January 2008","",NA,"?n",24097
"1262","NCT01266161","Multiple Dose Dental Pain Study Of Ibuprofen Extended Release","Pain","other","Drug: Ibuprofen 600 mg ER|Drug: Placebo","drug","Pfizer","Both","Child|Adult",139,"November 2010","January 2009","",NA,"?",24109
"1263","NCT01280331","Comparison of the Safety of Q8003 Versus Morphine Equivalent Doses of Its Components (Oxycodone and Morphine) in Bunionectomy Patients","Postoperative Pain","other","Drug: Q8003 (morphine sulfate and oxycodone hydrochloride)|Drug: Morphine sulfate|Drug: Oxy","drug","QRxPharma Inc.","Both","Adult|Senior",375,"January 2011","December 2008","",NA,"?n",24108
"1264","NCT01282268","Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome","Fragile X Syndrome","mental health","Drug: arbaclofen|Drug: placebo","drug","Seaside Therapeutics, Inc.","Both","Child|Adult",125,"May 2011","September 2011","",NA,"?n",24141
"1265","NCT01293201","Trial of STAHIST in Seasonal Allergic Rhinitis","Seasonal Allergic Rhinitis","other","Drug: STAHIST|Drug: Placebo","drug","Magna Pharmaceuticals, Inc.","Both","Child|Adult",290,"March 2011","August 2011","",NA,"?",24140
"1266","NCT01307800","A Study of LY2140023 in Patients With Schizophrenia","Schizophrenia","mental health","Drug: LY2140023|Drug: Placebo","drug","Eli Lilly and Company","Both","Adult",1100,"March 2011","August 2008","",NA,"?",24104
"1267","NCT01312922","Pipamperone/Citalopram (PNB01) Versus Citalopram (CIT) and Versus Pipamperone (PIP) in Major Depressive Disorder (MDD)","Major Depressive Disorder","mental health","Drug: PNB01 fixed dose combination of pipamperone and citalopram|Drug: Citalopram|Drug: Pip","drug","PharmaNeuroBoost N.V.","Both","Adult|Senior",555,"September 2011","March 2011","",NA,"?",24135
"1268","NCT01321359","A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis","Recurrent Herpes Simplex Labialis","other","Drug: Vehicle versus NB-001","drug","NanoBio Corporation","Both","Adult|Senior",907,"April 2011","March 2011","",NA,"?",24135
"1269","NCT01324466","A Multicenter Study of NB-001 in the Treatment of Recurrent Herpes Labialis (SHaRCS)","Recurrent Herpes Labialis","other","Drug: NB-001|Drug: Vehicle","drug","NanoBio Corporation","Both","Adult|Senior",847,"April 2011","March 2011","",NA,"?",24135
"1270","NCT01355874","Efficacy and Safety Study to Treat Subjects With Symptomatic Internal Hemorrhoids","Internal Hemorrhoids","cardiovascular","Drug: Iferanserin|Drug: Placebo|Drug: Iferanserin + Placebo","drug","Ventrus Biosciences, Inc","Both","Adult|Senior",403,"July 2011","January 2011","",NA,"?n",24133
"1271","NCT01357642","Epinephrine Inhalation Aerosol USP: For Evaluation Of Efficacy And Safety In Asthma Patients","Asthma","respiratory","Drug: Epinephrine inhalation aerosol|Drug: Placebo|Drug: epinephrine inhalation aerosol","drug","Amphastar Pharmaceuticals, Inc.","Both","Child|Adult|Se",373,"July 2011","June 2011","",NA,"?p",24138
"1272","NCT01372475","Hymovis™ Versus Placebo in Knee Osteoarthritis","Knee Osteoarthritis","other","Device: Hymovis Intra-articular Injection|Procedure: Phosphate Buffered Saline Injection","drug","Fidia Farmaceutici s.p.a.","Both","Adult|Senior",800,"March 2011","January 2011","",NA,"?",24133
"1273","NCT01375933","A Comparability Study of the Phase 3 Lot and a Single Commercial Lot of NicVAX in Healthy Adult Smokers","Smoking","other","Biological: NicVAX Vaccine","biolog","Nabi Biopharmaceuticals","Both","Adult",260,"May 2011","October 2010","",NA,"?",24130
"1274","NCT01400776","Safety & Efficacy WC3011 in the Treatment of Vulvovaginal Atrophy in Postmenopausal Women","Postmenopausal Vulvovaginal Atrophy","other","Drug: WC3011 Vaginal Gel|Drug: Vehicle","drug","Warner Chilcott","Female","Adult|Senior",722,"July 2011","December 2010","",NA,"?",24132
"1275","NCT01406561","Safety and Efficacy of OMS103HP-S Administered in Joint Irrigation Solution to Subjects Undergoing Arthroscopic Meniscectomy","Meniscal Tear","other","Drug: OMS103HP-S|Drug: Vehicle","drug","Omeros Corporation","Both","Adult|Senior",344,"August 2011","January 2011","",NA,"?n",24133
"1276","NCT01436032","Efficacy, Safety and Tolerability Study of N1539 in Subjects After Abdominal Laparoscopic Surgery","Laparoscopic Surgery","other","Drug: N1539|Drug: N1539|Drug: N1539|Drug: Ketorolac Tromethamine|Drug: Placebo","drug","Alkermes, Inc.","Both","Adult|Senior",50,"October 2011","August 2011","",NA,"?",24140
"1277","NCT01460511","Evaluation of Efficacy and Safety of E004 in Children With Asthma","Asthma","respiratory","Drug: Epinephrine Inhalation Aerosol","drug","Amphastar Pharmaceuticals, Inc.","Both","Child",70,"October 2011","January 2012","",NA,"?",24145
"1278","NCT01477853","A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)","Type 2 Diabetes Mellitus","endocrine and metabolic","Drug: Sitagliptin|Drug: Atorvastatin|Other: Placebo to sitagliptin|Other: Placebo to atorva","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",166,"October 2011","October 2010","",NA,"?",24130
"1279","NCT01484119","Efficacy, Safety, and Tolerability Study of ACT-129968 in Patients With Seasonal Allergic Rhinitis","Seasonal Allergic Rhinitis","other","Drug: ACT-129968|Drug: Placebo|Drug: Cetirizine","drug","Actelion","Both","Child|Adult|Se",630,"December 2011","September 2009","",NA,"?n",24117
"1280","NCT01506154","Safety & Efficacy Study of MRX-7EAT Patch in the Treatment of Pain of the Shoulder","Bursitis|Tendonitis|Shoulder Pain","other","Drug: MRX-7EAT","drug","IL Pharma Inc.","Both","Child|Adult|Se",210,"December 2011","March 2012","",NA,"?",24147
"1281","NCT01516541","A Study of Dalcetrapib in Patients With Stable Coronary Heart Disease, With Coronary Heart Disease Risk Equivalents or at Elevated Risk for Cardiovascular Disease","Cardiovascular Disease, Coronary Heart Disease, Dysli","cardiovascular","Other: Background care|Drug: dalcetrapib|Drug: Placebo","drug","Hoffmann-La Roche","Both","Adult|Senior",2220,"January 2012","January 2012","",NA,"?n",24145
"1282","NCT01531699","Antimicrobial Efficacy of ALT005 Ophthalmic Prep Solution in Healthy Volunteers","Infection Secondary to Surgical Procedure","other","Drug: ALT005 Ophthalmic Prep Solution|Other: saline control|Drug: Comparator Product","drug","Altacor Ltd.","Both","Adult|Senior",54,"February 2012","June 2011","",NA,"?",24138
"1283","NCT01551056","A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)","Allergic Conjunctivitis","other","Drug: AC-170 0.24%|Drug: AC-170 0%","drug","Aciex Therapeutics, Inc.","Both","Child|Adult|Se",91,"March 2012","September 2008","",NA,"?s",24105
"1284","NCT01569841","A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes","Diabetes|Diabetes Mellitus, Type 1","endocrine and metabolic","Drug: insulin degludec|Drug: insulin glargine","drug","Novo Nordisk A/S","Both","Adult|Senior",24,"April 2012","August 2009","",NA,"?",24116
"1285","NCT01654250","NWP09 in Children With Attention Deficit Hyperactivity Disorder (ADHD)","Attention Deficit Hyperactivity Disorder","mental health","Drug: NWP09|Drug: Placebo","drug","Pfizer","Both","Child",90,"July 2012","January 2010","",NA,"?",24121
"1286","NCT01660893","Comparison of Intranasal Kovacaine Mist, Tetracaine Alone, and Placebo for Anesthetizing Maxillary Teeth","Anesthesia","other","Drug: Tetracaine HCl 3% and oxymetazoline HCl 0.05%|Drug: Tetracaine HCl 3%|Drug: Placebo","drug","St. Renatus, LLC|Triligent International|Tegra Analytics","Both","Adult|Senior",140,"August 2012","October 2010","",NA,"?",24130
"1287","NCT01685242","A Single-Center,Evaluation of the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle","Allergic Conjunctivitis","other","Drug: AC-170 0.24%|Drug: AC-170 0%","drug","Aciex Therapeutics, Inc.","Both","Child|Adult|Se",100,"September 2012","December 2008","",NA,"?p",24108
"1288","NCT01779947","Study to Evaluate the Safety and Bioequivalence of Estradiol Vaginal Inserts, 10 mcg and Vagifem® 10 mcg and Compare to Placebo","Atrophic Vaginitis Due to Menopause","other","Drug: Estradiol Vaginal Tablets 10 mcg|Drug: placebo","drug","Amneal Pharmaceuticals, LLC","Female","Adult|Senior",519,"March 2012","April 2012","",NA,"?",24148
"1289","NCT00627016","A Study of Dexlansoprazole Modified Release Formulation to Treat Night Heartburn","Gastroesophageal Reflux","other","Drug: Dexlansoprazole|Drug: Placebo","drug","Takeda","Both","Adult",305,"March 2008","March 2009","Median Percentage of Nights Without Heartburn Over 4 Weeks as Assessed by Daily Diary.",99,"1",24111
"1290","NCT00639158","Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Ab","Dyslipidemias|Coronary Heart Disease|Combined (Atherogenic) Dyslipidemia|Mixed Dyslipid","cardiovascular","Drug: ABT-335|Drug: placebo|Drug: atorvastatin|Drug: ezetimibe","drug","Abbott","Both","Adult|Senior",543,"February 2008","October 2008","Median Percent Change in Triglycerides From Baseline to Final Visit",99,"1",24106
"1291","NCT00680017","30 Week Study of the Combination of ABT-335 and Rosuvastatin Compared to Rosuvastatin Monotherapy for Subjects With Dyslipidemia and Stage 3 Chronic Kidney Disease","Dyslipidemia|Kidney Disease","cardiovascular","Drug: ABT-335 plus rosuvastatin|Drug: Rosuvastatin","drug","AstraZeneca","Both","Adult|Senior",280,"June 2008","April 2011","Median Percent Change in Triglycerides From Baseline to Week 8.",99,"1",24136
"1292","NCT00770146","Safety and Efficacy of Mipomersen (ISIS 301012) As Add-on Therapy in High Risk Hypercholesterolemic Patients","Hypercholesterolemia|Coronary Heart Disease","cardiovascular","Drug: Mipomersen sodium|Drug: Placebo","drug","Genzyme, a Sanofi Company|Isis Pharmaceuticals|Sanofi","Both","Adult|Senior",158,"November 2008","May 2010","Percent Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) at the Primary Efficacy Time Point",99,"1",24125
"1293","NCT00894556","A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine (0462-087)","Acute Migraine","mental health","Drug: rizatriptan|Drug: Comparator: Placebo|Drug: Comparator: Sumatriptan","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",109,"June 2009","January 2010","Pain Relief (PR)",99,"1",24121
"1294","NCT00912093","A Study of Icatibant in Patients With Acute Attacks of Hereditary Angioedema (FAST-3)","Hereditary Angioedema","cardiovascular","Drug: Icatibant|Drug: Placebo","drug","Shire","Both","Adult|Senior",98,"June 2009","July 2012","Time to Onset of Symptom Relief for an Acute Attack， as Assessed by the Patient",99,"1",24151
"1295","NCT00958568","A Study in Relapse Prevention of Treatment-Resistant Depression","Treatment Resistant Depression","mental health","Drug: Olanzapine and Fluoxetine combination (OFC)|Drug: Fluoxetine","drug","Eli Lilly and Company","Both","Adult",892,"August 2009","March 2012","Time to Relapse by Any Criteria",99,"1",24147
"1296","NCT00961636","A Long-term Study of ERN/LRPT (Extended Release Niacin/Laropiprant [MK0524A]) in Patients With Dyslipidemia (0524A-102)","Dyslipidemia","cardiovascular","Drug: ER niacin (+) laropiprant (ERN/LRPT)|Drug: ER niacin (+) laropiprant (ERN/LRPT)|Drug: Extended-release niacin (ERN)|Drug: Placebo to ERN/LRPT","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",1152,"October 2009","January 2011","Number Participants With Days Per Week With Global Flushing Severity Score (GFSS) ≥4 Partitioned Into 6 Categories During the Postwithdrawal Period",99,"1",24133
"1297","NCT00105989","Duloxetine Versus Placebo in the Prevention of Recurrence of Major Depressive Disorder","Depressive Disorder, Major","mental health","Drug: Duloxetine|Drug: placebo","drug","Eli Lilly and Company|Boehringer Ingelheim","Both","Adult|Senior",514,"March 2005","January 2008","Percentage of Participants With Depressive Recurrence After Time (t) in Days",99,"1",24097
"1298","NCT00122681","Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18","Human Papillomavirus (HPV) Infection|Cervical Neoplasia","other","Biological: Cervarix™|Biological: Havrix™-based investigational formulation","biolog","GlaxoSmithKline","Female","Child|Adult",18729,"May 2004","November 2009","Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Associated With HPV-16 and/or -18 Cervical Infection",99,"1",24119
"1299","NCT00232596","Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy","Partial-Onset Seizures","mental health","Drug: Retigabine|Drug: Placebo","drug","GlaxoSmithKline|Valeant Pharmaceuticals International, Inc.","Both","Adult|Senior",306,"September 2005","January 2008","Percent Change in the 28-day Total Partial Seizure (PS) Frequency From Baseline (BL) to the End of the Double-blind (DB) Phase (Titration and Maintenance Phases)",99,"1",24097
"1300","NCT00235755","Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in Epilepsy","Partial-Onset Seizures","mental health","Drug: Retigabine|Drug: Retigabine|Drug: Placebo","drug","GlaxoSmithKline|Valeant Pharmaceuticals International, Inc.","Both","Adult|Senior",539,"December 2005","April 2008","Percent Change in the 28-day Total Partial Seizure (PS) Frequency From Baseline (BL) to the End of the Double-blind (DB) Phase (Titration and Maintenance Phases)",99,"1",24100
"1301","NCT00262067","A Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy in Untreated Metastatic Breast Cancer (RIBBON 1)","Metastatic Breast Cancer","cancer","Drug: Bevacizumab|Drug: Placebo|Drug: Chemotherapy","drug","Genentech, Inc.","Both","Adult|Senior",1237,"December 2005","July 2008","Progression-free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors (RECIST)",99,"1",24103
"1302","NCT00360490","Study in Women With Idiopathic Menorrhagia to Determine the Reduction in Menstrual Blood Loss (MBL) After Treatment With the Levonorgestrel-releasing Intrauterine Sy","Menorrhagia","other","Drug: Levonorgestrel IUS (Mirena, BAY86-5028)|Drug: Medroxyprogesterone acetate","drug","Bayer","Female","Adult|Senior",165,"July 2006","June 2008","The Change in Absolute Value From Baseline Menstrual Blood Loss (MBL) to the End-of-study MBL (Cycle 6)",99,"1",24102
"1303","NCT01355458","Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea","Rosacea","other","Drug: CD07805/47 gel|Drug: Placebo","drug","Galderma","Both","Adult|Senior",260,"May 2011","September 2011","Composite Success",99,"1",24141
"1304","NCT01355471","Phase 3 Efficacy and Safety Study of CD07805/47 Topical Gel in Subjects With Facial Erythema Associated With Rosacea","Rosacea","other","Drug: CD07805/47 Gel|Drug: Placebo","drug","Galderma","Both","Adult|Senior",293,"May 2011","November 2011","Composite Success",99,"1",24143
"1305","NCT01385371","A Study of SCH 697243 in Participants With Grass Pollen Allergy Symptoms, With or Without Asthma (P08067)","Rhinitis Allergic|Conjunctivitis","other","Biological: Grass (Phleum pratense) pollen allergen extract|Biological: Placebo for SCH 697243","biolog","Merck Sharp & Dohme Corp.","Both","Child|Adult",1501,"June 2011","August 2012","Average Total Combined Rhinoconjunctivitis Daily Symptom Score (DSS) and Rhinoconjunctivitis Daily Medication Score (DMS) Over the Entire Grass Pollen Season (GPS)",99,"1",24152
"1306","NCT00688064","Adapalene-BPO Gel Associated With Doxycycline Hyclate 100 mg in the Treatment of Severe Acne Vulgaris","Severe Acne Vulgaris","other","Drug: Adapalene BPO Gel associated with Doxycyline Hyclate|Drug: Vehicle Gel associated with Doxycycline Hyclate","drug","Galderma","Both","Child|Adult",459,"August 2008","February 2009","Percent Change From Baseline in Total Lesion Counts at Week 12.",99,"1",24110
"1307","NCT00090220","A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501) in Women (V501-019)","Healthy|Papillomavirus Infection","other","Biological: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Biological: Comparator: Placebo","biolog","Merck Sharp & Dohme Corp.","Female","Adult",3819,"June 2004","May 2009","Combined Incidence of HPV 6/11/16/18 Related Persistent Infection， Genital Warts， Vulvar Intraepithelial Neoplasia (VIN)， Vaginal Intraepithelial Neoplasia (VaIN)， Vulvar Cancer， Vaginal Cancer， Cervical Dysplasia， AIS， and Cervical Cancer",99,"1",24113
"1308","NCT00090285","An Investigational Study of Gardasil™ (qHPV, V501) Vaccine in Reducing the Incidence of Anogenital Warts in Young Men (V501-020)","Condylomata Acuminata","other","Biological: (Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|Biological: Comparator: placebo (unspecified)","biolog","Merck Sharp & Dohme Corp.","Male","Child|Adult",4065,"September 2004","July 2009","Incidence of Human Papillomavirus (HPV) Related External Genital Warts， Perineal Intraepithelial Neoplasia (PIN)， Penile， Perianal or Perineal Cancer",99,"1",24115
"1309","NCT00128661","Vaccine To Prevent Cervical Intraepithelial Neoplasia or Cervical Cancer in Younger Healthy Participants","Cervical Cancer|Precancerous Condition","cancer","Biological: human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine|Biological: hepatitis A inactivated virus vaccine","biolog","GlaxoSmithKline","Female","Adult",7466,"June 2004","December 2010","Number of Histopathologically Confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Cases Associated With HPV16 and/or HPV18 Infection Detected in the Preceding Cervical Cytology Specimen.",99,"1",24132
"1310","NCT00150176","To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770)","Schizophrenia","mental health","Drug: Asenapine - Open Label|Drug: Placebo - Double Blind|Drug: Asenapine - Double Blind","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",831,"April 2005","June 2008","Time to Relapse or an Impending Relapse",99,"1",24102
"1311","NCT00446199","Low-dose Hormone Therapy for Relief of Vasomotor Symptoms","Vasomotor Symptoms|Hot Flashes","other","Drug: 0.5mg DRSP / 0.5mg E2 (BAY86-4891)|Drug: 0.25mg DRSP / 0.5mg E2 (BAY86-4891)|Drug: Estradiol (E2 0.3mg)|Drug: Placebo","drug","Bayer","Female","Adult|Senior",735,"March 2007","October 2008","Change From Baseline to Week 12 in Weekly Frequency of Moderate to Severe Hot Flushes (Median Value)",99,"1",24106
"1312","NCT00999141","Efficacy and Safety of FS VH S/D 4 S-apr for Flap Adherence in Rhytidectomy","Face-lift|Facial Rhytidectomy","other","Biological: FS VH S/D 4 s-apr","biolog","Baxter Healthcare Corporation","Both","Adult|Senior",75,"September 2009","December 2009","Total Volume of Drainage on Each Side of the Face",99,"1",24120
"1313","NCT00549042","Study to Test the Effectiveness of Controlled-Release OROS® Hydromorphone HCl Compared to Placebo in Patients With Chronic Low Back Pain","Chronic Low Back Pain","other","Drug: Drug: OROS® hydromorphone at 4, 8, 16, and 32 mg tablets will be used to provide dos","drug","Mallinckrodt","Both","Adult|Senior",266,"September 2007","January 2009","",99,"1",24109
"1314","NCT00831662","The Effects of Diquafosol Tetrasodium Ophthalmic Solution, 2% in Subjects With Dry Eye Disease (P08637)","Dry Eye Disease","other","Drug: Diquafosol tetrasodium ophthalmic solution, 2%|Drug: Placebo","drug","Merck Sharp & Dohme Corp.","Both","Adult|Senior",490,"January 2009","December 2009","",99,"1",24120
"1315","NCT01007708","The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis","Onychomycosis","other","Drug: IDP-108|Drug: Vehicle","drug","Dow Pharmaceutical Sciences","Both","Adult|Senior",780,"November 2009","December 2011","",99,"1",24144
"1316","NCT01122602","Evaluate Analgesic Efficacy of Fast Release Aspirin","Drugs, Investigational","other","Drug: Acetylsalicyclic acid (Fast acting Aspirin, BAY1019036)|Drug: Acetylsalicyclic acid (","drug","Bayer","Both","Child|Adult",500,"April 2010","July 2010","",99,"1",24127
"1317","NCT00449878","Liprotamase Efficacy Trial in Patients With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency","Cystic Fibrosis|Exocrine Pancreatic Insufficiency","endocrine and metabolic","Drug: Liprotamase|Drug: Placebo","drug","Anthera Pharmaceuticals","Both","Child|Adult|Se",163,"May 2007","June 2008","",99,"1",24102
"1318","NCT00615836","""An Extension Study Investigating the Efficacy and Safety of a Fast-Dissolving (\""Melt\"") Formulation of Desmopressin for the Treatment of Nocturia in Adults""","Nocturia","other","Drug: lyophilisate oral of desmopressin|Drug: lyophilisate oral of desmopressin|Drug: lyoph","drug","Ferring Pharmaceuticals","Both","Adult|Senior",508,"December 2007","May 2010","",99,"1",24125
"1319","NCT00647699","Corneal Collagen Cross-linking for Progressive Keratoconus","Progressive Keratoconus","other","Drug: riboflavin ophthalmic solution|Device: UVA Irradiation","device","Avedro, Inc.","Both","Child|Adult|Se",147,"December 2007","April 2011","",99,"1",24136
"1320","NCT00729183","BMD Efficacy and Safety of Odanacatib in Postmenopausal Women (0822-031)","Osteoporosis","endocrine and metabolic","Drug: Odanacatib|Drug: Placebo","drug","Merck Sharp & Dohme Corp.","Female","Adult|Senior",214,"October 2008","March 2010","",99,"1",24123
"1321","NCT00744471","Tanezumab in Osteoarthritis Of The Hip","Arthritis|Osteoarthritis|Osteoarthritis, Hip","other","Biological: tanezumab|Biological: tanezumab|Biological: tanezumab|Biological: Placebo","biolog","Pfizer","Both","Adult|Senior",627,"November 2008","March 2010","",99,"1",24123
"1322","NCT00789750","Welchol as Add-on to Pioglitazone Therapy for Type 2 Diabetes Mellitus","Type 2 Diabetes Mellitus","endocrine and metabolic","Drug: Welchol|Drug: placebo|Drug: Pioglitazone","drug","Daiichi Sankyo Inc.","Both","Adult|Senior",562,"April 2009","July 2012","",99,"1",24151
"1323","NCT01055015","Double Blind Efficacy and Safety Study of Flexible-Dose vs Low-Dose Q8003 After Undergoing Primary Unilateral Total Knee Arthroplasty","Postoperative Pain","other","Drug: Flexible dose Q8003 (morphine sulfate and oxycodone hydrochloride)|Drug: Low dose Q80","drug","QRxPharma Inc.","Both","Adult|Senior",141,"February 2010","December 2010","",99,"1",24132
"1324","NCT01186770","A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation in Subjects With Chronic, Non-Malignant Pain","Opioid-Induced Constipation","other","Drug: Methylnaltrexone bromide|Drug: Oral Placebo","drug","Salix Pharmaceuticals","Both","Adult|Senior",700,"September 2010","May 2012","",99,"1",24149
"1325","NCT01240863","Study to Evaluate the Efficacy and Safety of Hydrocodone Bitartrate Extended-Release Tablets (CEP-33237) for Relief of Moderate to Severe Pain in Patients With Osteo","Pain","other","Drug: Hydrocodone|Drug: Placebo","drug","Cephalon|Teva Pharmaceutical Industries","Both","Adult|Senior",391,"November 2010","August 2011","",99,"1",24140
"1326","NCT01468025","Effectiveness of Theramine on Chronic Back Pain","Low Back Pain","other","Drug: Active Theramine and Active Naproxen|Other: Theramine and naproxen-like placebo|Drug:","drug","Targeted Medical Pharma","Both","Adult|Senior",127,"February 2009","July 2009","",99,"1",24115
"1327","NCT00324727","Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma","Intraocular Melanoma|Melanoma (Skin)|Metastatic Cance","cancer","Drug: melphalan|Drug: regional chemotherapy|Drug: systemic chemotherapy|Procedure: hepatic","drug","Delcath Systems Inc.|National Cancer Institute (NCI)","Both","Adult|Senior",93,"February 2006","August 2012","",99,"1",24152
"1328","NCT00366145","Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease","Graft Versus Host Disease","other","Biological: Mesenchymal Stem Cells|Biological: placebo","biolog","Osiris Therapeutics","Both","Child|Adult|Se",240,"July 2006","May 2009","",99,"1",24113
"1329","NCT00392574","Safety and Efficacy of Prulifloxacin Versus Placebo in Traveler's Diarrhea","Acute Gastroenteritis in Adult Travelers","other","Drug: Prulifloxacin|Drug: Placebo","drug","Optimer Pharmaceuticals","Both","Adult|Senior",282,"August 2006","February 2008","",99,"1",24098
"1330","NCT00448422","Safety and Efficacy of Prulifloxacin vs Placebo in Treatment of Acute Gastroenteritis in Adult Travelers","Acute Bacterial Gastroenteritis","other","Drug: prulifloxacin","drug","Optimer Pharmaceuticals","Both","Adult|Senior",268,"December 2006","August 2008","",99,"1",24104
"1331","NCT00459277","Efficacy & Safety Study of Nasalfent (Fentanyl Citrate Nasal Spray) for Treatment of Breakthrough Cancer Pain in Patients Taking Regular Opioids","Cancer Pain","other","Drug: Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)","drug","Archimedes Development Ltd","Both","Adult|Senior",73,"December 2006","July 2008","",99,"1",24103
"1332","NCT00507026","Efficacy and Safety of IV Diclofenac (DIV075V)for Pain After Elective Orthopedic Surgery","Postoperative Pain","other","Drug: IV Diclofenac|Drug: IV ketorolac|Drug: Placebo","drug","Javelin Pharmaceuticals","Both","Adult|Senior",277,"July 2007","December 2008","",99,"1",24108
"1333","NCT00690638","Safety and Efficacy Study of Dutogliptin/PHX1149T to Treat Type 2 Diabetes Mellitus","Type 2 Diabetes Mellitus","endocrine and metabolic","Drug: PHX1149T|Drug: PHX1149T|Drug: Placebo","drug","Phenomix|Forest Laboratories","Both","Adult|Senior",480,"July 2008","January 2010","",99,"1",24121
"1334","NCT00721955","Staccato® Loxapine Treatment of Agitation in Bipolar Disorder Patients","Bipolar I Disorder","mental health","Drug: loxapine|Drug: loxapine|Drug: placebo","drug","Alexza Pharmaceuticals, Inc.","Both","Adult",300,"July 2008","October 2008","",99,"1",24106
"1335","NCT01256684","DHEA Against Vaginal Atrophy - 3-Month Efficacy Study","Vaginal Atrophy","other","Drug: Placebo|Drug: DHEA|Drug: DHEA","drug","EndoCeutics Inc.","Female","Adult|Senior",255,"December 2010","August 2011","",99,"1",24140
"1336","NCT01323153","A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)","Coronary Heart Disease","cardiovascular","Drug: dalcetrapib|Drug: placebo","drug","Hoffmann-La Roche","Both","Adult|Senior",300,"March 2011","March 2012","",99,"1",24147
"1337","NCT01358760","Dehydroepiandrosterone (DHEA) Against Vaginal Atrophy","Vaginal Atrophy","other","Drug: Placebo|Drug: DHEA|Drug: DHEA","drug","EndoCeutics Inc.","Female","Adult|Senior",450,"June 2011","April 2012","",99,"1",24148
"1338","NCT00628589","Staccato® Loxapine Treatment of Schizophrenic Patients With Agitation","Schizophrenic Patients With Acute Agitation","mental health","Drug: loxapine|Drug: loxapine|Drug: placebo","drug","Alexza Pharmaceuticals, Inc.","Both","Adult",300,"February 2008","May 2008","",99,"1",24101
"1339","NCT00654069","Safety/Efficacy Study of Oxycodone HCl/Niacin to Treat Pain After Bunionectomy","Pain","other","Drug: Oxycodone HCl/Niacin Tablets 5/30 mg|Drug: Oxycodone HCl/Niacin 7.5/30 mg|Drug: Place","drug","Acura Pharmaceuticals Inc.","Both","Adult|Senior",405,"September 2007","February 2008","",99,"1",24098
"1340","NCT00688701","GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy","Diabetes Mellitus, Type 2","endocrine and metabolic","Drug: Lixisenatide (AVE0010)|Drug: Placebo|Device: Pen auto-injector","device","Sanofi","Both","Adult|Senior",361,"May 2008","December 2009","",99,"1",24120
"1341","NCT00805350","Efficacy and Safety of Eplivanserin 5mg/Day in Insomnia Characterized by Sleep Maintenance Difficulties","Primary Insomnia","mental health","Drug: Eplivanserin (SR46349)|Drug: Placebo","drug","Sanofi","Both","Adult|Senior",637,"December 2008","June 2009","",99,"1",24114
"1342","NCT01114308","A Six-Month Randomized Controlled Trial (RCT) of Probuphine Safety and Efficacy in Opioid Addiction","Opioid Dependency","mental health","Drug: Probuphine (buprenorphine implant)|Drug: placebo implant|Drug: Buprenorphine","drug","Titan Pharmaceuticals|National Institute on Drug Abuse (NIDA)","Both","Adult",287,"April 2010","May 2011","",99,"1",24137
